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Abstract 
High affinity and specific binding molecules are important tools for many biotechnological 
and pharmaceutical applications. They can be obtained in vitro by using selection technologies 
that allow molecules with the desired binding properties to be extracted from large collections of 
variants. My thesis describes the development of a new selection technology and its subsequent 
application to select binders from a Designed Ankyrin Repeat Protein (DARPin) library. 
 
In the first part of my thesis a new selection technology called ”SRP phage display“ was 
developed that allows the display of highly stable and fast folding proteins, such as DARPins, 
that are virtually refractory to conventional phage display. In SRP phage display, the proteins to 
be displayed are directed to the Escherichia coli cotranslational signal recognition particle (SRP) 
translocation pathway by using an appropriate signal sequence, whereas conventional phage 
display uses the posttranslational Sec translocation pathway. This simple change of the 
translocation route seems to prevent premature folding of stable and fast folding proteins in the 
cytoplasm and therefore allows their efficient translocation and subsequent display on 
filamentous phage particles. For example, the display levels of DARPins were improved up to 
700-fold by simply exchanging Sec-dependent for SRP-dependent signal sequences. This 
allowed more than 1000-fold enrichment per phage display selection round in model 
experiments. 
 
In the second part of my thesis, SRP phage display was used to generate a large phage 
DARPin library containing more than 1010 functional individual members. Using this library, 
well-behaved and highly specific DARPins were selected for a broad range of target proteins 
having affinities as low as 100 picomolar without affinity maturation. 
 
  xiii 
In conclusion, SRP phage display makes filamentous phage display accessible for 
DARPins, which allows, for example, selections under hash conditions, such as high 
temperatures or in the presence of denaturants. I envision that the use of SRP phage display 
would be also beneficial to increase the functional diversity of other libraries, especially for 
those containing stable and fast folding proteins. 
Zusammenfassung 
Proteinbindende Moleküle mit hoher Affinität und Spezifität sind wichtige Werkzeuge für 
viele biotechnologische und biomedizinische Anwendungen. Solche Moleküle mit den 
gewünschten Binde-Eigenschaften können mit Hilfe von in vitro Selektionstechnologien aus 
grossen Bibliotheken isoliert werden. Diese Arbeit beschreibt die Entwicklung einer neuen 
Selektionstechnologie und deren erfolgreiche Anwendung zur Isolierung von proteinbindenden 
Molekülen aus einer Bibliothek von „Designed Ankyrin Repeat Proteinen (DARPin)“. 
 
Der erste Teil dieser Arbeit beschreibt die Entwicklung von „SRP Phage Display“, einer 
neuen Selektionstechnologie die es ermöglicht, stabile und schnell faltende Proteine auf 
filamentösen Bakteriophagen zu präsentieren, was mit der konventionellen „Phage Display“ 
Technologie nicht möglich ist. In „SRP Phage Display“ wird das zu präsentierende Protein über 
den cotranslationalen Signalerkennungspartikel (SRP) Transportweg in das Periplasma von E. 
coli transportiert, wohingegen in der konventionellen „Phage Display“ Technologie der 
posttranslationale Sec Transportweg benutzt wird. Dieser einfache Wechsel des Transportweges 
verhindert die vorzeitige Faltung von stabilen und schnell faltenden Proteinen im Zytoplasma 
und erlaubt deshalb einen effizienten Transport ins Periplasma, was den Einbau und die 
Präsentation auf den Phagen Partikeln ermöglicht. Durch den einfachen Austausch der Signal-
sequenz wurde die Präsentation von verschiedenen DARPins auf den Phagen Partikeln bis zu 
700-fach verbessert, was zu einer bis zu 1000-fachen Anreicherung pro Selektionsrunde in 
Modellexperimenten führte. 
xiv 
 
 
Im zweiten Teil dieser Arbeit wurde „SRP Phage Display“ angewendet, um eine DARPin 
Bibliothek präsentiert auf Phagen zu generieren, die mehr als 1010 funktionelle Mitglieder 
enthält. In Selektions-Experimenten wurden hochspezifische Binder gegen eine Vielzahl von 
Zielmolekülen isoliert und Affinitäten von bis zu 100 picomolar ohne Affinitätsmaturierung 
erreicht. 
 
Zusammenfassend erweitert „SRP Phage Display“ die für DARPins zugänglichen 
Selektionstechnologien und erlaubt durch die Präsentation der DARPins auf filamentösen 
Bakteriophagen die Selektion von proteinbindenden Molekülen unter stringenten Bedingungen 
wie hoher Temperatur und Gegenwart von denaturierenden Reagenzien. Auch für andere 
Bibliotheken von stabilen und schnell faltenden Protein sollte „SRP Phage Display“ helfen, die 
funktionelle Diversität zu erhöhen. 
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1. General Introduction 
In the era of intensive genomic discovery, the number of identified genes is strongly 
increasing. One of the major challenges is to understand the function of the proteins encoded by 
these genes. However, many of these proteins are difficult to handle and therefore difficult do 
investigate. One promising approach to study such proteins is to generate specific binding 
proteins against them allowing detection, purification and many further experiments. However, 
the large number of interesting proteins greatly exceeds the capacity of conventional methods for 
monoclonal antibody production and subsequently led to the development of alternative 
techniques. 
My thesis addresses the development of a new selection technology for designed ankyrin 
repeat proteins (DARPins) and its applicability to enrich specific binding proteins from a 
DARPin library. The first part of this chapter will give a brief overview of the protein libraries 
and display scaffolds generally used for the generation of specific binding proteins. In the second 
part, different selection technologies with a focus on their limitations will be discussed. 
2. Libraries and Display Scaffolds 
Display scaffolds used to generate specific binding proteins can be very diverse in size, 
structure and composition of the interaction surface. Based on the parental proteins they are 
derived from, they can be grouped into immunoglobulin and non-immunoglobulin scaffolds1. To 
create molecules with novel binding specificities from such scaffolds, libraries which have 
randomized potential target interaction residues are generated. The proteins with the desired 
binding properties are then extracted from these large collections of variants by using different 
selection technologies (see below). 
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2.1 Immunoglobulin scaffolds 
Antibodies are currently by far the most frequently used binding molecules. The reason for 
that is to some extent historic. The molecular diversity of the immune system was the first source 
available to generate target-specific binding proteins. The target protein is injected into a 
laboratory animal that reacts in most cases with an immune response and thus produces specific 
antibodies. For further applications, the polyclonal sera or monoclonal antibodies, obtained by 
hybridoma technology, are used. There are several problems encountered when producing 
antibodies by immunization. Some target proteins are not immunogenic, others too toxic or just 
not stable enough to elicit an antibody response in the laboratory animal. To avoid immunization 
and to gain better control over the selection process, a broad range of synthetic or natural 
libraries of antibody fragments2 or even whole antibody molecules3 have been generated which 
can be used in combination with an appropriate selection technology (see below) for the fast and 
convenient selection of specific binding molecules. For all of these immunoglobulin-based 
binding molecules, the variable surface loops on the antibody framework, called complementary 
determining regions (CDRs) are responsible for the interaction with the target protein and confer 
affinity and specificity. The major limitations of whole antibody molecules are based on their 
complex composition. The large, multidomain assembly with glycosylation and disulfide bonds 
makes them relatively difficult and expensive to manufacture. Smaller versions of antibodies, 
such as scFv or Fab fragments can be produced in microbial hosts albeit at relatively low yields. 
Furthermore, the stability of many of these antibody fragments still relies on stabilizing 
intradomain disulfide bonds which do not form in the reducing intracellular environment of the 
cell which might represent a bottleneck for some applications. Additionally, many antibodies or 
antibody fragments have unfavorable biophysical properties, resulting for example in 
aggregation or low stability, even though the most advanced antibodies are great clinical 
successes. 
 
4  Chapter 1 
2.2 Non-immunoglobulin scaffolds 
Due to the advances in protein engineering and the availability of selection technologies, 
binding proteins based on non-immunoglobulin scaffolds have become an appealing alternative 
to overcome the above-mentioned limitations of antibodies and antibody fragments. 
Preferentially such alternative scaffolds are small single-chain proteins, not containing disulfide 
bonds or free cysteines, while retaining the advantageous properties of antibodies, such as 
specific high affinity binding. Additionally, they should have favorable biophysical properties 
such as being monomeric in solution, highly soluble, thermodynamically stable and fast folding, 
altogether facilitating high expression levels. Numerous alternative scaffolds have been 
investigated and are discussed in detail in ref. 1. 
DARPins comprise a recently established novel class of such non-immunoglobulin binding 
proteins, which rely on the modularity of repeat proteins4,5. Here, consensus design based on the 
sequence and structure analysis of natural ankyrin repeat proteins allows the discrimination of 
framework residues, which are important for stability of the scaffold and potential target 
interaction residues suitable to introduce the needed diversity. The resulting designed ankyrin 
repeat modules, composed of 33 amino acids (of which seven are randomized), were used to 
create combinatorial libraries of DARPins of different sizes. Most of the members of such 
DARPin libraries have very favorable biophysical properties5 and specific binders with high 
affinities have been selected against a broad range of target proteins by using ribosome display6-
10. My thesis describes the development of a new selection technology for designed ankyrin 
repeat proteins (DARPins) that allows selection conditions complementary to ribosome display. 
3. Selection technologies 
Natural evolution is based on consecutive rounds of diversification, selection of the fittest 
and amplification. A prerequisite for evolution is that the inheritable information is tightly linked 
to the functional principle and not mixed with competing individuals. This linkage allows the 
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genetic information (genotype) of each individual to be translated into its phenotype on which 
the selection pressure is applied, leading over several consecutive cycles to the enrichment of the 
fittest11. The linkage of phenotype and genotype is fundamental to all evolution processes and 
can be mimicked in the test tube for the directed evolution of proteins with desired properties. 
The key features of directed evolution are a genotypically diverse starting population (e.g. a 
combinatorial library, see above), a selection technology that allows the coupling of the genotype 
(i.e. the DNA encoding the displayed protein) and the phenotype (i.e. the displayed protein), a 
selection pressure and an amplification process. Different selection technologies use different 
strategies to achieve this linkage1,12. The success of every selection technology depends on the 
compatibility of the strategy used with the proteins to be displayed.  
3.1 Phage display 
Phage display13 was the first display technology developed and is still the most widely 
used platform for the directed evolution of polypeptides. The protein (phenotype) is displayed on 
the surface of a phage particle while the respective DNA (genotype) is encapsulated inside14,15. 
Typically, filamentous bacteriophages that infect Escherichia coli (e.g. f1/M13/fd) are used for 
the display of foreign proteins. The power of phage display lies in the high stability of this 
linkage and the robustness of the phage particle itself, which allows selections to be performed 
under a wide range of conditions, including high temperature and in the presence of denaturants. 
The limiting factor of this selection technology is the involvement of an in vivo step. Bacterial 
transformation practically limits the library size to less than 1011 members and the in vivo 
assembly of the phage particle is not compatible with all proteins to be displayed (e.g. successful 
translocation of the protein to the periplasm and lack of aggregation in the periplasm is a 
prerequisite). Additionally, affinity maturation which involves cycles of randomization and 
library reconstruction is very unattractive due to the laborious transformation step. A scheme of 
the selection cycle is depicted in Figure 1. Other phages such as lambda or T7 that assemble 
intracellularly have been used for the display of proteins but most of them were not yet 
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investigated for library applications. In my thesis, the development of a new selection technology 
called “SRP phage display” is described. It expands the range of proteins amenable to phage 
display by allowing the display of fast folding and stable proteins such as DARPins that are 
refractory to conventional phage display. 
3.2 Complete in vitro selection technologies 
To overcome the limitations caused by the involvement of living cells, complete in vitro 
display technologies16 have been developed of which most rely on the formation of a complex of 
the display scaffold and its encoding gene. Ribosome display, for example, is based on the 
formation of a non-covalent ternary complex of mRNA, ribosome and the displayed nascent 
polypeptide17. The formation of this ternary complex by in vitro translation allows the sampling 
of very large libraries, but due to its relatively low stability, the linkage of the genotype and the 
phenotype is only reliably maintained under non-denaturing buffer conditions at low 
temperature. The high sensitivity of the system to RNases additionally restricts the selection 
conditions applicable. A clear bonus of ribosome display is the built-in affinity maturation 
process, coming from the spontaneous mutations introduced during DNA amplification. The ease 
of increasing the mutations during the selection cycle by error-prone PCR makes this display 
technology a very powerful tool for affinity maturation of binding proteins. A scheme of the 
selection cycle is depicted in Figure 2. Ribosome display has been successfully used to select 
specific binders with high affinities from libraries of DARPins6-10. 
3.3 Cell surface display 
Display on microbial cell surfaces exists for a variety of hosts and uses a variety of surface 
proteins for membrane anchoring18. For example, the affinity maturation of a fluorescein binding 
scFv antibody fragment by screening randomly mutagenized libraries of 105-107 yeast surface-
displayed molecules enabled the isolation of clones with femtomolar antigen-binding affinity19. 
However, many of these systems have not yet been used in combination with highly diverse 
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naive libraries mainly due to the very low transformation efficiencies for most of the used host 
strains. One recent very promising approach is based on the anchoring of the display scaffold in 
the periplasmic membrane of E. coli, followed by disruption of the outer membrane, incubation 
with fluorescently labelled target protein and sorting of the spheroblasts20. This approach should 
allow libraries with sizes as large as for phage display to be generated. An extension of this 
system allows the functional display of full-length antibody libraries followed by the efficient 
selection of binders3. 
3.4 Other selection technologies 
A broad range of complete in vivo selection technologies that are based on the 
reconstitution of a protein activity upon binder-target interaction (e.g. enzymatic or 
transcriptional) have been described. Examples, therefore, are the protein fragment 
complementation assay (PCA)21 or yeast two-hybrid systems22. In all these systems, the 
interactions occur in vivo and the precise selection conditions are difficult to control. Display on 
microbeads by in vitro compartmentalization in the aqueous droplets of a water-in-oil emulsion23 
or protein-DNA linkage24 are other methods that have been used as selection technologies.  
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Figure 1: Schematic representation of a phage display selection cycle. A phage library displaying variants of the 
protein of interest on the surface while having the respective gene encapsulated inside the phage particle is used for 
the binding selection on the immobilized target [1]. After formation of the complexes between the binding protein 
and the target protein, unbound phage particles are washed away [2]. The bound phages are eluted from the 
immobilized target by a pH shift [3] and used for the infection of E. coli. Phage particles are amplified [4] and can 
then be analyzed or used as input for the next selection round.  
Introduction  9 
 
Figure 2: Schematic representation of a ribosome display selection cycle. An mRNA library encoding the proteins 
of interest without stop codon is translated in vitro [1]. After cooling, the translation yields stable ternary complexes 
of mRNA, ribosomes and nascent polypeptides. These complexes are used for the binding selection on the 
immobilized target [2]. After binding of the polypeptides to the target protein, unbound complexes are washed away 
[3]. The mRNA of the bound complex is eluted by dissociating the ribosomal complex with EDTA [4]. A reverse 
transcription reaction followed by PCR yields the genetic information of the selected clones [5]. The amplified 
genes can then be used as input for the next selection round starting with in vitro transcription [6] or cloned into 
plasmids for analysis. 
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4. The Project 
As outlined above, the success of any directed evolution experiment (the “selection”) 
depends on the compatibility of the selection technology used with the protein to be displayed 
(the “display scaffold”). This is crucial, since only functionally displayed library members will 
be accessible to the selection process and thereby contribute to the probability of finding 
individuals with the desired properties. In general, the larger the number of functionally 
displayed library members, the higher the probability to isolate diverse binders against a given 
target protein and the higher the affinities of the selected binders25. 
In my thesis, the development of a new selection technology called SRP phage display is 
described (Chapter 2, ref. 26). This technology expands the range of proteins amenable to 
display on filamentous phage particle by allowing the display of fast folding and stable proteins 
such as DARPins which are refractory to conventional phage display. In SRP phage display, the 
proteins to be displayed are directed to the E. coli cotranslational signal recognition particle 
(SRP) translocation pathway27 by using an appropriate signal sequence, whereas conventional 
phage display uses the posttranslational Sec translocation pathway28. This simple change in the 
use of the translocation route seems to prevent premature folding of stable and fast folding 
proteins in the cytoplasm and therefore allows their efficient translocation and subsequent 
display on filamentous phage particles. The applicability of the system was shown for a broad set 
of proteins and different signal sequences. 
Subsequently I investigated the potential of the developed display technology for library 
applications. We constructed a large phage DARPin library based on SRP phage display and 
performed selections on a panel of target proteins followed by the analysis of the thereby 
selected DARPins (Chapter 3 and Chapter 4, ref. 29). The successful selection of high affinity 
binders against a broad range of target proteins supports the strength of SRP phage display and 
also underscores the excellent quality of the current phage DARPin library. 
Introduction  11 
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Signal sequences directing cotranslational translocation
expand the range of proteins amenable to phage display
Daniel Steiner1, Patrik Forrer1,2, Michael T Stumpp1,2 & Andreas Plu¨ckthun1
Even proteins that fold well in bacteria are frequently displayed poorly on ﬁlamentous phages. Low protein presentation
on phage might be caused by premature cytoplasmic folding, leading to inefﬁcient translocation into the periplasm.
As translocation is an intermediate step in phage assembly, we tested the display levels of a range of proteins using different
translocation pathways by employing different signal sequences. Directing proteins to the cotranslational signal recognition
particle (SRP) translocation pathway resulted in much higher display levels than directing them to the conventional post-
translational Sec translocation pathway. For example, the display levels of designed ankyrin-repeat proteins (DARPins) were
improved up to 700-fold by simply exchanging Sec- for SRP-dependent signal sequences. In model experiments this exchange
of signal sequences improved phage display from tenfold enrichment to 41,000-fold enrichment per phage display selection
round. We named this method ‘SRP phage display’ and envision broad applicability, especially when displaying cDNA libraries or
very stable and fast-folding proteins from libraries of alternative scaffolds.
Phage display is an in vitro selection method that allows polypeptides
with desired properties to be extracted from large collections of
variants1,2. Most commonly, ﬁlamentous phages, such as f1, M13
and fd, that infect Escherichia coli are used for phage display.
Filamentous phages have been intensively investigated for the selection
of peptides or antibodies with desired properties from combinatorial
libraries3,4. Although the major coat protein (protein-8, p8) of the
ﬁlamentous phage M13, present atB2,700 copies, and all four minor
M13 coat proteins (p3, p6, p7, p9), present at B5 copies each, have
been used for display2, fusions with p3 have been used most
frequently. The peptide or protein of interest (POI) to be displayed
is placed between an N-terminal signal sequence and either the
whole mature p3 or its C-terminal domain. The POI fused to
p3 is translocated into the periplasm by the E. coli translocation
system while remaining anchored to the cytoplasmic membrane
by the C-terminal hydrophobic extension of p3. Upon completion
of the extrusion of the phage particle, the p3 fusion protein is
incorporated into the tip of the phage coat in a complex with
p6 (ref. 5).
Many intra- or extracellular proteins with different sizes and
structures have been functionally displayed on ﬁlamentous phage2.
Nevertheless, numerous proteins are only poorly selected from phage
display libraries, because they are displayed with very low efﬁciency or
are refractory to display6. There are many reasons why a POI might
fail to be displayed6; for example, (i) the POI can aggregate in the
periplasm7,8 or cytoplasm, sometimes resulting in E. coli lysis9;
(ii) certain disulﬁde-containing proteins are displayed at lower levels
than their nondisulﬁde-containing counterparts, presumably because
of inefﬁcient folding as a result of nonnative disulﬁde bond
formation10; (iii) the POI can be refractory to translocation into the
periplasm because of incompatibility of local sequence stretches with
translocation11 and (iv) the POI or the linking peptide to p3 can be
degraded by periplasmic or cytoplasmic proteases.
Various attempts have been made to circumvent poor display. The
host-cell toxicity of the p3 fusion protein can be limited when its
expression is reduced12. Periplasmic folding of the POI has been
improved when phage display vectors coexpressing the periplasmic
chaperones Skp13 or FkpA14 have been employed. In phagemid/helper
phage systems2, wild-type p3 and the fusion protein compete for
incorporation into the phage particles. Therefore, to improve display
levels in these phagemid systems, different helper phages have been
engineered that encode either no wild-type p3, or defective or
proteolysis-sensitive p3 variants15–18. Interestingly, the display level of
the Stoffel fragment of Taq DNA polymerase (Taq) was improved by
partial randomization of the signal sequence of Erwinia carotovora
pectate lyase PelB (PelBss) and subsequent selection for increased
display, but the mechanism of the improvement was not investigated18.
Despite these numerous improvements in phage display, many
proteins still display poorly2,6. DARPins19,20, which have been success-
fully selected by ribosome display for speciﬁc binding to different
target proteins from corresponding combinatorial libraries21,22, were
virtually refractory to display on ﬁlamentous phage using a standard
phagemid. DARPins have no cysteines, can be expressed in soluble
form with high yields in the cytoplasm of E. coli, show high thermo-
dynamic stability20 and fast cooperative folding (S. Wetzel & A.P.,
unpublished data), and are very resistant to proteolysis (H.K. Binz &
A.P., unpublished data). We therefore reasoned that premature cyto-
plasmic folding of DARPins, and proteins with similar properties,
Received 30 November 2005; accepted 12 May 2006; published online 2 July 2006; doi:10.1038/nbt1218
1Department of Biochemistry, University of Zu¨rich, Winterthurerstrasse 190, 8057 Zu¨rich, Switzerland. 2Molecular Partners AG, c/o Department of Biochemistry,
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might result in their inefﬁcient translocation into the periplasm and,
as a consequence their poor display levels.
Three major pathways23 are known for the translocation of poly-
peptides across the cytoplasmic membrane into the periplasm of
Gram-negative bacteria: the Sec pathway23, the signal recognition
particle (SRP) pathway24–26 and the Tat pathway27,28. The respective
signal sequences strongly favor the targeting of proteins to one of
these pathways. The Sec pathway translocates polypeptides post-
translationally, whereas the SRP pathway translocates polypeptides
cotranslationally. These two pathways converge at the Sec translocon,
which transports the polypeptides in an unfolded state across the
cytoplasmic membrane. In contrast to these two pathways, the Tat
pathway translocates only folded proteins post-translationally through
the Tat translocon.
The majority of secreted E. coli proteins and phage p3 (ref. 29) use
the Sec-dependent translocation pathway. In early phage display
experiments using well-secreted proteins, such as antibody fragments,
the translocation or display levels showed no major systematic
dependence on the signal sequence used, but the only signal sequences
tested were Sec dependent30. Consequently, bacterial Sec-dependent
translocation signal sequences, such as those from PhoA or OmpA,
have been used predominantly in phage display.
The Sec pathway can transport only polypeptides that are kept in an
unfolded conformation, either by intrinsic features of the protein or
by the specialized cytoplasmic chaperone SecB, and perhaps other
cytoplasmic chaperones27. Therefore, this pathway is inherently incap-
able of translocating proteins that do not remain in an unfolded state
in the cytoplasm. We reasoned that such inefﬁcient translocation
could also lead to inefﬁcient display, thus rendering phage display
selections very inefﬁcient or even impossible for proteins that fold
prematurely in the cytoplasm.
Indeed, the rapidly folding cytoplasmic protein thioredoxin can be
translocated into the periplasm only at very low yields using the Sec-
dependent PhoA signal sequence (PhoAss)31. However, the signal
sequence of DsbA (DsbAss) efﬁciently allowed the translocation of
this rapidly folding protein into the periplasm32. It has been shown33
that the reason for this effect is that DsbAss directs the fused protein to
the cotranslational SRP pathway, thereby obviating inhibitory effects
of cytoplasmic protein-folding on translocation.
We found that DsbAss and other signal sequences that engage the
SRP pathway allow the efﬁcient display of DARPins on ﬁlamentous
phage, and strongly improve the display levels of a range of other
proteins. No negative effects of the SRP-directing signal sequences
were observed, suggesting that this method, termed SRP phage display,
is generally applicable to expand the range of proteins that can be
efﬁciently displayed on ﬁlamentous bacteriophage.
RESULTS
Phagemids with Sec- or SRP-type signal sequences
To test whether cotranslational translocation mediated by the SRP
pathway would improve display of proteins on ﬁlamentous phage
particles, compared to the post-translational translocation using the
Sec pathway, we constructed two phagemid series, which are identical
except for the signal sequence. They contained either the signal
sequence of E. coli PhoA (PhoAss), directing the p3 fusion proteins
to be displayed to the post-translational Sec pathway, or the signal
sequence of E. coli DsbA (DsbAss)33, directing the p3 fusion proteins to
be displayed to the cotranslational SRP pathway. All further elements
of the phagemids and their expression cassettes are described in detail
in Figure 1 and Supplementary Figure 1 online. To test the applic-
ability of the SRP translocation pathway for phage display, we cloned
genes encoding a range of proteins into both phagemids (Table 1).
Increased display yields using DsbAss
The display yields of p3 fusion proteins on phage particles were
compared between phage particles produced from phagemids differ-
ing only in the signal sequence (PhoAss versus DsbAss). Phage
particles were puriﬁed by CsCl-gradient centrifugation, and the dis-
play yields were analyzed by western blot analysis (Fig. 2a,b). A single-
chain Fv antibody (scFv) showed about the same display yield,
independent of the signal sequence used. In stark contrast, all four
DARPins tested could be efﬁciently displayed only when using the
DsbAss-containing phagemids; when using the PhoAss-containing
phagemids, we could not detect displayed protein for the nonbinding
DARPin E3_5 (unselected DARPin, without target speciﬁcity)20 or
only very low amounts for the other DARPins tested.
To test the scope of this increased display, we compared
several other proteins with the DsbAss and PhoAss. The use of
lacZ p/o
FLAG
ss
Protein of interest (POI)
myc
G/S
CTp3
TAG
LamBss
MalEss
MglBss
OmpAss
PelBss
PhoAss
DsbAss
SfmCss
TolBss
TorTss
SRP
Sec
Figure 1 Scheme of the expression cassette of the pDST phagemid vector
series. The expression cassette is composed of a promoter/operator element
of the lacZ gene of E. coli (lacZ p/o), the coding sequences for the signal
sequence (ss) and a protein of interest (POI) to be displayed, a suppressable
stop codon (TAG), the coding sequences for a ﬂexible glycine/serine linker
(G/S) and for the C-terminal domain (amino acids 250–406) of protein 3
of ﬁlamentous phage M13 (CTp3), mediating incorporation of the fusion
protein into the phage particle, two stop codons (TGATAA, not depicted) and
a transcription terminator element (not depicted). The coding sequence of
the POI is ﬂanked by DNA sequences encoding a FLAG-tag (FLAG) and a
myc-tag (myc). Shown are the single letter amino acid sequences for the
LamB signal sequence (LamBss), the MalE signal sequence (MalEss), the
MglB signal sequence (MglBss), the OmpA signal sequence (OmpAss), the
PelB signal sequence (PelBss) and the PhoA signal sequence (PhoAss) as
representatives of signal sequences targeting the Sec pathway (Sec), and for
the DsbA signal sequence (DsbAss), the TorT signal sequence (TorTss), the
SfmC signal sequence (SfmCss) and the TolB signal sequence (TolBss) as
representatives of signal sequences targeting the SRP pathway (SRP). The
positively charged N-terminal region (n-region), the apolar hydrophobic core
and the more polar C-terminal region (c-region) of the signal sequences are
highlighted. They were assigned by the method described49, as implemented
on the website http://www.cbs.dtu.dk/services/SignalP/. It should be noted
that the Sec dependence of PelBss is only putative.
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DsbAss-containing phagemids resulted in considerably higher display
yields for p3 fusions with the phage l coat protein D (gpD)34,
thioredoxin (TrxA) and aminoglycoside phosphotransferase IIIa
(APH). Slightly higher display yields were observed with the DsbAss
for the leucine zipper region of GCN4, Taq and the bacteriophage l
protein-phosphatase (lPP). In every case tested to date the display
level was either maintained or increased by switching from PhoAss to
DsbAss. Displayed c-jun N-terminal kinase 2a2 (JNK2) could not be
detected with either signal sequence, suggesting that for this protein,
lack of display is not due to premature folding (see below). These
results demonstrate that the SRP-dependent DsbAss strongly increased
display levels of p3 fusion proteins on phage particles for most
polypeptides tested.
To quantify the protein display yields (Fig. 3), we analyzed phage
particles displaying the target-speciﬁc APH-binding DARPin 3a or the
JNK2-binding DARPin 2_3 (refs. 21,22) by enzyme-linked immuno-
sorbent assay of phage (phage ELISA) (Fig. 3a). Phage particles
displaying DARPins speciﬁcally binding to the target proteins APH
and JNK2 were compared after production under identical conditions
from either DsbAss-containing phagemids or PhoAss-containing
phagemids. Based on the detection of bound phage particles with
an anti-M13 antibody, an increased display yield of up to 600-fold was
observed when the SRP-dependent DsbAss was used (Fig. 3a,d).
To exclude any dependence on the E. coli strain, we conﬁrmed these
results of DsbAss causing improved display yields (obtained in E. coli
XL1-Blue) with another strain. Thus we tested the genotypically
different E. coli strain TG1, frequently used in phage display (data
not shown; for genotypes and strain references, see Supplementary
Table 1 online).
Faster enrichment when using DsbAss
To demonstrate that the higher display yields obtained by using
DsbAss also dramatically improved selection experiments, we mixed
two test mixtures containing four different types of phage particles
produced from phagemids encoding either DsbAss or PhoAss in
various ratios. For both test mixtures, phage particles displaying the
target-speciﬁc DARPins 3a and 2_3 (binding the proteins APH and
JNK2, respectively)21,22 were spiked at a ratio of 1:107 into phage
Figure 2 Display yields of the various POIs
on phage particles. (a,b) CsCl-puriﬁed phage
particles produced by the use of the respective
phagemid indicated and normalized by UV
absorbance to the same number of phage
particles were separated by SDS-PAGE, blotted
onto PVDF membranes and detected with
antibodies speciﬁc for the C-terminal domain of
protein 3 (anti-p3) (a) or the FLAG-tag (M1 anti-
FLAG) located at the N terminus of the POI (b).
The abbreviated names of the polypeptides are
indicated on top of the lanes and refer to the
polypeptides listed in Table 1. The display yields
are compared for each polypeptide using either
the PhoA signal sequences (lanes labeled ‘p’)
or the DsbA signal sequence (lanes labeled ‘d’)
translocating the corresponding fusion protein by
the Sec pathway or the SRP pathway, respectively. The molecular weights of marker proteins are indicated in kDa at both sides of the blot. The band at
62 kDa in the anti-p3 blot corresponds to wild-type p3 and provides an additional normalization of the amount of phage particles loaded. Wild-type p3 is
well known50 to run at a seemingly higher MW. Note that DARPin E3_5-p3 fusion runs at an apparently lower MW than other DARPin-fusions. This is also
observed for this very stable protein in nonfused form, for which mass spectrometry indicated the expected mass, and may indicate incomplete denaturation
on the SDS gel, compared to the less stable E3_19 which runs at the expected MW.
Table 1 Description of proteins tested for display on the surface of ﬁlamentous bacteriophage
Phagemid
Acc. no.b,
Protein Abbr. PhoAss DsbAss Descriptiona references
scFv_gpD scFv pDST24 pDST31 E1 - T245 of single-chain Fv binding to gpD unpublished
DARPin 3a 3a pDST22 pDST23 D13 - Q166 of DARPin 3a binding to APH ref. 22
DARPin JNK2_2_3 2_3 pDST34 pDST37 D13 - Q133 of DARPin JNK2_2_3 binding to JNK2 ref. 21
DARPin E3_5 E3_5 pDST30 pDST32 D13 - Q166 of nonbinding DARPin E3_5 GB: AAO25689, ref. 20
DARPin E3_19 E3_19 pDST65 pDST66 D13 - Q166 of nonbinding DARPin E3_19 GB: AAO25690, ref. 20
GCN4 GCN4 pDST39 pDST40 GCN4 derivative (RMKQLEDKVELLPKNYHLENEVARLKKLVGER) SP: P03069
pDDN2 gpD pDST41 pDST42 T21 - V110 of the capsid stabilizing protein of bacteriophage l SP: P03712
JNK2a2 JNK2 pDST45 pDST46 S2 - R424 of c-jun N-terminal kinase 2 (JNK2a2) SP: P45984
TrxA TrxA pDST47 pDST48 S1 - A108 of thioredoxin (trxA gene of E. coli) SP: P00274
Taq polymerase Taq pDST51 pDST52 S290 - E832 Stoffel fragment of Taq DNA polymerase SP: P19821
l-phosphatase lPP pDST53 pDST54 M1 - A221 of bacteriophage l Ser/Thr protein-phosphatase SP: P03772
APH APH pDST55 pDST56 A2 - F264 of aminoglycoside phosphotransferase (C19S, C156S, S194C) SP: P0A3Y5
aThe ﬁrst and last amino acid used are indicated in single letter amino acid code. bAccession numbers: GB, GenBank; SP, Swiss-Prot. DARPin, designed ankyrin-repeat protein; DsbAss, DsbA signal
sequence; PhoAss, PhoA signal sequence; scFv, single-chain Fv antibody fragment.
DARPins
An
ti-
p3
M
1 
an
ti-
FL
AG
scFv 3a 2_3 E3_19 E3_5 GCN4 gpD TrxA Taq APH JNK2
p dp dp dp dp dp dp dp dp dp dp dpkDa
83
62
47.5
32.5
83
62
47.5
32.5
kDa
83
62
47.5
32.5
83
62
47.5
32.5
d
λPP
a
b
NATURE BIOTECHNOLOGY VOLUME 24 NUMBER 7 JULY 2006 825
A R T I C L E S
18 Chapter 2
particles displaying the nonbinding DARPins E3_5 and E3_19 (un-
selected DARPins, without target speciﬁcity)20 (Table 2). Whereas the
APH- and JNK2-speciﬁc phage particles could be enriched from the
test mixture produced from DsbAss-encoding phagemids by a factor
of more than 1,000 per selection cycle (410% of the tested clones
were speciﬁc for their target after only two cycles of selection, as
determined by PCR with clone-speciﬁc primers), the corresponding
PhoAss-containing APH- and JNK-speciﬁc phagemids were not
enriched from the test mixture even after ﬁve selection cycles (no
speciﬁc clones were observed). To quantify the enrichment of phage
particles produced from phagemids encoding PhoAss, we spiked the
phage particles displaying target-speciﬁc DARPins at much lower
dilution (1:100 and 1:10) into phage particles displaying the non-
binding DARPins E3_5 and E3_19. One cycle of standard phage
display selections on the target proteins APH and JNK2 was per-
formed (Table 2). The enrichment of APH- and JNK2-speciﬁc phage
particles from these test mixtures was less than a factor of 10 per cycle
for PhoAss, as calculated from the number of speciﬁc clones. This
observed improvement in enrichment of 4100-fold in DsbAss-
containing compared to PhoAss-containing phage particles corre-
sponds well to the several hundredfold increased display level
observed by western blot analysis (Fig. 2) and quantitative ELISA
measurements (Fig. 3a,d).
Other SRP-type signal sequences increase display
To analyze if the SRP-dependence of the signal sequence is really the
key determinant for the observed increased display levels using
DsbAss, we tested additional signal sequences known to direct proteins
either to the SRP pathway or the Sec pathway. The phagemids
encoding the target-speciﬁc DARPins 3a and 2_3 (binding APH and
JNK2, respectively) were adapted by exchanging the signal sequences.
We additionally used the SRP-dependent signal sequences of the
E. coli proteins TolB (TolBss), SfmC (SfmCss) and TorT (TorTss)35
(Fig. 1). The E. carotovora PelB signal sequence (PelBss), which
is frequently used in phage display, was also tested and is probably Sec
dependent because it lacks a strongly hydrophobic region, a
typical feature of SRP-dependent signal sequences35. To quantify the
difference in display levels, the corresponding phage particles were
analyzed by phage ELISA (Fig. 3b–d) as described above. An increased
display yield of up to 700-fold was observed for the SRP-dependent
TorTss, compared to the Sec-dependent PhoAss. The SRP-dependent
SfmCss and TolBss gave an increased display yield up to 300-fold.
The putative Sec-dependent PelBss showed only a two- to sixfold
increased display yield, compared to PhoAss. For all SRP-dependent
signal sequences the ELISA readings obtained for phages displaying
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Figure 3 Increased display yields using SRP-dependent signal sequences. (a–c) The display yields
of the APH-binding DARPin 3a (ﬁlled symbols) or the JNK2-binding DARPin 2_3 (open symbols)
on phage particles were analyzed by phage ELISA. The signal from target-bound phage particles is
shown as a function of the number of phage particles applied per well. The display yields of phage
particles produced from phagemid variants encoding SRP-dependent signal sequences (SRP; DsbAss,
TorTss, TolBss or SfmCss) were compared to phage particles produced from phagemid variants
encoding Sec-dependent signal sequences (Sec; PhoAss or PelBss). The Sec dependence of PelBss
is only putative. (d) Quantiﬁcation of the ELISA data depicted in a–c. The increase in display level
(fold increase) for each signal sequence used corresponds to the number of phage particles giving a
signal of OD450 ¼ 0.5 relative to the number of PhoAss-containing phage particles giving a signal of
OD450 ¼ 0.5.
Table 2 Enrichment of phages displaying target-speciﬁc DARPinsa
Round of phage selection
(positive colonies/number of
colonies tested)b
Signal seq.
of phagemid Dilution Antigen 1st 2nd 3rd 4th 5th
DsbAss 1:107 APH 0/14 4/16 14/14 – –
JNK2 0/14 2/16 14/14 – –
PhoAss 1:107 APH 0/11 0/15 0/14 – 0/9
JNK2 0/14 0/16 0/14 – 0/11
1:102 APH 2/16 – – – –
JNK2 1/16 – – – –
1:101 APH 4/16 – – – –
JNK2 7/16 – – – –
aInput mixtures produced from phagemids encoding either PhoAss or DsbAss were produced
as described in Methods. To a 1:1 mixture of phage particles displaying the nonbinding
DARPins E3_5 and E3_19, phage particles displaying the target-speciﬁc DARPins 3a
(recognizing APH) or 2_3 (recognizing JNK2) were added in a 1:107 dilution for both mixtures
and, additionally, in 1:100 and 1:10 dilutions for the mixtures generated from phagemids
encoding the PhoAss. bColonies were screened by PCR using primers speciﬁc for the DARPins
3a or 2_3.
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the DARPin 3a were always somewhat lower than for the phages
displaying the DARPin 2_3.
Periplasmic levels of POIs correlate with display
We further wanted to investigate whether the increased display of
these proteins on phage particles correlates with elevated translocation
of these proteins to the periplasm and is not just caused by higher
cytoplasmic protein translation yields. We therefore expressed the
proteins from identical phagemids as used above (Table 2) in
the nonsuppressor E. coli strain JM83. In contrast to the suppressor
strain XL1-Blue, which is used for phage production, this nonsup-
pressor strain prevents read-through of the amber stop codon after the
C terminus of the POI (Fig. 1). Whole cell extracts or periplasmic
fractions were analyzed by western blotting (Fig. 4). To determine the
total amount of POI, we used the C-terminal myc-tag of the precursor
and mature protein for detection. The amount of periplasmically
located, mature POI was additionally determined with the anti-FLAG
antibody M1 that selectively recognizes the N-terminal FLAG-tag of
the mature POI (Fig. 1)—precise cleavage of the signal sequence after
translocation is required before this antibody can recognize the freely
accessible a-amino group as part of the FLAG tag of the mature POI36.
Detection of mature and precursor protein with the anti-myc
antibody showed that the total protein expression of the different
POIs is only inﬂuenced to a small extent by the signal sequence
(Fig. 4a). However, the translocation into the periplasm depends
directly on the signal sequence (Fig. 4b,c). As expected, the signals of
the periplasmic fractions detected with the anti-myc antibody
(Fig. 4b) on western blots correlated well with the signals from
whole-cell western blots developed with the anti-FLAG antibody M1
(Fig. 4c), which detects only mature protein. The mature protein is
thus located in the periplasm. Importantly, precursors of several
fusion proteins are accumulating in the cytoplasm when using PhoAss,
but not when using DsbAss, as seen in the whole cell blots with
detection of the C-terminal myc-tag (Fig. 4a).
Independent of the signal sequence used, the scFv antibody frag-
ment is well translocated across the cytoplasmic membrane. In stark
contrast, all four tested DARPins could be efﬁciently translocated only
when using the DsbAss-containing phagemids, and almost no protein
translocation could be detected when using the PhoAss-containing
phagemids. In agreement with previous observations32,33, the expres-
sion of TrxA from DsbAss-containing phagemids resulted in consid-
erably higher translocation yields. Only moderately higher
translocation yields were observed for Taq, phage l protein-
phosphatase (lPP) and phage l coat protein D (gpD). The unfused
zipper region of GCN4 could not be detected in any of the western
blots because of its small size. Very low translocation levels were
detected for APH. For JNK2a2, only small amounts of protein were
detected in the periplasmic fraction with the anti-myc antibody
(JNK2, Fig. 4b), whereas a number of insoluble degradation products
were detected with the anti-FLAG antibody M1 (JNK2, Fig. 4c),
suggesting that this degradation may lead to low display (Fig. 2).
When these results are compared to those in Figure 2, a strong
correlation between the translocation yields and the display levels of
the different POIs is observed.
Other Sec-type signal sequences cause low display
We analyzed additional signal sequences known to direct proteins to
the post-translational Sec-dependent translocation pathway. We chose
as the proteins to be displayed DARPin E3_5, a protein with very high
thermodynamic stability, and TrxA, a protein previously shown to be
efﬁciently translocated only by SRP-dependent signal sequences35. The
corresponding phagemids were adapted by exchanging the signal
sequences to the SRP-dependent signal sequences (TolBss, SfmCss or
TorTss), the Sec-dependent signal sequences (LamBss, MalEss, MglBss
or OmpAss)23 or the putative Sec-dependent PelBss (Fig. 1). To
compare the difference in display levels, we analyzed the correspond-
ing phage particles by western blotting (Fig. 5a). For DARPin E3_5
essentially no displayed protein could be detected with any of the
Figure 4 Protein translation and translocation
of the various unfused POIs to the periplasm.
(a–c) Whole cell and periplasmic extracts from
nonsuppressor E. coli JM83 cells, harboring the
respective phagemid and normalized to the same
amount of cells, were separated by SDS-PAGE,
blotted onto PVDF membranes and detected with
antibodies speciﬁc for the C-terminal myc-tag
(anti-myc) (a,b) and the N-terminal FLAG-tag
(M1 anti-FLAG) (c). The anti-FLAG antibody M1
selectively recognizes the N-terminal FLAG-tag
of the processed, mature POI (Fig. 1) having
a freely accessible a-amino group. The protein
translation and translocation yields are compared
for each polypeptide using either the PhoA signal
sequence (lanes labeled ‘p’) or the DsbA signal
sequence (lanes labeled ‘d’) to translocate the
corresponding protein by the Sec pathway or
the SRP pathway, respectively. The abbreviated
names of the polypeptides are indicated on top of
the lanes and refer to the polypeptides listed in
Table 1; for all other abbreviations see Figure 2.
Mature protein (open triangles) and precursor
protein (closed triangles) are indicated where
possible. The degradation products of JNK2
detected with the anti-FLAG antibody M1 in
whole cell extracts (c) could not be detected in the periplasmic fraction with the same antibody (data not shown), suggesting that the degradation products
are insoluble and pelleted during centrifugation.
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Sec-dependent signal sequences used, whereas all SRP-dependent
signal sequences gave display levels in the same range as found for
DsbAss (Figs. 2 and 5a). For TrxA the display yields were also
considerably higher for all SRP-dependent signal sequences tested than
for Sec-dependent signal sequences. However, in contrast to the
DARPin E3_5, where almost no displayed protein could be detected
for the Sec-dependent signal sequences, TrxA was displayed at mod-
erate levels when using the Sec-dependent MalEss, MglBss and
OmpAss and the putative Sec-dependent PelBss, yet substantially
lower than with the SRP-dependent signal sequences.
The periplasmic expression yields of the DARPin E3_5 and TrxA
correlate well with the display levels observed (Fig. 5a,b) and are also
higher for all SRP-dependent signal sequences than for the Sec-
dependent ones. This effect is not caused by increased protein
translation (Fig. 5b).
DISCUSSION
Some polypeptides are refractory to conventional ﬁlamentous phage
display because of their individual molecular properties. The reasons
have generally not been elucidated2. This
makes the success of the display of a parti-
cular polypeptide unpredictable.
A unique aspect of ﬁlamentous phage
assembly, in contrast to the assembly of
many other bacteriophages, is that it is
a secretory process. Incorporation of the
coat proteins into the growing phage
particle occurs in the cytoplasmic membrane,
and nascent phages are extruded from the
cell as they assemble2. This phage assembly
mechanism requires that the POI is translo-
cated across the cytoplasmic membrane
into the periplasm to be displayed on the
phage particle.
In conventional ﬁlamentous phage display,
signal sequences directing the POI to the Sec
pathway23 are used for translocation. In this
pathway, the polypeptide is ﬁrst synthesized
by the ribosome and then post-translationally
translocated, in its unfolded state, by the Sec
translocon. This post-translational transloca-
tion poses a challenge for keeping the protein
in a transport-competent, unfolded state.
Transport capability may be achieved by
intrinsic features of the polypeptide or by
its interaction with the specialized cytoplas-
mic chaperone SecB and perhaps other
cytoplasmic chaperones27. However, such
mechanisms may not be effective for fast-
folding and stable proteins; they may fold
prematurely in the cytoplasm making them
translocation incompetent.
By merely exchanging the signal sequence
targeting the Sec pathway (e.g., LamBss,
MalEss, MglBss, OmpAss or PhoAss) by
one targeting the SRP pathway (e.g., DsbAss,
SfmCss, TolBss and TorTss) in a standard
phage display system, we were able to
increase the functional display levels for
numerous proteins up to 700-fold (Fig. 3),
resulting in enrichment factors per selection
round of more than 1,000 (Table 2). This increase of the display levels
correlates well with an increase of translocation across the cytoplasmic
membrane into the periplasm and is not caused by an overall increase
in protein translation (Fig. 4).
Similar improvements of periplasmic expression levels when using
the SRP pathway instead of the Sec pathway for protein translocation
to the periplasm were described with the model protein TrxA33,35.
Using a total of ten signal sequences, targeting either the Sec or the
SRP pathway, we were able to demonstrate in the present study that
the improvements in display were indeed a result of the targeted
translocation pathway and not caused by individual properties of a
particular signal sequence (Fig. 3).
For all proteins tested, the display levels on phage particles using
SRP-dependent signal sequences were greater than or at least equal to
those obtained using the Sec-dependent signal sequences (Figs. 2 and
5). This is also true for proteins, such as an scFv-fragment, that are
already very well displayed using the conventional Sec-dependent
signal sequences. These ﬁndings strongly suggest that the use of the
cotranslational SRP pathway substantially expands the range of
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Figure 5 Display yields and periplasmic translocation of DARPin E3_5 and TrxA using various Sec- and
SRP-dependent signal sequences. (a) Phage particles, produced by the use of the respective phagemid
indicated and normalized by UV absorbance to the same number of phage particles, were separated by
SDS-PAGE, blotted onto PVDF membranes and detected with antibodies speciﬁc for the myc-tag (anti-
myc), located at the C terminus of the POI, or the FLAG-tag (M1 anti-FLAG), located at the N terminus
of the POI. (b) Whole cell extracts from JM83 cells harboring the respective phagemid indicated were
analyzed as described for Fig. 3a,c. The display, protein translation and translocation yields for DARPin
E3_5 and TrxA are compared between phagemids encoding Sec-dependent signal sequences (Sec;
LamBss, MalEss, MglBss, OmpAss, PelBss or PhoAss) and SRP-dependent signal sequences (SRP;
DsbAss, TorTss, TolBss or SfmCss). The Sec dependence of PelBss is only putative. SDS-PAGE of the
phage particles produced from phagemids encoding the DARPin E3_5 and whole cell extracts from
JM83 cells harboring the phagemids encoding the DARPin E3_5 were run at 60 1C to reduce the
partial refolding and therefore smearing of this very stable protein during separation. Control lane:
the phagemid encoding the scFv with PhoAss was used as control for western blotting of phage
particles or of whole cell extracts.
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proteins that can be efﬁciently displayed on phage particles without
having negative effects on already well-displayed proteins.
It is reasonable to assume that cotranslational SRP-dependent
translocation obviates the inhibitory effect of premature cytoplasmic
protein folding on translocation and thereby allows the display of fast-
folding and stable proteins that could not be displayed using the post-
translational Sec pathway (Figs. 2 and 5a). These latter proteins are
efﬁciently displayed only when SRP-dependent signal sequences are
used. Oxidized TrxA, for example, has a high DGo value of 8.1 kcal/
mol and a very fast burst phase in folding with a ﬁrst-order rate
constant of 400 s–1 (ref. 37).
DARPins possess even higher thermodynamic stabilities than TrxA
and have folding rates within the same order of magnitude. Thermal
and denaturant-induced unfolding studies revealed Tm values above
66 1C, and DG values between 9.5 and 21.1 kcal/mol. In addition,
DARPins show fast folding with ﬁrst-order rate constants around
800 s–1 (S.Wetzel & A.P., unpublished data). Interestingly, the less
stable DARPin E3_19 (DG value of 9.6 kcal/mol) is still displayed at
some low level when using Sec-dependent signal sequences, whereas
the more stable DARPin E3_5 (DG value of 14.8 kcal/mol) is
essentially not displayed (Figs. 2 and 5a). Interestingly, TrxA variants
having slower folding rates and lower thermodynamic stabilities than
the wild-type protein also show improved translocation by the Sec
pathway38. In line with our hypothesis, much higher display levels are
seen for TrxA wt when the SRP-dependent signal sequences are used
(Fig. 2). Whereas the Sec-dependent signal sequences do not enable
translocation of DARPin E3_5 and translocate TrxA only at a low level,
SRP-dependent signal sequences translocate both proteins, only at a
much higher level (Fig. 5b).
The SRP-dependent signal sequence only moderately improved the
display level for gpD, a protein with a DGo value of 5.1 kcal/mol39 and
a moderate folding rate with the fastest phase estimated at 5 s–1 (P.F. &
A.P., unpublished data). In contrast, antibody fragments can be
translocated and displayed equally well with the Sec- or SRP-
dependent signal sequences (Figs. 2 and 4). For antibody fragments,
no evidence of a decrease in translocation with increasing thermo-
dynamic stability is apparent40, presumably because the fastest phases
of folding of these proteins do not exceed 10 s–1 (ref. 41), and folding
rates of many such molecules are much smaller.
Proteins that need cytoplasmic cofactors for folding or function
may be refractory to display using the SRP translocation pathway. A
recently described phage display system based on the post-
translational Tat translocation pathway42 might be better suited for
the display of such proteins. Because it has been proposed that p3 itself
cannot be displayed with the Tat system42, the POI may have to be
secreted separately and then assembled in the periplasm. A general
limitation of this Tat-based approach is that only folded proteins can
be translocated through the Tat translocon43. For example, disulﬁde-
containing proteins such as antibody fragments can be secreted with
the Tat system, and presumably displayed, only from a strain that
allows disulﬁde formation in the cytoplasm43.
As with any selection technology, the success of phage display
selections strongly depends on the diversity of functionally displayed
library members. A large combinatorial DNA library alone does not
guarantee great functional diversity. We propose that SRP phage
display could increase the functional diversity of many libraries,
especially those expected to contain members with widely different
folding rates and stabilities, such as for example, cDNA libraries.
With SRP phage display, selections from such libraries
can probably be performed with similar enrichment factors and
numbers of selection rounds as typical for ‘Sec-compatible’ proteins
and peptides. The enrichment factor for displaying DARPins was
increased from about 10 to over 1,000 by switching to SRP phage
display (Table 2).
We envision that SRP phage display will be applicable to all
variants of phagemid or phage-based systems12,15–18,44,45, including
monovalent or polyvalent display, and will be compatible with all
ﬁlamentous-phage coat proteins used for display. SRP phage display
requires only the POI to be rerouted to the SRP pathway by simply
exchanging the signal sequence. CysDisplay45 and pJuFo phage
display44, two methods in which the POI is disulﬁde linked but not
directly fused to p3, may also beneﬁt from the SRP pathway. In these
systems, the POI would be translocated by the SRP pathway, whereas
the corresponding phage coat protein could still be translocated by
the conventional Sec pathway, in analogy to the strategy described for
the Tat pathway42.
We identiﬁed post-translational protein translocation across the
cytoplasmic membrane as a major bottleneck of conventional ﬁla-
mentous phage display. By redirecting the fusion proteins to the
cotranslational SRP pathway using an appropriate signal sequence, we
achieved efﬁcient display of a wide range of POIs, presumably by
avoiding premature folding in the cytoplasm. In particular, highly
stable and fast-folding POIs were refractory to display using a Sec-
dependent signal sequence, but can be efﬁciently displayed using a
SRP-dependent signal sequence. In all cases tested the protein display
levels were either maintained or improved by using a SRP-directing
signal sequence. Therefore, this method seems to be a simple and
broadly applicable way to expand the range of proteins that can be
efﬁciently displayed and selected on ﬁlamentous phage.
METHODS
Materials. All chemicals were of the highest quality and purchased from Fluka
unless stated otherwise. Oligonucleotides were from Microsynth. Vent DNA
polymerase, restriction enzymes and buffers were from New England Biolabs or
Fermentas. Helper phage VCS M13 was from Stratagene. All cloning and phage
ampliﬁcation was performed in E. coli XL1-Blue from Stratagene. Additionally,
E. coli TG1 was used for phage production. Periplasmic protein expression was
examined in the nonsuppressor E. coli strain JM83 obtained from the American
Type Culture Collection. Genotypes and references for the E. coli strains used
are described in the Supplementary Table 1 online.
Molecular biology. Unless stated otherwise, all molecular biology methods
were performed according to standard protocols46.
Cloning. The phagemid vectors (plasmids with phage origin) that were
prepared for the present study are described in detail in the Supplementary
Methods online. The DNA encoding the proteins to be displayed was inserted
into phagemids encoding either PhoAss or DsbAss, resulting in the phagemids
listed in Table 1. The ﬁrst and the last amino acids of the cloned proteins of
interest are given in Table 1 as well as the reference or accession number for
either GenBank or Swiss-Prot databases.
For the DARPins 3a and 2_3, phagemids encoding the PelBss (pDST80 and
pDST81, respectively), SfmCss (pDST86 and pDST87, respectively), TolBss
(pDST84 and pDST85, respectively) and TorTss (pDST88 and pDST89,
respectively) were generated.
For the DARPin E3_5 and thioredoxin (TrxA), phagemids encoding the
LamBss (pDST110 and pDST117, respectively), MalEss (pDST109 and
pDST116, respectively), MglBss (pDST111 and pDST118, respectively),
OmpAss (pDST103 and pDST104, respectively), PelBss (pDST105 and
pDST112, respectively), SfmCss (pDST108 and pDST115, respectively), TolBss
(pDST106 and pDST113, respectively) and TorTss (pDST107 and pDST114,
respectively) were generated. All signal sequences used are described in detail in
Supplementary Table 2 online.
Phage production and puriﬁcation. The protocols were adapted from refs.
47 and 48. Five ml 2 YT medium containing 1% glucose, 34 mg/ml
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chloramphenicol (cam) and 15 mg/ml tetracycline (tet) was inoculated with a
single colony of E. coli XL-1 Blue harboring the phagemid of interest, and the
cells were grown overnight at 30 1C with shaking. Five ml fresh 2 YTmedium
containing 1% glucose, 34 mg/ml cam and 15 mg/ml tet was inoculated with the
overnight cultures at a ratio of 1:100 (OD600E 0.04) and grown at 37 1C to an
OD600 of 0.5 with shaking. The cultures were infected with VCS M13 helper
phage at 1010 (at plaque forming units per ml (multiplicity of infectionB 20)
and the cells were incubated for 30 min at 37 1C without agitation and then for
30 min at 37 1C with shaking. The medium was changed by harvesting the cells
by centrifugation (3,500g, 24 1C, 10 min) and resuspending the pellet in 50 ml
of 2 YT medium containing 34 mg/ml cam, 50 mg/ml kanamycin (kan)
and 0.1 mM isopropyl-b-D-thiogalactoside (IPTG). After growth for 14 to
16 h at 30 1C with shaking, the cells were removed by centrifugation (5,600g,
4 1C, 10 min).
The culture supernatant was incubated on ice for 1 h with one-fourth
volume of ice-cold PEG/NaCl solution (20% polyethyleneglycol (PEG) 6000,
2.5 M NaCl). The precipitated phage particles were then collected by centri-
fugation (5,600g, 4 1C, 15 min) and redissolved in 1 ml of TBS150 (25 mM Tris/
HCl, 150 mM NaCl, pH 7.5). The phage particles were further puriﬁed by
CsCl-gradient centrifugation as described13. The total concentration of phage
particles was quantiﬁed spectrophotometrically48. The infective titer of the
phage samples was determined by titration on E. coli XL-1 Blue cells using
2 YT agar plates containing 1% glucose, 34 mg/ml cam and 15 mg/ml tet.
The colonies were counted after overnight incubation at 37 1C.
Phage blots.We applied 5  1011 phage particles, puriﬁed by CsCl gradient, to
15% SDS-PAGE under reducing conditions and transferred them to polyviny-
lidene ﬂuoride (PVDF) Immobilon-P Transfer Membranes (Millipore) by
electroblotting. The membranes were blocked with MTTBS150 (TBS150, 0.1%
Tween-20, 5% skimmed milk) for 1 h at about 22 1C and incubated with a
mouse anti-p3 antibody (MoBiTec) (1:1,000 in MTTBS150, 20 min at about
22 1C) as primary antibody, which recognizes the C-terminal domain of p3.
A F(ab¢)2 fragment goat anti-mouse IgG horseradish peroxidase conjugate
(Pierce) (1:10,000 in MTTBS150, 1 h at about 22 1C) was used as the
secondary antibody. The proteins were detected with ChemiGlow West sub-
strate (Alpha Innotech).
In a second experiment, the blocked membranes were incubated with mouse
anti-FLAG antibody M1 (Sigma) (1:5,000 in MTTBS150, 1 h at about 22 1C) as
primary antibody. A goat anti-mouse IgG alkaline phosphatase conjugate
(Sigma) (1:10,000 in MTTBS150, 1 h at about 22 1C) was used as secondary
antibody. The proteins were detected with the substrates 5-bromo-4-chloro-3-
indolyl phosphate (BCIP) and nitroblue tetrazolium (NBT).
Phage ELISAs. Phage ELISAs were carried out to assay the amount of
functionally displayed DARPins on M13 phage particles. The targets, biotiny-
lated APH and JNK2 proteins21, were immobilized as follows: Neutravidin
(66 nM, 100 ml/well; Pierce) in TBS150 was immobilized on MaxiSorp plates
(Nunc) by overnight incubation at 4 1C. The wells were blocked with 300 ml
BTTBS150 (TBS150, 0.1% Tween-20, 1% BSA) for 1 h at about 22 1C. Binding of
the biotinylated APH and JNK2 proteins (100 ml, E 1 mM) in BTTBS150 was
done for 1 h at 4 1C.
Dilution series of phage particles in BTTBS150 were pipetted to the wells
and incubated at about 22 1C for 2 h. After washing the wells ﬁve times with
300 ml TTBS150 (TBS150, 0.1% Tween-20) for 5 min, bound phage particles
were detected with mouse anti-M13 antibody horseradish peroxidase
conjugate (Amersham Pharmacia Biotech) and soluble BM Blue POD substrate
(Roche Diagnostics).
Phage panning. Phage particles displaying DARPins E3_5, E3_19, 3a and 2_3
were produced from either phagemids encoding the PhoAss (pDST30, pDST65,
pDST22 and pDST34, respectively) or from phagemids encoding the DsbAss
(pDST32, pDST66, pDST23 and pDST37, respectively). These phage particles
were subsequently mixed according to the experiment. To a 1:1 mixture of
phage particles displaying the nonbinding DARPins E3_5 and E3_19, phage
particles displaying the target-speciﬁc DARPins 3a or 2_3 were added in 1:107
dilutions (for phage particles produced from phagemids encoding the PhoAss,
additionally in 1:100 and 1:10 dilutions).
Biotinylated APH and JNK2 proteins were coated as described for the phage
ELISAs. To each well, 0.1 ml of phage particle mixtures (1013 colony-forming
units/ml) and 0.1 ml BTTBS150 were added and incubated for 2 h. After
washing with TTBS150 (3 for the ﬁrst selection cycle, 4 for the second cycle
and 5 for additional cycles) for 5 min and with TBS150 (3 for the ﬁrst
selection cycle, 4 for the second cycle and 5 for additional cycles) for 5 min,
the phage particles were eluted by incubating for 15 min with 0.2 ml elution
buffer (0.2 M glycine/HCl, pH 2.2) at about 22 1C, followed by an elution for
30 min with 0.2 ml trypsin (10 mg/ml in TBS150) at 37 1C. The combined
eluates (neutralized with 10 ml of 2 M Tris-base) were used for the infection of
4 ml of exponentially growing E. coli XL1-Blue cells. After 30 min at 37 1C
without agitation and 30 min at 37 1C with shaking, the cells were spread on
2 YT agar plates containing 1% glucose and 34 mg/ml cam and 15 mg/ml tet
and grown overnight at 37 1C. The cells were washed from the plates with 2
YT containing 1% glucose, 15% glycerol, 34 mg/ml cam and 15 mg/ml tet and
used for the phage production for the next cycle of panning. After each panning
cycle, the identity of 9 to 16 eluted phage particles was determined. This was
done by infection of E. coli with these phage particles and screening of the
colonies by PCR with clone-speciﬁc primers.
Western blot analysis of cellular extracts. Five ml 2 YTmedium containing
1% glucose, 34 mg/ml cam and 15 mg/ml tet were inoculated with a single
colony of E. coli JM83 harboring the phagemid of interest and grown overnight
at 30 1C with shaking. Fresh 5 ml 2 YT medium containing 1% glucose,
34 mg/ml cam and 15 mg/ml tet were inoculated with the overnight cultures at a
ratio of 1:100 (OD600 E 0.04) and grown at 37 1C to an OD600 of 0.5. The
medium was changed by harvesting the cells by centrifugation (3,500g, 24 1C,
10 min) and resuspending the pellet in 50 ml of 2 YT medium containing
34 mg/ml cam and 0.1 mM isopropyl-b-D-thiogalactoside (IPTG). After growth
for 14 to 16 h at 30 1C with shaking, the cells were harvested by centrifugation
(5,600g, 4 1C, 10 min) for the whole cell extracts or treated as described35 for
subcellular fractionation.
Western blot analysis of the whole cell extracts and periplasmic fractions was
carried out as described above. The blocked membrane was either incubated
with mouse anti-FLAG antibody M1 (Sigma) (1:5,000 in MTTBS150, 1 h at
about 22 1C) or mouse anti-myc antibody (Cell Signaling Technology) (1:1,000
in MTTBS150, 1 h at about 22 1C) as primary antibodies, then goat anti-mouse
IgG alkaline phosphatase conjugate as secondary antibody. The proteins were
detected with the substrates BCIP and NBT.
Note: Supplementary information is available on the Nature Biotechnology website.
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Supplementary Material 
Supplementary Methods 
Phagemid cloning. The phagemid pDST22, a derivative of the vector pMorph7 (ref. 1) 
which is functionally equivalent to the vector pAK100 (ref. 2) was the starting point for the 
cloning (Supplementary Fig. 1). It encodes the DARPin 3a and the signal sequence of the E. 
coli PhoA (PhoAss). The E. coli alkaline phosphatase (Swiss-Prot database accession number 
P00634) has the signal sequence MKQSTIALALLPLLFTPVTKA, given in single letter amino 
acid code. 
To allow direct experimental comparison to phagemids encoding the signal sequence of 
DsbA (DsbAss), a second phagemid called pDST23 was generated. The E. coli thiol-disulfide 
interchange protein DsbA (Swiss-Prot database accession number P0AEG4) has the signal 
sequence MKKIWLALAGLVLAFSASA, given in single letter amino acid code. To replace the 
PhoAss of pDST22, the oligonucleotides oDST4 (AGAGCATGCGTAGGAGAAAATAAAAT 
GAAAAAGATTTggctggcgctggctgg), oDST5 (TCTTTGTAGTCCGCCGATGCGCTAAACGC 
TAAAACTAAAccagccagcgccagcc), oDST6 (GCTCTagagcatgcgtaggag (XbaI)), and oDST8 
(GCGGATCCAtctttgtagtccgccg (BamHI)) that encode the E. coli DsbAss were designed (Lower 
case letters indicate the regions designed for annealing, restriction sites are underlined and 
restriction enzymes given in brackets).  
The oligonucleotides oDST4 and oDST5 were annealed and amplified with 
oligonucleotides oDST6 and oDST8 by PCR. The resulting DNA fragment encodes the DsbAss 
and is flanked by the restriction endonuclease sites XbaI and BamHI. This DNA fragment was 
digested with XbaI and BamHI and ligated into the similarly treated and dephosphorylated 
pDST22. The resulting phagemid pDST23 (Supplementary Fig. 1) was isolated and the 
sequence was verified by DNA sequencing. 
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The other phagemids used in this study are listed in Table 1 of the publication and were 
obtained as follows: The coding sequences of the proteins of interest were PCR amplified using 
appropriately designed PCR primers and template DNA. Thereby, either a BamHI or a BglII 
restriction site was introduced 5’ to each of the coding sequences and two restriction sites (EcoRI 
and PstI) were introduced 3’ to each of the coding sequences. These PCR fragments were 
digested either with BamHI or BglII and either EcoRI or PstI, and then ligated into the similarly 
treated and dephosphorylated phagemids pDST23 and pDST22. The open reading frame of the 
expression cassette for the fusion polypeptide comprising the cloned PCR product was 
maintained for all constructs, especially the correct reading frame for the C-terminal fusion to the 
C-terminal domain of phage protein 3 (CTp3) was maintained. The first and the last amino acids 
of the cloned proteins of interest (POI) are given in Table 1 of the publication as well as the 
reference or accession number for either the GenBank or the Swiss-Prot databases. The sequence 
of all phagemids was verified by DNA sequencing. 
For the designed ankyrin proteins (DARPins) 3a and 2_3, additional phagemids encoding 
the PelBss (pDST80 and pDST81, respectively), SfmCss (pDST86 and pDST87, respectively), 
TolBss (pDST84 and pDST85, respectively) and TorTss (pDST88 and pDST89, respectively) 
were generated, using the same cloning strategy with 4 oligonucleotides as described above for 
DsbAss, using appropriate oligonucleotides. 
For the DARPin E3_5 and thioredoxin (TrxA), additional phagemids encoding the 
LamBss (pDST110 and pDST117, respectively), MalEss (pDST109 and pDST116, respectively), 
MglBss (pDST111 and pDST118, respectively), OmpAss (pDST103 and pDST104, 
respectively), PelBss (pDST105 and pDST112, respectively), SfmCss (pDST108 and pDST115, 
respectively), TolBss (pDST106 and pDST113, respectively) and TorTss (pDST107 and 
pDST114, respectively) were generated. Again, the same strategy as for DsbAss was used. 
 Signal sequences used are described in detail in Supplementary Table 2 and E. coli 
strains used are described in detail in Supplementary Table 1. 
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Supplementary Table 1: E. coli strains 
Name Genotype Ref 
JM83 F- ara ∆(lac-proAB) rpsL (Strr)[Φ80, lacZ∆M15] thi a 
TGl F' [laclq lacZ∆M15 proAB+ traD36] hsd∆5 ∆(lac-proAB) supE thi b 
XL1-Blue F' [lacIq lacZ∆M15 proAB+ Tn10(Tetr)] endA1 supE44 gyrA96 hsdR17 lac 
recA1 relA1 thi 
c 
a Yanisch-Perron, C., Vieira, J. & Messing, J. Improved M13 phage cloning vectors and host strains: nucleotide sequences 
of the M13mp18 and pUC19 vectors. Gene 33, 103-119 (1985). 
b Gibson, T.J. (1984) Studies on the Epstein-Barr virus genome. PhD Thesis. Cambridge University, Cambridge, UK 
c Bullock, W.O., Fernandex, J.M. & Short, J.M. Xl1-Blue: A High Efficiency Plasmid Transforming recA Escherichia coli 
Strain With Beta-Galactosidase Selection. BioTechniques 5, 376-379 (1987). 
 
 
 
Supplementary Table 2: Signal sequences 
Abbr. Sourcea Amino acid sequenceb Accession numberc 
DsbAss E. coli thiol-d. interchange protein DsbA MKKIWLALAGLVLAFSASA P0AEG4 
LamBss E. coli lambda receptor protein LamB MMITLRKLPLAVAVAAGVMSAQAMA P02943 
MalEss E. coli maltose-binding protein MBP MKIKTGARILALSALTTMMFSASALA P0AEX9 
MglBss E. coli galactose-binding protein GBP MNKKVLTLSAVMASMLFGAAAHA P0AEE5 
OmpAss E. coli outer membrane protein A OmpA MKKTAIAIAVALAGFATVAQA P0A910 
PelBss Erwinia carotovora pectate lyase PelB MKYLLPTAAAGLLLLAAQPAMA P11431 
PhoAss E. coli alkaline phosphatase PhoA MKQSTIALALLPLLFTPVTKA P00634 
SfmCss E. coli chaperone protein SfmC MMTKIKLLMLIIFYLIISASAHA P77249 
TolBss E. coli protein TolB MKQALRVAFGFLILWASVLHA P0A855 
TorTss E. coli periplasmic protein TorT MRVLLFLLLSLFMLPAFS P38683 
a Organism and protein from which signal sequence is derived 
b Signal sequence given in single letter amino acid code 
c Swiss-Prot 
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Supplementary Figure 1: Schematic representation of the phagemid pDST22. In addition to the elements shown in 
Figure 1, the filamentous phage replication origin (Ff ori), the lac repressor gene from E. coli (lacI) producing lac 
repressor needed for the control of the lacZ p/o, the ColE1 origin of replication (ColE1 ori) for bacterial replication 
of the vector, the antibiotic resistance gene (cat) encoding a chloramphenicol acetyltransferase conferring 
chloramphenicol resistance, and the restriction sites XbaI, BamHI, PstI, and EcoRI are depicted. 
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1. Abstract 
There is an ever increasing demand to select specific, high-affinity binding molecules 
against target proteins of biomedical interest. The success of such selections strongly depends on 
the design and functional diversity of the library of binding molecules employed, as well as on 
the performance of the selection strategy. We have recently developed SRP phage display that 
allows filamentous phage display of highly stable and fast folding proteins, such as Designed 
Ankyrin Repeat Proteins (DARPins) that are virtually refractory to conventional phage display. 
DARPins comprise a novel class of binding molecules suitable to replace or complement 
antibodies in many biotechnological or biomedical applications; and so far all DARPins had 
been selected by using ribosome display. Here, we harnessed SRP phage display and generated a 
phage DARPin library containing more than 1010 individual members. We were able to select 
well behaved and highly specific DARPins against a broad range of target proteins having 
affinities as low as 100 picomolar directly from this library, without affinity maturation. Thus, 
SRP phage display makes filamentous phage display accessible for DARPins, allowing, for 
example, selections under hash conditions or on whole cells. We envision that the use of SRP 
phage display would be also beneficial for other libraries of stable and fast folding proteins. 
2. Introduction 
The demand for good quality binding molecules for biotechnological and biomedical 
applications is ever increasing. Antibodies are currently by far the most frequently used binding 
molecules, but proteins based on non-immunoglobin scaffolds have become an appealing 
alternative.1 From both antibody and non-antibody scaffolds, binding molecules with high 
affinity and high specificity against almost any chosen target protein can be generated in vitro 
using appropriately designed combinatorial libraries in combination with selection technologies 
such as phage display or ribosome display.1,2,3 The success of such selections is mainly based on 
the design and size of the combinatorial library and the selection technology employed. 
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Together, these factors will determine the functional size of the library that is accessible for the 
selection of binding molecules. Further important factors are the selection strategy chosen and 
the biophysical properties of the target protein; even with the best library and an optimized 
selection protocol it might be very difficult or even impossible to obtain reasonable binding 
molecules against a "sticky" and unstable target protein. 
The underlying principle of all selection technologies is the physical linkage of the 
phenotype (i.e. the displayed protein) and the genotype (i.e. the DNA encoding the displayed 
protein). Different selection technologies use different strategies to achieve this linkage. The 
success of any selection experiment depends on the compatibility of the strategy used with the 
proteins to be displayed. Ribosome display, for example, is a complete in vitro display 
technology that relies on the formation of a non-covalent ternary complex of mRNA, ribosome 
and the displayed nascent polypeptide.4 The formation of this ternary complex by in vitro 
translation allows the sampling of very large libraries, and the ease of introducing mutations by 
error-prone PCR allows efficient affinity maturation. However, the linkage of the genotype and 
the phenotype is only reliably maintained under non-denaturing buffer conditions, in the absence 
of RNases and at low temperature. In contrast, in filamentous phage display5 this linkage is very 
robust, allowing a broader range of selection conditions. Filamentous phage display achieves this 
robustness by physically linking the displayed protein to the surface of a very stable phage 
particle,6 which encapsulates the corresponding genotype. Nevertheless, the limiting factor in 
this selection technology is the involvement of an in vivo step to produce the protein displaying 
phage particles. The bacterial transformation needed limits the library size that can reasonably be 
achieved to usually much less than 1011 members. Furthermore, the in vivo assembly process of 
the phage particle is not necessarily compatible with a protein to be displayed (e.g. successful 
translocation of a protein to the periplasm is a prerequisite). Ideally, high affinity binders should 
be obtained directly in a single selection experiment, without further time consuming affinity 
maturations. 
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Fist of all the success of a phage selection experiment strongly depends on the 
transformed library size. In general, the larger the library size the higher the probability to isolate 
diverse binders against a given target protein and the higher the affinities of the selected 
binders.7 For example, to isolate antibody fragments with sub-nanomolar affinities libraries with 
more than 5 x 109 members were employed.8,9,10 Nevertheless, even more important than the 
transformed library size (number of independent clones), is the functional library size, i.e. the 
number of different correct molecules available for selections, as often only a fraction of all 
library members can be functionally displayed. Factors influencing the functional diversity are 
therefore, the above-mentioned compatibility of the selection system with the protein to be 
displayed, the actual library design and the size and quality of the assembled library using 
synthetic genes. 
In the case of libraries of designed binding molecules, the use of a very stable scaffold as 
starting point to introduce diversity helps to ensure that almost all library members are stable and 
well expressed proteins, as diversification of a scaffold will almost inevitably result in reduced 
stability. Another important aspect is the design of diversity, meaning the careful design of 
randomized parts into the scaffold; the challenge is here to introduce a diversity high enough to 
allow successful selections of binders against any target protein, yet low enough to not 
destabilize library members too much.  
In the case of designed ankyrin repeat proteins (DARPins),11,12 which comprise a novel 
class of binding proteins, we used consensus design13 to generate a very stable scaffold amenable 
to the introduction of the needed diversity. This consensus design is based on the sequence and 
structure analysis of natural ankyrin repeat proteins and allows the delineation of framework 
residues, which are important for stability of the scaffold, and the definition of potential target 
interaction residues (inspired by the study of natural ankyrin complexes) suitable to introduce the 
needed diversity. Most members of such DARPin libraries have very favorable biophysical 
Steiner et al.  35 
properties.12 They are very well expressed, monomeric in solution, highly soluble, 
thermodynamically stable and do show fast cooperative folding behavior. 
From such DARPin libraries, specific binders with high affinities have been selected for a 
broad range of target proteins14,15,16,17,18 by using ribosome display. Nevertheless, and much to 
our initial surprise, the display of DARPins on filamentous phage was highly inefficient using 
conventional systems, despite the good biophysical properties of the proteins. We identified this 
problem as one of inefficient translocation of the DARPins into the periplasm due to their 
premature folding in the cytoplasm, and one that can be solved by using the signal recognition 
particle (SRP) translocation pathway for phage display.19 
In SRP phage display,19 the proteins to be displayed are directed to the Escherichia coli 
cotranslational signal recognition particle (SRP) translocation pathway by using an appropriate 
signal sequence, whereas conventional phage display uses the posttranslational Sec translocation 
pathway. This simple change in the use of the translocation route seems to prevent premature 
folding of stable and fast folding proteins in the cytoplasm and therefore allows their efficient 
translocation and subsequent display on filamentous phage particles. These results indicated that 
the use of SRP phage display may help to obtain a high functional diversity of phage DARPin 
libraries leading to efficient selections. 
In the present study we describe the generation of a large phage DARPin library by using 
SRP phage display, selections on a panel of target proteins using this library and analysis of the 
thereby selected DARPins. In addition, we discuss the potential of SRP phage display to 
generate novel binding molecules with excellent properties for biotechnological or biomedical 
applications. 
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3. Results 
3.1 Construction of the phage DARPin library 
The phage DARPin library described here is based on the phagemid vector pPDV1 that 
allows the display of a protein of interest (POI) fused to the minor phage coat protein 3 (p3) on 
filamentous phage (Supplementary Figure 1). In contrast to most other phage display vectors, it 
fuses the POI to a signal sequence using the cotranslational signal recognition particle (SRP) 
pathway for the translocation of the POI-p3 fusion across the cytoplasmic membrane of E. coli. 
The use of the SRP pathway ensures the efficient display of stable and fast folding DARPins on 
phage particles.19 
We used the N3C DARPin library12 (N3C denoting an N-terminal capping repeat, three 
randomized internal repeats and a C-capping repeat) and brought it to the phage display format 
by PCR amplification and subcloning it into pPDV1. XL1-blue cells were transformed with the 
library yielding 2.6 x 1010 independent colonies (transformed library size; see Material and 
Methods for details). The transformed XL1-blue cells were infected with helper phage 
VCS M13, and subsequently IPTG was added to the culture to induce the expression and thus the 
display of the DARPins on the phage particles. For all initial rounds of selection, as described 
below, the input library phage particles were directly used from a frozen phage library stock. 
There was no need to reamplify the library to obtain functional display, as the DARPins 
displayed on phage particles seem to tolerate at least one freeze-thaw cycle very well. 
3.2 High functional diversity of the phage DARPin library 
The functional diversity of the transformed 2.6 x 1010 independent clones of the DARPin 
library was assessed by sequencing, determining the display level and subsequent cytoplasmic 
expression analysis. DNA sequencing of 55 randomly picked clones showed that 26 (47%) 
encode functional DARPin sequences, composed of 18 (33%) N3C, 7 (13%) N2C and 1 (2%) 
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N1C DARPin library members, all with different amino acids at randomized positions. The 
presence of library members having less than three internal repeats (N1C and N2C) can be 
attributed to in vitro recombination during library construction, requiring the PCR amplification 
of the DARPins, and do result from their repetitive nature. The remaining 29 (53%) clones had 
frameshifts, deletions or insertions in the DARPin sequence or contained no insert at all (non-
functional part of the library). Phage particles produced form the same 55 clones of the library as 
sequenced above were analyzed for DARPin display by western blotting. All 26 (47%) clones 
correct on sequence level showed bands at the size expected for a DARPin-p3 fusion protein and 
signal intensities similar to the signal obtained for a scFv using a standard phagemid for 
monovalent display. Thus, it can be assumed that single DARPins are displayed on about one to 
ten percent of phage particles.20 Of the non-functional part of the library only one clone encoding 
the N-terminal part of a DARPin, in frame with the phage coat p3, a prerequisite for display on 
phage particles showed a band on the western blot. To analyze cytoplasmic expression of the 
DARPins, a pool of DARPin inserts from the library was subcloned into pDST67 (see Materials 
and Methods), a vector for high-level, soluble cytoplasmic expression derived from pQE30 
(QIAgen), followed by small scale expression in 96-deep well plates and SDS-PAGE analysis of 
57 randomly picked clones which were not sequenced. Thirty-two (56%) of the clones showed 
expression levels of soluble DARPins above 0.1 mg/ml E. coli culture. Together, these results 
show that all clones that are correct on the amino acid level are well displayed on the phage 
particles and can be expected to be well expressed in the cytoplasm. Thus, we can estimate that 
the Phage DARPin library contains about 1.2 x 1010 correct clones which encode well-behaved 
displayable molecules (functional library size; 47% of the transformed library size), taking also 
into account that the library which was used as template contained at least 1010 individual 
members.14 
The non-functional part of the library may sometimes lead to the enrichment of 
background binding clones encoding defective DARPins that have parts of the scaffold replaced 
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by unstructured and sticky polypeptides. This background enrichment could be successfully 
circumvented in all cases by applying the optimized selection protocol described in detail in the 
Supplementary Material. 
3.3 Target protein preparation, immobilization and optimized selection protocol 
For the validation of the phage DARPin library we performed selections against a broad 
range of purified target proteins (Table 1). To avoid partial protein denaturation of the target due 
to direct immobilization on solid plastic (i.e. polystyrene) surfaces, samples of all target proteins 
were chemically or enzymatically (using an Avi-tag21) biotinylated. This allows selections to be 
performed either on biotinylated target protein bound to neutravidin or streptavidin, which are 
directly immobilized on a solid plastic surface (referred to as: “immobilized target protein”) or 
on biotinylated target protein in solution, which was subsequently captured with streptavidin-
coated beads (referred to as: “target protein in solution”). From the analysis of a number of 
selection experiments, we found that the most efficient enrichment of specific binders from our 
phage DARPin library is obtained with an optimized selection protocol which is composed of a 
first round of selection on immobilized target protein, followed by one to two further rounds of 
selection on target protein in solution. The development of this optimized selection protocol is 
described in the Supplementary Material. Unless stated otherwise, selections were performed 
at room temperature, enzyme-linked immunosorbent assay (ELISA) experiments were 
performed on biotinylated target protein bound to neutravidin, which had been directly 
immobilized on a solid plastic surface, and by using non-biotinylated target protein for 
competition experiments. The different selection approaches needed for the different target 
proteins and characterizations of the binders obtained are described below. This partial listing 
illustrates the versatility of the library, but also the great influence of the target protein on 
peculiarities of the selection. 
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3.4 Efficient selection of DARPins specific for huIgG1_Fc 
Binders against the Fc domain of antibodies are of interest not only as an in vitro 
detection reagent, but also for biomedical applications to, for example, extend the in vivo half-
life of molecules fused to such a binder by attaching to antibodies present in the blood stream. 
To enrich binders against the Fc domain of human IgG1 (huIgG1_Fc, Table 1) we performed 
three rounds of selection using our optimized selection protocol as described above. From each 
selection round we analyzed the recovered and amplified polyclonal pool of phage particles for 
target binding by phage ELISA. Enrichment of phage particles displaying target specific 
DARPins was already observed after the second selection round with a strong increase after the 
third round, and no background enrichment of phage particles binding to the corresponding non-
target-coated matrix was observed (Figure 1(a)).  
To screen individual DARPins for binding to their target protein, and at the same time 
eliminate any conceivable dependence on the p3-fusion format, we did not carry out single clone 
analysis with phages but directly subcloned the selected pool of binders from round three into the 
cytoplasmic expression vector pDST67. From 94 individual DARPins analyzed for full length 
huIgG1 binding by a crude extract ELISA (see Materials and Methods), 82 gave a specific 
binding signal (signal/background > 10) (Figure 1(b); Table 2). Crude cell extracts of ELISA-
positive clones were further analyzed by SDS-PAGE (Figure 1(c)), confirming that, in general, 
the excellent expression properties are maintained throughout. It should be noted that some 
DARPins having more than two internal repeats run at lower apparent molecular mass or show 
additional bands with faster running behavior. The same behavior was also observed for the 
respective purified proteins, even though they were subsequently shown by sequencing and MS 
to be precise in sequence and not degraded. As shown previously,12,19 this is due to an 
incomplete denaturation of these stable molecules by SDS. N2C DARPins do not have this 
extreme SDS resistance and do run where expected. Based on the ELISA signals, 21 clones were 
submitted for sequencing, resulting in eight different sequences of DARPins confirmed by 
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repeated ELISA experiments to bind the target protein (data not shown). The six most promising 
candidates (Table 2) named I_02, I_07, I_13 (N2C library members) and I_01, I_11, I_19 (N3C 
library members) were further analyzed. Expression and immobilized metal ion chromatography 
(IMAC) purification was performed in 96-well format in parallel with binders selected against 
other target proteins (see Material and Methods), yielding on average more than 1 mg of > 95% 
pure protein for each clone from 8 x 1.3 ml E. coli culture. These purified DARPins were used 
for all further experiments. 
To investigate the specificity of the selected DARPins, ELISA experiments with the four 
high-affinity clones I_01, I_02, I_07 and I_19 (Figure 1(c)) and the two lower affinity clones 
I_11 and I_13 (Figure 1(d)) were performed. All of the binders do show specific binding to full 
length human IgG1 (huIgG1) but do not bind to neutravidin, mouse IgG1 (muIgG1) or mouse 
IgG2b (muIgG2b). In the competition ELISA setup the binding to immobilized huIgG1 could be 
well inhibited by preincubation of the DARPins with free huIgG1 (Figure 1(c), (d)). From the 
concentrations of free huIgG1 needed for an inhibition of > 50% the affinities of these binders 
can be estimated to be in the nM range, as could be confirmed by surface plasmon resonance 
(SPR, see below). 
The binders were further characterized by size exclusion chromatography (SEC) and 
compared to the well characterized, non-binding DARPin E3_5 (ref. 12). At a concentration of 
10 µM four of the six clones tested eluted at the size expected for the monomer (Figure 2). 
Clone I_19 showed a second elution peak at lower elution volume, indicating some dimer 
formation at this concentration. I_01 elutes as a single peak but at lower elution volume (higher 
apparent molecular weight) than expected, indicating an increase hydrodynamic radius due to 
multimerisation or partial unfolding. Further analysis of this binder by SEC combined with 
multi-angle light scattering (SEC-MALS) revealed a clearly dimeric mass of the DARPin I_01. 
Four of the clones were further analyzed by SPR (Table 3 and Supplementary Figure 2) 
and the data obtained were evaluated with a global kinetic fit. I_19 had the highest affinity for 
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huIgG1_Fc (KD = 2.1 nM) and I_11 the lowest affinity (KD = 137 nM), in good agreement with 
the competition ELISA experiments performed. To calculate the affinity of I_19 we assumed 
that the DARPin would be completely monomeric at all concentrations used for the SPR 
measurements (the maximal DARPin concentration was 75 nM), and the global fit agrees very 
well with a 1:1 interaction (see Supplementary Material). 
In summary, we were able to enrich a diverse set of highly specific binders with affinities 
in the low nanomolar range in just three rounds of selection, from our phage DARPin library. 
3.5 Selection of DARPins binding to TNFα 
Antibodies to TNFα have been developed for a number of therapeutic applications,22 as 
has the soluble recombinant receptor of TNFα, Etanercept (EnbrelTM, see below),23 and binding 
molecules based on novel scaffolds are currently being developed to do the same. To enrich 
binders specific for the soluble trimeric form of TNFα (Table 1) we performed selections and 
screenings as described above for huIgG1_Fc using biotinylated TNFα (see Materials and 
Methods). Fast enrichment of phage particles displaying DARPins specific for TNFα was 
already observed after the second selection round. From round two and three, 94 individual 
DARPins each were screened by crude extract ELISA for TNFα binding, giving 15 and 87 
specific binding signals, respectively (Table 2). Based on the ELISA signals, 52 clones were 
submitted for sequencing, resulting in a highly diverse set of 29 different sequences of DARPins; 
interestingly, all selected DARPins were of the N3C type. Binders were expressed in the 
cytoplasm, purified by IMAC and further analyzed by SEC; they show high-level expression and 
most of them monomeric elution behavior, similar to the results obtained for the huIgG1_Fc 
binders described above. 
To investigate the specificity of the selected DARPins, ELISA experiments were 
performed (Figure 3). All of the binders do show specific binding to TNFα, do not interact with 
neutravidin, and in the competition ELISA setup the binding to immobilized TNFα could be well 
inhibited by preincubation of the DARPins with free TNFα. From the competition ELISA signals 
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obtained with 10 nM of free TNFα, the affinities of the binders were estimated to be in the low 
nM range. Interestingly, the binding of all selected DARPins can be almost completely inhibited 
by preincubation of the immobilized TNFα with Etanercept (EnbrelTM, recombinant human 
soluble tumor necrosis factor alpha receptor fused to Fc domain of human IgG1, Amgen, USA) 
(Figure 3). In the complementary experiment, where immobilized TNFα was preincubated with 
different DARPins, the inhibition of Enbrel binding could not be detected. It was clearly 
detected, however, in SPR measurements (see Supplementary Figure 4), where soluble TNFα, 
preincubated with DARPins could be prevented from binding to immobilized Enbrel. From SEC-
MALS experiments (see Supplementary Figure 5), the DARPin TNFα complex has only a 
molar mass of about 53.5 kDa (theoretical molecular weight for the TNFα trimer plus one 
DARPin is 70.2 kDa and for the TNFα trimer plus three DARPins is 106.2 kDa). It thus appears 
that the DARPins selected in this particular experiment do possibly not bind to the TNFα trimer 
but to another form of TNFα, while the dimeric Enbrel chelates the TNFα trimer. This 
information thus helps to steer further selections to other epitopes and stoichiometries. 
Up to this stage all binding and washing steps in the selection and ELISA experiments 
had been carried out using our standard buffers containing 0.1 % Tween-20. During further 
analysis, very much to our surprise we discovered that all the selected DARPins show specific 
TNFα binding that is dependent on the presence of the detergent Tween-20 in the binding buffer. 
In ELISA experiments, excellent and specific binding to the immobilized target protein was 
observed in buffers HBST, TBST and PBST all containing 0.1% (v/v) Tween-20, but not in the 
buffers alone. Also, in SEC experiments complex formation of the DARPins with TNFα could 
only be observed in PBST, but not in PBS alone. One speculation is that Tween-20 induces 
conformational changes in TNFα needed for the accessibility of the DARPin epitopes. To 
prevent the enrichment of such binders, Tween-20 could be omitted or replaced by other 
detergents in new selection approaches on TNFα. We did not further analyze these DARPins, 
since we do not expect them to bind their target protein in vivo. 
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3.6 Selection of DARPins to members of the ErbB receptor family 
Antibodies to ErbB1 (EGFR) and the other members of the ErbB receptor family, notably 
ErbB2 (HER2), are being developed as anti-tumor therapeutics.24 We describe in the present 
study the selection of DARPin binders against ErbB1, ErbB2 and ErbB4. The extracellular part 
of all members of this family is composed of four domains (domain I-IV).25 For both ErbB1 and 
ErbB4 the extracellular domains I-III of the respective receptor fused to huIgG1_Fc were used in 
selections (see Table 1). The different selection approaches performed on these two target 
proteins are described in detail in the Supplementary Material. 
Individual DARPins were screened for specific target protein binding by crude extract 
ELISA as described for huIGg1_Fc. For ErbB1, 97 out of 369 and for ErbB4, 55 out of 143 
screened clones gave a specific binding signal (Table 2). Based on ELISA signals 64 clones for 
ErbB1 and 48 clones for ErbB4 were submitted for sequencing. Surprisingly, this resulted in 
only one dominant ErbB1 binder (E_01) and five ErbB4 binders (B4_01, B4_02, B4_07, B4_33 
and B4_45), of which B4_02 was strongly overrepresented among the sequenced clones (about 
66 %). 
To increase the diversity of the selected binders and to avoid dominant enrichment of 
these binders we used a selection procedure termed “epitope-masking”.26 For this purpose we 
expressed and purified the two dominant binders (E_01 and B4_02) by IMAC and performed 
one round of selection on the two target proteins in solution in the presence of an only two-fold 
excess of the respective purified binder. By this partial masking of the epitope of the dominant 
binder we expected to select DARPins which recognize a different epitope, but at the same time 
still allow new high-affinity DARPins competing for the same epitope to be enriched. Using 
higher concentrations for competition resulted in a lower diversity of the selected binders (see 
below). For both target proteins equivalent amounts of amplified, partially enriched pools of 
phage particles after selection round one on immobilized target proteins (Supplementary Figure 
3(a) and 3(b)) and after selection round two on target proteins in solution (Supplementary 
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Figure 3(c) and 3(d)) were used as input. After one round of selection, input and output pools of 
phage particles were analyzed by phage ELISA for binding to their target protein in the absence 
and the presence of a large excess (2 µM) of the respective dominant binders (Figure 4(a) and 
4(b)). For ErbB1, the binding signal obtained on target protein alone was much higher than the 
signal obtained on ErbB1 in the presence of the DARPin E_01, indicating that most of the 
DARPins selected indeed recognize the same or an epitope overlapping with that of DARPin 
E_01 (Figure 4(a)). For ErbB4, the binding signal obtained on target protein alone or in the 
presence of B4_02 was identical, indicating that in this case, most of the selected DARPins 
recognize an epitope different from that of DARPin B4_02 (Figure 4(e)). 
To analyze the success of the epitope-masking, individual selected DARPins were first 
screened for binding to their target protein by crude extract ELISA as described for huIGg1_Fc. 
For ErbB1, 81 of 105, and for ErbB4, 84 of 94 screened clones gave a specific binding signal 
(Table 2). Based on the ELISA signals, 20 clones of each selection were submitted for 
sequencing, resulting in four new binders for ErbB1 and six new binders for ErbB4. Binders 
were expressed in the cytoplasm of E. coli, purified and further analyzed by SEC; they show 
high-level expression and most of them monomeric elution behavior, similar to the results 
obtained for the huIgG1_Fc binders described above. All of the clones did bind specifically to 
the respective target protein, as shown by competition ELISA, but only the ErbB1 binders (E_67, 
E_68, E_69) and ErbB4 binders (B4_50, B4_58) were analyzed in detail, as in these cases 
inhibition of ELISA signals to less than 50% was already observed with 10 nM (50 nM for 
E_69) competitor, suggesting a high affinity (cf Figure 1(d)). This was confirmed by SPR 
analysis (see below). 
3.7 Clones selected by epitope masking show diverse specificities 
Binding and epitope localization of the clones selected by epitope masking were tested by 
ELISA. All high-affinity ErbB1 and ErbB4 binders were tested for interaction with the 
respective biotinylated target protein bound to immobilized neutravidin, or the non-biotinylated 
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target protein bound to the immobilized DARPins (E_01 or B4_02, respectively) used for 
epitope-masking (Figure 5(a) and 5(b)). In the selection on ErbB1 using an only two-fold excess 
of E_01, three new high affinity clones were selected. E_69 recognized an epitope not competing 
with E_01, whereas the other two binders, E_67 and E_68, could not bind to their target 
immobilized over E_01. In contrast, the clone E_69 was very dominant when performing the 
same epitope-masking selection in the presence of a much higher excess (20-fold) of the 
masking DARPin E_01. This finding shows that somewhat higher diversities can be obtained by 
only partially masking the dominant epitope than by completely blocking it. In contrast, for 
ErbB4, one of the clones (B4_01) selected on ErbB4 in solution and both of the clones selected 
by epitope-masking recognized another epitope than B4_02. None of the binders did show cross-
reactivity when analyzed in ELISA experiments for binding to other receptors of the ErbB-
family (ErbB1, ErbB2 and ErbB4), which share about 50% sequence identity and have highly 
conserved structures (Figure 5(b) and (c)). Competition experiments were performed as 
described for huIgG1_Fc, and ELISA binding signals were inhibited to less than 50% already 
with 10 nM competitor (50 nM for E_69), suggesting low nanomolar affinities (data not shown). 
This was confirmed by SPR analysis (see below). 
Four well behaved clones for each of the target proteins were further analyzed by SPR 
(Table 3 and Supplementary Figure 2) and the data were evaluated with a global kinetic fit. 
Five of the measured binders showed affinities in the picomolar range, and the other binders 
were all below 15 nM. 
In conclusion, dominant epitopes on a target protein may hinder the direct selection of 
diverse binders. This hidden diversity present in the library can be made accessible, however, by 
masking the dominant epitope during the selection cycle. 
3.8 Epitope removal allows to select more diverse DARPins 
To enrich binders against ErbB2 containing all four domains (I – IV) of the extracellular 
part of the receptor and thus comprising the first 631 amino acid residues of the mature protein 
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(termed ErbB2-631, see Table 1), we performed three initial rounds of selection on target 
protein in solution. Good enrichment of phage particles displaying DARPins binding to ErbB2-
631 but not to ErbB2-509 (see Table 1), which only comprises the first 509 amino acid residues 
of the mature protein and therefore lacks domain IV, was observed after the third selection round 
as shown by phage ELISA (Figure 6(a)). This is in good agreement with previously performed 
ribosome display selections, where all selected high-affinity binders recognized domain IV, 
which seems to contain one ore more dominant epitopes of that protein.18 
We followed two strategies to obtain binders that recognize domain I – III of the target 
protein. First, we directly performed selections on ErbB2-509. Surprisingly, all of the selection 
approaches on ErbB2-509, independent of whether the selection had been performed on 
immobilized target protein or on target protein in solution, failed to yield an enrichment of target 
specific DARPins. We reasoned that this might be due to a lower stability or higher flexibility of 
the truncated version of the receptor at room temperature and therefore performed further 
selections at 4 °C. Indeed, after three rounds of selection on ErbB2-509 by using the optimized 
selection protocol at 4 °C, target-specific binding of the enriched pools was observed in phage 
ELISA (Figure 6(b)). For the pool of round three, specific binding to both target proteins 
ErbB2-631 and ErbB2-509 was observed and suggested that target stability is indeed a very 
important parameter for optimal selections. 
After round three, 94 individual DARPins were screened by crude extract ELISA for 
binding to ErbB2-509, resulting in 83 specific binding signals (Table 2). Based on the ELISA 
signals, 29 binders were sequenced, resulting in a diverse set of 13 different sequences of 
DARPins. Binders were expressed in the cytoplasm, purified and further analyzed by SEC; they 
show high-level expression and most of them monomeric elution behavior in SEC, similar to the 
results obtained for the huIgG1_Fc binders described above. 
ELISA experiments showed high specificity (no cross-reactivity with ErbB1 and ErbB4), 
and inhibition of ELISA signals to less than 50% was observed for more than half of the clones 
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using 10 nM competitor, suggesting nanomolar affinity (cf Figure 1(d)). Three of the binders 
(9_16, 9_26 and 9_29) were further analyzed by SPR measurements showing affinities in the 
low nM range (Table 3). 
The results obtained indicate that, similar to the epitope masking strategy described 
above, this strategy of removing an epitope by deleting a domain makes the hidden diversity of 
the library accessible for selection. It also shows that attention must be paid to the 
conformational integrity of the target protein, in this case by lowering the temperature during 
selection. 
Additionally, as described for ErbB1 and ErbB4, we again partially masked one of the 
epitopes (see above) on domain IV by adding a two-fold excess of the high affinity DARPin 
H10-2-G3 (ref. 27) in one round of selection on ErbB2-631. The amplified, partially enriched 
pool of phage particles after two rounds of selection on the target protein in solution (Figure 
6(a)) was used as input. Screening of 94 clones by crude extract ELISA resulted in 24 specific 
binding signals. Based on the ELISA signals 16 binders were sequenced, resulting in eight 
different sequences of which four had been already found in the selection on ErbB2_509. Of the 
three new binders two recognized ErbB2-509 as well as ErbB2_631 (domain I-III binders) and 
one (H_14) recognizes only ErbB2_631 (domain IV binder). Due to its exceptionally high 
binding signal binder H_14 was further analyzed by SPR measurements and the data were 
evaluated with a global kinetic fit showing an affinity in the picomolar range (Table 3) (C. Jost 
& A.P., unpublished data).  
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4. Discussion 
4.1 Large functional DARPin library obtained by SRP phage display 
The quality of a combinatorial library of binding proteins can be functionally described 
by the ability to isolate high affinity binders against a broad set of target proteins. Three major 
factors contribute to successful selections from such a library. First, the library design, which 
encompasses the scaffold used as well as its diversification strategy employed. Second, the 
theoretic diversity of the combinatorial DNA library and the percentage of clones that actually 
have sequences as specified. Finally, the display technology must be able to present all members 
of the library in a functional form allowing efficient selection. Together, these factors determine 
the functional diversity of the library which is accessible for the selection of binding molecules. 
We have developed SRP phage display that allows the efficient display of fast folding 
and stable proteins such as DARPins that are partially refractory to conventional phage display 
that uses Sec dependent translocation of the POI into the periplasm.19 We generated our phage 
DARPin library using the previously described combinatorial N3C DARPin library12,14 as 
template and a phagemid containing an SRP-dependent signal sequence.19 Analysis of single 
unselected members of this new library revealed that all clones that are correct on sequence level 
are also displayed on the phage particles at levels, comparable to the display yield obtained for a 
single chain Fv (scFv) antibody fragment using a conventional phagemid. This results in a 
functional library diversity of at least 1 x 1010 which is within the size reported for the largest 
phage libraries displaying non-immunoglobulin domains28 and within the size of large phage 
libraries displaying antibody fragments.7 
The functional part of the phage DARPin library is composed of N1C (4%), N2C (27%) 
and N3C (69%) DARPins as determined from the sequencing and display analysis of unselected 
clones. The constructs shorter than the N3C are probably side products of the PCR of the initial 
combinatorial N3C library necessary during construction; this is also regularly observed when 
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doing ribosome display selections and results from the repetitive nature of DARPins. 
Interestingly, we even selected N4C and N5C DARPins (Table 3). Since no repeat duplication 
or deletion that would indicate in vivo recombination of the DARPin scaffold was ever observed, 
we expect these longer constructs, just as the shorter ones to be already present to a low extent in 
the initial library. Since the selection for binding works well, as demonstrated by the successful 
selection against diverse targets, the occurrence of DARPins with a different number of repeats, 
(presumably) already in the initial library, can be seen as a source of additional diversity. A 
larger contiguous patch of randomized residues in the DARPins with more than three 
randomized repeats may allow binding to additional epitopes, where contacts by residues in the 
capping repeats might not have been favorable or where a larger binding surface is needed. An 
accumulation of these longer constructs during selections with epitope masking supports this 
theory. 
In just two to three phage display selection rounds we were able to select high affinity 
binders against a broad range of target proteins without a single failure (Table 2). This validates 
the high functional library diversity and the optimized diversity design of the DARPin scaffold, 
and that SRP phage display is robust to select specific binders from this library. Good 
performance of SRP phage display was recently also reported for the display of a library based 
on the fibronectin type III domain.29 We suppose that SPR phage display could increase the 
functional diversity of many other libraries, especially those expected to be composed of 
similarly stable and fast folding scaffolds or those containing members with widely different 
folding rates and stabilities, such as expected e.g., in cDNA libraries. 
It should be noted that also for SRP phage display, as reported for conventional phage 
display,30 it might be necessary to optimize the phagemid in combination with the scaffold used, 
in order to tune the expression level to achieve efficient but still monovalent display of the POI.  
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4.2 Selected DARPins have favorable biophysical properties 
The selected DARPins retain the favorable biophysical properties of the initial library 
members.12 They can be expressed in large amounts in soluble form in the cytoplasm of E. coli 
(Figure 1(b)), and routinely more than 100 mg protein is purified per one liter of shake-flask 
culture. Of the 84 clones analyzed by SEC, 46 (55 %) show a single peak at the elution volume 
expected for the monomer (Figure 2) and another 10 (12%) show a single peak at a too high 
elution volume, indicating interaction with the column material but were confirmed to be 
monomeric by SEC-MALS measurements. The other DARPins are presumably a mixture of 
monomer and dimer or elute at higher apparent molecular weight, indicating oligomerization or 
partial unfolding. Because of the broad diversity of clones isolated for each target, purely 
monomeric tight binding DARPins have always been found. 
The selected clones specifically recognize the target protein which they were selected on 
and do not cross-react with other proteins tested as shown by ELISA (Figure 5(c) and 5(d)), and 
these ELISAs were always carried out with recloned non-fused protein, and thus independent of 
being fused to the phage coat protein 3 or being displayed on phage particles.  
4.3 DARPins with picomolar affinities were selected on a regular basis 
The highest affinities of the selected binders are in the sub-nanomolar range (Table 3) 
and thus as good as the affinities obtained when performing ribosome display selections with the 
identical initial DARPin library.14,15,16 There are several factors which may contribute to this, at 
first, surprising observation. First, the functional size of the present phage library is very large, 
and is expected to cover the diversity of 1010 members present in the initial ribosome display 
library14 which was used as template. Therefore, the same input library will be sampled in 
ribosome display and phage display. Second, by the construction of the phage library, which 
involved PCR steps, also some additional variation has been introduced — and some may have 
existed already at the level of the synthetic individual modules — , as can be seen by the 
framework mutations regularly obtained in the selected clones. We have no evidence that these 
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would have been introduced during the selection and propagation steps in E. coli. Third, a 
growing experience in designing selection experiments, as summarized in the optimized 
selection protocol, may improve the quality of the selected clones. Ribosome display does allow, 
however, a seamless integration of additional randomization and affinity maturation steps, 
should they be needed.4,27 
From the comparison of affinities obtained form various antibody libraries, it is widely 
accepted that the affinities of the selected antibodies correlate with the size of the library.7 From 
phage antibody fragment libraries containing 107 to 109 members, affinities of up to 10 nM, and 
for libraries with over 5 x 109 members, sub-nanomolar affinities have been selected.7 From our 
phage DARPin library containing about 1010 functional members we obtained against all target 
proteins multiple DARPins with affinities in the low nanomolar or, in most cases, even the sub-
nanomolar range (Table 3). These affinities compare very favorably with those obtained for 
synthetic antibody repertoires of similar or even larger size.8,9,10,31 Our very promising results 
can be attributed to the optimized diversity design of the DARPin library as well as the high 
functional display rate of the SRP phage display system. This will make affinity maturation for 
most applications unnecessary. 
4.4 Broadening diversity of selected DARPins by epitope masking or removal 
One frequently observed phenomenon in phage display when performing selection 
experiments on certain target proteins is low diversity and narrow specificity of the selected 
binders, even when using large libraries (e.g. ref. 8, 32, 33, 34). Different to ribosome display, 
where due to the generation of mutations during the selections, low affinity binders may 
stochastically acquire mutations that make them survive selection rounds with high stringency, 
and thus, different binder families can be obtained in parallel experiments.35 In phage display, 
where the library is "static", there are many reasons why a certain binder might be selected with 
preference and dominate the selected pool: for example, (i) the binder has much higher affinity 
than the other binders; (ii) the binder is more efficiently displayed than the other binders, (iii) the 
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target protein contains a preferred binding site on its surface33 or (iv) there are only limited 
epitopes on the target protein accessible to potential binders. When performing selections on the 
receptors of the ErbB family we obtained binders with low diversity and/or narrow specificity, 
suggesting that some epitopes in this family appear to be very well suited for the DARPin 
binding interface such that they dominated the selection. The dominant DARPin E_01 was also 
shown to be displayed at slightly higher levels than other library members (data not shown) and 
both E_01 and B4_02 have very high affinities, indicating that also point (i) and (ii) can 
influence the selection of DARPins by phage display. Note that a much broader diversity was 
obtained for other targets (TNFα, huIgG1_Fc, CitS36 and others, data not shown). We followed 
several strategies to increase the diversity of the selected DARPins and to broaden the range of 
selected specificities.  
For ErbB1, where essentially only one binder was found in the primary selections, and 
for ErbB4, where one binder was very dominant (Table 2), we performed one round of selection 
on the target protein in the presence of a two-fold excess of the purified dominant binder using 
pools of phage particles partially enriched on the target protein as input. This strategy of epitope-
masking was recently described for antibodies.37,38 In both cases this approach resulted in 
increased diversity and specificity of the binders (Figure 6). For ErbB1, two of the three further 
analyzed clones still bound to the same or an overlapping epitope than the binder used for 
epitope-masking. This is presumably due to the low, two-fold excess of competitor used, leading 
only to a partial masking of the epitope, and thus making it possible to find binders to the same 
domain. 
For the full-length ectodomain of ErbB2 (ErbB2-631), the selection yielded a pool of 
binders that only recognize this full length ectodomain but not a truncated construct lacking 
domain IV (Figure 6(a)). Therefore, we performed selections on the truncated version. Probably 
due to the lower stability of ErbB2-509, selections on this target protein were only successful at 
low temperature. They yielded a pool of binders recognizing ErbB2-631 as well as ErbB2-509 
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(Figure 6(b)). Therefore, both strategies, epitope-masking and epitope removal, were 
successfully applied, and combining such binders recognizing different epitopes would give the 
possibility of constructing multivalent binders for a given target protein. 
4.5 Conclusions 
We have validated our phage DARPin library by successfully selecting well-behaved and 
high affinity binders against a broad range of target proteins. The SRP phage display used within 
this work has thus proven to be a powerful method to display libraries of fast folding and stable 
DARPins that would be refractory to conventional phage display using the Sec secretion 
pathway. Therefore we envision that this novel phage display method may also be beneficial for 
other libraries containing stable and fast folding proteins. The addition of phage display to the 
selection repertoire for the generation of specific DARPins further expands the application range 
of this novel class of binding molecules. 
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5. Materials and Methods 
5.1 Materials 
All chemicals were of highest quality and purchased from Fluka (Switzerland) unless 
stated otherwise. Oligonucleotides were from Microsynth (Switzerland). Vent DNA polymerase, 
restriction enzymes and buffers were from New England Biolabs (USA) or Fermentas 
(Lithuania). Helper phage VCS M13 was from Stratagene (USA). All cloning and phage 
amplification was performed in E. coli XL1-Blue from Stratagene (USA). 
5.2 Molecular biology 
Unless stated otherwise, all molecular biology methods were performed according to 
standard protocols.39 
5.3 Phagemid and expression vectors 
The phagemid pPDV1 (Supplementary Figure 1) is related to pDST23 (ref. 19) and 
comprises following features: (i) the signal sequence of E. coli DsbA (DsbAss) ensures efficient 
SRP phage display; (ii) sequences for display are inserted in the multiple cloning site (MCS) 
between the DsbAss and the coding sequence of the C-terminal domain (amino acids 250-406) 
of protein 3 (p3) of filamentous phage M13; (iii) the fusion protein (p3 fusion) is under the 
control of a lac promoter/operator element and the lacIq gene provides high levels of the lac 
repressor in cis; (iv) an amber stop codon (TAG) is interposed between the displayed sequence 
and the C-terminal domain of p3; (v) the fusion protein contains a Flag-tag; (vi) the vector 
carries a f1 origin of replication to permit production of virions using an appropriate helper 
phage, such as VCS M13; and (vii) the vector has a plasmid origin (ColE1 ori) and an antibiotic 
resistance marker (the gene for chloramphenicol acetyl transferase (cat) providing resistance to 
chloramphenicol (cam)) to allow propagation as a plasmid in E. coli. 
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The vector pDST67 was used for high-level, soluble cytoplasmic expression of the selected 
DARPins containing an N-terminal MRGS(H)6 tag. pDST67 is a derivative of pQE30 (QIAgen) 
in which the single amber stop codon (TAG) after the HindIII restriction site has been replaced 
by a double stop codon (TAA TGA), avoiding the formation of a read-through product when 
using suppressor E. coli strains such as XL1-Blue. pDST67 was generated via PCR cloning 
using the oligonucleotides oDST29 (5’-
GGCCAAGCTTAATTAATGACTGAGCTTGGACTCCTG-3’) and oDST30 (5’-
AAAGCCAAGCTAGCTTGGATTCTC-3’) and pQE30 as template. The resulting PCR product 
was HidIII/NheI digested and ligated into the identically treated and dephosphorylated pQE30 
vector. Coding sequences of the selected DARPins were cloned into pDST67 via BamHI/HindIII 
yielding pDST67_(DARPin Name). Protein expression and purification was done as described 
below. 
The vector pAT223 (GenBank accession number AY327138) was used for the expression 
of fusion proteins with an N-terminal avi-tag for in vivo biotinylation, followed by phage lambda 
protein D (pD) as fusion protein, followed by a His6-tag for IMAC purification and then the 
protein of interest, e.g. a DARPin to be biotinylated and immobilized. Coding sequences of the 
selected DARPins E_01 and B4_02 were cloned into pAT223 via BamHI/HindIII, yielding 
pDST126 and pDST127, respectively. Protein production, purification and confirmation of 
biotinylation was done as described.15 
5.4 Library construction 
The N3C DARPin library in the ribosome display format12 was PCR amplified using 
primers introducing a BamHI and HindIII site (EWT3 and WTC4, ref. 14), enabling subsequent 
subcloning into phagemid pPDV1. Two hundred PCR reactions of 50 µl yielded about 600 µg of 
purified PCR product that was ligated after restriction digest of the components using BamHI 
and HindIII into pPDV1. About 300 µg of ligated and purified DNA were first transformed by 
electroporation into MP1 cells (E. coli strain MC1061 (ref. 40) containing the F episome 
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transferred from XL1-blue cells) as these cells can be very efficiently transformed,41 yielding 
3.6 x 1010 independent colonies. From these cells the plasmid DNA was isolated and re-
transformed into XL1-blue cells, for subsequent phage production, yielding 2.6 x 1010 
independent colonies. The transformed XL1-blue cells were infected with helper phage 
VCS M13 and IPTG was subsequently added to the culture to induce the expression and thus the 
display of the DARPins, thereby producing the phage particles of the phage DARPin library. The 
DARPin displaying phage particles were PEG-precipitated from the culture supernatant, 
resuspended in PBS (137 mM NaCl, 3 mM KCl, 8 mM Na2HPO4, 1.5 mM KH2PO4, pH 7.4) 
containing 10% glycerol, aliquoted and stored at -80 °C. They were found to be stable for at least 
one year. 
5.5 Library characterization 
To determine the percentage of transformed clones encoding functional DARPins, 55 
randomly picked clones were sequenced using standard techniques. To analyze the fraction of 
DARPin-p3 fusion proteins displayed, phage particles produced form the 55 sequenced clones 
were analyzed by western blotting as described,19 using the anti-FLAG antibody M1 (Sigma, 
USA) for detection. Phage particles displaying a scFv, known to be well displayed using a 
conventional phagemid were used as a reference (phage particles produced form phagemid 
pDST24, ref. 19). To quantify the percentage of DARPins showing high level, soluble 
cytoplasmic expression, a pool of DARPin inserts from the phage library was subcloned into 
pDST67 via BamHI/HindIII. Small scale expression and 15% SDS-PAGE analysis of 57 
randomly picked clones which were not sequenced was performed. 
5.6 Target proteins 
Purified target proteins were used for all experiments and are described in detail in Table 
1. ErbB receptors were kindly provided by Dr. Tim Adams and coworkers (CSIRO, Melbourne, 
Australia). The Fc domain of human IgG1 was purchased from R&D Systems, UK. For 
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immobilization, aliquots of these target proteins (200 µg to 600 µg) were chemically biotinylated 
using EZ-Link Sulfo-NHS-SS-Biotin (Pierce, USA). Due to the size difference of the target 
proteins a variable molar excess of the biotinylating reagent relative to the target protein was 
used (4-fold for huIgG1_Fc, 9-fold for ErbB1, 6-fold for ErbB2-509, 6-fold for ErbB2-631 and 
9-fold for ErbB4). Reaction conditions were used according to the supplier’s manual (Pierce, 
USA). Successful biotinylation was confirmed by ELISA and Western blotting experiments, the 
extent of biotinylation was not quantified.  
Non-biotinylated and biotinylated TNFα, shown to be biologically active was expressed 
and purified from E. coli (C. Zahnd and A.P., unpublished data). In brief, human TNFα was 
amplified using the primers rTNFstopHind (5’-
GATGAGAAGCTTTCATTACAGGGCAATGATCCCAAAG-3’) and fTNFa (5’-
CACCACCATGGCTGTCAGATCATCTTCTCGAAC-3’). The resulting PCR product was 
NcoI and HindIII digested and ligated into the identically treated and dephosphorylated vector 
pAT222 (GenBank accession number AY327137), yielding the construct with an N-terminal 
Avi-tag21 used for the expression of biotinylated TNFα and into pQE60 (QIAgen) vector 
yielding the construct with no tag used for the expression of non-biotinylated TNFα. For 
biotinylation, the biotin-ligase BirA of E. coli was cotransformed and co-expressed with the Avi-
tagged construct in E. coli XL1-Blue to yield in vivo biotinylated TNFα as described21. The 
biotinylated TNFα was purified, via a monomeric avidin column. To allow intermolecular 
disulfide bond formation, the soluble protein was dialyzed against TBS (20 mM Tris, 150 mM 
NaCl, pH 7.6) containing 1 mM reduced glutathione (GSH) and 0.2 mM oxidized glutathione 
(GSSG). The trimeric species was obtained by preparative gel filtration in using TBS as running 
buffer. The TNFα construct with no tag was expressed in E. coli XL1-Blue, purified via a 
cationic exchange column using washing buffer (100 mM MES, pH 5.8) with a NaCl gradient 
from 150 mM to 1 M, followed by a dialysis step against the same GSH/GSSG buffer mentioned 
above and subsequent preparative gel filtration. The biological activity of both constructs was 
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shown by their cytolytic activity on L929 mouse fibroblast cells (ATTC, USA) and compared to 
commercial TNFα.  
5.7 Immobilization of target proteins 
Target proteins had to be immobilized for selection and ELISA experiments. To avoid 
partial protein denaturation of the target proteins that may result from direct immobilization on 
solid plastic (i.e. polystyrene) surfaces, biotinylated target proteins were bound to neutravidin or 
streptavidin, which had been directly immobilized on a solid plastic surface, as follows: 
neutravidin (66 nM, 100 µl/well, Pierce, USA) or streptavidin (66 nM, 100 µl/well Sigma, 
Switzerland) in PBS was immobilized on MaxiSorp plates (Nunc, Denmark) by overnight 
incubation at 4 °C. The wells were blocked with 300 µl PBSTB (PBS containing 0.1% Tween-
20, 0.2% BSA) for 1 h at RT. Binding of the biotinylated target proteins (100 µl, ~ 100 nM for 
selection and ~ 20 nM for ELISA) in PBSTB was allowed to occur for 1 h at 4 °C.  
For the first selection round on immobilized target protein, requiring larger volumes, 
neutravidin (66 nM, 4 ml/tube) in PBS was immobilized on MaxiSorp Immunotubes (Nunc, 
Denmark) by overnight incubation at 4 °C. The tubes were blocked with 4 ml PBSTB for 1 h at 
RT. Binding of the biotinylated target proteins (4 ml, ~ 100 nM) in PBSTB was allowed to occur 
for 1 h at 4 °C. 
For selections on immobilized target protein, neutravidin and streptavidin were used 
alternately in selection rounds to avoid selection of binders against these proteins. 
5.8 Selection of phage DARPins 
Unless stated otherwise, all steps of the phage display selection were carried out at room 
temperature. Selection rounds were performed either on biotinylated target protein in solution 
with subsequent capturing on streptavidin-coated magnetic beads (referred to as: “target protein 
in solution”) or on biotinylated target protein bound to neutravidin or streptavidin, which had 
been directly immobilized on a solid plastic surface (referred to as: “immobilized target 
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protein”), as described below. Very good results were obtained when performing the first 
selection round of selection on immobilized target protein, presumably because of the greater 
efficiency of capturing binders —especially important in the first round —, followed by further 
rounds on target protein in solution, presumably because of the lower enrichment of background 
binders (for the optimized selection protocol, see Supplementary Material). Protocols were 
adapted from ref. 42. 
5.9 Selection on target proteins in solution 
When the first selection cycle was done in solution, about 2.5 x 1013 phage particles of 
the phage DARPin library were incubated for 1 hour with 100 nM biotinylated target protein in 
2 ml PBSTB for the first round of selection. In subsequent selection rounds, about 1012 phage 
particles were used (see below). The phage-antigen complexes were then captured on 100 µl 
streptavidin-coated paramagnetic beads (10 mg/ml, Dynabeads MyOne Streptavidin T1, Dynal) 
for 20 min. After washing the beads eight times with PBST (PBS, 0.1% Tween-20) the phage 
particles were eluted with 200 µl of 100 mM triethylamine (Et3N, pH not adjusted) for 6 min, 
followed by 200 µl of 100 mM glycine-HCl, pH 2, for 10 min. Eluates were neutralized with 
100 µl of 1 M Tris-HCl, pH 7, or 18 µl of 2 M Tris-base, respectively, combined and used to 
infect 5 ml of exponentially growing E. coli XL1-Blue cells. After shaking for 1 hour at 37 °C, 
cells were expanded into 50 ml of fresh 2YT medium (5 g NaCl, 10 g yeast extract, 16 g tryptone 
per liter) containing 10 µg/ml cam and incubated at 37 °C with shaking. After a maximum of 5 h 
(shorter times if OD600 = 0.5 was reached earlier), isopropyl-β-D-thiogalactoside (IPTG) was 
added to a final concentration of 0.2 mM and 15 minutes later the phage library was rescued by 
infection with VCS M13 helper phage at 1010 pfu (plaque forming units) per ml (multiplicity of 
infection ∼ 20). Cells were grown overnight at 37 °C without the addition of kanamycin. Cells 
were removed by centrifugation (5600 g, 4 °C, 10 min) and 40 ml of the culture supernatant was 
incubated on ice for 1 hour with one-fourth volume of ice-cold PEG/NaCl solution (20 % 
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polyethyleneglycol (PEG) 6000, 2.5 M NaCl). The precipitated phage particles were then 
collected by centrifugation (5600 g, 4 °C, 15 min) and redissolved in 2 ml of PBS and used for 
the second round of selection. 
For the subsequent selection rounds, about 1012 of the amplified phage particles were 
used as input and incubated with 100 µl of streptavidin-coated paramagnetic beads for 1 h to 
remove unspecific and streptavidin binding phage particles. After removing the beads, phage 
particles were incubated for 1 hour with 100 nM biotinylated target protein, complexes were 
captured on fresh beads, beads were washed 12 times with PBST, phages eluted with 400 µl of 
100 mM glycine-HCl, pH 2, for 10 min, the eluate neutralized with 36 µl of 2 M Tris-base and 
phage particles amplified and purified as described above. 
After three rounds, enrichment of phage particles displaying DARPins binding 
specifically to the target protein was monitored by phage ELISA. About 5 x 1010 phage particles 
(estimated spectrophotometically43) of the initial library and the amplified pools of each 
selection round were pipetted to wells with and without immobilized target protein and incubated 
at RT for 2 h. After washing the wells four times with 300 µl of PBST, bound phage particles 
were detected with mouse anti-M13 antibody horseradish peroxidase conjugate (Amersham 
Pharmacia Biotech, UK) and soluble BM Blue peroxidase (POD) substrate (Roche Diagnostics, 
Germany). 
5.10 Selection on immobilized target proteins 
For the first selection cycle about 3.5 x 1013 phage particles of the phage DARPin library 
were added to an immunotube containing the immobilized target protein (biotinylated target 
protein bound to neutravidin, which had been directly immobilized on the solid plastic surface) 
and incubated with rotation for 2 h. After rinsing the tube ten times with PBST, the phage 
particles were eluted with 500 µl of 100 mM Et3N (pH not adjusted) for 6 min, followed by 500 
µl of 100 mM glycine-HCl, pH 2, for 10 min. Eluates were neutralized with 250 µl of 1 M Tris-
Steiner et al.  61 
HCl, pH 7, or 45 µl of 2 M Tris-base, respectively, combined and used to infect 13 ml of 
exponentially growing E. coli XL1-Blue cells. After shaking for 1 hour at 37 °C cells were 
expanded into 130 ml of fresh 2YT medium containing 10 µg/ml chloramphenicol (cam) and 
incubated at 37 °C with shaking. Phage amplification and precipitation was done as described 
above. 
In the subsequent selection rounds about 1012 of the amplified phage particles were first 
incubated in a blocked immunotube (coated either with neutravidin or streptavidin used for 
immobilization of the target protein in the previous round of selection and BSA) one hour to 
remove neutravidin, streptavidin or unspecific binding phage particles. For the binding selection 
the phage particles were incubated for one hour in four wells containing the immobilized 
biotinylated target protein (directly coated neutravidin or streptavidin were alternately used in 
subsequent selection rounds). The wells were washed 12 times with PBST, phages eluted from 
each well with 100 µl of 100 mM glycine-HCl, pH 2, for 10 min, the combined eluates 
neutralized with 36 µl of 2 M Tris-base and phage particles amplified and purified as described 
above. After three rounds, enrichment was determined by phage ELISA as described above. 
5.11 Selection with epitope-masking 
The respective DARPins used for the epitope masking were expressed in 50 ml shake 
flask cultures and purified by IMAC as previously described.12 Pools of phage particles already 
partially enriched for binders against the respective target protein (1-2 rounds of selection on the 
target protein alone as described above) were used as input. Biotinylated target protein (100 nM) 
was pre-incubated for 1 hour with the respective DARPin (200 nM or 2 µM) prior to performing 
a standard selection round on soluble target protein as described above. After one round of 
selection with epitope-masking, amplified phage particles were analyzed by phage ELISA. 
Binding to immobilized target protein alone and in the presence of an excess of the respective 
DARPin (2 µM) used for epitope-masking was done as described above. 
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5.12 Screening of single clones 
From the selected phage pools showing specific binding to the respective target protein 
the DNA fragments encoding the DARPin inserts were subcloned into the expression vector 
pDST67 via BamHI/HindIII. 
Single selected DARPins were expressed in 96-deep-well plates. In brief, 1.2 ml of 2YT 
medium containing 1 % glucose and 50 µg/ml ampicillin was inoculated with a single, randomly 
picked colony of E. coli XL1-Blue harboring pDST67 encoding one of the respective selected 
DARPins and incubated overnight at 37 °C with shaking. Fresh 2YT medium (1.1 ml) containing 
50 µg/ml ampicillin was inoculated with 100 µl of the overnight culture. After incubation at 
37 °C for 1-2 h with shaking, 100 µl of 6.5 mM IPTG in 2YT were added to each well and 
protein expression was continued for 4 hours. Cells were harvested by centrifugation, 
resuspended in 50 µl B-PER II (Pierce, USA) by vigorous shaking for 20 min at room 
temperature. Then, 950 µl PBSTB was added and cell debris removed from the crude extract by 
centrifugation. 
For the ELISA, 10 µl to 100 µl of the above crude extracts were applied to wells with or 
without immobilized target protein and incubated at RT for 1 h. After washing the wells three 
times with 300 µl PBSTB, wells were incubated with an anti RGS-His antibody (QIAgen, 
Germany) (1:5,000 in PBSTB, 1 h at RT), as primary antibody. A goat anti–mouse IgG alkaline 
phosphatase conjugate (Sigma, USA) (1:10,000 in PBSTB, 1 h at RT) was used as secondary 
antibody. The bound DARPins were detected with the substrate di-sodium 4-nitrophenyl 
phosphate (pNPP, 3 mM) (Fluka, Switzerland) in buffer containing 50 mM NaHCO3 and 50 mM 
MgCl2 (Figure 1(b)).  
5.13 96 well purification of DARPins 
Selected DARPins identified as binders were expressed 96-deep well plates as described 
above. Eight plates containing fresh 2YT medium were inoculated in parallel with the overnight 
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culture, resulting in a total expression culture volume of about 10 ml for each clone. Cells were 
lysed as described above, the 400 µl B-Per II lysates for each clone were pooled and 400 µl of 
TBS500 (50 mM Tris/HCl, pH 8, 500 mM NaCl), containing 20% glycerol and 40 mM imidazol, 
were added. After centrifugation the cleared lysates were used for the 96-well IMAC purification 
(SwellGel Nickel Chelated Discs, 96-well filter plate, Pierce, USA) according to the supplier’s 
manual, yielding on average more than 1 mg of > 95% pure protein for each clone. Purified 
proteins were used for all further expereiments. 
5.14 Analytical size-exclusion chromatography (SEC) 
All IMAC-purified DARPins were analyzed at 10 µM concentration on a Superdex 75 
gel-filtration column (Amersham Pharmacia Biotech, USA) using a Pharmacia SMART system 
at a flow-rate of 60 µl/min and with PBS as running buffer (Figure 2). Phage protein D (gpD) 
with an apparent mass of 17.6 kDa and phage protein SHP, a trimer with and apparent mass of 
50.2 kDa were used as molecular mass standards. 
A subset of DARPins showing too high or too low elution volume in SEC were further 
analyzed by SEC multi-angle light scattering (SEC-MALS) measurements as recently 
described.36 
5.15 Competition ELISA measurements 
Biotinylated target proteins were bound to neutravidin, which had been directly 
immobilized on a MaxiSorp plate as described above. For competition, purified DARPins were 
incubated with varying amounts of non-biotinylated target protein present before (1 h at RT) and 
during the binding reaction (12 min at RT). After washing the wells three times with 300 µl 
PBSTB, wells were incubated with an anti RGS-His antibody horseradish peroxidase conjugate 
(QIAgen, Germany) (1:5,000 in PBSTB, 1 h at RT) and the bound DARPins were detected with 
soluble BM Blue POD substrate (Roche Diagnostics, Germany). 
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5.16 Epitope mapping by ELISA 
Biotinylated target proteins as well as biotinylated DARPin-pD fusions (see above) were 
bound to neutravidin, which had been directly immobilized on a MaxiSorp plate as described 
above. To the wells with immobilized DARPin-pD fusions the respective non-biotinylated target 
protein (100 µl, ~ 20 nM) in PBSTB was added for binding for 1 h at 4 °C. Purified non-
biotinylated DARPins (100 µl, ~ 50 nM) were used for the binding reaction (1 h at RT) and 
detection of bound DARPins was performed as described for the ELISA using crude cell extracts 
(see above). 
5.17 Surface plasmon resonance (SPR) 
SPR was measured by using a BIAcore 3000 instrument (BIAcore, Sweden). All 
measurements were performed in HBST buffer (20 mM HEPES, 150 mM NaCl, 3 mM EDTA 
pH 7.4, 0.005% Tween-20) at a flow rate of 50 µl/min throughout. The following amounts of 
biotinylated target protein described in Table 1 were immobilized on SA chips (BIAcore): 
ErbB1 (1000 RU), ErbB2-509 (400 RU), ErbB4 (600 RU), huIgG1_Fc (500 RU). For the 
determination of kinetic data, the interactions were measured as follows: five minutes initial 
buffer flow, followed by a 2 to 15 min injection of DARPin at different concentrations (1 nM to 
250 nM) and a final off-rate measurement of 10 to 75 minutes with buffer flow. The signal of an 
uncoated reference cell and buffer response was always subtracted from the sensograms (double 
referencing). The kinetic data of the interaction were evaluated with a global fit using Scrubber 2 
(BioLogic Software Ltd, USA). All sensograms are shown in the Supplementary Figure 2. 
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Table 1: Description of target proteins used for the selectionsa 
Target Protein Abbr. Selected Bindersb Descriptionc Acc. no.d 
Fc of huIgG1 huIgG1_Fc I_xx P100 – K330 of human IgG1 (Fc domain) SP: P01857 
TNFα TNFα T_xx A76 - L233 of human tumor necrosis factor 
precursor (TNFα) 
SP: P01375 
ErbB1 (1-501)e ErbB1 E_xx L25 – S525 of human receptor tyrosine-protein 
kinase ErbB1 fused to huIgG1_Fc 
SP: P00533 
ErbB2 (1-631)e ErbB2-631 H_xx S22 – T652 of human receptor tyrosine-protein 
kinase ErbB2 
SP: P04626 
ErbB2 (1-509)e ErbB2-509 9_xx S22 – N530 of human receptor tyrosine-protein 
kinase ErbB2 
SP: P04626 
ErbB4 (1-500)e ErbB4 B4_xx Q26 – R525 of human receptor tyrosine-protein 
kinase ErbB4 fused to huIgG1_Fc 
SP: Q15303 
aAbbreviations used: Fc, fragment crystallizable; IgG1, immunoglobulin G1. bNomenclature of selected binders, xx corresponds 
to the number of a specific binder. cThe first and last amino acid used as denoted in the respective Swiss-Prot reference are 
indicated in single letter amino acid code. dAccession number: SP, Swiss-Prot. eErbB receptors and in parentheses the amino 
acids of the mature extracellular domain as described in ref. 44. 
 
 
Table 2: Summary of the phage selection of DARPins against different target proteins 
Target Protein Round of selection No. positive 
clonesa 
No. different 
sequencesb 
Abbr. of binders further analyzed 
in this study 
huIgG1_Fc R3 82/94 8/21 I_01/02/07/11/13/19 
TNFα R2/3c 102/188 29/52 T_01/02/07/08/09/16/25/27/37/40 
ErbB1 R2/3d 97/369 1/64 E_01 
ErbB1 R1 (epitope-masking)e 81/105 4/20 E_67/68/69 
ErbB2-509 R3 83/94 13/29 9_16/26/29 
ErbB2-631 R1 (epitope-masking)e 24/94 8/16 H_14 
ErbB4 R3 55/143 5/48 B4_01/02/07/33/45 
ErbB4 R1 (epitope-masking)e 84/94 6/20 B4_50/58 
CitS (ref. 36) R3/4 110/124 11/21 cp34_15/16 (ref. 36) 
aRatio of the number of positive clones to the total number of clones screened in ELISA experiments. bNumber of clones 
with different sequences confirmed by ELISA experiments using purified DARPins to bind the target protein., identified in 
the total number of clones sequenced. cSum of the analysis of the 2nd and 3rd round of selection. dSum of the analysis of the 
2nd and 3rd round of different selection approaches. eOne round of selections with epitope-masking using preselected pools 
as input as described in the results section. 
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Table 3: Affinities and binding kinetics of DARPins 
Target Protein Clone (NxC)a KD 
[nM] 
kon 
[105 M-1s-1] 
koff 
[10-3s-1] 
ErbB1b E_01 (N3C) 0.5 4.4 0.2 
 E_67 (N3C) 7.3 0.3 0.2 
 E_68 (N3C) 0.7 26 1.9 
 E_69 (N4C) 15 0.7 1.1 
ErbB2-509b 9_16 (N3C) 6.9 1.2 0.9 
 9_26 (N3C) 1.4 0.7 0.1 
 9_29 (N3C) 3.8 2.0 0.8 
ErbB2-631c H_14 (N3C) 0.2 4.1 0.1 
ErbB4b B4_01 (N4C) 0.1 7.3 0.1 
 B4_02 (N3C) 0.4 1.2 0.1 
 B4_50 (N4C) 0.3 35 1.0 
 B4_58 (N5C) 9.0 16 14 
IgG1_Fcb I_02 (N2C) 41 2.8 12 
 I_07 (N2C) 25 0.7 1.7 
 I_11 (N3C) 140 4.9 67 
 I_19 (N3C) 2.1 3.4 0.7 
CitSd cp34_15 (N3C) 10 - - 
 cp34_16 (N3C) 1.9 - - 
aName of the respective clone and in parentheses number of internal repeat modules (x) 
stacked between N-Cap (N) and C-Cap (C). bAssociation (kon) and dissociation (koff) rate 
constants were measured by using surface plasmon resonance, and the respective 
dissociation constants KD was calculated as (koff/kon). Kinetic data, evaluation with a 
global kinetic fit and statistical error in the parameters is given in the Supplementary 
Figure 2. cC. Jost & A.P., unpublished data. dDissociation constants KD were measured 
by using equilibrium titration (BioVeris) and are described in detail in ref. 36. 
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Figure 1: Selection, screening and characterization of binders against huIgG1_Fc. (a) The enrichment for the 
selection performed on huIgG1_Fc was analyzed by phage ELISA. Equivalent amounts of the initial library (Lib) 
and pools of amplified phage particles from each selection round (R1i, R2s and R3s, subscript i denotes selection on 
immobilized target protein, subscript s denotes selection on soluble target protein) were tested for binding to 
immobilized streptavidin, neutravidin and immobilized huIgG1_Fc. For each sample applied the signal of bound 
phage particles, detected with an anti-M13 antibody is shown. (b) ELISA screening to identify DARPins with 
affinity for huIgG1_Fc. E. coli extracts of randomly picked clones expressing soluble DARPins of selection round 
three were analyzed for binding to immobilized full length huIgG1 and BSA (control). Positions A1 - A10 and B1 - 
B9 of a 96-well plate are shown. (c) SDS-PAGE analysis of the E. coli extracts used for ELISA screening (Figure 
1b). Size of the SDS-PAGE protein marker (Mr) is indicated in kDa. (d) ELISA with high affinity huIgG1_Fc 
binders. To analyze specificity 1 nM solutions of the binders I_01, I_02, I_07 and I_19 were tested for binding on 
neutravidin, huIgG1, mouse IgG1 (muIgG1) and mouse IgG2b (muIgG2b), and in parallel, competition was tested 
by preincubation of 1 nM solutions of the DARPins with 10 nM or 100 nM free huIgG1 before binding on 
immobilized huIgG1. (e) ELISA with low affinity huIgG1_Fc binders and control DARPin E3_5. To analyze 
specificity, 5 nM solutions of the binders I_11, I_13 and control DARPin E3_5 were tested for binding on 
neutravidin, huIgG1, muIgG1 and muIgG2b, and in parallel, competition was tested by preincubation of 5 nM 
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solutions of the DARPins with 100 nM or 500 nM of free huIgG1 before binding on immobilized huIgG1. All full 
length IgGs were directly immobilized on solid supports. The first word in the legend denotes the protein 
immobilized, no comp. denotes the absence of a competitor and + huIgG1 denotes the presence of competitor in 
10 nM, 100 nM or 500 nM concentrations. 
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Figure 2: Size exclusion chromatography (SEC) of selected DARPins. The chromatograms of the six huIgG1_Fc 
binders and the unselected DARPin E3_5 are shown as examples. For each DARPin the number of repeats stacked 
between N-Cap (N) and C-Cap (C) is given in brackets. The molecular mass standards, phage protein D (gpD) with 
an apparent mass of 17.6 kDa and phage protein SHP, a trimer with an apparent mass of 50.2 kDa are indicated by 
arrows. 
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Figure 3: ELISA of selected TNFα binding DARPins. To analyze specificity 5 nM solutions of the selected 
DARPins were tested for binding on neutravidin, immobilized TNFα and immobilized TNFα preincubated with an 
excess (500 nM) of Etanercept (EnbrelTM, recombinant human soluble tumor necrosis factor alpha receptor fused to 
the Fc domain of human IgG1). In parallel, competition was tested by preincubation of 5 nM solutions of the 
DARPins with 10 nM or 100 nM free TNFα before binding on immobilized TNFα. Only a subset of the selected 
TNFα binders is shown and unselected DARPin E3_5 was used as control. The first word in the legend denotes the 
protein immobilized, no comp. denotes the absence of a competitor and + TNFα or + Enbrel denotes the presence of 
competitor (respective concentrations given in nM). 
 
 
Figure 4: Equivalent amounts of the input and output phage particles form one round of epitope-masking 
performed on ErbB1 (by adding soluble DARPin E_01) and on ErbB4 (by adding soluble DARPin B4_04) were 
analyzed by phage ELSIA as described in Figure 1. Additionally, binding was tested on the respective target protein 
preincubated with an excess of the respective DARPin (ErbB1 + E_01 or ErbB4 + B4_02). Subscript s denotes 
selection on target protein in solution. The first word in the legend denotes the protein coated, no comp. denotes the 
absence of a competitor and + E_01 or + B4_02 denotes the presence of 2 µM competitor.  
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Figure 5: ELISA of selected ErbB1 and ErbB4 binding DARPins. 50 nM solution of the selected (a) ErbB1 and 
(b) ErbB4 binders was tested for interaction with immobilized target protein (ErbB1 or ErbB4, respectively), target 
protein bound to immobilized DARPin used for epitope-masking during the selection round (E_01—ErbB1 or 
B4_02—ErbB4, respectively) and neutravidin. (c, d) Specificity was tested by applying a 50 nM solution of the 
selected ErbB1 (c) and ErbB4 (d) binders on immobilized ErbB-receptors (ErbB1, ErbB2-631 and ErbB4) and 
neutravidin. DARPin E3_5 was used as control in all experiments. ErbB1 binders E_67, E_68 and E_69 and ErbB4 
binders B4_50 and B4_58 were selected by epitope masking. 
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Figure 6: The enrichment for the selections performed on ErbB2-631 in solution at RT and on ErbB2-509 at 4 °C 
were analyzed by phage ELISA. Equivalent amounts of the initial library (Lib) and pools of amplified phage 
particles from each selection round (R1, R2 and R3) were tested for binding to immobilized streptavidin, neutravidin 
and immobilized ErbB2-631 and ErbB2-631. For each sample applied the signal of bound phage particles, detected 
with an anti-M13 antibody, is shown. For each round the subscript denotes if the selection was performed on 
immobilized target protein (i) or on target protein in solution (s). 
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8. Supplementary Material: 
 
Efficient Selection of DARPins with Subnanomolar Affinity using SRP Phage 
Dipslay (Daniel Steiner, Patrik Forrer and Andreas Plückthun) 
 
8.1 Supplementary Results: Development of the „optimized selection protocol“ 
This section describes the development of an optimized selection protocol for our 
DARPin phage library, based on experiences from the different selection approaches using 
members of the ErbB receptor family as target proteins. For both, ErbB1 and ErbB4, the 
extracellular domains I-III of the respective receptor fused to huIgG1_Fc were used as targets 
(see Table 1 of the publication). For the first panning we had performed three rounds of 
selection on immobilized target protein as described in the Material and Methods section of the 
publication. During the second and third selection rounds we added an excess of soluble 
huIgG_Fc (1 µM) to the selection reaction to counter-select binders against the Fc domain. From 
each selection round we analyzed the amplified pool of phage particles by phage ELISA 
(Supplementary Figure 3(a) and 3(b)). For ErbB1 good enrichment of phage particles 
displaying target specific DARPins was observed for the second and third round, with a slight 
enrichment of phage particles showing unspecific background binding (binding of non-target-
coated matrix) (Supplementary Figure 3(a)). For ErbB4 the enrichment of such background 
binding phage particles was much stronger, and almost equal signals were obtained on 
neutravidin, streptavidin and immobilized target protein (Supplementary Figure 3(b)). This 
background binding could be reduced by applying extensive prepanning steps on non-target-
coated matrix before performing the selection round on the target protein, but not to the level 
required for efficient screening of single clones (data not shown). Sequence analysis of some of 
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these background binders revealed defective DARPins of which part of the DARPin framework 
is not consensus due to multiple deletions or insertions (members of the non-functional part of 
the initial library). The C-terminal part of all of the clones analyzed was in frame with the phage 
coat protein, a prerequisite for display on phage particles. 
Selection on target protein in solution was previously reported to results in less 
background enrichment when compared to selections on immobilized target proteins.1 Thus, to 
avoid enrichment of phage particles with such background binding properties we performed 
another three rounds (starting with a fresh library aliquot) of selection on ErbB1 and ErbB4 in 
solution as described in the Material and Methods section of the publication. During the second 
and third selection rounds soluble huIgG1_Fc was added for competitions as described above. 
Analysis of the amplified pools of phage particles by phage ELISA showed for both selections 
highly specific binding signal on the respective target protein in round three (Supplementary 
Figure 3(c) and 3(d)) without enrichment of background binding phage particles. When 
comparing the results obtained for selection on immobilized ErbB1 (Supplementary Figure 
3(a)) and ErbB1 in solution (Supplementary Figure 3(c)) a faster enrichment of binders is 
revealed when performing the selection on immobilized target protein, however, with the 
disadvantage of a higher tendency for the enrichment of background binding phage particles. As 
a consequence, we combined both methods performing the first round of selection on 
immobilized target protein (high recovery of phage particles needed in order not to irreversibly 
lose binders), followed by two rounds on target protein in solution, turned out to be the most 
effective selection strategy and was used as optimized selection protocol for our phage DARPin 
library. Results obtained by using this protocol for selection of binders against ErbB1 
(Supplementary Figure 3(e)) do show fast enrichment of target specific binders without any 
enrichment of background binding phage particles (see also selections on huIgG1_Fc, TNFα and 
Her2-509 described in the results section of the publication). 
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8.2 Supplementary Discussion: Target protein dependent selection approaches 
Many methods of target protein presentation have been used for phage selections2 
including panning on whole cells, on tissues or even using living organisms, but if available, 
purified target protein is preferentially used. The biophysical properties of a purified target 
protein do strongly influence the selection procedure, and, therefore, the chance of successful 
selection of binders from a given library. For “well behaved” target proteins such as the 
huIgG1_Fc domain the selection is simple and straightforward (Figure 1(a) of the publication). 
For more complicated target proteins (e.g. membrane proteins or proteins with low stability) the 
careful design of the selection procedure is essential to guide the selection into the desired 
direction in order to obtain specific binders. Background enrichment, meaning the accumulation 
of binders that do unspecifically bind to the non-target coated matrix, was highly target-protein 
dependent in our hands. When comparing selections on immobilized ErbB1 and ErbB4, much 
lower background enrichment was observed for ErbB1 (Supplementary Figure 3(a)), than for 
ErbB4 where background binding signals were almost equal to the specific binding signals on 
the target protein (Supplementary Figure 3(b)). Prepanning on non-target coated matrix only 
slightly improved the result. Performing the selections on the same target protein in solution 
completely abolished unspecific background binding signals (Supplementary Figure 3(c) and 
3(d)). This might be attributed to the short capturing step and the possibility to change the 
reaction vial during the selection process.  
Target protein presentation not only has an influence on background enrichment but also 
on enrichment factors. Even if accompanied by background enrichment we observed a faster 
enrichment when performing selections on immobilized target protein, compared to selections on 
soluble target protein (Supplementary Figure 3(a) and 3(c)). One possible explanation is that 
the immobilization of the target protein on solid plastic support leads to a locally very high 
concentration of the target protein, favorable for the capturing of all potential binders, which is 
especially important for the first selection round. 
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From the observations described above we used for most other selections our optimized 
selection protocol composed of a first selection round on immobilized target protein, followed by 
two rounds of selection on soluble target protein. In the case of ErbB1 this lead to the very fast 
enrichment of specific binders (Supplementary Figure 3(e)) without any detectable background 
enrichment and was further successfully used for the selection on huIgG1_Fc, TNFα and ErbB2-
509. 
8.3 References 
1. Dennis, M.S. in Phage display in biotechnology and drug discovery. (ed. S.S. Sidhu) 143 
- 164 (CRC, Boca Raton; 2005). 
2. Bradbury, A.R. & Marks, J.D. Antibodies from phage antibody libraries. J. Immunol. 
Methods 290, 29-49 (2004). 
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Supplementary Figure 1. Schematic representation of the phagemid pPDV1. The expression cassette is composed 
of a lac promoter/operator element (lacP), the coding sequences for the signal sequence of E. coli DsbA (DsbAss) 
leading to SRP dependent translocation, the multiple cloning site (MCS) to introduce the gene encoding the protein 
of interest (POI) with the restriction sites BamHI, KpnI, PstI, and HindIII depicted, a suppressable stop codon 
(amber codon (TAG)), the coding sequences for a flexible glycine/serine linker (G/S) and for the C-terminal domain 
(amino acids 250-406) of protein 3 of filamentous phage M13 (p3_CT), mediating incorporation of the fusion 
protein into the phage particle. The coding sequence of the POI is flanked by DNA sequences encoding a FLAG-tag 
(FLAG), an enterokinase site (EK) and a His6 tag (6xHis). In addition, the vector carries a f1 origin of replication (f1 
ori) to permit production of virions using an appropriate helper phage, such as VCS M13; a plasmid origin (ColE1 
ori), the lacIq gene providing high levels of the lac repressor for the control of the lacP in cis and an antibiotic 
resistance marker (the gene for chloramphenicol acetyl transferase (cat), providing resistance to chloramphenicol) to 
allow propagation as a plasmid in E. coli 
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Supplementary Figure 2: Affinity determination of selected DARPins. Surface plasmon resonance (SPR) was 
measured using a BIAcore 3000 instrument (BIAcore, Uppsala Sweden). All measurements were performed in 
HBS-T buffer (20 mM HEPES, 150 mM NaCl, 3 mM EDTA pH 7.4, 0.005% Tween-20) at a flow rate of 50 µl/min. 
The following amounts of biotinylated target protein described in Tabel 1 of the man publication were immobilized 
on SA chips (BIAcore): ErbB1 (1000 RU), ErbB2 (509) (400 RU), ErbB4 (600 RU), huIgG1_Fc (500 RU). For the 
determination of kinetic data, the interactions were measured as follows: five minutes initial buffer blow, followed 
by a 2 to 15 min injection of DARPin at different concentrations (1 nM to 250 nM) and a final off-rate measurement 
of 10 to 75 minutes with buffer flow. The signal of an uncoated reference cell and buffer response was always 
subtracted from the sensograms (double referencing). The kinetic data of the interaction were evaluated with a 
global fit using Scrubber 2 (BioLogic Software Ltd). For each DARPin analyzed a representative set of curves with 
the corresponding fits are shown below. The statistical errors in the parameters given are those obtained from the 
best fit error and underline data quality and the good description of the data by the model. However, the true error of 
the parameter, estimated from measurements of independent protein preparations will be at least ±20%. Results are 
shown for DARPins binding ErbB1: (a) E_01, (b) E_67, (c) E_68 and (d) E_69, ErbB2: (e) 9_16, (f) 9_26 and (g) 
9_27, ErbB4: (h) B4_01, (i) B4_02, (j) B4_50 and (k) B4_58 and huIgG1_Fc: (l) I_02, (m) I_07, (n) I_11 and (o) 
I_19. 
a) E_01 
 
KD = 496 ± 2 pM   kon = (44.2 ± 0.2) x 104 M-1s-1   koff = (0.2194 ± 0.0007) x 10-3s-1 
DARPin concentrations [nM]: 1, 2.5, 5, 7.5, 10, 15, 25, 40 
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b) E_67 
 
KD = 7.3 ± 0.1 nM   kon = (2.95 ± 0.04) x 104 M-1s-1   koff = (0.215 ± 0.002) x 10-3s-1 
DARPin concentrations [nM]: 2, 5, 10, 20, 35, 50, 80, 120 
 
c) E_68 
 
KD = 724 ± 3 pM   kon = (258.6 ± 0.8) x 104 M-1s-1   koff = (1.873 ± 0.006) x 10-3s-1 
DARPin concentrations [nM]: 1, 2.5, 5, 7.5, 10, 15, 25 
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d) E_69 
 
KD = 15.20 ± 0.08 nM kon = (7.32 ± 0.03) x 104 M-1s-1   koff = (1.113 ± 0.003) x 10-3s-1 
DARPin concentrations [nM]: 1, 2, 5, 10, 20, 35, 50, 75 
 
e) 9_16 
 
KD = 6.90 ± 0.02 nM  kon = (12.36 ± 0.01) x 104 M-1s-1   koff = (0.853 ± 0.003) x 10-3s-1 
DARPin concentrations [nM]: 1, 2, 5, 10, 20, 35, 50, 75 
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f) 9_26 
 
KD = 1.36 ± 0.03 nM  kon = (7.38 ± 0.01) x 104 M-1s-1   koff = (0.101 ± 0.002) x 10-3s-1 
DARPin concentrations [nM]: 2, 5, 10, 20, 35, 50, 75 
 
g) 9_29 
 
KD = 3.83 ± 0.03 nM  kon = (20.25 ± 0.04) x 104 M-1s-1   koff = (0.776 ± 0.007) x 10-3s-1 
DARPin concentrations [nM]: 1, 2, 5, 10, 20, 35, 50, 75 
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h) B4_01 
 
KD = 80 ± 2 pM  kon = (72.8 ± 0.5) x 104 M-1s-1   koff = (0.058 ± 0.001) x 10-3s-1 
DARPin concentrations [nM]: 2.5, 5, 7.5, 10, 15, 25, 40, 60 
 
i) B4_02 
 
KD = 387 ± 3 pM   kon = (11.63 ± 0.06) x 104 M-1s-1   koff = (0.045 ± 0.004) x 10-3s-1 
DARPin concentrations [nM]: 1, 2.5, 5, 7.5, 10, 15, 25, 40, 60 
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j) B4_50 
 
KD = 273.7 ± 0.7 pM  kon = (348 ± 2) x 104 M-1s-1   koff = (0.952 ± 0.003) x 10-3s-1 
DARPin concentrations [nM]: 1, 2.5, 5, 7.5, 10, 15 
 
k) B4_58 
 
KD = 9.00 ± 0.01 nM  kon = (159.3 ± 0.05) x 104 M-1s-1   koff = (14.34 ± 0.05) x 10-3s-1 
DARPin concentrations [nM]: 1, 2.5, 5, 7.5, 10. 15, 20, 35, 50, 75 
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l) I_02 
 
KD = 41.1 ± 0.1 nM  kon = (28.29 ± 0.06) x 104 M-1s-1   koff = (11.62 ± 0.02) x 10-3s-1 
DARPin concentrations [nM]: 10, 25, 50, 75, 100, 150 
 
m) I_07 
 
KD = 24.5 ± 0.1 nM  kon = (7.03 ± 0.03) x 104 M-1s-1   koff = (1.723 ± 0.007) x 10-3s-1 
DARPin concentrations [nM]: 10, 20, 35, 50, 75, 100 
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n) I_11 
 
KD = 137 ± 1 nM   kon = (48.6 ± 0.3) x 104 M-1s-1   koff = (66.5 ± 0.5) x 10-3s-1 
DARPin concentrations [nM]: 10, 25, 50, 75, 100, 150, 250 
 
o) I_19 
 
KD = 2.07 ± 0.01 nM  kon = (33.7 ± 0.3) x 104 M-1s-1   koff = (0.695 ± 0.004) x 10-3s-1 
DARPin concentrations [nM]: 2, 5, 10, 20, 35, 50, 75 
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Supplementary Figure 3. Selection approaches on ErbB1 and ErbB4. The enrichments for the selections performed 
on (a) immobilized ErbB1, (b) immobilized ErbB4, (c) ErbB1 in solution, (d) ErbB4 in solution and (e) ErbB1 by 
using the optimized selection protocol were analyzed by phage ELISA. Equivalent amounts of the initial library 
(Lib) and pools of amplified phage particles from each selection round (R1, R2 and R3) were tested for binding to 
immobilized streptavidin, neutravidin, immobilized ErbB1 and ErbB4. For each sample applied the signal of bound 
phage particles, detected with an anti-M13 antibody, is shown. For each round the subscript denotes if the selection 
was performed on immobilized target protein (i) or on target protein in solution (s). 
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TNFα (5 nM) + T_25 (200 nM)
TNFα (15 nM)
TNFα (1 nM) + T_25 (200 nM)
TNFα (15 nM) + T_25 (200 nM)
TNFα (1 nM)
TNFα (5 nM)
Analyte:
 
Supplementary Figure 4. Surface plasmon resonance (SPR) was measured using a BIAcore 3000 instrument 
(BIAcore, Uppsala Sweden). Measurements were performed in HBST buffer (20 mM HEPES, 150 mM NaCl, pH 
7.4, 0.1% Tween-20) at a flow rate of 50 µl/min. Enbrel was directly coupled to a dextran-chip according to the 
manufacturer’s protocol (CM5, Biacore, 350 RU) and soluble TNFα (1 nM, 5 nM and 15 nM) alone and 
preincubated with DARPin T_25 (200 nM) injected for 4 minutes and the dissociation recorded for 20 minutes with 
buffer flow. The signal of an uncoated reference cell was subtracted from the sensograms. 
 
Supplementary Figure 5. Characterization of the DARPin T_07 – TNFα complex formation by size-exclusion 
chromatography combined with multi-angle light scattering (SEC-MALS). The OD280 signals are depicted as solid 
lines (left y-axis) and the molar mass of the respective elution peak indicated with filled circles (right y-axis). TNFα 
alone (red line), T_02 alone (grey line) and TNFα preincubated with an equimolar amount of DARPin (blue line) 
were analyzed at the concentrations described in the figure. The weight-average molar mass over the respective 
elution peaks are: TNFα alone (52.8 kDa, red circles), T_02 alone (18.8 kDa, grey circles) and TNFα preincubated 
with an equimolar amount of DARPin (53.5 kDa, blue circles). Protein samples were incubated in PBS containing 
0.1% Tween-20 for at least 1 h at room temperature before injection and concentrations for TNFα are given for the 
monomer. 
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Abstract
The determination of 3D structures of membrane proteins is still extremely diﬃcult. The co-crystallization with speciﬁc binding pro-
teins may be an important aid in this process, as these proteins provide rigid, hydrophilic surfaces for stable protein–protein contacts.
Also, the conformational homogeneity of the membrane protein may be increased to obtain crystals suitable for high resolution struc-
tures. Here, we describe the eﬃcient generation and characterization of Designed Ankyrin Repeat Proteins (DARPins) as speciﬁc binding
molecules for membrane proteins. We used both phage display and ribosome display to select DARPins in vitro that are speciﬁc for the
detergent-solubilized Na+-citrate symporter CitS of Klebsiella pneumoniae. Compared to classical hybridoma technology, the in vitro
selection systems allow a much better control of the structural integrity of the target protein and allow the use of other protein classes
in addition to recombinant antibodies. We also compared the selected DARPins to a Fab fragment previously selected by phage display
and demonstrate that diﬀerent epitopes are recognized, unique to each class of binding molecules. Therefore, the use of several classes of
binding molecules will make suitable crystal formation and the determination of their 3D structure more likely.
 2007 Elsevier Inc. All rights reserved.
Keywords: Co-crystallization; Designed ankyrin repeat proteins (DARPins); In vitro selection; Membrane protein; Multi-angle (static) light scattering
(MALS); Na+-citrate symporter CitS; Phage display; Recombinant antibody Fab fragment; Ribosome display; Protein engineering
1. Introduction
Multitopic membrane proteins, such as channels, trans-
porters or receptors, are involved in many fundamental
biological processes and today, the majority of drug targets
are integral membrane proteins. Therefore, there is an
immediate and growing need for high-resolution structure
information to gain detailed insight into the function of
membrane proteins at the atomic level.
In the diﬀerent genomes analyzed to date, 20–30% of all
open reading frames encode integral membrane proteins
(Wallin and von Heijne, 1998). As of September 2006, only
about 100 membrane protein structures2,3 have been depos-
ited in the Protein Data Bank (Berman et al., 2000), and
this even includes all homologs from diﬀerent species and
a number of relatively robust bacterial outer membrane
proteins with b-barrel topology. The even smaller number
of non-redundant a-helical membrane proteins remains in
stark contrast to the about 12,0004 solved structures of
non-redundant5 soluble proteins. This contrast points out
the diﬃculties in membrane protein structure
determination.
1047-8477/$ - see front matter  2007 Elsevier Inc. All rights reserved.
doi:10.1016/j.jsb.2007.01.013
* Corresponding author. Fax: +41 44 635 57 12.
E-mail address: plueckthun@bioc.unizh.ch (A. Plu¨ckthun).
1 Present address: Department of Biochemistry, University of Washing-
ton, Seattle, WA 98195, USA.
2 www.mpibp-frankfurt.mpg.de/michel/public/memprotstruct.html
3 http://blanco.biomol.uci.edu/Membrane_Proteins_xtal.html
4 http://www.pdb.org/pdb/holdings.do
5 Proteins with less than 70% identity.
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1.1. Crystallization of membrane proteins
A major bottleneck in structure determination of mem-
brane proteins is the production of high quality crystals.
The diﬃculties are mainly attributed to the inherent pro-
tein ﬂexibility and conformational inhomogeneity of the
detergent-solubilized membrane protein–detergent com-
plex. Additionally, the polar surface of those membrane
proteins having only very short solvent-exposed loops can-
not reach beyond the detergent layer wrapped around the
hydrophobic surface, and therefore stable protein–protein
contacts essential for crystal packing are not formed.
1.2. Co-crystallization
A relatively new approach to overcome these problems
is the co-crystallization of membrane proteins with anti-
body fragments (reviewed in Hunte and Michel, 2002).
For successful co-crystallization a stable complex of an
antibody fragment bound to a structural epitope present
in the native conformation of the membrane protein is
needed. Thereby, the bound antibody fragment reduces
the protein ﬂexibility and increases the conformational
homogeneity of the membrane protein–detergent complex
since it recognizes—ideally—only the native and functional
conformation of the membrane protein. This speciﬁcity can
also be exploited during membrane protein puriﬁcation to
increase the homogeneity of the protein sample (Kleymann
et al., 1995). Equally important, the bound antibody frag-
ment provides additional polar surfaces to mediate stable
protein–protein contacts for well-ordered crystal packing.
However, this speciﬁcity comes at a cost: a new binding
molecule fulﬁlling all the above requirements has to be gen-
erated for each membrane protein structure to be solved.
Published co-crystals of membrane proteins and anti-
body fragments include cytochrome c oxidase from Para-
coccus denitriﬁcans (PDB entries 1QLE/1AR1),
cytochrome bc1 complex from Saccharomyces cerevisiae
alone (PDB entries 1EZV/1KB9) and in complex with
cytochrome c (PDB entry 1KYO), potassium channel
KcsA from Streptomyces lividans (PDB entries 1K4C/
1K4D/1R3I/1R3J/1R3K/1R3L/2BOB/2BOC), and the
ClC chloride channel from Escherichia coli (PDB entries
1OTS/1OTT/1OTU). Interestingly, in all crystal structures
the antibody fragment ﬁlls the gap between adjacent mem-
brane proteins in the crystal lattice and mediates important
protein–protein interactions for well-ordered packing.
1.3. Monoclonal antibodies
In all published examples the antibody fragments used
for co-crystallization were ultimately derived from mono-
clonal antibodies, and Fab fragments were either produced
by proteolysis of the IgG or the antibody fragment genes
from hybridomas were cloned and expressed in E. coli.
Several fundamental problems are encountered, how-
ever, in the generation of monoclonal antibodies with the
desired properties from animals. When the solubilized
membrane protein is injected into the animals, the deter-
gent is diluted and the further fate of the protein and its
conformational integrity cannot be controlled. The use of
adjuvants such as mineral oil casts an additional shadow
of doubt on maintaining the native structure for a long
time. The membrane protein is processed by antigen-pre-
senting cells and at the same time, some molecules need
to be bound to IgM on the surface of B-cells, which triggers
the antibody response in the animal. It is at least doubtful
whether the conformational epitopes would still be intact
at this stage, unless the protein is very stable. Subsequent
screening of hybridomas for reactivity with the native state
of the protein will detect those antibodies that bind to epi-
topes present in the folded structure—if such antibodies
have been elicited at all. However, when producing anti-
bodies against less rigid molecules, e.g. GPCRs, it is highly
likely that most binders that do crossreact with the native
protein will be directed against exposed N- or C-terminal
tails (Niebauer et al., 2006) or extracellular compact
domains, rather than that binders recognize the loops con-
necting the helices in their native conformation. If the pro-
tein denatures during the immunization process, many
‘‘real’’ conformational epitopes will be lost and conforma-
tion-speciﬁc antibodies are not found.
1.4. Our approach
Here, we demonstrate the use of in vitro selection meth-
ods to overcome the above limitations and we report a fast
downstream screening process to eﬃciently identify suit-
able binding partners of membrane proteins for co-crystal-
lization. After we showed in a previous study that
conformation-speciﬁc, high-aﬃnity antibody Fab frag-
ments that bind to the detergent-solubilized Na+-citrate
symporter CitS can be generated by phage display (Ro¨thlis-
berger et al., 2004), we now expand this approach to
another selection system as well as to another class of bind-
ing proteins. With the use of a diﬀerent class of binding
proteins the shape of the binding module can be varied
and we intended by using diﬀerent binding molecules to
obtain binders to diﬀerent epitopes. Both factors can lead
to diﬀerent crystal packing, which should clearly increase
the chance of crystal formation suitable for high resolution
structure determination.
1.5. Recombinant Fab fragments and Designed Ankyrin
Repeat Proteins
The two classes of binding proteins investigated and
compared here are antibody Fab fragments and Designed
Ankyrin Repeat Proteins (DARPins). The heterodimeric
Fab fragment (Fig. 1a) consists of the entire light chain
(VL and CL domains) and the Fd fragment (VH and CH
domains) of the heavy chain, which—in the format used
in this study—are not disulﬁde-linked to each other (Ro¨th-
lisberger et al., 2004). The antigen binding site is formed by
T. Huber et al. / Journal of Structural Biology 159 (2007) 206–221 207
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the VL and VH domains and is constituted of three loops
(complementarity determining regions, CDRs) from each
domain, which are highly diverse in sequence and length.
We have used a fully synthetic antibody library, based on
the original HuCAL consensus design (Knappik et al.,
2000), but limiting the library to the most stable and best
expressing VH and VL frameworks (Ewert et al., 2003),
which are randomized in all 6 CDRs and were used in
the format of Fab fragments (Ro¨thlisberger et al., 2004).
Even though the in vitro selection by phage display and
the subsequent preparation of milligram quantities of
Fab fragments is possible, there are still good reasons to
explore alternative frameworks. First, the Fab fragment
contains four intramolecular disulﬁde bonds and can thus
not be exposed to reducing conditions that some mem-
brane proteins may require, and second, the preparation
of Fab fragments for crystallization trials typically requires
ﬁve to ten liters of E. coli culture. Finally, despite the vari-
ety of shapes of antibody binding sites, caused by the
length and sequence variation of the CDRs, we have no
information on how many diﬀerent epitopes we actually
targeted on a given detergent-solubilized integral mem-
brane protein.
Ankyrin repeat proteins occur in all phyla and mediate
important protein–protein interactions in all cell compart-
ments (Bork, 1993). Their modular structure is built from
stacked, 33-amino acid repeats, each forming a b-turn fol-
lowed by two antiparallel a-helices and a loop connecting
to the b-turn of the next repeat. Using a combination of
sequence and structural alignments, potential interaction
residues were identiﬁed in the b-turn and ﬁrst a-helix
and were randomized in the library design, while con-
served intra- and inter-repeat interactions characteristic
for the ankyrin fold were preserved (Fig. 1b) (Binz
et al., 2003). Varying numbers of designed ankyrin repeats
(typically 2 or 3) were cloned in between specialized N-
and C-terminal capping-repeats which seal the hydropho-
bic core of a stack of the ankyrin repeats that are carrying
the potential binding interface. These DARPins are
termed N2C and N3C, respectively, denoting their inter-
nal repeat numbers. This procedure yielded libraries of
DARPins with varying size of randomized interaction sur-
face. Their members have very favorable biophysical
properties, very high expression yields (Binz et al., 2003)
and have been selected for speciﬁc binding to soluble tar-
gets before (Binz et al., 2004).
1.6. In vitro selection
The interest in rapid isolation of speciﬁc, high-aﬃnity
polypeptide binders against a broad range of target mole-
cules lead to the development of diﬀerent display technolo-
gies (Hoogenboom, 2005; Binz et al., 2005). The underlying
principle of all these display technologies is the linkage of
phenotype and genotype. Thereby, speciﬁc binders with
desired properties can be enriched from large collections
of variants over several consecutive selection cycles. In
the present study, phage display and ribosome display were
used.
1.7. Phage display
The most widely used display technology is phage dis-
play, where the protein (phenotype) is displayed on the sur-
Fig. 1. (a) Surface and corresponding cartoon representation of a Fab fragment. Left, side view where the binding site is on top. The surface of the light
chain (VL + CL) is depicted in light grey and its binding site (CDRs) in red. The corresponding elements of the heavy chain (VH + CH) are dark grey and
the CDRs are depicted in blue. In the cartoon representation, the two chains are colored green (light chain) and cyan (heavy chain). Right, top view on the
binding site of the Fab fragment. (b) Surface and corresponding cartoon representation of an N3C consensus DARPin (PDB entry: 1MJ0). The variable
positions are colored red in the surface representation. The individual repeats are colored diﬀerently in the cartoon picture. Side view (left) and top view
(right) on the binding site. Figures were generated with PyMol (DeLano, 2002).
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face of a ﬁlamentous phage particle while the respective
DNA (genotype) is encapsulated inside (Smith and Petre-
nko, 1997; Hoogenboom, 2002). The power of phage dis-
play lies in the robustness of the phage particle, which
allows selections to be performed under a wide range of
conditions, including the presence of many detergents. A
limiting step in phage display, however, is the involvement
of E. coli transformation, which restricts the diversity of
the initial library to 109–1010 members. In the case of aﬃn-
ity maturation, this in vivo step makes the iteration between
random mutagenesis, repeated library construction and
selection unattractive, as it is very laborious. Furthermore,
the in vivo ampliﬁcation of the phage particles can lead to a
bias in selection due to growth advantage of certain clones.
However, the assembly pathway of ﬁlamentous phages
allows heterodimers (e.g. Fab fragments) to be displayed
on the phage surface. A scheme of the selection cycle is
depicted in Fig. 2a.
1.8. Ribosome display
To overcome the limitations caused by the involvement
of living cells, ribosome display was developed as a com-
pletely in vitro display technology (Hanes and Plu¨ckthun,
1997). This method relies on the formation of a non-cova-
lent ternary complex of mRNA (genotype), ribosome and
nascent polypeptide (phenotype). These complexes are
formed during in vitro translation, and therefore very large
libraries of up to 1014 members can be sampled (limited by
the amount of cell-free translation extract used and the
amount of diverse input DNA). The ease of introducing
mutations during the selection cycle by methods such as
error-prone PCR or DNA shuﬄing makes this display
technology a very powerful tool for aﬃnity maturation of
binding proteins. The relatively low stability of the ternary
complex narrows the range of selection conditions, but we
show here that selection in detergent for binding to a solu-
a b
Fig. 2. (a) Schematic representation of a phage display selection cycle. A phage library displaying variants of the protein of interest on the surface while
having the respective gene encapsulated inside the phage particle is used for the binding selection on the immobilized target [1]. After formation of the
complexes between the binding protein and the membrane protein, unbound phage particles are washed oﬀ [2]. The bound phages are eluted from
the immobilized target by a pH shift [3] and used for the infection of E. coli. Phage particles are ampliﬁed [4] and can then be analyzed or used as input for
the next selection round. (b) Schematic representation of a ribosome display selection cycle. An mRNA library encoding the proteins of interest without
stop codon is translated in vitro [5]. After cooling, the translation yields stable ternary complexes of mRNA, ribosomes and nascent polypeptides. These
complexes are used for the binding selection on the immobilized target [6]. After binding of the polypeptides to the membrane protein, unbound complexes
are washed oﬀ [7]. The mRNA of the bound complex is eluted by dissociating the ribosomal complex with EDTA [8]. A reverse transcription reaction
followed by PCR yields the genetic information of the selected clones [9]. The ampliﬁed genes can then be used as input for the next selection round
starting with in vitro transcription [10] or cloned into plasmids for analysis.
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bilized membrane protein is possible. A scheme of the
selection cycle is depicted in Fig. 2b.
1.9. Na+-citrate symporter CitS as model target
The model system used for this study is the Na+-citrate
symporter CitS from Klebsiella pneumoniae, a typical inte-
gral membrane protein of the helix-bundle type. CitS has a
predicted molecular mass of about 50 kDa and belongs to
the family of 2-hydroxy-carboxylate transporters (2HCT)6
found exclusively in bacteria. Currently, almost 40 mem-
bers of the 2HCT family are known (Sobczak and Lolk-
ema, 2005). The determined hydropathy proﬁle is highly
conserved throughout the family, and it is assumed that
all members of the 2HCT family share a common fold.
However, no 3D structure is available so far for any mem-
ber of the 2HCT family. CitS is responsible for citrate
uptake during the anaerobic breakdown of citrate in K.
pneumoniae which ultimately leads to ATP formation. CitS
transports the citrate dianion (Hcit2) in symport with two
Na+ ions and one H+ ion across the membrane. A topol-
ogy model of CitS was determined using PhoA fusions,
site-directed Cys labeling, insertion of reporter proteins,
and expression in an in vitro translation/insertion system
(van Geest and Lolkema, 2000). According to this model,
CitS consists of 11 transmembrane segments (TMS) with
the N-terminus in the cytoplasm and the C-terminus in
the periplasm and relatively short loops connecting the
TMS (Fig. 3a). CitS is so far the only member of the
2HCT family that has been puriﬁed to homogeneity and
functionally reconstituted into proteoliposomes (Pos and
Dimroth, 1996). Therefore, it is assumed that CitS is in a
functional state when detergent-solubilized. This is not
only important for crystallographic studies of the mem-
brane protein but is also crucial for successful in vitro
selections.
There are certain advantages of using detergent-solubi-
lized membrane proteins as targets for selection over the
use of whole cells or reconstituted proteoliposomes. The
advantages are the accessibility of both extracellular and
intracellular epitopes, the higher monodispersity of the tar-
get, and the simpliﬁcation of the selection procedure. Nev-
ertheless, it must be kept in mind that the detergent may
also shield regions (epitopes) of the membrane protein
and that the membrane protein might, at least in principle,
adopt a non-functional conformation.
2. Materials and methods
2.1. Protein expression and puriﬁcation
2.1.1. Na+-citrate symporter CitS from K. pneumoniae
CitS containing an N-terminal His tag. The amino acid
sequence M-G-(H)10 was fused to the N-terminus of the
full length CitS (M83146, aa M1-I446) in the vector
pET16b (the expressed protein is termed HisCitS, Fig. 3b)
and expressed in E. coli C43(DE3) (Miroux and Walker,
1996) as described by Ka¨stner et al. (2000). E. coli
C43(DE3) cells were lysed using a French press and CitS
was directly solubilized with 2% DDM in 20 mM
Tris–HCl, pH 7.5 and 300 mM NaCl. The cleared lysate
containing the solubilized CitS was puriﬁed by IMAC
(Ni2+–NTA, Qiagen). The eluate was further passed over
a size-exclusion chromatography column (Superose 6 10/
300 GL, GE Healthcare).
Biotinylated CitS. The vector pMalccitSabirA (Ka¨stner
et al., 2000) was used to express biotinylated CitS. Biotin
ligase BirA was co-expressed from the same plasmid allow-
ing in vivo biotinylation. Two constructs were cloned in the
vector pMalccitSabirA. One had the biotin acceptor
domain (BAD) of oxaloacetate decarboxylase from K.
pneumoniae (J03885, aa V492-A596) fused to the C-termi-
nus of CitS (the expressed protein is termed CitSBAD,
Fig. 3b) (Ka¨stner et al., 2000), the other carried an Avi
tag (G-L-N-D-I-F-E-A-Q-K-I-E-W-H-E) fused to the C-
terminus (the expressed protein is termed CitSAvi,
Fig. 3b). Both constructs were expressed in E. coli DH5a
as described by Ka¨stner et al. (2000). Cells were lysed using
a French Press and biotinylated CitS was directly solubi-
lized with 2% DDM in 100 mM sodium phosphate, pH 7,
6 Abbreviations used: 2HCT, 2-hydroxy-carboxylate transporters; 4NPP,
4-nitrophenyl phosphate; AP, alkaline phosphatase; BAD, biotin acceptor
domain; BSA, bovine serum albumin; CDR, complementary determining
region; DARPin, Designed Ankyrin Repeat Protein; DDM, n-dodecyl-a-
D-maltopyranoside; ECL, electrochemiluminescence; HuCAL, human
combinatorial antibody library; IMAC, immobilized metal ion aﬃnity
chromatography; IPTG, isopropyl-b-D-thiogalactopyranoside; KD, equi-
librium dissociation constant; MALS, multi-angle (static) light scattering;
MBP, maltose binding protein; pfu, plaque forming units; SEC, size-
exclusion chromatography; TMS, transmembrane segment.
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Fig. 3. (a) Simpliﬁed topology model of CitS. It contains 11 transmem-
brane segments, with the N-terminus (N) in the cytoplasm and the C-
terminus (C) in the periplasm. The segments Vb and Xa are thought to
extend into the membrane. The segment AH is an amphipathic surface
helix. This ﬁgure is adapted from Sobczak and Lolkema (2005). (b)
Schematic representation of the three CitS constructs with corresponding
annotation used in this study. The length of the boxes is proportional to
the actual length of the protein chain.
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300 mM NaCl and 10% glycerol. Solubilized CitS was puri-
ﬁed from the cleared lysate by a monomeric avidin column
(Pierce). To remove the free biotin the eluate was passed
over a desalting column (NAP-5, GE Healthcare) and sub-
sequently dialyzed twice against 250 buﬀer volumes each.
2.1.2. Designed Ankyrin Repeat Proteins (DARPins)
Selected DARPins were cloned into pQE30-based (Qia-
gen) vectors containing an N-terminal M-R-G-S-(H)6 tag.
Behind the DARPin coding region, the vector contained
either the double stop codon TAA-TGA (pQE30ss; the
expressed protein is termed HisDARPin) or a ﬁve times
repeated myc-tag (M-E-Q-K-L-I-S-E-E-D-L-N-E)5,
(pQE30myc5; the expressed protein is termed DARPinmyc5)
in front of the double stop codon. Expression of DARPins
was performed in E. coli XL1-Blue (Stratagene) in dYT
medium (5 g NaCl, 10 g yeast extract, 16 g tryptone for 1
liter of media). Expression was induced with 1 mM IPTG
(ﬁnal concentration) at an OD600 of 0.6 and continued
for 3–4 h at 37 C.
Cells were resuspended in lysis buﬀer (40 mM Tris–HCl,
pH 7.5, 300 mM NaCl, 20 mM imidazole, 10% glycerol,
and 1 mg/ml lysozyme), and passed through a French
press, and the cleared lysate was applied to an IMAC col-
umn (Ni2+–NTA, Qiagen). Elution fractions were passed
over a desalting column (NAP-5, GE Healthcare).
2.2. Ribosome display
The PCR-ampliﬁed N3C DARPin DNA-library,
described previously (Binz et al., 2004), was transcribed
in vitro and selection was performed by ribosome display
as described by Hanes and Plu¨ckthun (1997). MaxiSorp
plates (Nunc) were coated with NeutrAvidin (100 ll,
66 nM, overnight at 4 C), blocked with BSA (200 ll,
0.5%, 1 h at room temperature) and CitSBAD was immobi-
lized via its biotin residue on NeutrAvidin (100 ll, 200 nM
CitSBAD, 1 h at 4 C, 10 mM Tris–HCl, pH 7.5, 150 mM
NaCl, and 0.05% DDM). Binding and washing buﬀers
(50 mM Tris–HOAc, pH 7.5, 150 mM NaCl, 50 mM
Mg(OAc)2, 0.5% BSA, and 0.05% DDM) contained
DDM as detergent to keep the membrane protein in its
functional conformation. The translation mix, containing
the ternary mRNA–ribosome–DARPin complexes, was
ﬁrst pre-panned in two wells (30 and 60 min) against bio-
tinylated MBP, immobilized the same way as CitSBAD to
remove DARPins that would bind to the plate for other
reasons than recognizing CitS. Subsequently, the transla-
tion mix was transferred to the well containing immobilized
CitSBAD. The library was incubated for 45 min, and the
washing time was increased from round to round (15 min
total washing time in the ﬁrst round to 90 min total wash-
ing time in the fourth round). After washing, the mRNA
was eluted with 100 ll elution buﬀer (50 mM Tris–HOAc,
pH 7.5, 150 mM NaCl, and 25 mM EDTA). A total num-
ber of four rounds of ribosome display were performed.
The number of PCR cycles after reverse transcription was
reduced from round to round from 45 to 35 to 30 to 25,
adjusting to the yield due to progressive enrichment of
binders in each round.
2.3. Phage display
The generation and characterization of the DARPin-
phage library based on SRP-Phage display (Steiner et al.,
2006) will be described elsewhere (Steiner et al., manuscript
in preparation). All steps of the phage display selection
were performed at room temperature. For the ﬁrst selec-
tion cycle 1.6 · 1013 phage particles displaying the DARPin
library were incubated for 1 h with 100 nM biotinylated
CitSBAD in 2 ml of CitS-buﬀer (20 mM potassium phos-
phate, pH 7.0, 500 mM NaCl, 20% glycerol, and 0.1%
DDM) containing 0.4% BSA. The phage–antigen com-
plexes were captured on 100 ll streptavidin-coated para-
magnetic beads (10 mg/ml, Dynabeads MyOne
Streptavidin T1, Dynal) for 20 min. After washing the
beads eight times with CitS-buﬀer the phage particles were
eluted with 200 ll of 100 mM Et3N for 6 min, followed by
200 ll of 100 mM glycine, pH 2, for 10 min. Eluates were
neutralized with 100 ll of 1 M Tris–HCl, pH 7, or 18 ll
of 2 M Tris–base, respectively, combined and used to infect
5 ml of exponentially growing E. coli XL1-Blue cells (Strat-
agene). After shaking for 1 h at 37 C cells were plated on
dYT agar plates containing 10 lg/ml chloramphenicol and
1% glucose and grown overnight at 37 C. The cells were
scraped oﬀ the plates and used to inoculate 15 ml of dYT
containing 10 lg/ml chloramphenicol to an initial OD600
of 0.1. The culture was incubated at 37 C with shaking
and at an OD600 of 0.5 the phage library was rescued by
infection with VCSM13 helper phage (Stratagene) at
1010 pfu (plaque forming units) per ml (multiplicity of
infection 20). After 1 h at 37 C, 45 ml of fresh dYT con-
taining 10 lg/ml chloramphenicol, 16.7 lg/ml kanamycin,
and 0.27 mM IPTG were added and the culture grown
overnight at 30 C. Cells were removed by centrifugation
(5600g, 4 C, 10 min) and the culture supernatant was incu-
bated on ice for 1 h with one-fourth volume of ice-cold
PEG/NaCl solution (20% polyethyleneglycol (PEG) 6000,
2.5 M NaCl). The precipitated phage particles were then
collected by centrifugation (5600g, 4 C, 15 min) and resus-
pended in 3 ml of CitS-buﬀer and used for the second
round of selection.
For the subsequent selection rounds, 1012 of the ampli-
ﬁed phage particles were used as input, beads were washed
12 times with CitS-buﬀer, phages eluted with 400 ll of
100 mM glycine, pH 2 for 10 min, the eluate neutralized
with 36 ll of 2 M Tris–base and used to infect 5 ml of expo-
nentially growing E. coli XL1-Blue cells.
Infection was allowed to occur for 1 h at 37  C and cells
were directly expanded into 50 ml of fresh dYT containing
10 lg/ml chloramphenicol. After 3–4 h at 37 C, IPTG was
added to a ﬁnal concentration of 0.2 mM and 15 min later
VCSM13 helper phage was added to a ﬁnal concentration
of 1010 pfu per ml. Cells were grown overnight at 37 C
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without the addition of kanamycin and phage particles har-
vested as described above.
To determine enrichment of binders, ampliﬁed poly-
clonal phage pools from each selection round were ana-
lyzed by phage ELISA as described by Ro¨thlisberger
et al. (2004). Further, single clones of round three and four
were randomly picked and analyzed by phage ELISA.
Positive clones were sequenced and recloned into pQE30ss
and pQE30myc5 for further analysis.
2.4. Analytical size-exclusion chromatography (SEC)
Size-exclusion chromatography was performed on an
Agilent 1100 HPLC system. A molar excess of selected
DARPins (30–60 lM) was mixed with HisCitS (15–30 lM)
and incubated in 10 mM Tris–HCl, pH 7.5, 150 mM NaCl,
0.05% DDM for at least 30 min at 10 C for complex for-
mation. For analysis of the ternary CitS–DARPin–Fab
fragment complex, HisCitS (15 lM) was incubated with
both DARPin (30 lM) and Fab fragment (30 lM) for
60 min at 10 C for complex formation. With a well plate
autosampler (Agilent 1100) sample volumes of 75 ll were
loaded on a Superdex 200 10/300 GL column (GE Health-
care) with a ﬂow rate of 0.5 ml/min. Fractions of 250 ll
were collected with an analytical fraction collector (Agilent
1100).
2.5. Multi-angle light scattering (MALS)
SEC-MALS measurements were performed on an Agi-
lent 1100 HPLC system connected to a tri-angle light scat-
tering detector and a diﬀerential refractometer
(miniDAWN Tristar and Optilab, respectively; Wyatt
Technology, Santa Barbara, CA, USA). Speciﬁc refractive
index increment (dn/dc) values of 0.186 ml/g (Wen et al.,
1996) and 0.133 ml/g (Strop and Bru¨nger, 2005) were used
for the protein and the detergent fraction (DDM), respec-
tively. Sample volumes of 200 ll with a CitS protein con-
centration of 20 lM were injected on a Superose 6 10/300
GL column (GE Healthcare). The data were recorded
and processed using the ASTRA V software (Wyatt Tech-
nology). To determine the detector delay volumes and nor-
malization coeﬃcients for the MALS detector, a BSA
sample (Sigma, A8531) was used as reference. Neither
despiking nor a band broadening correction was applied.
2.6. ELISA
Buﬀers for binding and washing in all ELISA experi-
ments were 10 mM Tris–HCl, pH 7.5, 150 mM NaCl
(TBS) supplemented with 0.05% DDM (TBS-D), 0.2%
BSA (TBS-B) or both (TBS-DB), if not stated otherwise.
2.6.1. Crude extract ELISA
2.6.1.1. Coating. AMaxiSorp Plate (Nunc) was coated with
protein A (Sigma, 100 ll, 10 lg/ml in 100 mM phosphate,
pH 7.0, and 150 mM NaCl) for 2 h at 4 C and blocked
for 2 h with 0.2% BSA (Fluka, 200 ll TBS-B) at room tem-
perature. The wells were incubated with 100 ll of a 1:500
dilution of anti-myc antibody (Cell signaling, 9B11) in
TBS-B for 1 h at 4 C.
2.6.1.2. Crude extract from single clones. One milliliter med-
ium (dYT containing 1% glucose and 100 lg/ml ampicillin)
was inoculated with single colonies of E. coli XL1-Blue,
harboring pQE30myc5 encoding a selected DARPin, in a
96-deep-well plate and was grown overnight at 37 C.
One milliliter of fresh dYT with 100 lg/ml ampicillin was
inoculated with 100 ll of the overnight culture. After incu-
bation for 2 h at 37 C, expression was induced with IPTG
(1 mM ﬁnal concentration) and continued for 3 h. Cells
were harvested, resuspended in 100 ll B-PERII (Pierce)
and incubated for 15 min at room temperature with vor-
texing from time to time. Then, 900 ll TBS-D was added
and cell debris was removed by centrifugation.
2.6.1.3. ELISA of lysate. Of each lysate, 100 ll were
applied to a well of a MaxiSorp plate containing immobi-
lized anti-myc antibody and incubated for 45 min. After
extensive washing with TBS the plate was incubated with
40 nM biotinylated CitSBAD in TBS-DB for 45 min. For
competition experiments, 400 nM of the competitor was
pre-incubated with biotinylated CitS. After washing with
TBS-D, binding was detected with streptavidin-AP conju-
gate (Roche, 1:1000 dilution in TBS-DB, 30 min at 4 C)
by using di-sodium 4-nitrophenyl phosphate (4NPP,
Fluka) as a substrate for AP. The color development was
stopped by addition of 3 M NaOH (100 ll) and measured
at 405 nm (540 nm reference wavelength) with a plate
reader (HTS 7000 Plus, Perkin-Elmer). As negative control
the crude extract of an expression culture containing the
expression vector without an insert was used.
2.6.2. Competition ELISA with puriﬁed proteins
2.6.2.1. Fab directly coated/detection of biotinylated CitS.
MaxiSorp plates were coated directly with 250 nM Fab
fragment (in TBS, puriﬁed as described by Ro¨thlisberger
et al. (2004)), incubated for 2 h at 4 C and blocked with
200 ll TBS-B for 1 h. The plate was then incubated with
40 nM biotinylated CitSBAD in TBS-DB for 45 min. For
competition experiments, 400 nM of the competitor was
pre-incubated with biotinylated CitSBAD. Detection of the
bound protein was done as above. In the negative control
no Fab fragment was coated.
2.6.2.2. Sandwich ELISA/detection of DARPin via myc tag.
Coating of MaxiSorp plates with 250 nM Fab fragment
was carried out as described above. Then the plate was
incubated with 40 nM HisCitS in TBS-DB for 45 min. After
washing, puriﬁed DARPinmyc5 (50 nM in TBS-DB) was
added to the well for 30 min. Detection was performed
by incubation with anti-myc antibody (1:1000 dilution in
TBS-DB; 45 min at 4 C) followed by, after washing,
goat anti-mouse antibody fused to AP (Sigma, 1:2000 in
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TBS-DB; 30 min at 4 C). Color development and mea-
surements were carried out as above. In negative controls
there was either no Fab fragment coated or the Fab frag-
ment was incubated with buﬀer only instead of HisCitS.
2.7. Determination of dissociation constants by equilibrium
titration
To determine the dissociation constants of the DARPins
electrochemiluminescence (ECL)-based equilibrium titra-
tion was performed using the ECL-detection system of Bio-
Veris (Witney, Oxfordshire). Streptavidin-coupled
paramagnetic beads were coated with CitSAvi, and bound
DARPinmyc5 was detected by an anti myc-tag antibody
(Cell signaling, 9B11), which in turn was detected with an
anti-mouse IgG labeled with the BV-tag (BioVeris). The
BV-tag consists of a tris(2,2 0-bipyridine)ruthenium(II)
complex, covalently linked to the protein, that emits light
when electrooxidized in the presence of aliphatic amines,
such as tri-n-propylamine (Miao et al., 2002). The amount
of DARPin bound to immobilized CitSAvi was measured as
a function of competing HisCitS in solution. The assay buf-
fer used for all dilution, wash and assay steps was 10 mM
Tris–HCl, pH 7.5, 150 mM NaCl containing 0.05%
DDM and 0.2% BSA (TBS-DB). Coating of the beads with
CitSAvi was performed at 4 C, all other steps at room
temperature.
2.7.1. Detection mix
A suspension of 40 lg/ml streptavidin-coupled para-
magnetic beads (Dynabeads MyOne Streptavidin T1,
Dynal biotech) was washed and then incubated with
2.5 nM CitSAvi for 45 min under vigorous shaking. The
beads were washed to remove free CitSAvi. Subsequently,
anti-myc antibody (Cell signaling, 9B11) as well as anti-
mouse IgG antibody carrying the BV-tag (BioVeris) were
added, each at 1:200 dilutions.
2.7.2. Assay
Dilutions of HisCitS in the range from 50 pM to 2 lM
were mixed with 5 nM of DARPinmyc5 and 15 ll of detec-
tion mix to yield a total assay volume of 150 ll. Under vig-
orous shaking, the samples were incubated at room
temperature for at least 4 h. Subsequently, ECL signals
were detected in 96-well format with a M1M analyzer (Bio-
Veris Corporation). The plate was incubated for 10 min in
the M1M analyzer under shaking.
2.7.3. Data analysis
The DARPin can either bind to immobilized CitSAvi on
the beads or to free HisCitS in solution. This can be
described by two equilibria, assuming a 1:1 interaction
Eq. (1).
CþACA and Cb þACbA ð1Þ
where C is the His-tagged CitS (HisCitS), A is the myc-
tagged DARPin (DARPinmyc5) and Cb is the bound Avi-
tagged CitS (CitSAvi) present on the beads.
Assuming the same dissociation constant KD for both
equilibria and that each CitS monomer interacts with one
DARPin independently, we derived Eq. (2) from the basic
equations that describe the two equilibria Eq. (1) (see
Online Supplement for derivation)
ECL ¼ Const:
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where [C]t is the total concentration of added HisCitS, [Cb]t
is the total amount of CitSAvi present on the beads (given
as a molar concentration in the assay), [A]t is the total con-
centration of added DARPinmyc5, Const. is a proportional-
ity constant that correlates the concentration of CbA to the
measured signal, ECL is the measured signal and BG is the
background signal.
The parameters KD, [A]t, Const. and BG were ﬁtted to
the data using Eq. (2) with Prism 4 (GraphPad software
Inc.). Measurements where carried out in duplicates. In
order to be able to compare the diﬀerent DARPins in
one plot the ECL signals were normalized between 0 and
1 according to the ﬁtted curves.
3. Results
We describe here the selection of Designed Ankyrin
Repeat Proteins (DARPins) by ribosome display and
phage display for binding to detergent-solubilized Na+-cit-
rate symporter CitS. We adapted several methods to be
able to quickly and eﬃciently screen and characterize the
binding proteins. Furthermore, we compare the obtained
DARPins to a previously selected HuCAL Fab fragment
binding to CitS.
We used CitS immobilized via a biotinylation tag as the
target for selection. Both constructs (see Fig. 3b), CitS car-
rying a C-terminal BAD domain (CitSBAD) or an Avi tag
(CitSAvi), were functional in E. coli, as determined with
an in vivo assay based on growth of transformed E. coli
on Simmons citrate agar (Ka¨stner et al., 2000). We previ-
ously found the biotin–NeutrAvidin/streptavidin interac-
tion to be the most robust linkage for immobilizing
detergent-solubilized membrane proteins. By contrast, the
binding of many other tags to their cognate antibodies is
weakened by detergent. The immobilization via the His
tag to immobilized Ni2+–NTA is much too weak (Lata
and Piehler, 2005) and further destabilized by the deter-
gent-containing buﬀer (Ott and Plu¨ckthun, unpublished
experiments). Even though we cannot prove directly that
CitS is active in detergent, it can be reconstituted into lipid
vesicles from the detergent mixture (Pos and Dimroth,
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1996). Therefore, it is a reasonable assumption that it is in
a state very close or identical to that in the native bilayer.
3.1. Ribosome display selection against CitS
For ribosome display, biotinylated CitS (CitSBAD) was
immobilized to microtiter plates coated with NeutrAvidin.
The selected DARPin pools of all four rounds of ribosome
display were subcloned into the expression vector pQEmyc5.
After transformation, randomly picked single clones were
sequenced to estimate the diversity of the pools. None of
the 12 sequenced clones of each round carried the same
DARPin. This result indicates that the pools are still
diverse and that a wide variety of diﬀerent binding mole-
cules can be obtained. A strong enrichment of binding sig-
nal was observed after the fourth selection round by
ELISA of the pool (data not shown).
Single clones (70) of the fourth round were further ana-
lyzed by crude extract ELISA. To quickly and reliably
screen for positive clones, the selected DARPins were
immobilized on the plate via the myc-tag, and the binding
of solubilized membrane protein was detected. In this
setup, the membrane protein was exposed to a minimum
of washing and incubation steps (see Section 2). About
35% of the clones (25 out of 70 initially screened clones)
showed a binding signal to CitSBAD. To test whether bind-
ing was really speciﬁc for the membrane protein, free
HisCitS, carrying no biotinylation tag, was used as compet-
itor. For around 40% of the positive clones (10 out of 70
initially screened clones) the binding signal was decreased
or even reduced to the background level upon addition of
excess competitor HisCitS, consistent with speciﬁc binding.
None of the sequenced CitS-speciﬁc DARPins showed the
same sequence, indicating that even more DARPins may be
found with further screening.
About half of the clones showing binding signal (15 of
25 clones) were false-positive. For biotinylation, BAD
(biotin acceptor domain from oxaloacetate decarboxylase
(Schwarz et al., 1988), about 100 amino acids long) was
fused to CitS, and the presence of an additional folded
domain in the selection procedure has apparently also
resulted in—unwanted—selection of some DARPins spe-
ciﬁc for the BAD domain. Nevertheless, as determined by
ELISA of the selection pools (data not shown), a greater
percentage of non-CitS binders that became enriched is
due to truly unspeciﬁc binding and only a smaller percent-
age shows binding to BAD.
3.2. Phage display selection against CitS
The phage display library used for the selection has a
functional diversity of 1.1 · 1010 (Steiner et al, in prepara-
tion). Since DARPins are normally cytoplasmic proteins
that fold very fast and are very stable, they are not compat-
ible with standard phage display systems, and they have to
be directed to the E. coli signal recognition particle (SRP)
translocation pathway by the use of an appropriate signal
sequence (Steiner et al., 2006). With the appropriate phage-
mid, phage display is then at least as eﬃcient as with
libraries of other proteins and peptides.
Since unspeciﬁc binding was observed in ribosome dis-
play, where CitS had been immobilized to a microtiter
plate, the selection procedure in phage display was carried
out by ﬁrst letting solubilized CitSBAD bind to DARPin-
carrying phages in solution and then capturing the
complexes with streptavidin-coated beads. This ‘‘solution
panning’’ requires larger amounts of CitSBAD, but has
the advantage of reducing unspeciﬁc interaction with the
plate surface.
Four rounds of selection on solubilized CitSBAD in solu-
tion, followed by capturing of the antigen with streptavi-
din-coated paramagnetic beads, were performed. An
enrichment of the binding signal was observed already after
the second selection round. After the third and fourth
round of selection, 62 clones each were screened in phage
ELISA format for binding to immobilized CitSBAD in the
absence or presence of an excess of soluble HisCitS as com-
petitor. Eighty-nine percent of the clones (110 out of 124
initially screened clones) showed a binding signal on immo-
bilized CitSBAD, of which 17% (19 clones) could be inhib-
ited by the addition of competitor (HisCitS). Sequencing
revealed 11 diﬀerent sequences (around 9% of initially
screened clones).
Compared to panning on microtiter plates, solution
panning lead to a reduction of unspeciﬁc binders, but the
percentage of—undesired—BAD-speciﬁc binders was
increased (data not shown). While in the ribosome display
experiment described above the membrane protein was
immobilized via its biotin tag prior to adding the ribosomal
complex (thereby making the BAD domain less accessible),
in phage display the selection was carried out in solution
and the BAD domain was fully accessible. To increase
the fraction of binders speciﬁc for CitS itself, a prepanning
step on the BAD domain alone can be included, or a CitS
version without BAD domain (e.g. carrying an Avi tag) can
be used in the future. It should be emphasized that either
immobilization strategy, solution panning or plate pan-
ning, can of course be used with either display technology,
phage display or ribosome display.
3.3. Size-exclusion chromatography (SEC) of complexes
By using SEC, the formation of stable complexes in
solution can be monitored directly. Additionally, the
potential aggregation tendency of any selected binder can
be assessed, usually an undesired property for co-crystalli-
zation. Furthermore, the use of puriﬁed HisDARPins for
the subsequent analysis eliminates possible inﬂuences of
the phage or crude lysate on the binding and solubility
behavior.
The subset of diﬀerent DARPins chosen based on eﬃ-
cient inhibition of ELISA signals by soluble HisCitS and
on sequencing (10 from ribosome display and 11 from
phage display, as described above) was further analyzed
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by SEC. A molar excess of puriﬁed DARPin was mixed
with HisCitS and loaded on a SEC column. Since the bind-
ing stoichiometry of CitS–DARPin complexes was not
known, the DARPin was used in excess (relative to the sub-
unit concentration of the presumed dimeric CitS) and at
micromolar concentrations to allow complex formation
of all CitS molecules. Complex formation is indicated by
a shift of the CitS elution peak to smaller elution volume
(i.e. bigger molecular size) relative to the uncomplexed
HisCitS. SDS–PAGE analysis of the corresponding peak
fraction of the presumed complex showed that the fraction
contained both CitS and DARPin (Fig. 4).
Only a few of the initially screened binders (1 out of the
70 from ribosome display and 2 out of 124 from phage dis-
play) fulﬁlled the stringent criteria of forming complexes
that showed a clear shift in elution volume and having only
one distinct elution peak (i.e. no aggregation or residual
uncomplexed CitS). We further characterized this one
DARPin selected by ribosome display (cr34_8C4) and the
two selected by phage display (cp34h_15 and cp34h_16)
in more detail and compared them to each other and to
the Fab fragment (f3p4) that had been previously selected
as binder to solubilized CitS by phage display (Ro¨thlisber-
ger et al., 2004). An overview of the properties of the char-
acterized binders is given in Table 1.
3.4. SEC-MALS of CitS and complexes
The SEC system was further connected to a multi-angle
(static) light scattering (MALS) detector and a diﬀerential
refractive index detector (dRI). These two detectors
together with the UV-detector allow the direct comparison
of the corresponding molar masses of CitS alone and the
complexes. The scattered light (the Rayleigh ratio R(h))
measured by the MALS-detector is directly proportional
to the product of the weight-average molar mass and the
solute concentration (Wyatt, 1993; Wen et al., 1996; Fol-
ta-Stogniew and Williams, 1999). Either a UV-detector or
a dRI-detector alone can be used to calculate online the
concentration of a soluble, non-conjugated protein. In con-
trast, as membrane proteins consist of a protein core sur-
rounded by a detergent fraction, both UV-detector and
dRI-detector are required to calculate molar masses. If
the UV-extinction coeﬃcient and the diﬀerential refractive
index increment (dn/dc) of the protein and the detergent
are known, the molar masses of the protein fraction and
the detergent fraction can be determined. In case of CitS,
we calculated the UV-extinction coeﬃcient based on the
amino acid sequence and assumed a dn/dc of 0.186 g/ml
(Wen et al., 1996) for the protein fraction and a dn/dc of
0.133 (Strop and Bru¨nger, 2005) for the detergent fraction
(DDM). In our buﬀer, we detect for CitS a monodisperse
peak with a molar mass of the protein fraction (protein
without detergent) of 105–115 kDa (Fig. 5a). This molar
mass corresponds to the CitS dimer (theoretical molar
mass of 100 kDa including His tag). The dimeric state of
CitS is in agreement with single molecule ﬂuorescence spec-
troscopy experiments (Ka¨stner et al., 2003).
In the case of the CitS complexes, we ﬁrst have to
assume an extinction coeﬃcient, as we do not know the
binding stoichiometry initially. In the case of the CitS–
Fab fragment complex (molar masses of both are about
50 kDa) only a 2:1 (CitS:Fab fragment) stoichiometry gives
a meaningful result. The molar mass of the protein fraction
is then determined to be 155–165 kDa (Fig. 5b). For the
smaller CitS–DARPin complexes, however, the assump-
tion of diﬀerent binding stoichiometries (2:2 CitS:DARPin
or 2:1 CitS:DARPin) and therefore diﬀerent extinction
coeﬃcients does not lead to an unequivocal distinction
and therefore both stoichiometries remain possible.
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Fig. 4. Superposition of size-exclusion chromatography (SEC) elution
proﬁles. Free CitS (dashed line, peak 2), free DARPin cp34h_15 (short
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Table 1
Properties of selected DARPin in comparison to a selected Fab fragment
cr34_8C4 cp34_15 cp34_16 f3p4a
Protein class DARPin DARPin DARPin Fab
fragment
Selection
method
Ribosome
display
Phage
display
Phage
display
Phage
display
Molar mass
(kDa)
18.2 18.2 18.4 47.9
pI 5.1 5.3 4.9 4.8
Aﬃnity (nM) 2.5 ± 0.6b 5.4 ± 1.9b 1.3 ± 0.3b 4 ± 2c
Yieldd (mg/
liter)
>30e >75e >20e 3
a Previously described by Ro¨thlisberger et al. (2004).
b Equilibrium titration (BioVeris).
c Competition BIAcore.
d Yield of puriﬁed protein from a 1 liter E. coli shake ﬂask culture.
e IMAC column was strongly overloaded, therefore the yield is greatly
underestimated.
T. Huber et al. / Journal of Structural Biology 159 (2007) 206–221 215
Huber et al. 103
Nevertheless, we can clearly demonstrate a larger molar
mass of the complexes by the increased Rayleigh ratio
R(h), compared to CitS alone.
3.5. Competition ELISA
DARPinsmyc5 were immobilized via the myc-tag on a
MaxiSorp plate coated with anti-myc antibody and the
binding of biotinylated CitSBAD was competed with a 10-
fold excess of either non-biotinylated HisCitS to conﬁrm
speciﬁcity, or a 10-fold excess of another HisDARPin or
Fab fragment (f3p4) to test whether they recognize identi-
cal or overlapping binding epitopes.
The binding signal of all DARPins can be reduced to
background levels with an excess of free HisCitS (Fig. 6a).
This ﬁnding demonstrates that the characterized DARPins
bind speciﬁcally to solubilized CitS, conﬁrming the results
from the ﬁrst ELISA screens. All analyzed DARPins do
recognize the same or overlapping epitopes, as the binding
of one DARPin to CitS can be inhibited with an excess of
another free DARPin. However, the Fab fragment (f3p4)
seems to recognize a diﬀerent epitope, as it does not signif-
icantly reduce the binding signal of the DARPins.
To further conﬁrm this ﬁnding, the setup of the ELISA
was inverted. The Fab fragment (f3p4) was directly coated
on the plate and its binding to CitSBAD alone or to CitSBAD
pre-incubated with either non-biotinylated HisCitS, free
Fab fragment (f3p4) or free HisDARPin was compared.
The binding signal could be fully competed with excess of
HisCitS or Fab fragment (f3p4) but not with any of the
selected DARPin. These results strongly indicate that the
two scaﬀolds do indeed recognize diﬀerent, non-overlap-
ping epitopes (Fig. 6b).
3.6. Sandwich complex with Fab, CitS and DARPin
To determine if the selected DARPins and the Fab frag-
ment (f3p4) can bind simultaneously to CitS and can there-
fore form a ternary complex, we performed a sandwich
ELISA. In this setup, the Fab fragment (f3p4) was immo-
bilized directly on the plate and subsequently incubated
with HisCitS and DARPinmyc5. The binding of the
DARPinmyc5 to the HisCitS–Fab complex was detected. In
the negative controls, the Fab fragment was either incu-
bated with BSA instead of HisCitS or BSA was coated on
the well instead of the Fab fragment. The binding signal
of the DARPin to HisCitS-Fab complex is signiﬁcantly
higher than that of the negative controls (Fig. 6c), and
therefore the ternary complex seems to be formed for all
DARPins.
If the DARPin, the Fab fragment and CitS are able to
form a ternary complex, an additional shift in size-exclu-
sion chromatography should be observed. The DARPin
(cp34h_15), the Fab fragment (f3p4) and HisCitS were incu-
bated for 1 h at 10 C and the mixture was injected on a
SEC column. The elution proﬁle of the putative ternary
complex is indeed shifted, compared to the binary complex
of CitS and DARPin (Fig. 7) and the SDS–PAGE analysis
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Fig. 5. (a) Characterization of CitS with size-exclusion chromatography combined with multi-angle light scattering (SEC-MALS). CitS (200 ll, 20 lM)
was loaded on a Superose 6 column. Only the protein fraction of CitS contributes to the UV-A280 signal (solid line), whereas both the protein and the
detergent fraction contribute to the diﬀerential refractive index signal (dashed-dotted line). The membrane protein–detergent complex elutes at 16.1 ml.
The molar mass of the protein fraction is calculated to be 105–115 kDa (ﬁlled circles), which corresponds to a CitS dimer (theoretical molar mass of
100 kDa). With 125–140 kDa, the detergent fraction (grey triangles) has a slightly larger molar mass. The empty detergent (DDM) micelles, originating
from concentration of the sample prior to injection, elute at 17.9 ml and have a calculated molar mass of 74–76 kDa and are characterized by a peak in
refractive index, but not in UV-A280. (b) Characterization of CitS–Fab fragment complex with size-exclusion chromatography combined with multi-angle
light scattering (SEC-MALS). CitS (20 lM) was incubated with excess of Fab fragment (f3p4, 60 lM) complex for 1 h at 4 C and loaded (200 ll) on a
Superose 6 column. The UV-A280 signal is depicted as solid line, the diﬀerential refractive index increment as dashed-dotted line. The molar mass of the
protein fraction of the CitS–Fab fragment–detergent complex is 155–165 kDa (ﬁlled circles). This corresponds to the molar mass of one Fab fragment
bound to a CitS dimer (theoretical molar mass 150 kDa). The molar mass of the detergent fraction is indicated with grey triangles. The elution peak of the
excess of Fab fragment (UV-A280 at 18.5 ml, and ﬁlled circles for the molar mass) superimposes with the empty detergent micelle (peak in diﬀerential
refractive index at 17.9 ml and grey triangles for the molar mass).
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of the elution peak reveal the presence of CitS, DARPin
and Fab fragment in this peak fraction. Beside the main
peak of the ternary complex, an additional peak appears,
indicating higher aggregates. This peak shows the same
SDS–PAGE band pattern as the main peak (data not
shown).
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Fig. 6. (a) Competition ELISA assay of DARPins and Fab fragment reveals whether the binding molecules recognize the same or diﬀerent epitopes.
DARPinsmyc5 (40 nM) were immobilized and binding to CitSBAD (40 nM) was detected. The binding signal without competition was normalized to 1.
Competition with excess of HisDARPin and Fab fragment (all 400 nM) was examined. DARPins compete with each other for the same epitope, as the
binding signal is clearly reduced. In contrast, there is no signiﬁcant decrease when competed with the Fab fragment (f3p4). Competition with HisCitS
(400 nM) is included as a control for speciﬁc binding. (b) Competition ELISA assay. The binding of CitSBAD to the immobilized Fab fragment (f3p4,
250 nM) was competed with an excess of either non-biotinylated HisCitS, Fab fragment or HisDARPins (all 400 nM). Both HisCitS and Fab fragment
reduce the binding signal to background levels, which demonstrates the speciﬁcity of the binding. All DARPins do not signiﬁcantly inﬂuence the binding,
indicating that they bind to another epitope than the Fab fragment. (c) Sandwich ELISA assay. The Fab fragment f3p4 was immobilized on the plate
(250 nM) and incubated with HisCitS (40 nM). The amount of DARPinmyc5 that binds was detected via the myc-tag. Binding signal of DARPinmyc5 to the
CitS–Fab complex (grey), binding to HisCitS on a BSA-coated plate (black) and to Fab fragment without HisCitS (white).
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3.7. Aﬃnity determination by equilibrium titration
After demonstrating the speciﬁcity of the selected binder
in ELISA experiments and the formation of well deﬁned
stable complexes in SEC experiments, the binding aﬃnity
of the selected DARPins was assessed by equilibrium titra-
tion in solution. This method is suitable for determination
of dissociation constants (KD) in a high-throughput format
needed for the fast characterization of larger number of
binding proteins (Haenel et al., 2005). Constant amounts
of DARPin were incubated with varying amounts of
HisCitS as competitor and the detection mix containing
CitSAvi coated on magnetic streptavidin beads and two
detection antibodies. The binding signal was detected with
a BioVeris workstation. The binding curves reveal dissoci-
ation constants (KD) in the low nanomolar range (1–6 nM)
for all DARPins (Fig. 8) tested. Even though CitS is a
dimer, the data could be ﬁtted well to a simple model
(Eq. (2), see Section 2), where each CitS monomer interacts
with one DARPin independently. We cannot exclude a
more complicated model, where the two binding sites
may inﬂuence each other, but we can get a reasonable ﬁt
to the binding data already for the simple model.
4. Discussion
Future eﬀorts in the structure determination of mem-
brane proteins will have to be focused on the develop-
ment of new tools and technologies to expedite the
process and increase the likelihood of success. Co-crystal-
lization with binding molecules is a promising approach
to achieve crystals suitable for high resolution structure
determination. However, the generation of new monoclo-
nal antibody fragments by the classical hybridoma
approach for each membrane protein is not only a costly
and time-consuming procedure but may not even be par-
ticularly promising for helical, multi-spanning ﬂexible
membrane proteins. The fundamental obstacle is that
the conformational integrity of the detergent-solubilized
proteins cannot be controlled once injected into an animal.
In contrast, the use of synthetic libraries and in vitro selec-
tion technologies, such as phage display and ribosome
display, provide a powerful tool to generate such binding
molecules in a fast and reliable way. Furthermore, selec-
tion conditions can be adapted to the need of the target
protein as the binding step is performed in vitro.
Since the Na+-citrate symporter CitS is a multi-spanning
integral membrane protein with relatively short loops, it
serves us as a model system for selecting such binding pro-
teins for stabilization and mediating additional crystal con-
tacts. By carrying out the comparative analysis of diﬀerent
selections systems and classes of binding molecules, we
could demonstrate that both selection technologies (ribo-
some display and phage display) can be applied. To gener-
ate binding molecules against as many epitopes as possible
several scaﬀolds (e.g. DARPin and Fab fragment) need to
be considered simultaneously.
4.1. DARPins vs. Fab fragments
Although both scaﬀolds (DARPin and Fab fragment)
compared in this study are used in nature for speciﬁc and
high aﬃnity binding interactions, they have quite diﬀerent
properties, each with its advantages and disadvantages.
DARPins can be obtained in extremely high yields (up to
200 mg soluble protein per liter E. coli shake ﬂask culture),
and they tolerate the presence of reducing agents, as
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retardation from this size-exclusion column (Ro¨thlisberger et al., 2004).
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DARPins do not contain any disulﬁde bonds or free cyste-
ines. The Fab fragments are about 2.5 times the size of
DARPins (50 vs. 18 kDa, Fig. 1) and may present a larger
hydrophilic surface for stable protein–protein contacts in
the crystal. As the binding site resides at the tip of the
Fab fragment, compared to a more shallow binding groove
along the DARPin, the Fab fragment can protrude further
out and potentially leave more space in the crystal for the
membrane bound detergent molecules. However, Fab frag-
ments are built from several domains and therefore display
more conformational ﬂexibility than the very rigid and sta-
ble ankyrin fold. Most importantly, the binding surface is
realized completely diﬀerently in the two scaﬀolds. In
DARPins, the binding residues reside in stable secondary
structure elements and short b-turns, displaying an ideal
shape complementary to folded proteins (Fig. 1), whilst
being less suitable to bind unstructured peptides. There-
fore, both the molecular design and the in vitro selection
strategy signiﬁcantly increase the likelihood of obtaining
binders against structural epitopes, rather than unstruc-
tured tails. In antibodies, ﬂexible loops with varying size
form the binding site to ensure the recognition of a wide
range of antigens (such as small molecules, peptides or
entire proteins). Therefore, completely independent epi-
topes can be bound by the two scaﬀolds (as shown in this
study), which can and should be exploited for the in vitro
generation of binding molecules for co-crystallization.
4.2. Ribosome display vs. phage display
This study demonstrates that both phage display and
ribosome display are well suited for in vitro selection of
binding proteins, even in detergent-containing buﬀers
needed for membrane proteins. Phage display, when car-
ried out in solution, showed higher enrichment of binding
molecules after four cycles than ribosome display, which
was carried out on immobilized membrane protein in the
example described here. However, fast enrichment
obtained by very stringent selection conditions can lead
to lower diversity within the selected binding molecule pop-
ulation, with the caveat that none of the selected binders
may have the desired properties needed for co-crystalliza-
tion. It is therefore important to ﬁnd the right balance
between the number of selection cycles, the stringency of
washing steps and the selection system applied. We would
like to reemphasize that both ribosome display and phage
display can be carried out in solution or on surfaces (see
next section).
4.3. Solution panning vs. surface panning
The—unwanted—selection of BAD-speciﬁc DARPins
shows how the applied immobilization method can inﬂu-
ence the outcome of a selection. First, the use of a fusion
protein for selection always bears a risk to generate
unwanted binders against the fusion partner. However, if
a fusion partner is needed because of solubility or stability
issues, fusion proteins should be changed between subse-
quent selection rounds or a prepanning step on the fusion
partner should be included. Second, the immobilization
of the antigen prior to the panning step can mask potential
binding epitopes. The use of a longer linker between pro-
tein and immobilization tag or a mixture of antigens which
carry the immobilization tag either at the N- or the C-ter-
minus can circumvent such an event.
4.4. Workﬂow
We established an eﬃcient workﬂow for the character-
ization of potential binding proteins that allows rapid
identiﬁcation of binding molecules suitable for co-crystalli-
zation (Table 2). First, we had to evaluate and adapt the
Table 2
Overview of the workﬂow for the screening and characterization of DARPins after the selection
Step Ribosome display Phage display Comments
Pool ELISA Fourth round (then 70 clones
were picked for screening)
Third and fourth round (then 62 clones of
each round were picked for screening)
Deﬁnes of which round the analysis of single clones is
worthwhile
Crude extract
ELISA
35% (25)a n.d.b Clones that show binding
Phage ELISA n.a.c 89% (110)a Clones that show binding
Competition
ELISA
14% (10) 17% (19) Competition with free CitS indicates speciﬁcity
Sequencing 14% (10) 9% (11) Identiﬁcation of non-identical DARPin sequences
SEC 1.4% (1) 1.6% (2) Formation of a well deﬁned, stable complex in
solution, no aggregation even at high concentration
Aﬃnity 2.5 nM 1.3 nM, 5.4 nM Equilibrium titration for aﬃnity determination;
ranking of binders according to the KD
Competition
ELISA
All recognize overlapping epitopes as all are competable Competition with free DARPins distinguishes
overlapping or diﬀerent epitopes
Binding proteins that pass each screening step are given as percentage of the number of initially screened binders.
a For this study, initially 70 single clones of ribosome selection and 124 of phage display selection were screened (then 62 from round 3 and 62 from
round 4). In parentheses the absolute number of clones is given.
b n.d., not done.
c n.a., not applicable.
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methods, with respect to reliability to work under condi-
tions required for membrane proteins. Then, we chose a
format to screen and fully characterize the binding mole-
cules with the least eﬀort and time consumption. As ﬁrst
screen, single clone crude extract ELISA is used. This assay
must distinguish speciﬁc binding to the membrane protein
from binding to fusion partners, tags, streptavidin or BSA
used for blocking. The most straightforward test for all of
the requirements above in a single experiment is the compe-
tition of the binding signal with the membrane protein
itself. This assay also tests whether binding occurs only
to a surface-bound form of the membrane protein, which
would indicate that binding is most probable to a non-
native state of the membrane protein. As second screen,
SEC is performed using puriﬁed DARPins to check for
complex formation in solution. Binding proteins which
show complete complex formation and form no soluble
aggregates are then retested at high concentration (data
not shown), in order to predict whether they might be
aggregation-prone under crystallization conditions. As last
screen, a KD determination of the binder will help to fur-
ther rank the selected binders to ensure the isolation of
intact complexes. A competition ELISA with several puri-
ﬁed DARPins ﬁnally reveals whether the binding proteins
recognize the same or diﬀerent, non-overlapping epitopes.
Even without robotic systems, several hundreds of
clones can by analyzed by ELISA a day. A SEC-system
with an autosampler runs 20–30 samples a day, and with
the BioVeris workstation we can determine the binding
aﬃnities of around 20 binding proteins a day, both with
a minimum of hands-on time. We have developed a work-
ﬂow that allows us to obtain a characterized binder for co-
crystallization within the time period of less than a month.
5. Conclusions
We have selected speciﬁc and high-aﬃnity binding mole-
cules to the Na+-citrate symporter CitS and established an
eﬃcient way of characterizing them. All steps of the charac-
terization (ELISA, automated SEC-MALS, aﬃnity deter-
mination with BioVeris) are compatible with higher
throughput to obtain binding molecules against one or pref-
erentially several membrane proteins. Additionally, the use
of two classes of binding molecules is very useful to obtain
binders against diﬀerent epitopes. Therefore, the combina-
tion of in vitro selection and screening presented here opens
up a robust approach for the generation of speciﬁc, high-
aﬃnity binding molecules suitable for co-crystallization
experiments with membrane proteins. Indeed, preliminary
results of co-crystallization with selected DARPins seem
to corroborate this approach, as well-diﬀracting crystals
of CitS complexes have been obtained.
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110 Chapter 4
Derivation of equations for the affinity determination
The two equilibria of CitS and DARPin in the assay solution can be described by
Eq. 1, when assuming a 1:1 interaction.
(Eq. 1)
Here C is the his-tagged CitS (HisCitS) in solution, A is the myc-tagged DARPin
(DARPinmyc5) and Cb is the bound AVI-tagged CitS (CitSAVI) present on the beads.
The equilibria are characterized by the following basic relationships (Eq. 2 to 6):
][
]][[
1
CA
AC
KD = (Eq. 2)
][
]][[
2
AC
AC
K
b
b
D = (Eq. 3)
][][][ CACC t += (Eq. 4) ][][][][ ACCAAA bt ++= (Eq. 5)
][][][ ACCC bbtb += (Eq. 6)
where [C] is the concentration of free HisCitS, [C]t is the total concentration of added
HisCitS, [Cb] is the uncomplexed amount of CitSAVI, present on beads, [Cb]t is the total
amount of CitSAVI present on the beads, [A] is the concentration of free DARPinmyc,
[A]t is the total concentration of added DARPinmyc, and [CA] and [CbA] are the
concentrations of the corresponding complexes. All bead-bound species are treated
like molecules in solution and therefore molar concentrations were used. KD1 and KD2
are the dissociation constants of the two equilibria. We assume here that the
dissociation constants KD1 and KD2 are the same (therefore, named KD). Using the
mass balances in Eq. 2 and Eq. 3, we obtain:
C + A CA and Cb + A CbA
KD1 KD2
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From these two equations, it follows that
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Combining Eq. 8 and Eq. 9 will give Eq. 10:
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Solving Eq. 10 for [CbA] will yield Eq. 11 (solution of the quadratic equation).
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The measured ECL signal is proportional to the concentration of bound complex
[CbA]. Taking also a term of background binding (BG) into account we obtain Eq. 12.
BGACConstECL b + = ][. (Eq. 12)
where Const. is simply a proportionality constant which is obtained from the fit and
relates the measured ECL signal to bound complexes. We can then express the
measured ECL signal by Eq. 13.
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We thus fit the parameters KD, [A]t, Const. and BG. Even though [A]t should be
known, possible errors in the concentration of active molecules make it advisable to
fit this term as well.
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1. Discussion and Conclusions 
The quality of a combinatorial library of binding proteins can be functionally described 
by the ability to isolate high affinity binders against a broad set of target proteins1. Three major 
factors contribute to successful selections from such a library. First, the library design, which 
encompasses the scaffold used as well as its diversification strategy employed. Second, the 
theoretic diversity of the combinatorial DNA library and the percentage of clones that actually 
have sequences as specified. Finally, the display technology must be able to present all members 
of the library in a functional form allowing efficient selection. Together, these factors determine 
the functional diversity of the library which is accessible for the selection of binding molecules. 
The observation that the display of highly stable and fast folding proteins, such as 
DARPins, on filamentous phage is very inefficient using a conventional phage display system 
was the starting point of my thesis. I identified posttranslational protein translocation across the 
cytoplasmic membrane as a major bottleneck of this display technology. By simply directing the 
proteins to be displayed to the E. coli cotranslational signal recognition particle (SRP) 
translocation pathway by using an appropriate signal sequence I was able to solve this problem. 
This simple change in the use of the translocation route seems to prevent premature folding of 
stable and fast folding proteins in the cytoplasm and therefore allows their efficient translocation 
and subsequent display on filamentous phage particles. For all stable and fast folding proteins 
tested, the display levels on phage particles using SRP-dependent signal sequences were strongly 
increased and for all other proteins the display levels were at least equal to those obtained using 
the Sec-dependent signal sequences. This is also true for proteins, such as a scFv-fragment 
tested, that are already very well displayed using the conventional Sec-dependent signal 
sequences. Thus, SRP phage display seems to be a simple and broadly applicable way to expand 
the range of proteins that can be efficiently displayed on phage particles without having negative 
effects on already well displayed proteins. Therefore, I expected SRP phage display to increase 
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the functional diversity of many libraries, especially those containing stable and fast folding 
proteins, such as DARPins.  
 
The logical subsequent step was to use SRP phage display to generate a large phage 
DARPin library using the previously described combinatorial N3C DARPin library2,3 as 
template. As expected, all clones correct at sequence level were shown to be efficiently 
displayed, resulting in a functional library diversity of at least 1 x 1010. Using this library I was 
able to select in just two to three phage display selection rounds well behaved and highly specific 
DARPins against a broad range of target proteins without a single failure until now, which is 
technically true, but the outcome of selections on TNFα is somehow unusual (see Chapter 3). 
The selected DARPins do show high specificity, have affinities as low as about 100 picomolar 
without affinity maturation, and retain the favorable biophysical properties of the initial library 
members such as high expression level, being monomeric in solution and high solubility. The 
fast enrichment, the high affinities, the very good biophysical properties of the selected binders 
compare very favorable with results described for antibody or other non-immunoglobulin phage 
libraries. This can be attributed to the optimized diversity design of the DARPin library as well 
as the high functional display rate of the SRP phage display. 
 
The results described in my thesis show that the newly developed selection technology 
SRP phage display ensures a high functional diversity of a phage DARPin library leading to 
efficient selections. Thus, SRP phage display has proven to be a powerful method to display 
libraries of fast folding and stable proteins that would be refractory to conventional phage 
display using the Sec secretion pathway. Good results using SRP phage display were recently 
also reported for the display of a fibronectin type III domain library and subsequent selections4. 
This scaffold has previously been displayed by using conventional phage display5 but the change 
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to SRP phage display seems to give superior results, supporting the broad applicability of our 
technology.  
 
I expect SRP phage display to be also beneficial for other libraries containing members 
with widely different folding rates and stabilities, such as e.g. cDNA libraries. Here, a 
conventional phage display system using the Sec translocation pathway is expected to select 
against members with fast folding rates. In contrast, a recently described phage display system 
using the Tat translocation pathway6 which only translocates natively folded proteins and is 
therefore expected to select against members that need disulfide bonds for proper folding or even 
against proteins with slow folding rates. Selection of a mutant with an increased folding rate by 
using a selection system based the Tat translocation pathway was reported recently, supporting 
this hypothesis7. 
2. Outlook 
Thus, SRP phage display makes filamentous phage display accessible for DARPins, 
allowing additional selection approaches for DARPins not applicable to ribosome display and 
will therefore help to broaden the scope of DARPin application. For example, selections under 
hash conditions, such as high temperatures or in the presence of denaturants which may be 
valuable ways to select for highly stable interactions with their target proteins. Selections on 
target proteins in their natural environment such as for example whole cells, tissue sections or 
even in vivo may be even more important8. The spectrum of possible applications of such 
selections is broad and includes for example selections for functions such as internalization9, 
thus opening the door to completely new drugs. 
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1. Introduction 
Appendix one contains supplementary data of Chapter 3 of my thesis. One of the main 
goals of my thesis was to validate the constructed phage DARPin library by selecting binders 
against a broad range of target proteins. In Chapter 3, a detailed characterization is described 
only for a small subset of the DARPins selected. To facilitate the use of the selected binders in 
future projects and collaborations, each subchapter of this Appendix 1 summarizes data of the 
DARPins selected against one specific target protein. The characterizations include for all 
selected binders: sequence alignment, SEC analysis and specificity and affinity determination by 
ELISA (some data is redundant to Chapter 3). All experiments were performed in analogy to 
the protocols given in the Material and Methods section of Chapter 3. The last subchapter 
comprises a small statistical analysis of the sequences of naive library members and selected 
binders and an evaluation of the SEC measurements recorded for all selected DARPins. Table 1 
summarizes selections on the different target proteins and the resulting binders. 
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Table 1: Summary of the phage display selections of DARPins against different target proteins 
Selection Selected DARPins 
Target  
(sel. Rounds) No. positive 
clonesa 
No. different 
sequencesb 
No ELISA 
signal (false 
positive) 
Low ELISA 
signal (low 
affinity binders)c 
High ELISA signal 
(high affinity binders)d 
huIgG1_Fc 
(R3) 
82/94 11/21 
(8/21) 
 I_10, I_14, 
I_15 
I_06, I_03 I_01, I_02, I_07, I_11, 
I_13, I_19 
TNFα 
(R2/3)e 
102/188 29/52 
(29/52) 
- T_03, T_04, 
T_06, T_10, 
T_11, T_19, 
T_33, T_35, 
T_41, T_44,  
T_51 
T_01, T_02, T_07, 
T_08, T_09, T_ 16, 
T_25, T_27, T_37, 
T_40, T_12, T_13, 
T_15, T_30, T_45, 
T_47, T_49, T_52 
ErbB1 
(R2/3)e 
97/369 5/64 
(1/64) 
E_17, E_31, 
E_36 
E_64 E_01 
ErbB1 
(R1, ep.)g 
81/105 4/20 
(4/20) 
- E_72 E_67, E_68, E_69 
ErbB2-509 
(R3) 
83/94 13/29 
(13/29) 
- 9_12, 9_33 9_16, 9_26, 9_29, 
9_01, 9_02, 9_03 9_04, 
9_10, 9_18, 9_20, 9_30 
ErbB2-631 
(R1, ep.)g 
24/94 9/16 
(8/16)h 
H_11 H_13 H_14, H_01, H_03 
ErbB4 
(R3) 
55/143 7/48 
(5/48) 
B4_11, B4_14 - B4_01, B4_02, B4_07, 
B4_33, B4_45 
ErbB4 
(R1, ep.)g 
84/94 12/20 
(6/20) 
B4_55, B4_56, 
B4_63, B4_64, 
B4_65, B4_68 
B4_49, B4_53, 
B4_57, B4_60 
B4_50, B4_58 
aRatio of the number of positive clones to the total number of clones screened in ELISA experiments. bNumber of clones with 
different sequences, identified in the total number of clones sequenced. In parentheses number of different clones confirmed by 
competition ELISA experiments using purified DARPins to bind the target protein. cBinders giving low ELISA signal 
(signal/background < 3) indicating either low affinity of low concentrations of active binder (atypical SEC, no monodisperse 
population as judged by SEC). d In bold letters binders described in Chapter 3 of my thesis. eSum of the analysis of the 2nd and 
3rd round of selection.  fSum of the analysis of the 2nd and 3rd round of different selection approaches. gOne round of selection 
with epitope-masking (ep.) as described in Chapter 3 of my thesis. hFour of the clones sequenced were already found in the 
selection on ErbB2-509 and are not listed. 
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2. DARPins binding the Fc domain of human IgG1  
The “fragment crystallizable” region (Fc region) of antibodies is responsible for interaction 
with cell surface receptors (Fc receptors) and proteins of the complement system and thereby 
mediates effector functions such as activation of the complement system or cytotoxic cells1. The 
Fc domain of IgGs is a glycosylated disulfide-linked homodimer, composed of the second and 
third constant domain of the antibody's heavy chain. The aim of this project was to select binders 
with a broad range of affinities against the Fc domain of human IgG1 (huIgG1_Fc, P100 – 
K330). High affinity clones, when coupled to a label, could be used as in vitro detection 
reagents, alternative to commercially available secondary antibodies (e.g. Western blotting and 
ELISA). Additionally, for in vivo applications, binders with different affinities could be tested to 
construct fusion proteins (e.g. DARPin heterodimers) with a “tailored” serum half-life by 
hijacking of antibodies present in the blood stream. 
Selection and screening of binders against huIgG1_Fc is described in detail in Chapter 3 
of my thesis. Based on ELISA and SDS-PAGE analysis, 21 clones were submitted for 
sequencing, resulting in eleven different sequences (Fig. 1). After expression and purification by 
immobilized metal ion chromatography (IMAC) purification in the 96-well format, all binders 
were analyzed by size exclusion chromatography (SEC) and compared to the well characterized, 
non-binding DARPin E3_5 (ref. 2) (Fig. 2). To investigate the specificity of the selected 
DARPins, ELISA experiments were performed. All of the binders were tested for interacting 
with full length human IgG1 (huIgG1), neutravidin, mouse IgG1 (muIgG1) and mouse IgG2b 
(muIgG2b). In the competition ELISA setup, DARPins were preincubated with free huIgG1 
(Fig. 3a, b). As a result, highly specific DARPins to human IgG1 were obtained with affinities 
ranging from 2 to 140 nM. Due to the low binding signal, clones I_10, I_14 and I_15 were 
considered as false positives (no affinity for the target protein or affinity below the detection 
limit of the experiments). Clones I_03 and I_06 gave low binding signal, probably due to the low 
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concentration of active binder present (see SEC Fig. 2), which can probably be attributed to 
framework mutations (Fig. 1) 
Four of the clones were further analyzed at multiple concentrations by surface plasmon 
resonance (SPR) (Table 3 and Supplementary Figure 2 of Chapter 3) and the data obtained 
were evaluated with a global kinetic fit. Additionally, the binding kinetics of these clones were 
determined by resonant acoustic profiling (RAP) performed by John Watkins and coworkers 
(Akubio Ltd., Cambridge, United Kingdom). Comparison of the SPR and RAP results is shown 
in Table 2. Unfortunately, DARPin concentrations for RAP measurements were only estimated 
by a single measurement using a NanoDrop ND-1000 spectrophotometer (NanoDrop 
Technologies, USA), affecting the accuracy of the association constants and thereof calculated 
affinity constants. DARPin concentrations for SPR measurements were determined directly 
before kinetic analysis using an Agilent 8453 UV-Visible Spectrophotometer (Agilent 
Technologies, Germany), giving highly reproducible values. Nevertheless, range and order of the 
affinities and binding kinetics measured with SPR and RAP are in good agreement. 
 
 
Table 2: Comparison of the affinities and binding kinetics of huIgG1_Fc binding 
DARPins determined by SPR and RAP 
Clone (NxC) a Measurement b KD 
[nM] 
kon 
[104 M-1s-1] 
koff 
[10-3s-1] 
I_02 (N2C) SPR 41 28 12 
 RAP 57 36 20 
I_07 (N2C) SPR 25 7.0 1.7 
 RAP 14 18 2.5 
I_11 (N3C) SPR 140 49 67 
 RAP 130 50 66 
I_19 (N3C) SPR 2.1 34 0.7 
 RAP 3.2 47 1.5 
a Name of the respective clone and in parentheses number internal of repeat modules (x) stacked between N-Cap 
(N) and C-Cap (C). b Association (kon) and dissociation (koff) constants were measured by using surface plasmon 
resonance (SPR) or resonant acoustic profiling (RAP) and respective dissociation constants KD calculated as 
(koff/kon). Kinetic data and evaluation with a global kinetic fit of the SPR measurements is given in Chapter 3: 
Supplementary Figure 2. Data of the RAP measurements were produced John Watkins and coworkers (Akubio 
Ltd., Cambridge, United Kingdom). 
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1 30
 DARPin NxC D L G K K L L E A A R A G Q D D E V R I L M A N G A D V N A
 I_02 N2C D L G K K L L E A A R A G Q D D E V R I L M A N G A D V N A
 I_07 N2C D L G K K L L E A A R A G Q D D E V R I L M A N G A D V N A
 I_13 N2C D L G K K L L E A A R A G Q D D E V R I L M A N G A D V N A
 I_01 N3C D L G K K L L E A A R A G Q D D E V R I L M A N G A D V N A
 I_03 N3C D L G K K L L E A A R A G Q D D E V R I L M A N G A D V N A
 I_06 N3C D L G K K L L E A A R A G Q D D E V R I L M A N G A D V N A
 I_10 N3C D L G K K L L E A A R A G Q D D E V R I L M A N G A D V N A
 I_11 N3C D L G K K L L E A A R A G Q D D E V R I L M A N G A D V N A
 I_14 N3C D L G K K L L E A A R A G Q D D E V R I L M A N G A D V N A
 I_15 N3C D L G K K L L E A A R A G Q D D E V R I L M A N G A D V N A
 I_19 N3C D L G K K L L E A A R A G Q D D E V R I L M A N G A D V N A
1 33
 DARPin NxC x D x x G x T P L H L A A x x G H L E I V E V L L K x G A D V N A
 I_02 N2C R D M S G Y T P L H L A A H M G H L E I V E V L L K N G A D V N A
 I_07 N2C S D K S G Y T P L H L A A H I G H L E I V E V L L K H G A D V N A
 I_13 N2C F D M S G Y T P L H L A A Y D G H L E I V E V L L K N G A D V N A
 I_01 N3C N D I S G Y T P L H L A A Y V G H Q E I V E V L L K N G A D V N A
 I_03 N3C I D W D G Y T P L H L A A Y F G H L E I V E V L L K H G A D V N A
 I_06 N3C I D F F G N T P L H L A A I Y G H L E I V E V L L K Y G A D V N A
 I_10 N3C N D I Q G L T P L H L A A R T G H L E I V E V L L K Y G A D V N A
 I_11 N3C I D T I G L T P L H L A A H D G H L E I V E V L L K N G A D V N A
 I_14 N3C T D Q F G T T P L H L A A I N G H L E I V E V L L K N G A D V N A
 I_15 N3C E D Y S G L T P L H L A A D D G H L E I V E V L L K Y G A D V N A
 I_19 N3C D D N K G D T P L H L A A S F G H L E I V E V L L K N G A D V N A
1 33
 DARPin NxC x D x x G x T P L H L A A x x G H L E I V E V L L K x G A D V N A
 I_02 N2C K D N W G D T P L H L A A I F G H L E I V E V L L K N G A D V N A
 I_07 N2C H D S W G D T P L H L A A T F G H L E I V E V L L K H G A D V N A
 I_13 N2C N D L W G D T P L H L A A T R G H L E I V E V L L K Y G A D V N A
 I_01 N3C D D T W G D T P L H L A A L F G H L E I V E V L L K Y G A D V N A
 I_03 N3C H D E Y G R T P L H L A A E S G H L E I V E V L L K Y G A D V N A
 I_06 N3C M D K H G H T L L H L A A V L G H L E I V E V L L K N G A D V N A
 I_10 N3C W D S H G S T P L H L A A T L G H L E I V E V L L K H G A D V N A
 I_11 N3C A D N W G I T P L H L A A R R G H L E I V E V L L K H G A D V N A
 I_14 N3C Q D F F G N T P L H L A A W H G H L E I V E V L L K N G A D V N A
 I_15 N3C S D R A G L T P L H L A A N N G H L E I V E V L L K N G A D V N A
 I_19 N3C D D Y F G D T P L H L A A W S G H L E I V E V L L K Y G A D V N A
1 33
 DARPin NxC x D x x G x T P L H L A A x x G H L E I V E V L L K x G A D V N A
 I_02 N2C ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~
 I_07 N2C ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~
 I_13 N2C ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~
 I_01 N3C H D R F G F T P L H L A A S S G H L E I V E V L L K H G A D V N A
 I_03 N3C N D Y D G H T P L H R L L M L V T W K S L K F C L K N G A D V N T
 I_06 N3C S D I H G H T P L H L V A K V G H L E I V E V L L K H G A D V N A
 I_10 N3C N D Y T C T T P L H L A A R Y G H L E I V E V L L K Y G A D V N A
 I_11 N3C D D V Q G N T P L H L T A H H G H L E I V E V L L K H G A D V N A
 I_14 N3C H D D Y G N T P L H L A A F R G H L E I V E V L L K H S A D V N A
 I_15 N3C H D N H G F T P L H L A A V A G H L E I V E V L L K N G A D V N A
 I_19 N3C Q D Q R G F T P L H L A A I A G H L E I V E V L L K Y G A D V N A
1 25
 F, Y, W
 DARPin NxC Q D K F G K T A F D I S I D N G N E D L A E I L Q
 I_02 N2C Q D K F G K T A F D I S I D N G N E D L A E I L Q  I, L, V, P, A, M, C
 I_07 N2C Q D K F G K T A F D I S I D N G N E D L A E I L Q
 I_13 N2C Q D K F G K T A F D I S I D N G N E D L A E I L Q  G
 I_01 N3C Q D K F G K T A F D I S I D N G N E D L A E I L Q
 I_03 N3C Q D K F G K T A F D I S I D N G N E D L A E I L Q  H
 I_06 N3C Q D K F G K T A F D I S I D N G N E D L A E I L Q
 I_10 N3C Q D K F G K T A F D I S I D N G N E D L A E I L Q  S, T, N, Q
 I_11 N3C Q D K F G K T A F D I S I D N G N E D L A E I L Q
 I_14 N3C Q D K F G K T A F D I S I D N G N E D L A E I L Q  R, K
 I_15 N3C Q D K F G K T A F D I S I D N G N E D L A E I L Q
 I_19 N3C Q D K F G K T A F D I S I D N G N E D L A E I L Q  D, E
C-Cap
C-Cap
1st repeat
2nd repeat
3rd repeat
 
Figure 1: Sequences of selected huIgG1_Fc binding DARPins. The original consensus sequence is shown on top 
with randomized positions indicated by x. In the lines below, only residues that differ from the consensus sequence 
are printed in color, residues identical to the consensus sequence are printed in gray and deletions and missing 
amino acids are printed in black. Note that the N-terminal MRGSHHHHHHGS and the C-terminal KLN, which are 
not part of the DARPin sequence, are not shown. Amino acids are colored by type as indicated at the end of the 
alignment. 
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Figure 2: Size exclusion chromatography (SEC) of 
selected huIgG1_Fc-binding DARPins. The 
chromatograms of the eleven huIgG1_Fc binders and 
the unselected DARPin E3_5 are shown. For each 
DARPin the number of repeats stacked between N-
Cap (N) and C-Cap (C) is given in parentheses. The 
molecular mass standards, phage protein D (gpD) with 
an apparent mass of 17.6 kDa and phage protein SHP, 
a trimer with an apparent mass of 50.2 kDa, are 
indicated with arrows. 
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Figure 3: Specificity and affinity estimation of selected huIgG1_Fc binders. (a) ELISA with high affinity 
huIgG1_Fc binders. To analyze specificity, 1 nM solutions of the binders I_01, I_02, I_03, I_07 and I_19 were 
tested for binding on neutravidin, huIgG1, mouse IgG1 (muIgG1) and mouse IgG2b (muIgG2b) and, in parallel, 
competition experiments were performed by preincubation of 1 nM solutions of the DARPins with 10 nM or 
100 nM free huIgG1 (10 nM or 100 nM) before binding on immobilized huIgG1. (b) ELISA with low affinity 
huIgG1_Fc binders and control DARPin E3_5. To analyze specificity, 5 nM solutions of the binders I_06, I_10, 
I_11, I_13, I_14, I_15 and control DARPin E3_5 were tested for binding on neutravidin, huIgG1, muIgG1 and 
muIgG2b and, in parallel, competition experiments were performed by preincubation of 5 nM solutions of the 
DARPins with 100 nM or 500 nM of free huIgG1 (100 nM or 500 nM) before binding on immobilized huIgG1. All 
full length IgGs were directly immobilized on solid supports. The first word in the legend denotes the protein 
immobilized, no comp. denotes the absence of a competitor and + huIgG1 denotes the presence of competitor in 
10 nM, 100 nM or 500 nM concentrations. 
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3. DARPins binding tumor necrosis factor alpha (TNFα)  
Tumor necrosis factor alpha (TNFα) is a pro-inflammatory cytokine that is responsible for 
a broad range of signal events leading to apoptosis, cellular proliferation and differentiation3. 
TNFα is produced as a type II membrane protein which spontaneously assembles into 
homotrimers. Upon proteolytic cleavage, the soluble trimeric form of TNFα is released from the 
membrane. Both soluble and membrane bound form can interact with the two main receptors 
TNF-R1 and TNF-R2. Overexpression of TNFα has been identified as one of the key players in 
many human diseases such as rheumatoid arthritis. The aim of this project was to validate the 
phage DARPin library and to select binders to TNFα and test whether binders can be obtained 
that can block TNFα action in a similar fashion as the clinically used soluble recombinant 
receptor of TNFα Etanercept (EnbrelTM) or the two antibodies Infliximab (RemicadeTM) and 
Adalimumab (HumiraTM). 
Selection and screening of binders against the soluble form of TNFα is described in detail 
in Chapter 3 of my thesis. Based on ELISA and SDS-PAGE analysis, 52 clones were submitted 
for sequencing, resulting in 29 different sequences (Fig. 4). Interestingly, all selected binders are 
N3C DARPins with a quite high prevalence of hydrophobic amino acids at the randomized 
positions of the first and second internal repeat, as well as many cysteines and deletions, without 
showing a selected consensus. After expression and purification by immobilized metal ion 
chromatography (IMAC) purification in the 96-well format, all binders were analyzed by size 
exclusion chromatography (SEC) and compared to the well characterized, non-binding DARPin 
E3_5 (ref. 2) (Fig. 5). To investigate the specificity of the selected DARPins, ELISA 
experiments were performed (Fig. 6). All of the binders do show specific binding to TNFα, do 
not interact with neutravidin and binding can be almost completely inhibited by preincubation of 
the immobilized TNFα with soluble Enbrel (for further experiments see below). In the 
competition ELISA setup, the binding of all clones to immobilized TNFα could also be well 
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inhibited by preincubation with free TNFα. From the competition ELISA signals obtained with 
10 nM of free TNFα, the affinity of most of the binders was estimated to be in the low nM range. 
To determine the affinity, a subset of the selected DARPins (T_02, T_07, T_08, T_25, 
T_37 and T_40) was further analyzed by competition ELISA measurements using dilution series 
of free TNFα for competition (Fig. 7a). Inhibition of ELISA signals to less than 50% was 
observed for all clones tested using 3 nM competitor, suggesting single digit nanomolar affinity. 
To determine the binding kinetics, the selected DARPins were further analyzed by surface 
plasmon resonance (SPR, Biacore) measurements. Interestingly, none of the selected DARPins 
did show binding to TNFα which had been immobilized via the biotin label (present at an N-
terminal Avi-tag on TNFα) to a flow cell of a streptavidin coated chip (SA, Biacore), while 
Enbrel gave a high and specific binding signal, confirming the immobilization of the target 
protein. Unfortunately, the exact reason for this behavior could not be determined. However, the 
observation that the refractive index signal of the TNFα-coated flow cell decreased over time 
might indicate that the integrity of the TNFα homotrimer is not maintained under these 
experimental conditions. Thus, a possible explanation could be that the DARPins only bind to 
the intact trimer, while Enbrel also recognizes other forms of TNFα. 
The SPR measurements were then also performed in the inverted setup. The DARPins 
T_02 and T_25 were directly coupled to a dextran-chip (CM5, Biacore) and soluble TNFα was 
injected at different concentrations over the flow cells (Fig. 7b, c). The kinetic data of the 
interactions were evaluated with a global fit using Scrubber 2 (BioLogic Software Ltd), resulting 
in a dissociation constant of 12 nM for T_02 and 7 nM for T_25, which is in reasonable 
agreement with the affinities estimated by the competition ELISA experiments (Fig. 7a). 
Interestingly, in an ELISA setup the binding of all selected DARPins can be almost 
completely inhibited by preincubation of the immobilized TNFα with soluble Etanercept 
(EnbrelTM, recombinant human soluble tumor necrosis factor alpha receptor fused to Fc domain 
of human IgG1) (Amgen, USA) (Fig. 6 a, b). However, in the same ELISA setup, when the 
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immobilized TNFα was preincubated with different DARPins (T_02, T_07, T_08, T_25, T_37, 
T_40), the binding of Enbrel could not be inhibited, even not at very low concentrations of 
Enbrel (Fig. 8a). This seemingly “unidirectional” competition of the two classes of binding 
molecules can probably be explained by their different affinities for the target protein. The 
affinities of the tested DARPins are in the low nanomolar range (see above). Literature values 
for the affinity of Enbrel range from 65 pM (ref. 4) to 1.15 nM (ref. 5). The former value seems 
to be much more realistic, since in the SPR experiments carried out here the evaluation of 
injections of Enbrel by a global fit resulted in an affinity of about 130 pM (data not shown). Due 
to this 100-fold difference in affinity of the two classes of binding molecules it might be possible 
that the dimeric Enbrel is able to displace the bound DARPins in the setup of the ELISA 
experiment.  
The competition of the DARPin T_25 with Enbrel for binding to TNFα was further 
analyzed in kinetic SPR measurements. Enbrel was directly coupled to a dextran-chip (CM5, 
Biacore) and soluble TNFα alone or TNFα preincubated with an excess of the DARPin (200 nM) 
was injected at different concentrations over the flow cells (Fig. 8b). For all concentrations 
addition of the DARPin strongly reduced the binding signal obtained compared to TNFα alone, 
and at 1 nM TNFα concentration the DARPin (at 200 nM) could almost completely inhibit the 
binding of TNFα to the immobilized Enbrel. Therefore, the DARPins and Enbrel are competing 
for binding to the target protein, however in strong favor for the dimeric Enbrel. 
In all experiments described above (phage selection, ELISA and SPR measurements), the 
binding and washing steps were carried out using standard buffers containing 0.1% (v/v) Tween-
20 (buffers used are indicated in all figures). During further analysis, very much to my surprise, I 
discovered that all the selected DARPins show specific TNFα binding that is dependent on the 
presence of the detergent Tween-20 in the binding buffer. For example, in ELISA experiments, 
excellent and specific binding to the immobilized target protein was observed in buffer PBST 
(PBS containing 0.1% (v/v) Tween-20), but not in PBS alone (Fig. 9). Identical Tween-20 
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dependent binding in ELISA experiments was observed using TBS or HBS as buffers (data not 
shown) and also in SPR measurements, binding of TNFα to the immobilized DARPins could 
only be detected in HBST (HBS containing 0.1% (v/v) Tween-20) but not in HBS alone. In stark 
contrast, Enbrel did show identical TNFα binding signals independent of the buffer composition 
used (Fig. 9). To further analyze if this effect of detergent-dependent binding can also be 
observed in solution, complex formation of the two DARPins T_07 and T_37 with the target 
protein was investigated by SEC using PBS and PBST as running buffers (Fig. 10). DARPins 
and TNFα alone and both co-injected were analyzed. The apparent molecular weight of TNFα 
was 45 kDa in PBS and 40 kDa in PBST, most probably representing the homo-trimeric form of 
the protein, which has a theoretical molecular weight of 52.2 kDa. As expected, only in the 
buffer containing Tween-20 a shift to higher molecular weight indicating complex formation was 
observed (Fig. 10b, d). In PBS, co-injection of the binders and TNFα resulted in an elution 
chromatogram identical to the sum of the chromatograms of the single components (Fig. 10a, c). 
One possible speculation to explain these findings is that Tween-20, present during all selections, 
induces conformational changes in TNFα needed for the accessibility of the DARPin epitopes. 
To further investigate the composition of the DARPin- TNFα complex, DARPin T_07 and 
TNFα alone and both co-injected were analyzed by SEC-MALS as described6. Measurements 
and data evaluation was performed by Thomas Huber and the results obtained are depicted in 
Figure 11. For the DARPin T_07 the weight-average molar mass over the peak obtained from 
SEC-MALS measurements (MWMALS) was determined to be 18.8 kDa, in good agreement with 
the molecular weight calculated from the amino acid composition (MWcalc = 18 kDa). For TNFα 
the MWMALS was determined to be 52.8 kDa, also in good agreement with the 
MWcalc = 52.2 kDa of the homo-trimeric form of the protein. Complex formation of TNFα 
coinjected with an equimolar amount of the DARPin T_07 is clearly indicated by a shift of 
0.6 ml of the elution peak to a smaller elution volume (bigger molecular size) relative to the 
uncomplexed TNFα. However, the MWMALS was determined to be 53.5 kDa which cannot be 
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explained by the complex formation of one or more DARPins with the intact homo-trimeric form 
of TNFα, which would result in a MWcalc of at least 70.2 kDa (homo-trimeric TNFα plus one 
DARPin). One reasonable model to explain the measured molecular mass would be the complex 
formation of the homo-dimeric form of TNFα with one DARPin (MWcalc = 52.8 kDa). In the 
case of TNFα coinjected with a threefold lower amount of the DARPin T_07 complex formation 
can be observed, but the elution peak seems to be a mixture of different molecular species as 
indicated by the shape of the elution peak and the molar mass distribution over the peak. We 
cannot exclude a more complicated model containing mixtures of species, as the MALS can only 
detect the weight-average molar mass. All in all, the complex formation of TNFα with the 
DARPin can not be explained by the stable interaction of one or three DARPins with the homo-
trimeric form of TNFα and seems to follow a more complicated mechanism. 
To summarize, the selected DARPins seem to bind to a non-native epitope on TNFα, also 
depending on the presence of Tween-20. It should be remembered that the TNFα used (with and 
without Avi-tag) was recombinantly produced in E. coli (see Chapter 3). To prevent the 
enrichment of such binders, Tween-20 could be omitted or replaced by other detergents in new 
selection approaches on TNFα. I did not further analyze these DARPins, since I do not expect 
them to bind their target protein in vivo. 
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1 30
 DARPin NxC D L G K K L L E A A R A G Q D D E V R I L M A N G A D V N A
 T_01 N3C D L G K K L L E A A R A D Q D D E V R I L M A N G A D V N A
 T_02 N3C D L G K K L L E V A R A G Q D D E V R I L M A N G A D V N A
 T_03 N3C D L G K K L L E A A R A G Q D D E V R I L M A N G A D V N A
 T_04 N3C D L G K K L L E A A R A G Q D D E V R I L M A N G A D V N A
 T_06 N3C D L G K K L L E A A R A G Q D D E V R I L M A N G A D V N A
 T_07 N3C D L G K K L L E A A R A G Q D D E V R I L M A N G A D V N A
 T_08 N3C D L G K K L L E A A R A G Q D D E V R I L M A N G A D V N A
 T_09 N3C D L G K K L L E A A R A S Q D D E V R I L M A N G A D V N A
 T_10 N3C D M G K K L L E A A R A G Q D D E V R I L M A N G A D V N A
 T_11 N3C D L G K K L L E A A R A G Q D D E V R I L M A N G A D V N A
 T_12 N3C D L G K K L L E A A R A G Q D D E V R I L M A N G A D V N A
 T_13 N3C D L G K K L L E A A R A G Q D D E V R I L M A N G A D V N A
 T_15 N3C D L G K K L L E A A R A G Q D D E V R I L M A N G T D V N A
 T_16 N3C D L G K K P L E A A R A G Q D D E V R I L M A N G A D V N A
 T_19 N3C D L G K K L L E A A R A G Q D D E V R I L M A N G A D V N A
 T_25 N3C D L G K K L L E A A R A G Q D D E V R I L M A N G A D V N A
 T_27 N3C D L G K K P L E A A R A G Q D D E V R I L M A N G A D V N A
 T_30 N3C D L G K K L L E A A R A G Q D D E V R I L M A N G A D V N A
 T_33 N3C D L G K K L L E A A R A G Q D D E L R I L M A N G A D V N A
 T_35 N3C D L G K K L L E A A R A G Q D D E V R I L M A N G A D V N A
 T_37 N3C D L G K K L L E A A R A G Q D D E V R I L M A N G A D V N A
 T_40 N3C D L G K K L L E A A R A S Q D D E V R I L M A N G A D V N A
 T_41 N3C D L G K K L L E A A R A G Q D D E V R I L M A N G A D V N A
 T_44 N3C D L G K K L L E A A R A G Q D D E V R I L M A N G A D V N A
 T_45 N3C D L G K K L L E A A R A G Q D D E V R I P M A N G A D V N A
 T_47 N3C D L G K K L L E A A R A G Q D D E V R I L M A N G A D V N A
 T_49 N3C D L G K K L L E A A R A G Q D D E V R I L M A N G A D V N A
 T_51 N3C D L G K K L L E A A R A G Q D D E V R I L M A N G A D V N A
 T_52 N3C D L G K K L L E A A R A G Q D D E V R I L M A N G A D V N A
1 33
 DARPin NxC x D x x G x T P L H L A A x x G H L E I V E V L L K x G A D V N A
 T_01 N3C N D I W G I T P L H L A A I F G H L E I V E F L L K N G A D V N A
 T_02 N3C A D H Q S F T P L H L Y A I F G H L E I V E V L L K N G A D V N A
 T_03 N3C Q Y H E G W T P L H L A A I F G H L E I V E V L L K N G A D V N A
 T_04 N3C D D K Q G L T P L H L A A A F G H L E I V E V L L K N G A D V N A
 T_06 N3C M D F . . L T P L H L A A A F G H L E I V E F L L K H G A D V N A
 T_07 N3C Y D W K G L T P L H L A A I F G H L E I V E S A M . N G A D V N A
 T_08 N3C W D F L G L I P L R L A A A F G H L E I V E V L L K N G A D V N A
 T_09 N3C N D F Q G I T P L H L A A I F G H L E I V E V L L K N G A D V N A
 T_10 N3C K D F F V F T P L H L A A A I D H P E I V E V L L K N G A D V N A
 T_11 N3C D D V F . Y T P L H L A A I F G H L E I V E V L L K N G A D V N A
 T_12 N3C D D F Y A V F T P L Y L A A T F G H L E I V E V L L K N G A D V N A
 T_13 N3C M D M G K M T P L H L A A A I G H L E I V E F C L K Y G A D V N A
 T_15 N3C Y D T K V F T P L H L A A A T G H L E I V E F C L K Y G A D V N A
 T_16 N3C Y D I V G I T P L H L A A I F G H L E I V E V L L K N G A D V N A
 T_19 N3C M D K K G I T P L H L A A T F G H L E I V E V L L K Y G T D V N A
 T_25 N3C D D R R G I P P L H L A A I F G H L E I V E V L L K H G A D V N A
 T_27 N3C Y D R H G L T P L H L V A I F G H L E I V E V L L K H G A D V N A
 T_30 N3C E D T L G I T P L H L A A I T G H L E I V E F C L K Y G A D V N A
 T_33 N3C N D F R G I T P L H L S A A F G H L E I V E V L L K N G A D V N A
 T_35 N3C F D . R G I T P L H L A A T F G H L E I V E V V L K Y G A D V N A
 T_37 N3C H D K R G I T P L H L A A I T G H L E M V E V L L . H G A D V N A
 T_40 N3C N D R V G F T P L H L A A M F G H L E L V E V L L K N G A D V N A
 T_41 N3C D D T I G F T P L H L A A I F G H L E I V E V L L K Y G A D V N A
 T_44 N3C L D Y N V I T P L H L A A A L G H L E I V E V L L K N G T D V N A
 T_45 N3C A D F K G L T P L H L A A T T G H L E I V E F L L K Y G A D V N A
 T_47 N3C N D F K G W T P L H L A A T F G H L E F V E V L L K N G A D V N A
 T_49 N3C E D R I V F T P L H L A A I F G H L E I V E V L L K N G A D V N A
 T_51 N3C Y D D F G N I P L H L A A A W G H L E I V E V L L K N G A D V N A
 T_52 N3C N D N R G L T P L H L A A A L G H L E I V E V P L K N G A D V N A
1 33
 DARPin NxC x D x x G x T P L H L A A x x G H L E I V E V L L K x G A D V N A
 T_01 N3C S D F S G F T P L H L A A Y K G H L E I V E V L L K H G A D V N A
 T_02 N3C S D W H G N T P L H L A A W I G H L E I V E V L L K Y G A D V N A
 T_03 N3C F D A Q G Y T P L H L A A L I G H L E I V E V L L K N G A D V N A
 T_04 N3C L V E A G F T P L H L A A Y I G H L E I V E V L L K Y G A D V N A
 T_06 N3C W D A S G Y T P L H L A A W S G H L E I V E V L L K N G A D V N A
 T_07 N3C I D F S G R T P L H L A A L I G H L E I V E V L L K Y G A D V N A
 T_08 N3C K D T Y G I T P L H L A A M N G H L E I V E V L L K N G A D V N A
 T_09 N3C Y D Q M G M T P L H L A A W T G H L E I V E V L L K H G A D V N A
 T_10 N3C Q D S A G M T P L H L A A W S G H L E I V E V L L K N G A D V N A
 T_11 N3C Y D N A V H T P L H L A A W L G H L E I V E V L L K Y G A D V N A
 T_12 N3C K D K T G L T P L H L A A W L G H L E I V E V L L K H G A D V N A
 T_13 N3C W D L S G K T P L H L A A W A G H L E I V E V L L K N G A D V N A
 T_15 N3C V D S I G H T P L H L A A F T G H L E I V E V L L K H G A D V N A
 T_16 N3C Y D M Q V N T P L H L A A W L G H L E I V E V L L K N G A D V N A
 T_19 N3C S D Y T G K T P L H L A A W I G H L E I V E V L L K Y G A D V N A
 T_25 N3C H D M Q G R T P L H L A A Y T G H L E I V E V L L K Y G A D V N A
 T_27 N3C I D I I G Y T P L H L A A W S G H L E I V E V L L K N G A D V N A
 T_30 N3C M D Y T G K T P L H L A A L T G H L E I V E V L L K N G A D V N A
 T_33 N3C I D S I G M T P L H L A A W I G H L E I V E V L L K N G A D V N A
 T_35 N3C H D F T G E T P L H L A A W L G H L E I V E V L L K Y G A D V N A
 T_37 N3C V D I Q G R T P L H L A A W I G H L E I V E V L L K Y G A D V N A
 T_40 N3C I D F Q G K T P L H L A A Q L G H L E I V E V L L K Y G A D V N A
 T_41 N3C T D Q V G M T P L H L A A W T G H L E I V E V L L K H G A D V N A
 T_44 N3C N D K N G H T P L H L A A W I G H L E I V E V L L K N G A D V N D
 T_45 N3C L D L A G K T P L H L A A W I G H L E I V E V L L K N G A D V N A
 T_47 N3C L D L Q G Y T P L H L A A F I G H L E I V E V L L K H G A D V N S
 T_49 N3C N D M M G Y T P L H L A A W I G H L E I V E V L L K Y G A D V N A
 T_51 N3C . . L Y G T T P L H L A A N F G H L E I V E V L L K H G A D V N A
 T_52 N3C L D S V G D T P L H L A A W I G H L E I V E V L L K H G A D V N A
C-Cap
1st repeat
2nd repeat
 
Figure 4: Continued next page. 
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1 33
 DARPin NxC x D x x G x T P L H L A A x x G H L E I V E V L L K x G A D V N A
 T_01 N3C N D A T G T T P L H L A A K K G H L E I V E V L L K N G A D V N A
 T_02 N3C T D H S G S T P L H L A A T L G H L E I V E V L L K Y G A D V N A
 T_03 N3C I D P V G Y T P L H L A A H K G H L E I V E V L L K H G A D V N A
 T_04 N3C Y D F S G T T P L H L A A N S G H L E I V E V L L K N G A D V N A
 T_06 N3C V D I E G K T P L H L A A N K G H L E I V E V L L K H G A D V N A
 T_07 N3C H D S A G S T P L H L A A T K G H L E I V E V L L K Y G A D V N A
 T_08 N3C L D N T G S T P L H L A A N Y G H L E I V E V L L K H G A D V N A
 T_09 N3C D D T H G A T P L H L A A H T G H L E I V E V L L K Y G A D V N A
 T_10 N3C V D F S G N T P L H L A A E K G H L E I V E V L L K N G A D V N A
 T_11 N3C T D H N G S T P L H L A A S K G H L E I V E V L L K Y G A D V N A
 T_12 N3C Q D V Q G N T P L H L A A S H G H L E I V E V L L K N G A D V N A
 T_13 N3C F D R D G D T P L H L A A N Q G Q L E I V E V L L K Y G A D V N A
 T_15 N3C N D Q F G D T P L H L A A V R G H L E I V E V L L K Y G A D V N A
 T_16 N3C E D S Y G N T P L H L A A D K G H L E I V E V L L K N G A D V N A
 T_19 N3C F D D I G H T P L H L A A H K G H L E I V E V L L K H G A D V N A
 T_25 N3C I D F T G H T P L H L A A F R G H L E I V E V L L K H G A D V N A
 T_27 N3C S D V T G S T P L H L A A D K G H L E I V E V L L K Y G A D V N A
 T_30 N3C T D F H G N T P L H L A A A V G H L E I V E V L L K Y G A D V N A
 T_33 N3C Q D D F G H T P L H L A A E K G H L E I V E V L L K N G A D V N A
 T_35 N3C W D D D G S T P L H L A A N L G H L E I V E V L L K H G A D V N A
 T_37 N3C M D D F G E T P L H L A A R T G H L E I V E V L L K H G A D V N A
 T_40 N3C L D A R G I T P L H L A A I H G H P E I V E V L L K Y G A D V N A
 T_41 N3C Q D R L G R T P L H L A A Q I G H L E I V E V L L K N G A D V N A
 T_44 N3C H D E K G K T P L H L A A D N G H L E I V E V L L K Y G A D V N A
 T_45 N3C N D A S G M T P L H L A A V R G H L E I V E V L L K N G A D V N A
 T_47 N3C T D Y D G T T P L H L A A D F G H L E I V E V L L K H G A D V N A
 T_49 N3C L D S F G S T P L H L A A T H G H L E I V E V L L K Y G A D V N A
 T_51 N3C K D V R G H T P L H L A A T Q G H L E I V E V L L K Y G A D V N A
 T_52 N3C M D D M G F T P L H L A A N K G H L E I V E V L L K Y G A D V N A
1 25
 DARPin NxC Q D K F G K T A F D I S I D N G N E D L A E I L Q
 T_01 N3C Q D K F G K T A F D I S I D N G N E D L A E I L Q
 T_02 N3C Q D K F G K T A F D I S I D N G N E D L A E I L Q
 T_03 N3C Q D K F G K T A F D I S I D N G N E D L A E I L Q
 T_04 N3C Q D K F G K T A F D I S I D N G N E D L A E I L Q
 T_06 N3C Q D K F G K T A F D I S I D N G N E D L A E I L Q
 T_07 N3C Q D K F G K T A F D I S I D N G N E D L A E I L Q  F, Y, W
 T_08 N3C Q D K F G K T A F D I S I D N G N E D L A E I L Q
 T_09 N3C Q D K F G K T A F D I S I D N G N E D L A E I L Q  I, L, V, P, A, M, C
 T_10 N3C Q D K F G K T A F D I S I D N G N E D L A E I L Q
 T_11 N3C Q D K F G K T A F D I S I D N G N E D L A E I L Q  G
 T_12 N3C Q D K F G K T A F D I S I D N G N E D L A E I L Q
 T_13 N3C Q D K F G K T A F D I S I D N G N E D L A E I L Q  H
 T_15 N3C Q D K F G K T A F D I S I D N G N E D L A E I L Q
 T_16 N3C Q D K F G K T A F D I S I D N G N E D L A E I L Q  S, T, N, Q
 T_19 N3C Q D K F G K T A F D I S I D N G N E D L A E I L Q
 T_25 N3C Q D K F G K T A F D I S I D N G N E D L A E I L Q  R, K
 T_27 N3C Q D K F G K T A F D I S I D N G N E D L A E I L Q
 T_30 N3C Q D K F G K T A F D I S I D N G N E D L A E I L Q  D, E
 T_33 N3C Q D K F G K T A F D I S I D N G N E D L A E I L Q
 T_35 N3C Q D K F G K T A F D I S I D N G N E D L A E I L Q
 T_37 N3C Q D K F G K T A F D I S I D N G N E D L A E I L Q
 T_40 N3C Q D K F G K T A F D I S I D N G N E D L A E I L Q
 T_41 N3C Q D K F G K T A F D I S I D N G N E D L A E I L Q
 T_44 N3C Q D K F G K T A F D I S I D N G N E D L A E I L Q
 T_45 N3C Q D K F G K T A F D I S I D N G N E D L A E I L Q
 T_47 N3C Q D K F G K T A F D I S I D N G N E D L A E I L Q
 T_49 N3C Q D K F G K T A F D I S I D N G N E D L A E I L Q
 T_51 N3C Q D K F G K T A F D I S I D N G N E D L A E I L Q
 T_52 N3C Q D K F G K T A F D I S I D N G N E D L A E I L Q
C-Cap
3rd repeat
 
Figure 4: Sequences of selected TNFα binding DARPins. The original consensus sequence is shown on top with 
randomized positions indicated by x. In the lines below, only residues that differ from the consensus sequence are 
printed in color, residues identical to the consensus sequence are printed in gray and deletions and missing amino 
acids are printed in black. Note that the N-terminal MRGSHHHHHHGS and the C-terminal KLN, which are not 
part of the DARPin sequence, are not shown. Amino acids are colored by type as indicated at the end of the 
alignment. 
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Figure 5: Continued next page. 
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Figure 5: Size exclusion chromatography (SEC) of 
selected TNFα-binding DARPins. The chromatograms 
of the 34 TNFα binders and the unselected DARPin 
E3_5 are shown using PBS as running buffer. For 
each DARPin the number of repeats stacked between 
N-Cap (N) and C-Cap (C) is given in parentheses. The 
molecular mass standards, phage protein D (gpD) with 
an apparent mass of 17.6 kDa and phage protein SHP, 
a trimer with an apparent mass of 50.2 kDa, are 
indicated with arrows. 
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Figure 6: ELISA of selected TNFα binding DARPins. (a, b) To analyze specificity, 5 nM solutions of the selected 
DARPins were analyzed for binding on neutravidin, immobilized TNFα and immobilized TNFα preincubated with 
500 nM Etanercept (EnbrelTM) (recombinant human soluble tumor necrosis factor alpha receptor fused to Fc domain 
of human IgG1). In parallel, competition experiments were performed by preincubation of 5 nM solutions of the 
DARPins with free TNFα (10 nM or 100 nM) before binding on immobilized TNFα. DARPin E3_5 was used as 
negative control. For each sample applied, the signal of bound DARPins, detected with an anti RGS-His antibody is 
shown. The first word in the legend denotes the protein immobilized, no comp. denotes the absence of a competitor 
and + TNFα or + Enbrel denotes the presence of competitor (respective concentrations are given in nM). All 
binding and washing steps were carried out in PBST (PBS containing 0.1% (v/v) Tween-20) and concentrations for 
TNFα are given for the monomer. 
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Figure 7: Affinity estimation for a subset of the selected TNFα binding DARPins: (a) To quantify the affinity by a 
competition ELISA experiment, 2 nM solutions of the DARPins (T_02, T_07, T_08, T_25 and T_40) were analyzed 
for binding on neutravidin and immobilized TNFα. In parallel, competition experiments were performed by 
preincubation of 2 nM solutions of the DARPins with free TNFα (3 nM, 6 nM, 9 nM 12 nM and 36 nM) before 
binding on immobilized TNFα. For each sample applied, the signal of bound DARPins, detected with an anti RGS-
His antibody is shown. The first word in the legend denotes the protein immobilized, no comp. denotes the absence 
of a competitor and + TNFα denotes the presence of competitor (respective concentrations are given in nM). All 
binding and washing steps were carried out in PBST (PBS containing 0.1% (v/v) Tween-20) and concentrations for 
TNFα are given for the monomer. (b, c) Surface plasmon resonance (SPR) was measured using a BIAcore 3000 
instrument (BIAcore, Uppsala Sweden). Measurements were performed in HBST buffer (20 mM HEPES, 150 mM 
NaCl, pH 7.4, 0.1% Tween-20) at a flow rate of 50 µl/min. The DARPins T_02 (b) and T_25 (c) were directly 
coupled to a dextran-chip (CM5, Biacore, 260 RU and 300 RU, respectively) and soluble TNFα (once 15 nM and 
twice 50 nM) injected for 4 minutes and the off-rate measured for 20 minutes with buffer flow. The signal of an 
uncoated reference cell was subtracted from the sensograms. The kinetic data of the measurements was evaluated 
with a global fit using Scrubber 2 (BioLogic Software Ltd). Curves with the corresponding fits are shown in the 
figure and the kinetic data are indicated in each graph. 
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Figure 8: Competition of DARPins with recombinant TNF receptor fusion protein Enbrel for TNFα binding. (a) In 
the ELISA setup, solutions of Enbrel (0.5 pM to 16 pM) were analyzed for binding to immobilized TNFα (TNFα, no 
DARPin) and immobilized TNFα preincubated with and in the presence of 0.5 µM solutions of the DARPins T_02, 
T_07, T_25, T_37, E3_5 indicated on the x-axis. For each sample applied, the signal of bound Enbrel, detected with 
an anti-human antibody is shown. All binding and washing steps were carried out in PBST (PBS containing 0.1% 
(v/v) Tween-20). (b) Surface plasmon resonance (SPR) was measured using a BIAcore 3000 instrument (BIAcore, 
Uppsala Sweden). Measurements were performed in HBST buffer (20 mM HEPES, 150 mM NaCl, pH 7.4, 0.1% 
Tween-20) at a flow rate of 50 µl/min. Enbrel was directly coupled to a dextran-chip (CM5, Biacore, 350 RU) and 
soluble TNFα (1 nM, 5 nM and 15 nM) alone and preincubated with DARPin T_25 (200 nM) injected for 4 minutes 
and the dissociation recorded for 20 minutes with buffer flow. The signal of an uncoated reference cell was 
subtracted from the sensograms. 
TNFα (5 nM) + T_25 (200 nM)
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TNFα (15 nM) + T_25 (200 nM)
TNFα (1 nM)
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Figure 9: Buffer-dependent TNFα binding in ELISA. DARPins as described above and Enbrel were analyzed for 
binding to TNFα under different conditions. Ten nM solutions of the selected DARPins and Enbrel were tested for 
binding to neutravidin and TNFα immobilized via neutravidin (TNFα) in PBST (PBS containing 0.1% (v/v) Tween-
20) or PBS alone. For each sample applied, the signal of bound DARPins, detected with an anti RGS-His antibody 
or the signal of bound Enbrel, detected with an anti-human antibody is shown. Identical results were obtained for 
buffers HBS and TBS (data not shown). 
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Figure 10 
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Figure 10: Tween-20 dependent binding of DARPins T_07 (a, b) and T_37 (c, d) to TNFα. The SEC elution 
chromatograms of TNFα (top), T_07 (middle) and both proteins coinjected (bottom) are shown using (a, c) PBS or 
(b, d) PBST (PBS containing 0.1% (v/v) Tween-20) as running buffer. TNFα was used at 8 µM and DARPins T_07 
and T_37 at 10 µM concentrations. Elution volumes are indicated: T_07 and T_37 (dotted line), TNFα (dashed line) 
and TNFα-T_07 and TNFα-T_37 complexes (solid line). The molecular mass standards are described in Figure 5 
and indicated with arrows and concentrations for TNFα are given for the monomer. 
 
 
 
Figure 11: Characterization of the DARPin T_07 – TNFα complex formation by size-exclusion chromatography 
combined with multi-angle light scattering (SEC-MALS). The OD280 signals are depicted as solid lines (left y-axis) 
and the molar mass of the respective elution peak indicated with filled circles (right y-axis). TNFα alone (red line), 
T_02 alone (grey line), TNFα preincubated with an equimolar amount of DARPin (blue line) and TNFα 
preincubated with a threefold lower amount of DARPin (green line) were analyzed at the concentrations described 
in the figure. The weight-average molar mass over the respective elution peaks are: TNFα alone (52.8 kDa, red 
circles), T_02 alone (18.8 kDa, grey circles), TNFα preincubated with an equimolar amount of DARPin (53.5 kDa, 
blue circles) and TNFα preincubated with a threefold lower amount of DARPin (50 - 60 kDa, green circles). Protein 
samples were incubated in PBS containing 0.1% Tween-20 for at least 1 h at room temperature before injection and 
concentrations for TNFα are given for the monomer. 
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4. DARPins binding receptor tyrosine kinase ErbB1/EGFR 
The ErbB receptor tyrosine kinase family comprises four members: ErbB1 (EGFR, Her1), 
ErbB2 (Her2), ErbB3 (Her3) and ErbB4 (Her4). They are all composed of an extracellular ligand 
binding region, a single membrane spanning region and a cytoplasmic tyrosine kinase domain. 
ErbB2 has no known ligand binding affinity and ErbB3 lacks tyrosine kinase activity7. The 
extracellular region of the ErbB receptors is composed of four domains (I-IV) which are quite 
heavily glycosylated (e.g. ErbB1 is glycosylated at eight positions8). Structural studies of these 
receptors have provided valuable insight into receptor activation by their ligands, leading to 
homo- and heterodimerization of the receptors7. In particular ErbB1 and ErbB2 have been 
implicated in the development of many human cancers and are therefore intensively pursued as 
therapeutic targets9.  
The target protein ErbB1 (ref. 10, 11) was kindly provided by Dr. Tim Adams (CSIRO, 
Melbourne, Australia) (L25 – S525 of human receptor tyrosine-protein kinase ErbB1 fused to 
huIgG1_Fc). This truncated version of the extracellular region of ErbB1 comprising domains I-
III but not domain IV and is described in detail in ref. 12. The aim of this project was to select 
binders against ErbB1 which can inhibit activation of the receptor by its ligands in a similar 
fashion as the clinically used monoclonal antibodies (mAbs) Erbitux (Cetuximab)13 or 
Panitumumab (ABX-EGF).  
Primary selections, selection with epitope masking and screening of binders against 
ErbB1 are described in detail in Chapter 3 of my thesis and resulted in nine different sequences 
(Fig. 12). Clones E_01, E_17, E_31 and E_36 are from primary selections and clones E_67, 
E_68, E_69, E_72 form the selection with epitope masking. After expression and purification by 
immobilized metal ion chromatography (IMAC) purification in the 96-well format, all binders 
were analyzed by size exclusion chromatography (SEC) and compared to the well characterized, 
non-binding DARPin E3_5 (ref. 2) (Fig. 13). To investigate the specificity of the selected 
DARPins, ELISA experiments were performed. Due to the low binding signal in all ELISA 
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experiments, clones E_17, E_31 and E_36 were considered as false positives (no affinity for the 
target protein or affinity below the detection limit of the experiments). As almost expected, none 
of the binders did show crossreactivity when analyzed in ELISA experiments for binding to 
other receptors of the ErbB-family (ErbB2 and ErbB4), which share about 50% sequence 
identity and have highly conserved structures (Fig. 14a). In the competition ELISA setup, either 
DARPins were preincubated with free ErbB1 or the immobilized receptor preincubated with its 
ligand epidermal growth factor (EGF) or the clinically used mAb Erbitux (Fig. 15). The clones 
E_01, E_64, E_67 and E_68 bind an epitope overlapping with Erbitux, whereas E_69 and E_72 
recognize a non-overlapping epitope. Preincubation of the receptor with EGF did only partially 
reduce the binding signal of E_01, E_64, E_67 and E_68. This is a bit surprising, since Erbitux is 
known to compete with EGF for binding and, therefore, one would expect that these binders that 
share an overlapping epitope with Erbitux to compete with EGF for receptor binding. One 
possible explanation might be that ErbB1 partially loses its conformational flexibility upon 
immobilization and therefore can no longer adopt its extended conformation needed for high 
affinity ligand binding11. Therefore, the high affinity DARPins might displace the ligand from 
the receptor, resulting in the partial inhibition seen in Figure 15.  
Furthermore, binding and epitope localization of the clones was analyzed by ELISA. All 
ErbB1 binders were tested for interaction with the respective immobilized target protein or the 
target protein bound to immobilized DARPin (E_01) which was used for “epitope-masking” 
during the selection (Fig. 14b). Of the clones selected by “epitope-masking” (E_67, E_68, E_69, 
E_72) only E_69 and E_72 recognize an epitope not competing with E_01, in good agreement 
with the results obtained for target binding in the presence of Erbitux (Fig. 15).  
Four well behaved clones (E_01, E_67, E_68 and E_69) were further analyzed at 
multiple concentrations by surface plasmon resonance (SPR) (Table 3 and Supplementary 
Figure 2 of Chapter 3) and the data were evaluated with a global kinetic fit. Two of the binders 
showed affinities in the pM range and the other binders were in the low nM range. 
144  Appendix 1 
1 30
 DARPin NxC D L G K K L L E A A R A G Q D D E V R I L M A N G A D V N A
 E_64 N2C D L G K K L L E A A R A G Q D G E V R I L M A N G A D V N A
 E_01 N3C D L G K K L L E A A R A G Q D D E V R I L M A N G A D V N A
 E_17 N3C D L G K K L L E A A R A G Q D D E V R I L M A N G A D V N A
 E_31 N3C D L G K K L L E A A L A G Q D D E V R I L M A N G A D V N A
 E_36 N3C D L G K K L L E A A R A G Q D D E V R I L M A N G A D V N A
 E_67 N3C D L G K K L L E A A R A G Q D D E V R I L M A N G A D V N A
 E_68 N3C D L G K K L L E A A R A G Q D D E V R I L M A N G A D V N A
 E_72 N3C D L G K K L L E A A R A G Q D D E V R I L M A N G A D V N A
 E_69 N4C D L G K K L L E A A R A G Q D D E V R I L M A N G A D V N A
1 33
 DARPin NxC x D x x G x T P L H L A A x x G H L E I V E V L L K x G A D V N A
 E_64 N2C H D S Y G W T P L H L L A . D G H P E I V E V L L K H G A D V N A
 E_01 N3C D D T W G W T P L H L L A Y Q G H L E I V E V L L K N G A D V N A
 E_17 N3C S D N D G N T P L H L L A T S G H L E I V E V L L K H G A D V N A
 E_31 N3C H D F H G D T P L H L L A F D G H L E I V E V L L K H G A D V N A
 E_36 N3C K D N A G I T P L H L L A K V G H L E I V E V L L K Y G A D V N A
 E_67 N3C T D N D G N T P L H L S A W I G H L E I V E V L L K H G A D V N A
 E_68 N3C F D Y W G M T P L H L L A D N G H L E I V E V L L K H G A D V N A
 E_72 N3C I D S T G F T P L H L L A A S G H L E I V E V L L K N G A D V N A
 E_69 N4C D D N A G R T P L H L L A N F G H L E I V E V L L K N G A D V N A
1 33
 DARPin NxC x D x x G x T P L H L A A x x G H L E I V E V L L K x G A D V N A
 E_64 N2C K D M T G D T P L H L A A S W G H L E I V E V L L K Y G A D V N A
 E_01 N3C Y D Y I G W T P L H L A A D . G H L E I V E V L L K N G A D V N A
 E_17 N3C F D S D G N T P L H L A A S T G H L E I V E V L L K Y G A D V N A
 E_31 N3C K D T A G R T P L H L T A K D G H L E I V E V L L K N G A D V N A
 E_36 N3C D D E H G D T P L H L A A T D G H L E I V E V L L K N G A D V N A
 E_67 N3C D D L L G M T P L H L A A D T G H L E I V E V L L K Y G A D V N A
 E_68 N3C S D N F G F T P L H L A A F Y G H L E I V E V L L K H G A D V N A
 E_72 N3C A D N I G L T P L H L A A K Y G H L E I V E V L L K Y G A D V N A
 E_69 N4C K G H H C N T P L H L A A W A G H L E I V E V L L K Y G A D V N A
1 33
 DARPin NxC x D x x G x T P L H L A A x x G H L E I V E V L L K x G A D V N A
 E_64 N2C ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~
 E_01 N3C S D Y I G D T P L H L A A H N G H L E I V E V L L K H G A D V N A
 E_17 N3C H D M D G A T P L H L A A N S G H L E I V E V L L K H G A D V N A
 E_31 N3C K D S A G I T P L H L A A H H G H L E I V E V L L K Y G A D V N A
 E_36 N3C S D H E G K T P L H L A A H Y G H L E I V E V L L K N G A D V N A
 E_67 N3C R D T R G K T P L H L A A R D G H L E I V E V L L K H D A D V N A
 E_68 N3C F D M W G N T P L H L A A Q N G H L E I V E V L L K N G A D V N A
 E_72 N3C N D E D G I T P L H L A A Y W G H L E I V E V L L K N G A D V N A
 E_69 N4C D D D E G Y T P L H L A A D I . D L E I V E V L L K Y G A D V N A
1 33
 DARPin NxC x D x x G x T P L H L A A x x G H L E I V E V L L K x G A D V N A
 E_64 N2C ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~
 E_01 N3C ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~
 E_17 N3C ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~
 E_31 N3C ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~
 E_36 N3C ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~
 E_67 N3C ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~
 E_68 N3C ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~
 E_72 N3C ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~
 E_69 N4C W D M Y G R T P L H L A A S A G H L E I V E V L L K Y G A D V N A
1 25
F, Y, W
 DARPin NxC Q D K F G K T A F D I S I D N G N E D L A E I L Q
 E_64 N2C Q D K F G K T A F D I S I D N G N E D L A E I L Q I, L, V, P, A, M, C
 E_01 N3C Q D K F G K T A F D I S I D N G N E D L A E I L Q
 E_17 N3C Q D K F G K T A F D I S I D N G N E D L A E I L Q G  H
 E_31 N3C Q D K F G K T A F D I S I D N G N E D L A E I L Q
 E_36 N3C Q D K F G K T T F D I S I D N G N E D L A E I L Q S, T, N, Q
 E_67 N3C Q D K F G K T A F D I S I D N G N E D L A E I L Q
 E_68 N3C Q D K F G K T A F D I S I D N G N E D L A E I L Q R, K
 E_72 N3C Q D K F G K T A F D I S I D N G N E D L A E I L Q
 E_69 N4C Q D K F G K T A F D I S I D N G N E D L A E I L Q D, E
3rd repeat
4th repeat
C-Cap
C-Cap
1st repeat
2nd repeat
 
Figure 12: Sequences of selected ErbB1 binding DARPins. The original consensus sequence is shown on top with 
randomized positions indicated by x. In the lines below, only residues that differ from the consensus sequence are 
printed in color, residues identical to the consensus sequence are printed in gray and deletions and missing amino 
acids are printed in black. Note that the N-terminal MRGSHHHHHHGS and the C-terminal KLN, which are not 
part of the DARPin sequence, are not shown. Amino acids are colored by type as indicated at the end of the 
alignment. 
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Figure 13: Size exclusion chromatography (SEC) of 
selected ErbB1-binding DARPins. The 
chromatograms of the nine ErbB1 binders and the 
unselected DARPin E3_5 are shown. For each 
DARPin the number of repeats stacked between N-
Cap (N) and C-Cap (C) is given in parentheses. The 
molecular mass standards, phage protein D (gpD) with 
an apparent mass of 17.6 kDa and phage protein SHP, 
a trimer with an apparent mass of 50.2 kDa, are 
indicated with arrows. 
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Figure 14: ELISA of selected ErbB1 binding DARPins. (a) Specificity was tested by applying 50 nM solutions of 
the selected ErbB1 binders on immobilized ErbB-receptors (ErbB1, ErbB2-631, ErbB2-509 and ErbB4). (b) To 
determine the epitope the binders were further tested for binding to immobilized target protein (ErbB1), target 
protein bound via immobilized DARPin used for epitope-masking during the selection round (E_01—ErbB1) and 
neutravidin. DARPin E3_5 was used as control in all experiments. 
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Figure 15: Specificity and affinity estimation of selected ErbB1 binders. (a) ELISA with high affinity ErbB1 
binders. To analyze specificity, 1 nM solutions of the binders E_01 and E_68 were tested for binding on neutravidin 
and ErbB1 and, in parallel, competition experiments were performed by preincubation of 1 nM solutions of the 
DARPins with free ErbB1 (10 nM and 100 nM) before binding on immobilized ErbB1. (b) ELISA with medium 
affinity ErbB1 binders. To analyze specificity, 5 nM solutions of the binders E_64, E_67, E_69 and E_72 were 
tested as described above using 10 nM and 100 nM free ErbB1 for competition. (c) ELISA with low affinity ErbB1 
binders. To analyze specificity, 25 nM solutions of the binders E_17, E_31and E_36 were tested as described above 
using 50 nM and 250 nM free ErbB1 for competition. The first word in the legend denotes the protein immobilized, 
no comp. denotes the absence of a competitor and + ErbB1, + Erbitux or + EGF denotes the presence of competitor 
(respective concentrations are given in nM). 
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5. DARPins binding receptor tyrosine kinase ErbB2/Her2  
A general introduction to the ErbB receptor tyrosine kinase family is given in the ErbB1 
subchapter four of Appendix one. Two different constructs of the target protein ErbB2 (ref. 7) 
were kindly provided by Dr. Tim Adams (CSIRO, Melbourne, Australia): ErbB2-631, the 
complete extracellular region of the human receptor (S22 – T652 of human receptor tyrosine-
protein kinase ErbB2) containing domains I – IV and ErbB2-509, the truncated version (S22 – 
N530 of human receptor tyrosine-protein kinase ErbB2) comprising only domains I-III (see ref. 
14 and ref. 15, respectively). The aim of this project was to select binders against ErbB2 which 
can either inhibit activity of the receptor in a similar fashion as the clinically used mAb 
Trastuzumab (HerceptinTM)14 or that can block ErbB2 homo- or heterodimerization as described 
for the clinically used mAb Pertuzumab (OmnitargTM or 2C4)16.  
In previous selections using ribosome display high affinity DARPin binders have been 
generated against ErbB2 (ref. 17, 18). Surprisingly, these binders almost exclusively recognize 
domain IV of the receptor (data not shown), which seems to provide a dominant epitopes during 
the selection processes. To obtain binders that recognize domain I – III of the receptor I followed 
two selections strategies which are described in detail in Chapter 3 of my thesis. Screening of 
the ErbB2 binding DARPins was done together with Christian Jost (C.J.) and is described in his 
Diploma thesis. Selection on ErbB2-509, lacking domain IV, resulted in 13 different sequences 
(Fig. 16, names starting with 9_). Selection on ErbB2-631 in the presence of a two-fold excess of 
the high affinity DARPin H10-2-G3 (ref. 18) (masking one of the dominant epitopes on domain 
IV) resulted in nine different sequences of which four were already found in the selection on 
ErbB2-509 (Fig. 16, names starting with H_). After expression and purification by immobilized 
metal ion chromatography (IMAC) purification in the 96-well format, all binders were analyzed 
by size exclusion chromatography (SEC) and compared to the well characterized, non-binding 
DARPin E3_5 (ref. 2) and ErbB2 binding DARPin H10-2-G3 (Fig. 17). To investigate the 
specificity of the selected DARPins, ELISA experiments were performed. As almost expected, 
Data: ErbB2 binders   149
none of the binders showed crossreactivity when analyzed in ELISA experiments for binding to 
other receptors of the ErbB-family (ErbB1 and ErbB4), which share about 50% sequence 
identity and have highly conserved structures (Fig. 18). Comparing the binding of the clones to 
ErbB2-631 and ErbB2-509 revealed that only one of the selected DARPins (H_14) recognizes 
domain IV of the receptor, showing the success of the selection strategy used. Detailed analysis 
of DARPin H_14 was done by C.J. and is described in his Diploma thesis; H_14 has an affinity 
of about 0.2 nM (SPR measurement), competes in an ELISA experiment with H10-2-G3 for 
binding and can completely block interaction of Herceptin with the receptor (shown in an SPR 
experiment). In cell based assays, this clone was the only one showing significant anti-
proliferative activity. 
Furthermore, a subset of the ErbB2-509 binding DARPins was analyzed in the 
competition ELISA setup. Binding to the immobilized target protein was tested with and without 
preincubation with free ErbB2-509 (Fig. 19). Three well behaved ErbB2-509 binding DARPins 
(9_16, 9_26 and 9_29) and were further analyzed at multiple concentrations by surface plasmon 
resonance (SPR) (Table 3 and Supplementary Figure 2 of Chapter 3) and the data evaluated 
with a global kinetic fit. All of the measured binders showed affinities in the low nM range. 
None of the ErbB2-509 binders shows complete competition with Pertuzumab for binding to the 
receptor and also none of them shows anti-proliferative activity in cell based assays (experiments 
done by C.J., which are described in his Diploma thesis). 
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1
 DARPin NxC D L G K K L L E A A R A G Q D D E V R I L M A N G A D V N A
 9_10 N2C D L G K K L L E A A R A G Q D D E V R I L M A N G A D V N A
 9_01 N3C D L G K K L L E A A R A G Q D D E V R I L M A N G A D V N A
 9_02 N3C D L G K K L L E A A R A G Q D D E V R I L M A N G A D V N A
 9_03 N3C D L G K K L L E A A R A G Q D D E V R I L M A N G A D V N A
 9_04 N3C D L G K K L L E A A R A G Q D D E V R I L M A N G A D V N A
 9_12 N3C D L G K K L L E A A R A G Q D D E V R I L M A N G A D V N A
 9_16 N3C D L G K K L L E A A R A G Q D D E V R I L M A N G A D V N A
 9_18 N3C D L G K K L L E A A R A G Q D D E V R I L M A N G A D V N A
 9_20 N3C D L G K K L L E A A R A G Q D D E V R I L M A N G A D V N A
 9_26 N3C D L G K K L L E A A R A G Q D D E V R I L M A N G A D V N A
 9_29 N3C D L G K K L L E A A R A G Q D D E V R I L M A N G A D V N A
 9_30 N3C D L G K K L L E T A R A G Q D D E V R I L M A N G A D V N A
 9_33 N3C D L G K K L L E A A R A G Q D D E V R I L M A N G A D V N A
 H_01 N3C D L G K K L L E A A R A G Q D D E V R I L M A N G A D V N A
 H_03 N3C D L G K K L L E A A R A G Q D D E V R I L M A N G A D V N A
 H_13 N3C D L G K K L L E A A R A G Q D D E V R I L M A N G A D V N A
 H_14 N3C D L G K K L L E A A R A G Q D D E V C I L M A N G A D V N A
 H_11 N4C D L G K K L L E A A R A G Q D D E V R I L M A N G A D V N A
1
 DARPin NxC x D x x G x T P L H L A A x x G H L E I V E V L L K x G A D V N A
 9_10 N2C S D F Y G K T P L H L A A T I G H L K I V E V L L K Y G A D V N A
 9_01 N3C E D . E G R T P L H L A . . . G H L E I V E V L L K N G A D V N A
 9_02 N3C S D Y Y G I T P L H L A A H T G H L E I V E V L L K H G A D V N A
 9_03 N3C K D W Y G I T P L H L A A D T G H L E I V E V L L K H G A D V N A
 9_04 N3C N D F Y G I T P L H L T A A F G H L E I V E V L L K N G A D V N A
 9_12 N3C H D F Y G K T P L H L A A Y S G H L E I V E V L L K H G A D V N A
 9_16 N3C H D F H G L T P L H L A A G M G H L E I V E V L L K N G A D V N A
 9_18 N3C I D W H G T T P L H L A A D T G H L E I V E V L L K Y G A D V N A
 9_20 N3C H D W H G L T P L H L A A G M G H L E I V E V L L K N G A D V N A
 9_26 N3C K D F Y G I T P L H L A A A Y G H L E I V E V L L K H G A D V N A
 9_29 N3C H D F Y G I T P L H L A A N F G H L E I V E V L L K H G A D V N A
 9_30 N3C T D F Y G L T P L H L A A Y Y G H L E I V E V L L K N G A D V N A
 9_33 N3C I D W H G T T P L H L A A D T G H L E I V E V L L K N G A D V N A
 H_01 N3C H D F Y G K T P L H L A A A I G H L E I V E V L L K N G A D V N A
 H_03 N3C H D W H G I T P L H L A A F Y G H L E I V E V L L K N G A D V N A
 H_13 N3C K D F Y G K T P L H L A A N L G H L E I V E V L L K H G A D V N A
 H_14 N3C T D I H G H T P L H L A A A M G H L E I V E V L L K N G A D V N A
 H_11 N4C D D F F G E T P L H L A A A L G H L E I V E V L L K H G A D V N A
1
 DARPin NxC x D x x G x T P L H L A A x x G H L E I V E V L L K x G A D V N A
 9_10 N2C T D W . G N T P L H L A A I N G H L E I V E V L L K H G A D V N A
 9_01 N3C A D A S G H T P L H L A A H L G H L E I V E V L L K H G A D V N A
 9_02 N3C R . N W G W T P L H L A A M T G H L E I V E V L L K Y G A D V N A
 9_03 N3C F D S Y T G H T P L H L A A Q K G Q L E I V E V L L K Y G A D V N A
 9_04 N3C R D F T G . T P L H L A A T E G H L E I V E V L L K Y G A D V N A
 9_12 N3C V D Y . G I T P L Y L A A A T G H L E I V E V L L K Y G A D V N A
 9_16 N3C V D T D G I T L L H L A A Y Y G H L E I V E V L L K H G A D V N A
 9_18 N3C T D F F G V T P L H P A A Y W G H L E I V E V L L K N G A D V N A
 9_20 N3C D D T D G F T P L H L A A H I G H L E I V E V L L K H G A D V N A
 9_26 N3C H D W N G W T P L H L A A K Y G H L E I V E V L L K H G A D V N A
 9_29 N3C F D Y . D N T P L H L A A D A G H L E I V E V L L K Y G A D V N A
 9_30 N3C S D W N G Y T P L R L A A D A G H L E I V E V L L K N G A D V N A
 9_33 N3C A D A S G H T P L H L A A H L G H L E I V E V L L K H G A D V N A
 H_01 N3C T D Y . G L T P L H L A A D N G H L E I V E V L L K N G A D V N A
 H_03 N3C F D D Y D G S T P L H L A A W M G H L E I V E V L L K H G A D V N A
 H_13 N3C L D . F G D T P L H L A A D D G H L E I V E V L L K Y G A D V N A
 H_14 N3C N D W R G F T P L H L A A L N G H L E I V E V L L K N G A D V N A
 H_11 N4C M D N Y G F T P L H L A A Y R G H L E I V E V L L K H G A D V N A
1
 DARPin NxC x D x x G x T P L H L A A ~ x x G H L E I V E V L L K x G A D V N A
 9_10 N2C ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~
 9_01 N3C W D K F G V T P L H L A A ~ D H G H L E I V E V L L K N G A D V N A
 9_02 N3C V D E D G D T P L H L A A ~ T H G H L E I V E V L L K Y G A D V N A
 9_03 N3C I D R H G K T P L H L A A ~ L M G H L E I V E V L L K Y G A D V N A
 9_04 N3C V D I H G M T P L H L A A ~ L T G H L E I V E V L L K H G A D V N A
 9_12 N3C D D Y D G Q T P L H L A A ~ M E G H L E I V E V L L K Y G A D V N A
 9_16 N3C H D Y A G S T P L H L A A ~ N T G H L E I V E V L L K N G A D V N A
 9_18 N3C E D T K G M T P L H L A A ~ F I G H L E I V E V L L K Y G A D V N A
 9_20 N3C S D I T G N T P L H L A A ~ I H G H L E I V E V L L K N G A D V N A
 9_26 N3C I D N A G K T P L H L A A ~ A H G H L E I V E V L L K Y G A D V N A
 9_29 N3C S D R D G H T P L H L A A ~ R E G H L E I V E V L L K N G A D V N A
 9_30 N3C F D Q F G S T P L H L A A ~ A T G H L E I V E V L L K Y G A D V N A
 9_33 N3C W D K F G V T P L H L A A ~ D H G H L E I V E V L L K N G A D V N A
 H_01 N3C F D F T G R T P L H L A A ~ S Q G H L E I V E V L L K N G A D V N A
 H_03 N3C T D H F G N T P L H L A A ~ A M G H L E I V E V L L K H G A D V N A
 H_13 N3C Q D M A G S T P L H L A A ~ N T G H L E I V E V L L K H G A D V N A
 H_14 N3C T D T A G N T P L H L A A ~ W F G H L E I V E V L L K N G A D V N A
 H_11 N4C D D S L G W T P L H L A A A Y M G H L E I V E V L L K H G A D V N A
30
33
33
33
C-Cap
1st repeat
2nd repeat
3rd repeat
 
Figure 16: Continued next page. 
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1
 DARPin NxC x D x x G x T P L H L A A x x G H L E I V E V L L K x G A D V N A
 9_10 N2C ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~
 9_01 N3C ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~
 9_02 N3C ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~
 9_03 N3C ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~
 9_04 N3C ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~
 9_12 N3C ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~
 9_16 N3C ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~
 9_18 N3C ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~
 9_20 N3C ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~
 9_26 N3C ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~
 9_29 N3C ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~
 9_30 N3C ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~
 9_33 N3C ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~
 H_01 N3C ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~
 H_03 N3C ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~
 H_13 N3C ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~
 H_14 N3C ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~
 H_11 N4C T D K F G I T P L H L A A H H G H L E I V E V L L K Y G A D V N A
1 25
 DARPin NxC Q D K F G K T A F D I S I D N G N E D L A E I L Q
 9_10 N2C Q D K F G K T A F D I S I D N G N E D L A E I L Q
 9_01 N3C Q D K F G K T A F D I S I D N G N E D L A E I L Q
 9_02 N3C Q D K F G K T A F D I S I D N G N E D L A E I L Q
 9_03 N3C Q D K F G K T A F D I S I D N G N E D L A E I L Q  F, Y, W
 9_04 N3C Q D K F G K T A F D I S I D N G N E D L A E I L Q
 9_12 N3C Q D K F G K T A F D I S I D N G N E D L A E I L Q  I, L, V, P, A, M, C
 9_16 N3C Q D K F G K T A F D I S I D N G N E D L A E I L Q
 9_18 N3C Q D K F G K T A F D I S I D N G N E D L A E I L Q  G
 9_20 N3C Q D K F G K T A F D I S I D N G N E D L A E I L Q
 9_26 N3C Q D K F G K T A F D I S I D N G N E D L A E I L Q  H
 9_29 N3C Q D K F G K T A F D I S I D N G N E D L A E I L Q
 9_30 N3C Q D K F G K T A F D I S I D N G N E D L A E I L Q  S, T, N, Q
 9_33 N3C Q D K F G K T A F D I S I D N G N E D L A E I L Q
 H_01 N3C Q D K F G K T A F D I S I D N G N E D L A E I L Q  R, K
 H_03 N3C Q D K F G K T A F D I S I D N G N E D L A E I L Q
 H_13 N3C Q D K F G K T A F D I S I D N G N E D L A E I L Q  D, E
 H_14 N3C Q D K F G K T A F D I S I D N G N E D L A E I L Q
 H_11 N4C Q D K F G K T A F D I S I D N G N E D L A E I L Q
C-Cap
4th repeat
33
 
Figure 16: Sequences of selected ErbB2 binding DARPins. The original consensus sequence is shown on top with 
randomized positions indicated by x. In the lines below, only residues that differ from the consensus sequence are 
printed in color, residues identical to the consensus sequence are printed in gray and deletions and missing amino 
acids are printed in black. Note that the N-terminal MRGSHHHHHHGS and the C-terminal KLN, which are not 
part of the DARPin sequence, are not shown. Amino acids are colored by type as indicated at the end of the 
alignment. 
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Figure 17: Size exclusion chromatography (SEC) of selected ErbB2 binding DARPins. The chromatograms of 
the 16 ErbB2 binders, the previously selected ErbB2 binding DARPin H10-2-G3 and unselected DARPin E3_5 
are shown. For each DARPin the number of repeats stacked between N-Cap (N) and C-Cap (C) is given in 
parentheses. The molecular mass standards, phage protein D (gpD) with an apparent mass of 17.6 kDa and phage 
protein SHP, a trimer with an apparent mass of 50.2 kDa, are indicated with arrows. 
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Figure 18: ELISA of selected ErbB2 binding DARPins. Specificity was tested by applying 50 nM solutions of the 
selected ErbB2 binders on immobilized ErbB-receptors (ErbB1, ErbB2-631, ErbB2-509 and ErbB4). DARPin E3_5 
was used as control. 
 
 
Figure 19: Specificity and affinity estimation of subset of selected ErbB2_509 binders. To analyze specificity, 
5 nM solutions of the binders were tested for binding on neutravidin and ErbB2_509 (509) and, in parallel, 
competition experiments were performed by preincubation of 5 nM solutions of the DARPins with 10 nM or 
100 nM of free ErbB2_509 (10 nM and 100 nM) before binding on immobilized ErbB2_509. The first word in the 
legend denotes the protein immobilized, no comp. denotes the absence of a competitor and + ErbB2-509 denotes the 
presence of competitor in 10 nM or 100 nM concentrations. 
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6. DARPins binding receptor tyrosine kinase ErbB4  
A general introduction to the ErbB receptor tyrosine kinase family is given in the ErbB1 
subchapter four of Appendix one. The target protein ErbB4 (ref. 19) was kindly provided by Dr. 
Tim Adams (CSIRO, Melbourne, Australia) (Q26 – R525 of human receptor tyrosine-protein 
kinase ErbB4 fused to huIgG1_Fc). This truncated version of the extracellular region of ErbB4 
comprises domains I-III but not domain IV. The aim of this project was to validate the phage 
DARPin library by selecting binders against ErbB4. Such binders could inhibit activation of the 
receptor by its ligands or prevent homo- and heterodimerization of the receptor. Since ErbB4 has 
no clinical relevance as yet, binders were not further investigated in any collaboration. 
Primary selections, selections by epitope masking and screening of binders against ErbB4 
are described in detail in Chapter 3 of my thesis and resulted in 19 different sequences (Fig. 20). 
Clones B4_01 to B4_45 are from primary selections and clones B4_49 to B4_68 form the 
selection with epitope masking. After expression and purification by immobilized metal ion 
chromatography (IMAC) purification in the 96-well format, all binders were analyzed by size 
exclusion chromatography (SEC) and compared to the well characterized, non-binding DARPin 
E3_5 (ref. 2) (Fig. 21). To investigate the specificity of the selected DARPins, ELISA 
experiments were performed. As almost expected, none of the binders did show crossreactivity 
when analyzed in ELISA experiments for binding to other receptors of the ErbB-family (ErbB1 
and ErbB2), which share about 50% sequence identity and have highly conserved structures 
(Fig. 22a). Further the ErbB4 binding DARPins were analyzed in the competition ELISA setup. 
Binding to the immobilized target protein was tested with and without preincubation with free 
ErbB4 (Fig. 23). Due to the low binding signal in this ELISA experiment, clones B4_11, B4_14, 
B4_55, B4_56, B4_63, B4_64, B4_65 and B4_68 were considered as false positives (no affinity 
for the target protein or affinity below the detection limit of the experiments). 
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Furthermore, binding and epitope localization was tested by ELISA. All ErbB4 binders 
were tested for interaction with the respective immobilized target protein or the target protein 
bound to immobilized DARPin (B4_02) which was used for “epitope-masking” during the 
selection (Fig. 22b). One of the clones (B4_01) selected in the primary selections and four of the 
clones selected by “epitope-masking” (B4_, B4_50, B4_57, B4_58 and B4_60) recognized 
another epitope than B4_02. 
Four well behaved clones (B4_01, B4_02, B4_50 and B4_58) were further analyzed at 
multiple concentrations by surface plasmon resonance (SPR) (Table 3 and Supplementary 
Figure 2 of Chapter 3) and the data evaluated with a global kinetic fit. Three of the measured 
binders showed affinities in the pM range and the other binder is in the low nM range. 
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1
 DARPin NxC D L G K K L L E A A R A G Q D D E V R I L M A N G A D V N A
 B4_14 N2C D L G K K L L E A A R A G Q D D E V R I L M A N G A D V N A
 B4_02 N3C D L G K K L L E A A R A G Q D D E V R I L M A N G A D V N A
 B4_07 N3C D L G K K L L E A A R A G Q D D E V R I L M A N G A D V N A
 B4_11 N3C D L G K K L L E A A R A G Q D D E V R I L M A N G A D V N A
 B4_33 N3C D L G K K L L E A A R A G Q D D E V R I L M A N G A D V N A
 B4_45 N3C D L G K K L L E A A R A G Q D D E V R I L M A N G A D V N A
 B4_49 N3C D L G K K L L E A A R A G Q D D E V R I L M A N G A D V N A
 B4_53 N3C D L G K K L L E A A R A G Q D D E V R I L M A N G A D V N A
 B4_55 N3C D L G K K L L E A A R A G Q D D E V R I L M A N G A D V N A
 B4_57 N3C D L G K K L L E A A R A G Q D D E V R I L M A N G A D V N A
 B4_60 N3C D L G K K L L E A A R A G Q D D E V R I L M A N G T D V N A
 B4_63 N3C D L G K K L L E A A R A G Q D D E V R I L M A N G A D V N A
 B4_65 N3C D L G K K L L E A A R A G Q D D E V R I L M A N G A D V N A
 B4_68 N3C D L G K K L L E A A R A G Q D D E V R I L M A N G A D V N A
 B4_01 N4C D L G K K L L E A A R A G Q D D E V H I L M A N G A D V N A
 B4_50 N4C D L G K K L L E A A R A G Q D D E V R I L M A N G A D V N A
 B4_56 N4C D L G K K L L E A A L A G Q D D E V R I L M A N G A D V N A
 B4_58 N5C D L G K K L L E A T R A G Q D D E V R I L M A N G A D V N A
 B4_64 N6C D L G K K L L E A A R A G Q D D E V R I L M A N G A D V N A
1
 DARPin NxC x D x x G x T P L H L A A x x G H L E I V E V L L K x G A D V N A
 B4_14 N2C S D D A G N T P L H L A A S F G H L E I V E V L L K Y G A D V N A
 B4_02 N3C K D N A G K T A L H L A A V W G H L E I V E V L L K N G A D V N A
 B4_07 N3C R D V F G W T P L H L A A V D G H L E I V E V L L K Y G A D V N A
 B4_11 N3C S D R V G K T P L H L A A Q K G H L E I V E V L L K N G A D V N A
 B4_33 N3C E D A T G F T P L H L A A V W G H L E I V E V L L K N G A D V N A
 B4_45 N3C R D D G G T T P L H L A A N H G H L E I V E V L L K Y G A D V N A
 B4_49 N3C N D T L G Y T P L H L A A . S G H L E I V E V L L K N G A D V N A
 B4_53 N3C N D L W G Q W T P L H L A A H I G H L E I V E V L L K N G A D V N A
 B4_55 N3C S D F W G V T P L H L A A I W G H L E I V E V L L K H G A D V N A
 B4_57 N3C K D R L G V T P L H L A A M F G H L E I V E V L L K Y G A D V N A
 B4_60 N3C R D Q L G F T P L H L A A Y T G H L E I V E V L L K Y G A D V N A
 B4_63 N3C A D S W G W T P M H L A A T Y G H L E I V E V L L K Y G A D V N A
 B4_65 N3C F D W I G D T P L H L A A T W G H L E I V E V L L K Y G A D V N A
 B4_68 N3C D D S V G H T P L H L A A M W G H L E I V E V L L K N G A D V N A
 B4_01 N4C V D W M G D T P L H L A A F Y G H L E I V E V L L K N G A D V N A
 B4_50 N4C H D R Y G V T P L H L A A Y F G H L E I V E V L L K N G A D V N A
 B4_56 N4C Y D V M G S T P L H L A A F F G H L E I V E V L L K H G A D V N A
 B4_58 N5C F D S N G I T P L H L A A F F G H L E I V E V L L K N G A D V N A
 B4_64 N6C F D S S G H T P L H L A A S Y G H L E I V E V L L K N G A D V N A
1
 DARPin NxC x D x x G x T P L H L A A x x G H L E I V E V L L K x G A D V N A
 B4_14 N2C A D N W G H T P L H L A A T F G H L E I V E V L L K H G A D V N A
 B4_02 N3C Y D A S G Y T L L H L A A R M G H L E I V E V L L K Y G A D V N A
 B4_07 N3C R D V A G R T P L H L A A S F G H L E I V E V L L K Y G A D V N A
 B4_11 N3C G D A H G F T P L H L A A D N G H L E I V E V L L K Y G A D V N A
 B4_33 N3C N D Q Y G Y T P L H L A A R M G H L E I V E V L L K H G A D V N A
 B4_45 N3C N D R Y G Y T T L H L A A R H G H L E I V E V L L K H G A D V N A
 B4_49 N3C M D L W G S T P L H L A A Y W G H L E I V E V L L K N G A D V N A
 B4_53 N3C N D E W G L T P L H L A A W N G H L E I V E V L L K Y G A D V N A
 B4_55 N3C Q D D D G H T P L H L A A F I G H L E I V E V L L K N G A D V N A
 B4_57 N3C D D R I I G T T P L H L A A F N G H L E I V E V L L K H G A D V N A
 B4_60 N3C R D Y W G Y T P L H L A A T K G H L E I V E V L L K Y G A D V N A
 B4_63 N3C V D N W G I T P L H L A A Y D G H L E I V E V L L K H G A D V N A
 B4_65 N3C K D K D G Y T P L H L T A F I G H L E I V E V L L K H G A D V N A
 B4_68 N3C L D S I G L T P L H L A A Y H G H L E I V E V L L K Y G A D V N A
 B4_01 N4C K D T W G D T P L H L A A L L G R L E I V E V L L K H G A D V N A
 B4_50 N4C D D H D G Y T P L H L A A D K G H L E I V E V L L K H G A D V N A
 B4_56 N4C H D I N G I T P L H L A A Y W G H L E I V E V L L K N G A D V N A
 B4_58 N5C H D S Y G S T P L H L A A N R G H L E I V E V L L K Y G A D V N A
 B4_64 N6C R D N N G L T P L H L A A T I G H L E I V E V L L K N G A D V N A
1
 DARPin NxC x D x x G x T P L H L A A x x G H L E I V E V L L K x G A D V N A
 B4_14 N2C ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~
 B4_02 N3C R D R F G S T P L H L A A W H G H L E I V E V L L K H G A D V N A
 B4_07 N3C V D Y T G T T P L H L A A W H G H L E I V E V L L K H G A D V N A
 B4_11 N3C D D Y A G K T P L H L A A R H G H L E I V E V L L K Y G A D V N A
 B4_33 N3C I D V L G T T P L H L A A W H G H L E I V E V L L K N G A D V N A
 B4_45 N3C F D N T G Q T P L H L A A W H G H L E I V E V L L K Y G A D V N A
 B4_49 N3C F D E I G W T P L H L A A N T G H L E I V E V L L K H G A D V N A
 B4_53 N3C D D N L G W T P L H L A A I D G H L E I V E V L L K Y G A D V N A
 B4_55 N3C L D T D G S T P L H L A A Y F G H L E I V E V L L K H G A D V N A
 B4_57 N3C M D M N G F T P L H L A A F N G H L E I V E V L L K N G A D V N A
 B4_60 N3C D D E V G Y T P L H L A A Q S G H L E I V E V L L K Y G A D V N A
 B4_63 N3C H D N S G E T P L H L A A A T G H L E I V E V L L K Y G A D V N A
 B4_65 N3C R D N R G D T P L H L A A V F G H L E I V E V L L K H G A D V N A
 B4_68 N3C T D S V G W T P L H L A A W D G H L E I V E V L L K N G A D V N A
 B4_01 N4C I D M R G T T P L H L A A P A G H L E I V E V L L K Y G A D V N A
 B4_50 N4C D D S M G N T P L H L A A R H G H L E I V E V L L K H G A D V N A
 B4_56 N4C H D N W G L T P L H L A A L S G H L E I V E V L L K N G A D V N A
 B4_58 N5C F D S T G Q T P L H L A A S Q G H L E I V E V L L K Y G A D V N A
 B4_64 N6C T D T W G I T P L H L A A F R G H L E I V E V L L K Y G A D V N A
3rd repeat
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1st repeat
2nd repeat
 
Figure 20: Continued next page. 
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1
 DARPin NxC x D x x G x T P L H L A A x x G H L E I V E V L L K x G A D V N A
 B4_14 N2C ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~
 B4_02 N3C ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~
 B4_07 N3C ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~
 B4_11 N3C ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~
 B4_33 N3C ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~
 B4_45 N3C ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~
 B4_49 N3C ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~
 B4_53 N3C N ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~
 B4_55 N3C ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~
 B4_57 N3C ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~
 B4_60 N3C ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~
 B4_63 N3C ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~
 B4_65 N3C ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~
 B4_68 N3C ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~
 B4_01 N4C D D V H G N T P L H L A A M S G H L E I V E V L L K Y G A D V N A
 B4_50 N4C N D F M G S T P L H L A A W S G H L E I V E V L L K H G A D V N A
 B4_56 N4C R D V N G D T P L H L A A D K G H L E I V E V L L K Y G A D V N A
 B4_58 N5C S D R M G F T P L H L A A Y T G H L E I V E V L L K N G A D V N A
 B4_64 N6C R D V D G D T P L H V A A L R G H L E I V E V L L K H G A D V N A
1
 DARPin NxC x D x x G x T P L H L A A x x G H L E I V E V L L K x G A D V N A
 B4_14 N2C ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~
 B4_02 N3C ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~
 B4_07 N3C ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~
 B4_11 N3C ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~
 B4_33 N3C ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~
 B4_45 N3C ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~
 B4_49 N3C ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~
 B4_53 N3C ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~
 B4_55 N3C ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~
 B4_57 N3C D ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~
 B4_60 N3C ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~
 B4_63 N3C ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~
 B4_65 N3C ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~
 B4_68 N3C ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~
 B4_01 N4C ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~
 B4_50 N4C ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~
 B4_56 N4C ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~
 B4_58 N5C K D F V G W T P L H L A A Y R G H L E I V E V L L K H G A D V N A
 B4_64 N6C Y D I N G A T P L H L A A T V G H L E I V E V L L K Y G A D V N A
1
 DARPin NxC x D x x G x T P L H L A A x x G H L E I V E V L L K x G A D V N A
 B4_14 N2C ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~
 B4_02 N3C ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~
 B4_07 N3C ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~
 B4_11 N3C ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~
 B4_33 N3C ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~
 B4_45 N3C ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~
 B4_49 N3C ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~
 B4_53 N3C ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~
 B4_55 N3C ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~
 B4_57 N3C ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~
 B4_60 N3C ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~
 B4_63 N3C ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~
 B4_65 N3C ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~
 B4_68 N3C ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~
 B4_01 N4C ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~
 B4_50 N4C ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~
 B4_56 N4C ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~
 B4_58 N5C ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~ ~
 B4_64 N6C D D S Q G N T P L H L A A D Y G H L E I V E V L L K H G A D V N A
1
 DARPin NxC Q D K F G K T A F D I S I D N G N E D L A E I L Q
 B4_14 N2C Q D K F G K T A F D I S I D N G N E D L A E I L Q
 B4_02 N3C Q D K F G K T A F D I S I D N G N E D L A E I L Q
 B4_07 N3C Q D K F G K T A F D I S I D N G N E D L A E I L Q F, Y, W
 B4_11 N3C Q D K F G K T A F D I S I D N G N E D L A E I L Q
 B4_33 N3C Q D K F G K T A F D I S I D N G N E D L A E I L Q I, L, V, P, A, M, C
 B4_45 N3C Q D K F G K T A F D I S I D N G N E D L A E I L Q
 B4_49 N3C Q D K F G K T A F D I S I D N G N E D L A E I L Q G
 B4_53 N3C Q D K F G K T A F D I S I D N G N E D L A E I L Q
 B4_55 N3C Q D K F G K T A F D I S I D N G N E D L A E I L Q H
 B4_57 N3C Q D K F G K T A F D I S I D N G N E D L A E I L Q
 B4_60 N3C Q D K F G K T A F D I S I D N G N E D L A E I L Q S, T, N, Q
 B4_63 N3C Q D K F G K T A F D I S I D N G N E D L A E I L Q
 B4_65 N3C Q D K F G K T A F D I S I D N G N E D L A E I L Q R, K
 B4_68 N3C Q D K F G K T A F D I S I D N G N E D L A E I L Q
 B4_01 N4C Q D K F G K T A F D I S I D N G N E D L A E I L Q D, E
 B4_50 N4C Q D K F G K T A F D I S I D N G N E D L A E I L Q
 B4_56 N4C Q D K F G K T A F D I S I D N G N E D L A E I L Q
 B4_58 N5C Q D K F G K T A F D I S I D N G N E D L A E I L Q
 B4_64 N6C Q D K F G K T A F D I S I D N G N E D L A E I L Q
C-Cap
4th repeat
5th repeat
6th repeat
33
33
33
25
 
Figure 20: Sequences of selected ErbB4 binding DARPins. The original consensus sequence is shown on top with 
randomized positions indicated by x. In the lines below, only residues that differ from the consensus sequence are 
printed in color, residues identical to the consensus sequence are printed in gray and deletions and missing amino 
acids are printed in black. Note that the N-terminal MRGSHHHHHHGS and the C-terminal KLN, which are not 
part of the DARPin sequence, are not shown. Amino acids are colored by type as indicated at the end of the 
alignment. 
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Figure 21: Size exclusion chromatography (SEC) of selected ErbB4 binding DARPins. The chromatograms of 
the 19 ErbB4 binders and the unselected DARPin E3_5 are shown. For each DARPin the number of repeats 
stacked between N-Cap (N) and C-Cap (C) is given in parentheses. The molecular mass standards, phage protein 
D (gpD) with an apparent mass of 17.6 kDa and phage protein SHP, a trimer with an apparent mass of 50.2 kDa, 
are indicated with arrows. 
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Figure 22: ELISA of selected ErbB4 binding DARPins. (a) Specificity was tested by applying 50 nM solutions of 
the selected ErbB4 binders on immobilized ErbB-receptors (ErbB1, ErbB2-631, ErbB2-509 and ErbB4). (b) To 
determine the epitope the binders giving a signal in (a) were further tested for binding to immobilized target protein 
(ErbB4), target protein bound to immobilized DARPin used for epitope-masking during the selection round 
(B4_02—ErbB4) and neutravidin. DARPin E3_5 was used as control in all experiments. 
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Figure 23: Specificity and affinity estimation of selected ErbB4 binders. (a) ELISA with high affinity ErbB4 
binders. To analyze specificity, 1 nM solutions of the binders B4_01, B4_02, B4_07, B4_33, B4_45, B4_50 and 
B4_58 were tested for binding on neutravidin and ErbB4 and, in parallel, competition experiments were performed 
by preincubation of 1 nM solutions of the DARPins with free ErbB4 (10 nM and 100 nM) before binding on 
immobilized ErbB4. (b) ELISA with medium affinity ErbB4 binders. To analyze specificity, 5 nM solutions of the 
binders B4_11, B4_14, B4_49, B4_53, B4_55, B4_56, B4_57 and B4_60 were tested as described above using 
10 nM and 100 nM of free ErbB4 for competition. (c) ELISA with low affinity ErbB4 binders. To analyze 
specificity, 25 nM solutions of the binders B4_63, B4_64, B4_65 and B4_68 were tested as described above using 
50 nM and 250 nM of free ErbB4 for competition. The first word in the legend denotes the protein immobilized, no 
comp. denotes the absence of a competitor and + ErbB4 denotes the presence of competitor in 10 nM, 50 nM, 
100 nM or 250 nM concentrations. 
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7. Amino acid sequence and SEC analysis of selected and unselected 
DARPins  
7.1 Amino acid sequence analysis 
In this subchapter, an analysis of the amino acid sequences of selected and unselected 
DARPins of the phage DARPin library is described. DNA sequencing of 55 randomly picked 
clones of the naive library showed that about half of the clones (29) had either a frameshift in the 
DARPin sequence or contained no insert at all (non functional part of the library). Of the 26 
clones with correct DARPin sequences 18 (69%) encode for N3C, 7 (27%) for N2C and 1 (4%) 
for N1C DARPin library members, all encoding different amino acids at randomized positions 
(Fig. 24a). The presence of library members containing less than three internal repeats (N1C and 
N2C) can be attributed to the stepwise library building or the repetitive nature of the DARPins, 
leading to an in vitro recombination during PCR amplification. DNA sequencing of selected 
clones resulted in 84 different sequences of which 72 (86%) encode for N3C, 6 (7%) for N2C, 4 
(5%) for N4C, 1 (1%) for N5C and 1 (1%) for N6C DARPin library members, all encoding 
different amino acids at randomized positions (Fig. 24b). Only one of the clones giving specific 
binding signals encoded a non-functional member of the naive library (I_03, part of the third 
internal repeat is not consensus, Fig. 1). Comparing the size distribution of DARPins before and 
after selections reveals a clear shift to members with an increased number of internal repeat 
modules.  
The reduced proportion of N1C and N2C DARPins after selections might be of 
experimental origin. Prior to the screening of single clones, the pools of selected DARPins had to 
be subcloned from the phagemid into the expression vector. During this process, which involves 
gel-purification of the inserts, minor populations of binders with a smaller size might have been 
reduced. DARPins containing more than three internal repeat modules are probably already 
present in the initial library but to a very low extent, since no repeat duplication indicating in 
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vivo recombination during amplification in E. coli was observed. Such clones are selected most 
probably due to their favorable binding properties in preference. A larger contiguous patch of 
randomized residues in the DARPins with more than three randomized repeats may allow 
binding to additional epitopes, where contacting by residues in the capping repeats might not 
have been favorable or where a larger binding surface is needed. An accumulation of these 
longer constructs during after selections with epitope masking supports this theory. 
Furthermore, all sequences were analyzed for framework mutations, including point 
mutations of conserved framework residues and insertions or deletion at any sequence position. 
From this preliminary analysis of the first five selections described in my thesis, the number of 
clones containing one ore more framework mutations almost double from 41% for naive library 
members to 78% for selected DARPins (Fig. 24). Even more interesting is the distribution of the 
framework mutations over the sequence of the DARPin molecules (Fig. 25). To allow an overall 
analysis of DARPins varying in size form N2C to N6C, internal repeat modules were classified 
into three groups: first repeat (adjacent to N-Cap), middle repeat (no interface with N-Cap or C-
Cap) and last repeat (adjacent to C-Cap). Members of the naive library show a more or less 
random distribution of such framework mutations over the whole sequence (Fig. 25a). In stark 
contrast, selected binders show a strong gradual decrease in framework mutations from the N- to 
the C-Cap (Fig. 25b). There are two potential explanations why binders with higher numbers of 
framework mutations and biased distribution of framework mutations were selected in 
preference. The first possible explanation is based on the selection system. Clones containing an 
increased number of framework mutations, especially in the more stable N-terminal part, might 
have lower stability and are therefore displayed at higher level on filamentous phage particles 
and are subsequently selected in preference. The high display level of one of the most stable 
DARPins E3_5 (ref. 2) by using SRP phage display20 speaks against this hypothesis. However, I 
observed a slightly higher display level for selected DARPins having one or more framework 
mutations, compared to the display level of DARPins from the naive library having no 
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framework mutations (Fig. 26), supporting this hypothesis. The second possible explanation is 
based on the shape of the binding surface of the DARPins. Here, framework mutations would 
introduce flexibility into the rigid DARPin scaffold and thereby allow an adaptation of the 
binding surface, needed for the interaction with certain epitopes18. The biased distribution of 
framework mutations could be explained by the lower intrinsic stability of the C-Cap, already 
providing the flexibility needed for binding but at the same time also reducing the tolerance of 
destabilizing framework mutations in itself and in its close proximity. 
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Figure 24: Size distribution and fraction of clones containing framework mutations: (a) naive library DARPins 
(unselected) and (b) selected DARPins. Depicted are the number of clones (y-axis) as a function of the DARPin size 
(x-axis; number of repeats stacked between N-Cap (N) and C-Cap (C)). The fraction of clones without framework 
mutation (no fm) are indicated in black and the fraction of clones having one or more framework mutations (≥ 1 fm) 
are indicated in gray. Point mutations of conserved framework residues and insertions or deletions at any sequence 
position were counted as framework mutations. 
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Figure 25: Distribution of the framework mutations over the DARPin sequences: (a) naive library DARPins and (b) 
selected DARPins. Depicted is the average of framework mutations (point mutations of conserved framework 
residues and insertions or deletions at any sequence position) found per repeat (y-axis). Different repeats are 
grouped into N-terminal capping repeat (N-Cap), fist repeat (1st. rep., adjacent to N-Cap), middle repeat (mid. rep., 
no interface with N-Cap or C-Cap), last repeat (last rep., adjacent to C-Cap) and C-terminal capping repeat (C-Cap). 
 
Figure 26: Display analysis of selected and unselected library members. (a) Phage particles produced in parallel by 
the use of the phagemid pPDV1 (encoding selected DARPins with framework mutations, unselected DARPins 
without framework mutations, no DARPin) or the phagemid pDST24 (encoding the PhoAss and the scFv_gpD20) 
purified by PEG/NaCl precipitation and normalized by UV absorbance to the same number of phage particles were 
separated by SDS-PAGE, blotted onto PVDF membranes and detected with an antibody specific for the FLAG-tag 
(M1 anti-FLAG) located at the N-terminus of the POI. The molecular weights of marker proteins are indicated 
in kDa at the left side of the blot. (b) Signal intensities were analyzed using Scion Image software (Scion 
Corporation, Release Alpha 4.0.3.2.). It should be noted that phage particles were not purified by CsCl gradient 
centrifugation and the error in the measured phage concentrations will be at least ±20%. 
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7.2 SEC analysis 
SEC analysis was performed with all 84 DARPin binders obtained from the selections on 
the different target proteins (elution chromatograms are shown in each respective subchapter). 
Clones were divided into three groups based on their elution chromatogram (characteristic 
examples of each group are shown in Figure 27); 60 (71%) eluted in a single peak (potentially 
monomeric), 14 (17%) in multiple peaks (probably mixtures of monomeric and multimeric 
species) and 10 (12%) in ”atypical“ elution chromatograms (no defined peaks or peak in the void 
volume) (Fig. 28a).  
Clones eluting in a single peak were further grouped, based on the shape of the elution 
peak (Fig. 28b). The shape of the elution peak of DARPin E3_5 was taken as reference for a 
symmetric peak and peak asymmetry judged by eye. Of the 60 clones giving a single peak, 35 
(58%) eluted as a symmetric peak, 5 (8%) with a shoulder in front of these peaks and 20 (33%) 
with tailing (Fig. 28b). A shoulder in front of the elution peak probably indicates a small 
percentage of multimeric species and a tailing of the peak (front of peak steeper than rear) 
probably indicates interaction of the protein with the column material. 
Furthermore, single peaks were grouped according to their apparent molecular weight 
(MWapp) derived from the elution volume of the peak maximum. DARPin E3_5 eluted at a factor 
1.48 higher than the calculated molecular weight (MWcalc) as derived from the molecular weight 
standard on the column, slightly above the factor published2. Based on results from SEC multi-
angle light scattering (SEC-MALS) measurements (see below), this factor ±25% was used to 
define a range in which the eluted DARPins are expected to be monomeric (1.11 x MWcalc ≤ 
MWapp ≤ 1.85 x MWcalc). Of the 60 clones giving a single peak, 46 (77%) eluted at the expected 
MWapp, 10 (17%) at too low MWapp (indicating column interaction) and 4 (7%) at too high 
MWapp (indicating oligomerization or an elongated shape, probably due to partial unfolding) 
(Fig. 28c). 
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DARPins eluting as a single peak but at too high or too low MWapp were further analyzed 
by SEC-MALS as described6. Measurements and data evaluation was performed by Thomas 
Huber and data from SEC and SEC-MALS are summarized in Table 3. The two binders (9_03 
and 9_26) eluting at too low MWapp (MWapp/MWcalc ≤ 1.11) as well as the two binders (T_09 
and T_16) eluting at with a MWapp slightly above the expected value (MWapp/MWcalc ~ 1.7) 
clearly showed a monomeric mass calculated from SEC-MALS measurements (MWMALS). In 
contrast, the four binders (B4_53, B4_56 I_01 and H_01) eluting at too high MWapp 
(MWapp/MWcalc ≥ 2.2) showed a MWMALS clearly indicating a dimeric mass or a high fraction of 
dimeric species, validating the chosen cutoff of ±25% with respect to E3_5. 
Of the totally 84 clones analyzed by SEC, only 29 (35%) elute as a single symmetric peak 
with the elution volume expected for the monomer, including single peaks with a slight shoulder 
or tailing increases this number to 46 (55%). To estimate the percentage of all binders being 
monomeric, DARPins with a too low MWapp can also be counted, as shown by SEC-MALS, 
resulting in a final value of 56 (67%) of monomeric binders. 
 
Table 3: Molecular weight calculations of DARPins with atypical elution 
volumes in SEC 
DARPin MWcalc (kDa)a MWapp (kDa)b MWMALS (kDa)c 
B4_53 18.6 42 (2.3) 30 (1.6) 
B4_56 21.8 56 (2.6) 43 (2.0) 
I_01 18.3 54 (3.0) 40 (2.2) 
H_01 18.1 42 (2.3 ) 33 (1.8) 
T_16 18.3 31 (1.7) 20 (1.1) 
T_09 18.3 31 (1.7) 20 (1.1) 
9_26 18.4 10 (0.6) 19 (1.0) 
9_03 18.5 15 (0.8) 19 (1.0) 
a Molecular weight calculated from the sequence. b Apparent molecular weight determined by gel-
filtration, in parentheses MWapp/MWcalc. c Observed molecular weight determined by SEC-multi-
angle light scattering (MALS) (measurements performed by T. Huber), in parentheses 
MWMALS/MWcalc. 
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Figure 27: Grouping of DARPins based on SEC 
analysis. DARPins were divided into five groups 
based on their elution chromatogram: single 
symmetric peak, single peak with a shoulder, single 
peak with tailing, multiple peaks and “atypical” 
elution chromatogram. The elution chromatograms 
of two representative examples of each group and 
of the unselected DARPin E3_5 are shown. For 
each DARPin the number of repeats stacked 
between N-Cap (N) and C-Cap (C) is given in 
parentheses. The molecular mass standards, phage 
protein D (gpD) with an apparent mass of 17.6 kDa 
and phage protein SHP, a trimer with an apparent 
mass of 50.2 kDa, are indicated with arrows. 
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Figure 28: Summary of collected SEC data. (a) The number of clones eluting in a single peak, in multiple peaks or 
not as defined peaks or as peak in the void volume (atypical) are plotted for the DARPins of different length and the 
sum of all DARPins. (b) The clones eluting as a single peak (sp) were grouped according to the shape of their 
elution peak. The number of clones giving a sp that is symmetric, sp with a shoulder or sp with tailing are plotted as 
described above. (c) The clones eluting as a single peak were additionally grouped according to their elution 
volume. The number of clones eluting at too low (MWapp ≤ 1.11 x MWcalc), expected (1.11 x MWcalc ≤ MWapp ≤ 
1.85 x MWcalc) or too high apparent molecular weight (MWapp ≥ 1.85 x MWcalc) are plotted as described above. 
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7.3 Comparing SEC and sequences 
The aim of comparing the recorded SEC elution profiles with the sequences of the 
respective DARPins was to find out if there is a correlation between the behavior in SEC and the 
occurrence of framework mutations in general or certain patterns of framework mutations. 
Binders were grouped based on their behavior in SEC and framework mutations analyzed. One 
possible grouping is depicted in Figure 29. The only clear observation is the low occurrence of 
framework mutations in the C-Cap of binders eluting as a single symmetric peak or single peak 
with a shoulder. No correlation of a non-monomeric elution profile in SEC with an increased 
number of framework mutations or pattern of framework mutations was observed. Even more 
interesting, about half of the clones giving an ”atypical“ elution chromatogram in SEC had no 
framework mutations at all, indicating a high influence of the randomized positions on the SEC 
behavior of the DARPins.  
Furthermore, all sequences were analyzed for the occurrence of charged or hydrophobic 
amino acid. Also in this case no correlation of a non-monomeric elution profile in SEC with over 
all increased or decreased charge or hydrophobicity was observed. 
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Figure 29: Distribution of the framework mutations over the DARPin sequences for groups of DARPins having 
different SEC behavior. Depicted is the average of framework mutations (point mutations of conserved framework 
residues and insertions or deletion at any sequence position) found per repeat (y-axis) plotted for the DARPins 
having different SEC behavior. Labeling of the SEC behavior is done as described in Figure 28 and grouping of the 
different repeats as in Figure 25. 
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7.4 Surface analysis of selected DARPins 
Since no clear correlation between amino acid sequence of the selected DARPins and 
behavior in SEC was found, the binders were further analyzed for the occurrence of hydrophobic 
patches or charge clusters on their surface which might lead to multimerisation or aggregation. 
All DARPins with a non-monomeric elution profile in SEC and a subset of the binders showing 
monomeric behavior were submitted for modeling of their three-dimensional structure (SWISS-
MODEL21) using the “automated mode” which selects the template structure based on sequence 
similarity. Models of each DARPin were subsequently analyzed for surface charge distribution 
and surface hydrophobicity using MOLMOL22 (Fig. 30). 
Analysis of the hydrophobicity of the surface of the DARPins revealed that most DARPins 
selected by phage display show an increased occurrence of hydrophobic residues in the concave 
binding surface of the DARPins compared to the DARPins used as templates. Especially large 
hydrophobic patches were observed for the clones T_01, T_40, B4_57 and I_06 showing an 
atypical SEC behavior, clones T_49, T_41 and T_27 giving multiple peaks in SEC and the 
reference clone H10_2_G3. The hydrophobicity of the back side is unaltered in all clones 
analyzed.  
Analysis of the charge distribution only shows a clustering of positive charges for the 
reference clone E3_19 and the two clones T_01 and T_25 showing atypical SEC behavior. 
Over all the surface analysis showed that there is an increased occurrence of hydrophobic 
and positive charge patches for some clones with atypical SEC behavior and clones giving 
multiple peaks in SEC. This might be the reason for their non-ideal behavior. However, for most 
other clones no correlation was observed indicating that mutations disturbing hydrophobic core 
packing, salt bridges and H-bonds will probably affect the structural integrity of the DARPin and 
thereby influence their behavior in SEC. 
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Figure 30: Charge distribution and hydrophobicity of the surface of selected DARPins. The charge distribution 
(even pages: red indicates negative potential; blue, positive potential) and hydrophobicity (odd pages: hydrophobic 
side-chains colored in green) of the different DARPins are depicted. The front view of the concave binding surface 
of the DARPins is shown on the left side and the back view on the opposite side is shown on the right side. 
DARPins E3_5 (PDB entry: 1MJ0), H10_2_G3 (PDB entry: 2JABA), 3a (PDB entry: 2BKKB), E3_19 (PDB entry: 
2BKGA), off7 (PDB entry: 1SVXA), and 1108_19 (PDB entry: 2J8SD) with known structures are shown as 
references (highlighted in purple). For orientation, corresponding ribbon representations of DARPin E3_5 are shown 
on top of the respective surface representation. Depicted below is the surface of models of the selected DARPins 
generated by using SWISS-MODEL21. For each selected DARPin the structure of the DARPin with highest 
sequence identity was used as a template (respective PDB entry given in brackets). DARPins with atypical SEC 
behavior (T_01, T_25, 9_30, 9_04, T_40, B4_57, I_06, T_45 and 9_10, highlighted in yellow), DARPins that elute 
in SEC with multiple peaks (T_49, T_33, T_41, T_27, I_19, B4_68, E_68, B4_60, B4_58, 9_18, 9_33, 9_12 and 
T_51, highlighted in light blue), DARPins having framework mutations (+fm) and eluting as a single peak at the 
expected molecular weight (T_08, I_14, I_11, I_10, E_67, B4_45 and I_15, highlighted in dark gray) and DARPins 
having no framework mutations (no fm) and eluting as a single peak at the expected molecular weight (E_72, E_36, 
E_17, 9_20 and B4_33, highlighted in light gray) are depicted. The figures and the charge calculations were made 
using MOLMOL22. 
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Figure 30: Continued next page 
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  Hydrophobicity of DARPin Surface 
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Figure 30: Continued next page 
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Glossary of terms 
• CAT: chloramphenicol acetyl transferase 
• cfu: colony forming units 
• cam: chloramphenicol 
• DARPin: designed ankyrin repeat protein 
• E. coli: Escherichia coli 
• kan: kanamycin 
• p3: minor phage coat protein 3 
• PBS: phosphate buffered saline 
• PD: phage display 
• pfu: plaque forming units 
• ps: packaging signal 
• SRP: signal recognition particle 
• ssDNA: single stranded DNA 
• TBS: Tris buffered saline 
• tet: tetracycline 
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Introduction 
Phage display readings and protocols 
This manual describes the use of a designed ankyrin repeat protein (DARPin) phage 
display library (for details see Appendix data sheet: PD library #1) to select target-specific 
DARPins by filamentous phage display (Fig. 1). Before starting a phage display project we 
strongly recommend to understand the basic principles behind phage display. Compact 
and easy understandable general information on phage biology and phage display can be 
found in recent book chapters 1,2 or more detailed information in reviews 3,4 (a complete 
listing of all references can be found at the end of this manual) 
 
• Ref. 1: Russel, M., Lowman, H. B. & Clackson, T. (2004). Introduction to phage biology and 
phage display. In Phage Display: A Practical Approach (Lowman, H. B. & Clackson, T., 
eds.), pp. 1-26. Oxford University Press, New York, USA. 
• Ref. 2: Dennis, M. S. & Lowman, H. B. (2004). Phage selection strategies for improved 
affinity and specificity of proteins and peptides. In Phage Display: A Practical Approach 
(Lowman, H. B. & Clackson, T., eds.), pp. 61-83. Oxford University Press, New York, USA. 
• Ref. 3: Smith, G. P. & Petrenko, V. A. (1997). Phage Display. Chem Rev 97, 391-410. 
• Ref. 4: Bradbury, A. R. & Marks, J. D. (2004). Antibodies from phage antibody libraries. J 
Immunol Methods 290, 29-49. 
 
Many protocols on phage display have been published. A list of some public available 
phage display manuals is given below: 
 
• Protocols from G. Smith lab:  
→ http://www.biosci.missouri.edu:16080/smithGp/PhageDisplayWebsite/PhageDisplayWeb
siteIndex.html 
• Protocols from A. Bradbury and G. Smith lab: 
→ http://www.bio.com/protocolstools/ 
• Protocols from D. Neri lab: 5 
→ Ref 5: Viti, F., Nilsson, F., Demartis, S., Huber, A. & Neri, D. (2000). Design and use of 
phage display libraries for the selection of antibodies and enzymes. Methods Enzymol 
326, 480-505. 
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→ http://www.pharma.ethz.ch/institute_groups/biomacromolecules/protocols/eth 
• Protocols from S. Sidhu lab: 6 
→ Ref 6: Sidhu, S. S., Lowman, H. B., Cunningham, B. C. & Wells, J. A. (2000). Phage 
display for selection of novel binding peptides. Methods Enzymol 328, 333-63. 
DARPins 
DARPins constitute a novel substance class of binding molecules based on repeat 
proteins7. Repeat proteins are, next to antibodies, the most abundant class of binding 
molecules found in nature. They are found in all phyla, they occur intra- and extracellularly 
and they are involved in diverse biological processes, such as cell cycle control, 
transcription regulation, innate and adaptive immunity, vesicular trafficking, cell 
differentiation, apoptosis, cellular scaffolding or bacterial invasion. Interestingly, jawless 
fish have variable lymphocyte receptors, which consist of repeat protein modules instead 
of the immunoglobulin-type antigen receptors of jawed vertebrates8. 
High-affinity target-specific DARPins with great potential in biotechnological, diagnostic or 
therapeutic applications can easily be generated9. Selected DARPins possess the high 
specificities and high affinities of antibodies. Unlike antibodies, DARPins do not contain 
disulfide bonds enabling intracellular applications10. DARPins are built of consecutive 
homologous repeats, which assemble to form elongated domains with a continuous 
hydrophobic core. Combinatorial libraries of DARPins were constructed and members of 
these libraries are generally very well expressed, monomeric in solution, highly soluble, 
and possess high thermodynamic stabilities11.  
DARPin phage display 
The very high stability and folding properties of DARPins made it necessary to develop a 
novel phage display vector for their efficient display on phage particles12. Translocation of 
proteins into the periplasm of Escherichia coli (E. coli) is an intermediate step in 
filamentous phage assembly and using the conventional posttranslational Sec-dependent 
translocation pathway was found to be the bottleneck in the display of DARPins. Using the 
cotranslational signal recognition particle (SRP) translocation pathway resulted in up to 
700-fold improved display levels of DARPins when compared to using the Sec pathway. 
This novel method is termed “SRP phage display”. 
• The phagemid vector pMPAG3 is used for the efficient display of DARPins on filamentous 
phage particles (for details see Appendix data sheet: pMPAG3). 
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→ Phagemid vector for monovalent filamentous phage display using the minor phage coat 
protein p3 as fusion partner (p3-DARPin fusion protein) for display. 
→ Vector providing SRP phage display functionality for the efficient display of DARPins. 
→ Vector carrying a f1 origin of replication to permit production of virions using an 
appropriate helper phage, such as VCSM13. 
→ Vector carrying a plasmid origin (ColE1) and providing resistance to chloramphenicol 
(cam) to allow propagation in E. coli. 
• The provided DARPin phage display library (for details see Appendix data sheet: PD library 
#1) is based on pMPAG3 and contains: 
→ 2.6 x 1010 independent chloramphenicol resistant clones of which 42% are correct 
DARPins, resulting in the functional library size of 1.1 x 1010.  
→ 25% of the clones are N3C DARPin library members. 
→ 17% of the clones are N2C DARPin library members 
→ 58% of the clones (non functional part of the library) had either frame shifts in the 
DARPin sequence or no insert at all. 
Advantages of DARPin phage display 
• The high functional diversity of the PD library #1 provides the essential basics that high 
affinity DARPins can be selected; it is expected that low nM or even pM binders will be 
obtained on a regular basis. 
• Selected DARPins maintain their excellent target-specificity and stability independent of 
being tethered to a phage particle or not. 
→ Selected DARPins possess a very wide potential application range, ranging form in vitro 
applications such as immunohistochemistry, over intracellular applications for target 
validation to in vivo therapeutic applications. 
• Most of the selected DARPins will have the excellent biophysical properties inherent in this 
novel substance class. 
• It is anticipated that this DARPin phage display library will be an excellent tool for the 
selection of DARPins for target protein binding directly on cells, on tissue or even in vivo (in 
mice). 
• So far successful selections against a panel of nine target proteins ranging form the 
detergent-solubilized Na+-citrate symporter CitS of Klebsiella pneumoniae (T. Huber et al. J. 
Struct. Biol. 159, 206-221(2007)) to the Fc domain of human IgG1 (D. Steiner et al. 
manuscript in preparation). 
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Work flow of a selection project and selection cycle 
 
 
 
 
Figure 1: Work flow of a selection project 
Schematic representation of the workflow of a selection project. Respective protocols found 
in this manual are given in parentheses.  
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Figure 2: Work flow of a selection cycle 
Schematic representation of a phage display selection cycle. A phage library displaying the 
proteins of interest on their surface while having the respective gene encapsulated inside 
the phage particle (coupling of the genotype and phenotype) is used for the binding 
selection on the immobilized target protein [1]. After formation of the complexes between 
the binding protein and the target protein (solubilised membrane protein depicted), unbound 
phage particles are washed off [2]. The bound phages are eluted from the immobilized 
target by a pH shift [3] and used for the infection of E. coli. Phage particles are amplified [4] 
and can then be analyzed or used as input for the next selection round. 
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General Reagents and Equipment 
• For a detailed description of all equipments, reagents and solutions needed see Materials 
(p. 278 ff.) 
• PD library #1 (for details see Appendix data sheet: PD library #1) 
→ DARPin phage display library based on pMPAG3. 
→ A procedure for repropagation of the PD library #1 is provided (Protocol 08). 
• pMPAG3 (for details see Appendix data sheet: pMPAG3) 
→ Phagemid, which was used to construct the PD library #1; may be used as a negative 
control phagemid. 
• pMPAG6 and pDST67 (for details see Appendix data sheet: pMPAG6, pDST67) 
→ Plasmids for the cytoplasmic expression of DARPins in E. coli (e.g. XL1-Blue). 
→ pMPAG6 contains lacIq, pDST67 not. Thus, pDST67 has to be used in a lacIq host 
background (e.g. XL1-Blue). 
→ Single DARPin sequences or pools of DARPin sequences may be transferred from 
pMPAG3 into pMPAG6 or pDST67 using the corresponding BamHI and HindIII 
restriction sites (Protocol 18). 
• Bacterial strain: E. coli XL1-Blue13 (Stratagene, no 200268) 
→ F' [lacIq lacZ∆M15 proAB+ Tn10(Tetr)] endA1 supE44 gyrA96 hsdR17 lac recA1 relA1 thi 
• VCSM13 helper phage (Stratagene, no 200251) 
→ Helper phage derived from M13 K07, carries kanamycin (kan) resistance. A protocol for 
VCSM13 stock preparation and storage is provided (Protocol 03) 
• Control DARPin (I_19) and control target protein (human IgG1 whole molecule) 
→ DARPin I_19 binding to Fc part of human IgG1 with high affinity (KD = 2 nM) 
→ Using the phagemid pMPAG3 (I_19), phage particles displaying I_19 can be prepared 
which can be used as positive control in selection and phage ELISA experiments 
→ Using the espression vector pDST67 (I_19) soluble I_19 can be expressed which can be 
used as positive control in ELISA experiments. 
→ Full length human IgG1 is used as controll target protein (for immobilization and 
capturing see Protocol 11, Protocol 12) 
• Solution for phage decontamination: Helipur (B.Braun Melsungen AG, no. 6505520) 
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General phage working rules 
• Phage contaminations in flasks, bottles etc. may accumulate as one performs selections 
from phage display libraries. Precautions need to be taken throughout the protocol to avoid 
any carry over of phage. Autoclaving alone is not sufficient enough to remove all phage 
contamination. Ensure that all non-disposable plasticware and glassware (e.g. centrifuge 
bottles, shaker flasks) is completely phage free by soaking it for 3 hr in 2% (v/v) helipure 
solution (B.Braun Melsungen AG, no. 6505520), followed by manual washing, washing in 
dishwasher and then autoclaving. 
• If available do all phage work in an extra “phage-room” or “phage-hood”. 
• Wherever possible use disposable pipettes and disposable plasticware. The use of 
polypropylene tubes is recommended as phage may adsorb non-specifically to other types 
of plastic. Do all work with phage samples using a clearly labeled set of “phage-pipettes” 
and a clearly labeled “phage waste”. 
• Use filter tips and “phage-pipettes” whenever working with solutions containing phage or 
phagemid particles. 
• Be especially careful when working with highly concentrated phage particle solutions like 
described in Protocol 04. 
• Wear gloves whenever working with phage samples, change before touching phage free 
equipment to keep contaminations as low as possible. 
• Do not grow phage free cultures and phage cultures in the same incubator. 
• Always check log-phase E. coli XL1-Blue cultures for phagemid or helper phage 
contaminations by antibiotic resistance (cam, kan). XL1-Bue is only tetR. Contaminations 
are difficult to see because filamentous bacteriophages do not lyse the host cells but just 
lead to slower growth. 
• Solutions containing phage must be collected. For decontamination add 2% (v/v) helipur, 
incubate for 24 h, autoclave and transfer to liquid waste. 
• Aspirate phage containing supernatants (e.g. during selection) into filter flask containing 
helipure solution (Connect plastic tubing and Pasteur pipette to a filter flask). 
• Remove phage solution from antigen coated wells either by aspirating or by rapidly inverting 
the plate over a plastic tray (decontaminate liquid as described above) followed by blotting 
dry on stacked paper towels (discard to phage-waste). 
• Clean lab bench and hood frequently with 2% (v/v) helipure solution followed by water and 
70% EtOH. 
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• Before starting a new selection clean phage free pipettes and “phage pipettes” by soaking 3 
hr in 2% (v/v) helipure solution followed by extensive washing in water and 70% EtOH. 
•  
 
 
Phage display manual   203 
 
Bacteria, Filamentous Bacteriophage and 
Phagemid 
Filamentous Bacteriophage: 
• Most commonly, filamentous phages such as f1, M13 and fd that infect E. coli are used for 
phage display (termed Ff phages). In contrast to most other bacteriophages, filamentous 
phages do not lyse the host cells upon release of their progeny. The newly produced 
filamentous phage particles are assembled in the periplasmic membrane and continuously 
extruded from the cells into the culture medium, resulting in a reduced growth rate of 
infected cells. 
• The phage coat encapsulates single stranded DNA (ssDNA) encoding 11 proteins needed 
for replication and assembly in the E. coli host cell (three for ssDNA generation, three for 
phage assembly and five for phage coat formation). Additionally, the replication origins for + 
and – strand synthesis and the packaging signal (ps) for ssDNA incorporation into the 
phage particles are encoded on the phage genome. 
E. coli host cells 
• Efficient filamentous bacteriophage infection depends on the presence of the F-pilus on the 
E. coli surface (only in F’, male strains). Genetic information for F-pilus formation is 
contained on an F’ plasmid. F-pilus expression is reduced when growing E. coli past log-
phase and also when growing cells at temperatures below 34°C (ref. 1). Thus growth at 
37°C to OD600 = 0.4 - 0.6 is recommended (Protocol 01). 
Phagemid 
• DARPins are displayed on phage particles by using a “phagemid” vector (for details see 
Appendix data sheet: pMPAG3). Such phagemid vectors are plasmids carrying an Ff origin 
and can thus be packaged into filamentous phage particles. pMAPG3 contains a gene 
coding for the DARPin fused to the gene of the phage coat protein 3 (p3) which is under the 
control of a weak promoter, a gene coding for an antibiotic resistance (cam), a plasmid 
origin of replication, a Ff origin of replication to allow production of single-stranded vector 
and a ps for encapsulation of the ssDNA into phage particles. All the information for phage 
replication and production is missing on phagemids. 
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Phage Particles 
• Dependent on the DNA encapsulated one can differentiate between two types of phage 
particles: helper phage particles and phagemid particles.  
• Helper phage particles (VCSM13 is used in this manual) encapsulate helper phage 
ssDNA which contains all the genetic information of wild type filamentous phage M13 
needed for phage replication and production. Additionally, VCSM13 carries a kanamycin 
resistance that allows antibiotic selection of helper phage infected cells, mutations in the ps 
that reduce packaging efficiency of its ssDNA and mutations that allow infection of bacteria 
already harboring a plasmid with Ff origin of replication (interference-resistance) 1. (see 
Protocol 02,Protocol 03) 
• Phagemid particles encapsulate phagemid ssDNA. To produce such phage particles E. 
coli cells harboring a phagemid need to be coinfected with helper phage (see above) which 
provides all information for phage replication and production in trans. The cells will then 
produce all phage proteins from the helper phage genome (large excess of wild-type-p3) as 
well as in a small amount phage p3 fusion protein encoded by the phagemid. Therefore, the 
majority of the phage particles extruded by the cell will display only wild-type-p3 (5 copies 
per phage particle) and less than 10% of the produced phage particles will contain one copy 
of the p3-DARPin fusion (phenotypic diversity, monovalent display). Because the helper 
phage ssDNA is poorly packaged, the majority of the phage particles will contain the 
phagemid ssDNA preserving the link between genotype and phenotype but all phagemid 
particle preparations will contain a low percentage of helper phage particles (genotypic 
diversity). The phagemid particles can infect E. coli were phagemid ssDNA is replicated as 
double stranded DNA without further phage replication. (see Protocols 06, 07, 08, 09 and 
10) 
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Table 1: Comparison of helper phage and phagemid particles 
 Phage particles 
 Helper phage particles Phagemid particles 
Encapsulated genome helper phage ssDNA 
(VCSM13) 
phagemid ssDNA 
(pMPAG3) 
Packaging efficiency of 
encapsulated ssDNA 
low high 
Infectious yes yes 
Replicable as phage 
particles 
yes no 
(helper phage needed) 
Antibiotic resistance of 
infected cells 
kanamycin chloramphenicol 
Typical concentration in 
culture supernatant 
~ 1011 pfu/ml ~ 1012 cfu/ml 
Comments  preparations of phagemid 
particles do always contain 
helper phage particles 
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Protocol 01 Exponential bacterial cultures (log-phase cultures) 
Comments 
• This is a general protocol for the production of log-phase bacterial cultures. 
• Phage infection depends on the presence of the F-pilus on the bacteria surface. F-pilus 
expression is reduced when growing E. coli past log-phase and also when growing cells at 
temperatures below 34°C (ref. 1). Thus growth at 37°C to OD600 = 0.4 - 0.6 is 
recommended. 
• E. coli XL1-Blue is the preferred host for phage propagations giving high yields of page 
particles. Alternatively, E. coli TG 1 or other strains may be used (different protocols 
needed). 
• E. coli XL1-Blue must be grown on agar plates and in media containing tetracycline (tet) to 
keep bacteria infective (tet resistance on F’-plasmid that contains genes encoding for F-
pilus formation). Do always grow XL1-Blue from fresh colonies because subculturing can 
occasionally lead to emergence of tet resistant cells which are not infectable. 
• Prepare your own glycerol stocks of E. coli XL1-Blue. Grow liquid culture (2YT/tet) of a 
single colony of E. coli XL1-Blue to late log phase (OD600 = 1 – 2), add 15% (v/v) of sterile 
glycerol, mix and freeze in liquid N2. Prepare several glycerol stocks and store at -80°C 
and only use one at the time. Test the culture for phagemid and helper phage 
contaminations by plating on 2YT/tet/cam and 2YT/kan agar plates. Test as well for amp 
resistance and for plaque formation (Protocol 02). Additionally, test culture for proper 
infection with phagemid particles and helper phage particles (Protocol 06). This 
cumbersome procedure ensures that you are starting from a good stock of host cells 
necessary for the whole selection. 
• It is strongly recommended to plate E. coli XL1-Blue from the glycerol stock in use each 
week on a fresh 2YT/tet agar plate.  
• Test every E. coli XL1-Blue culture used during the selection for contamination by plating 
on a 2YT/tet/cam and a 2YT/kan agar plate.  
• E. coli XL1-Blue at OD600 = 1 contains about 5 x 108 cfu/ml. 
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Equipment and Reagents (see p. 278 ff. for details)  
• E. coli XL1-Blue 
• 2YT/tet media 
• 2YT/tet agar plates (round) 
• 2YT/kan agar plates (round or square) 
• 2YT/cam/tet agar plates (round or 
square) 
• Culture flasks (100 ml or 300 ml) 
• Culture tubes (14 ml) 
Method 
Day 1 
1. Streak out E. coli XL1-Blue from your stock on a 2YT/tet agar plate and incubate overnight 
at 37°C. (Seal with parafilm and store plate at 4°C and use for max one week) 
Day 2 
2. Inoculate 5 ml of 2YT/tet media in a 14 ml culture tube with a single colony of E. coli XL1-
Blue and grow overnight at 37°C with shaking at 220 rpm (pre-culture). 
Use medium without innoculation as negative control for medium contamination 
Day 3 (log-phase culture) 
3. Inoculate fresh 2YT/tet media with the pre-culture at a ratio of 1:25 to 1:200 (see below) 
and grow at 37°C with shaking to OD600 of 0.4-0.6 (log-phase culture) 
The efficiency of infection is greatly reduced above OD600 of 0.6. Adjust volume of log-
phase culture depending on the amount needed for the experiment. Use shaker flasks 
without baffles. If you have problems estimating the time needed to be ready for 
infection, inoculate at different dilutions (see Table, e.g. 1:50, 1:100 and 1:200). This 
allows you to have log phase cultures for a time span of about 1.5 h (the doubling time 
of XL1-Blue is about 35 – 40 min). 
 
Table 2: Inoculations for log-phase cultures 
Inoculation ratio Time to OD600 = 0.5 
1:25 ∼ 1h 00 min 
1:50 ∼ 1h 40 min 
1:75 ∼ 2h 00 min 
1:100 ∼ 2h 20 min 
1:150 ∼ 2h 40 min 
1:200 ∼ 3h 00 min 
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4. Use log-phase culture for the infections. 
5. To check for contaminations plate 50 µl aliquots of the log-phase culture on 2YTcam/tet 
and 2YT/kan agar plates and incubate at 37°C overnight and 24 hours, respectively. 
Day 4 
6. Check 2YT/kan and 2YTcam/tet agar plates for colonies (contamination). 
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Titering, propagating and purifying helper 
phage particles 
• There are two methods for determining the concentration of viable, infective helper phage 
particles: titration by plaque forming units and titration by colony forming units. 
• Titration by plaque forming units: For helper phage particles, determining the 
concentration of viable particles involves counting phage plaques on a lawn of host bacteria 
(plaque forming units per ml, pfu/ml) (Protocol 02). Turbid plaques are visible due to the 
reduced growth of infected host cells. It is advisable to follow this procedure of plaque 
isolation whenever propagating helper phages to ensure that a pure culture of viable helper 
phage is obtained (Protocol 03). 
• Titration by colony forming units: For helper phage particles containing an antibiotic 
resistance (e.g. kan for VCSM13) titration by colony forming units can be performed as 
described for phagemid particles (Protocol 06). However, this method gives only an 
estimate and is not recommended for accurate titration of helper phages. During recovery in 
solution helper phage particles that are released from host cells short time after infection will 
consequently re-infect other host cells. Therefore, concentration of viable particles will be 
strongly overestimated. 
• A convenient alternative to determine the concentration phage particle preparations is the 
estimation by absorbance (Protocol 05). However, calculations based on absorbance 
normally overestimate the concentration of viable, infective particles by a factor 2-10. 
• A typical yield of helper phage particles in the supernatant of XL1-Blue phage cultures 
grown in 2YT would be 1011-1012 phage/ml. 
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Protocol 02 Helper Phage titration by plaque forming units (pfu) 
Comments 
• This is a general procedure for the titration of stocks of helper phage particles (e.g. 
VCSM13) to determine the concentration of infectious particles. A single plaque obtained 
should be used for amplification of the helper phage particles (Protocol 03). 
Equipment and Reagents (see p. 278 ff. for details) 
• Helper phage VCSM13  
• E. coli XL1-Blue log-phase culture 
(Protocol 01)  
• 2YT/cam/tet agar plates (round or 
square) 
• 2YT/kan agar plates (round or square) 
• 2YT/tet agar plate (round) 
• 2YT top agar  
• 50°C water bath 
Method 
Day 1,2 
1. E. coli XL1-Blue plating and pre-culture (Protocol 01). 
Day 3 (Titering of helper phage) 
2. Prewarm 2YT/tet agar plates to 37°C. 
3. Prepare 5 ml E. coli XL1-Blue log-phase culture (Protocol 01). 
4. Perform serial dilutions of helper phage stock in 2YT media down to about 103-105 
particles/ml. 
5. Melt 2YT top agar by microwaving and cool to 50°C in a water bath. 
Complete melting of the top agar is essential. 
6. Mix 0.01 ml of each phage dilution with 0.1 ml of log-phase XL1-Blue cells in a 14 ml tube. 
7. To each tube, add 3 ml of 2YT top agar and mix carefully, but quickly. 
Avoid formation of bubbles, making plaques difficult to count 
8. Immediately pour the top agar mixture evenly onto a 2YT/tet agar plate. To test for 
contamination do the same procedure using only log-phase XL1-Blue cells.  
If top agar is to cold, lumps will form, making plaques difficult to count. 
9. Additionally, check for contamination of log-phase XL1-Blue cells by plating 50 µl on a 
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2YT/tet/cam and a 2YT/kan agar plate. 
10. Allow the top agar to solidify at RT, and then incubate the plates at 37°C overnight. 
Plaques should appear as turbid discs against a background lawn of cells. 
11. Calculate the phage concentration in the original stock solution (pfu/ml) taking the serial 
dilutions into account. 
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Protocol 03 Helper Phage amplification from single plaque 
Comments 
• This is a procedure for propagation of helper phage particles (VCSM13) from a single 
plaque (Protocol 02). 
Equipment and Reagents (see p. 278 ff. for details) 
• 2YT/tet agar plate containing well 
separated single plaques (Protocol 02). 
• E. coli XL1-Blue log-phase culture 
(Protocol 01) 
• PBS-G (PBS containing 10 % v/v 
glycerol) 
• 2YT/kan media 
• 2YT/cam/tet agar plates (round or 
square) 
• 2YT/kan agar plates (round or square) 
Method 
Day 1,2 
1. E. coli XL1-Blue plating and pre-culture (Protocol 01). 
Day 3 (Phage amplification from single plaques) 
2. Prepare E. coli XL1-Blue log-phase culture (Protocol 01).  
3. Pick a single isolated plaque using a sterile Pasteur pipette and add it to 1 ml of log phase 
XL1-Blue cells.  
4. Check for contamination by plating 50 µl log-phase XL1-Blue cells on a 2YT/tet/cam and a 
2YT/kan agar plate. 
5. Incubate for 1 h at 37°C with shaking. 
6. Dilute the cells into 25-1000 ml of 2YT/kan media. 
Volume dependent on amount of helper phage needed for the planed selection 
experiments (Can be stored for several months at -80°C). Use flasks without baffles. 
7. Incubate the culture for 12-15 h at 37°C with shaking. 
8. Precipitate and purify the helper phage as described in Protocol 04. Resuspend the 
phage in ~ 1:20 of culture volume PBS-G to a final concentration of about 1013 phage/ml 
(OD269 = 1.0 for a solution containing 5 x 1012 phage/ml).  
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9. For long term storage freeze small aliquots of helper phage in liquid N2 and store at -80°C. 
Helper phage stocks can be stored at 4°C for several weeks. 
10. Determine the phage titer (Protocol 02) of a thawed helper phage sample (pfu/ml) and 
use this value for the selections. Test helper phage stock for phagemid contamination by 
plating infected cells on 2YT/tet/cam agar plate. 
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Protocol 04 Phage precipitation and purification 
Comments 
• This is a general procedure for the precipitation of helper phage and phagemid particles 
from cell culture supernatants. 
• Typically, culture supernatants from XL1-Blue phage cultures grown in 2YT yield about 
1011-1012 phage/ml. 
• This procedure is used to produce concentrated working stocks of helper phage particles 
(Protocol 03), stocks of phagemid particles (Protocol 07), phage library stocks (Protocol 
08) and DARPin displaying phagemid particles during selection cycles (Protocol 09 and 
Protocol 10) from the supernatant of respective cell cultures. 
• To avoid contaminations with phage particles be especially careful when working with such 
highly concentrated phage particle solutions (see General Phage Working Rules p.201) 
Equipment and Reagents (see p. 278 ff. for details) 
• Cell culture containing helper phage or 
phagemid particles (Protocol 03, 08, 11 
and 12) 
• Polypropylene tubes (50 ml) 
• Micro tubes (2 ml) 
• PBS 
• PBS-G 
• PEG/NaCl (5x)  
Method 
Day 1 
1. Centrifuge the culture containing phage particles for 10 min at 16’000g and 4°C. 
If volume is not too large use 50 ml disposable tubes. You can also centrifuge for 15 
min at 5’600 g and 4°C. This way you will have more cell debris in the supernatant 
which will be removed in Step 4. 
2. Transfer supernatant to a fresh tube and add 1/4 volume of ice cold PEG/NaCl (5x) 
solution (2 ml to every 8 ml culture supernatant) to precipitate phage. Incubate for 1 hour 
on ice. 
If the culture supernatant contains about 1011-12 phage/ml, precipitating phage will 
immediately be visible as turbid clouds after addition of the PEG/NaCl (5x) solution. For 
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phage samples with higher concentrations, 10 min incubation on ice can be sufficient to 
precipitate most of the phage particles. Longer incubation on ice (up to 12 h) will help to 
precipitate phage from less concentrated culture supernatants. 
3. Centrifuge in a swing rotor for 15 min at 5’600g and 4°C. Decant the supernatant. Respin 
briefly and remove the remaining supernatant with a pipette. 
It is important not to spin phage too fast, as they will be difficult to resuspend, and 
phage titer will decrease. 
4. Resuspend phage pellet in 1/20 of the initial culture supernatant volume PBS-G using a 
pipette. Transfer into sterile 2 ml tubes. For complete resuspension incubate the phage 
solution on an orbital shaker at 800 rpm for 15 min at 4°C. Pellet insoluble matter (cell 
debris) by centrifugation for 10 min at 11’000g and 4°C. 
Phage particles start to precipitate at concentrations higher than 1014 phage/ml 
5. Transfer the supernatant to a clean tube and estimate the phage concentration by 
absorbance (Protocol 05) 
6. Titrate helper phage or phagemid particles on XL1-Blue cells to determine the 
concentration of infectious phage particles (pfu or cfu) as described in Protocol 02 and 
Protocol 06. 
Ideally, the concentrated phage stock will have concentrations 1012-13 cfu/ml. 
7. VCSM13 helper phage and phagemid particles may be kept at 4°C for days. Nevertheless, 
it is advisable to aliquot them and store them at -80°C after flash freezing in liquid nitrogen. 
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Protocol 05 Estimating of phage concentrations by absorbance 
Comments 
• Adapted form protocol by G. Smith, based on calculations done by Day et al. 14 
• This is a procedure for estimating the concentration of phage particles by absorbance. 
However, calculations based on absorbance normally overestimate the concentration of 
viable, infective particles by a factor 2-10. 
• Unlike icosahedral phage like T4 and λ, which have roughly equal weight ratios of protein 
to DNA, filamentous phage have about 6 times more protein than DNA; the protein 
therefore contributes substantially to the absorption spectrum, accounting for the broad 
plateau at 260–280 nm, with a shallow maximum at 269 nm. 
Equipment and Reagents (see p. 278 ff. for details) 
• purified filamentous phage sample 
(Protocol 04) 
• PBS-G 
Method 
Day 1 
1. Measure UV absorption spectrum of purified filamentous phage sample (Protocol 04) 
dissolved in PBS-G, which also serves as the blanking solution in the reference cuvette. 
 
Figure 3: UV absorption spectrum of purified filamentous phage sample:  
Ideally, OD269 should be slightly higher than OD260. To high OD260 indicate the presence of 
DNA debris in the sample. This calculation often overestimates the amount of infectious 
phage particles by a factor of 2-10.  
 
2. Calculate the concentration of phage in virions/ml from the difference between A269 and 
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A320 as follows:  
particle phagemidor  ebases/phag ofnumber 
106)( virions/ml
16
320269 ×⋅−= AA  
 
(VCSM13 = ~12’500 bases, pMPAG3_N3C = ~ 4’500 bases) 
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Titering and propagating phagemid particles 
• It is important that whenever working with bacteria harboring the phagemid pMPAG3 the 
chloramphenicol concentration should not be above the recommended 10 µg/ml. Higher 
concentrations will strongly reduce transformation and infection efficiency, phagemid 
particle production and growth of host bacteria.  
• After transformation or infection with phagemid pMPAG3 recovery in non-selective media 
for 1 h is essential before plating on or growing in selective media to allow accumulation of 
the resistance conferring protein (CAT). 
• For more complete suppression of the lac-promoter of pMPAG3 under non-induced 
conditions, 1% glucose is added to all agar plates used. 
• Determining the concentration of viable phagemid particles involves infection of bacteria 
and counting of resulting antibiotic-resistant colonies (colony forming units per ml, cfu/ml) 
(Protocol 06).  
• Due to the lack of the genes (on phagemids) needed for replication as phage particles, 
titering for plaque forming units (Protocol 02) cannot be applied for phagemid particles. 
• Each phagemid particle preparation will contain helper phage particles. In theory, the 
reduced efficiency of the helper phage packaging signal should significantly reduce the 
number of helper phage particles in any phagemid preparation. However, the number of 
helper phage can sometimes equal, or exceed, the number of phagemid particles, which 
can significantly compromise subsequent selections15. We never observed such excessive 
numbers of helper phage particles in our phagemid particle preparations. Nevertheless, we 
recommend when titering phagemid particle preparations for cfu on cam agar plates always 
to titer for helper phage particles on kan agar plates in parallel. The ratio of cfu (kan) to cfu 
(cam) should be below one (concentration of viable helper phage particles will be strongly 
overestimated (for explanation see p. 209)). 
• A convenient alternative to determine the concentration of phage or phagemid particle 
preparations is an estimation of concentrations by absorbance (Protocol 05). However, 
calculations based on absorbance normally overestimate the concentration of viable, 
infective particles. 
• Different protocols for the amplification phagemid particles will be given in this manual:  
→ Protocol 07: Amplification of monoclonal phagemid particles  
→ Protocol 08: Amplification of a library of phagemid particles  
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→ Protocol 13, 14: Two methods for the amplification of a polyclonal selection output of 
phage paritlces 
→ Protocol 16: Amplification of monoclonal phagemid particles in a 96-well format for 
screening  
• General information for the production of DARPin-displaying phagemid particles: 
→ IPTG induces the expression of the p3-DARPin fusion protein and thus ensures their 
display (0.2 mM IPTG is sufficient for full induction). 
→ Coinfection with helper phage VCSM13: There is no need to add kan to select for helper 
phage coinfected cells since helper phage particles are provided in excess over cells 
(>20 x multiplicity of infection). Addition of kan reduces cell growth and phage particle 
yield (In case of kan addition add final concentration of 12.5 µg/ml one hour after 
VCM13 addition. Not recommended.) 
• A typical yield of phagemid particles in the supernatant of XL1-Blue phage cultures grown in 
2YT would be 1011-1012 phagemid particles/ml. 
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Protocol 06 Phagemid titration by colony forming units (cfu) 
Comments 
• This is a procedure to determine the phagemid or helper phage titers in terms of colony 
forming units (cfu) of a phage solution by counting the number of infectious phage particles 
either containing the phagemid or the helper phage genome, respectively.  
• For helper phage (VCSM13), values obtained can vary strongly with the time of recovery in 
solution (helper phages will be propagated from infected cells short time after infection). 
Equipment and Reagents (see p. 278 ff. for details) 
• E. coli XL1-Blue log-phase culture 
(Protocol 01)  
• Phagemid particle solution to be titrated 
• 96-deep well plate 
• 2YT/tet/cam agar plates (square) 
• 2YT/kan agar plates (square) 
Method 
Day 1,2 
1. E. coli XL1-Blue plating and pre-culture (Protocol 01). 
Day 3  
2. Prewarm 2YT/tet/cam and 2YT/kan agar plates to 37°C. 
Keep lid ajar to allow plates to dry. 
3. Prepare E. coli XL1-Blue log-phase culture (Protocol 01).  
4. Perform serial dilutions of phagemid particles in 2YT media down to about 103-105 
phage/ml. 
See below for 96-well plate titration and recommended dilutions for a phage sample 
prepared in Protocol 04. 
5. For each phage dilution, mix 0.1 ml of phage with 0.9 ml of log-phase XL1-Blue cells. 
6. Incubate for 1 h at 37°C with shaking. 
Incubation for 1 h is essential before plating on selective media to allow accumulation of 
the resistance conferring proteins 
7. Plate on 2YT/tet/cam (phagemid) or 2YT/kan (helper phage) agar plates.  
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By dispensing 10 µl of each sample onto the upper part of sloped (~ 45°) 2YT agar 
plates. The applied 10 µl drop should slowly run down the plate, but not reach its 
bottom. A maximum of 12 samples can be applied per square plate. 
8. Check log-phase XL1-Blue cells for contamination by plating 10 µl on a 2YT/tet/cam and a 
2YT/kan agar plate as described in Step 7. 
9. Incubate plates overnight at 37°C. 
Incubation of up to 24 h is needed for the 2YT/kan (helper phage) agar plates. 
Sometimes, smaller and larger colonies can be observed on 2YT/kan agar plates (no 
reason for concern). 
10. Count colonies at an appropriate dilution and calculate cfu/ml for each phage, phagemid 
solution. 
Drops applied in Step 7 should result in a lane of colonies that can be counted. 
 
11. If you have multiple samples to be titrated, serial dilutions may be performed in 96-deep 
well plates using a multichannel pipette. Clean pipette tips must be used for each dilution 
step.  
 
Figure 4: 96-well plate titration 
96-well plate titration and recommended dilutions for a phage particle sample prepared in 
Protocol 04. (dilutions for initial phage particle concentrations ranging from 1010 to 1013 
cfu/ml) 
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Protocol 07 Phagemid particle amplification from single colonies 
Comments 
• This protocol allows the medium scale production of individual phagemid clones in a 50 ml 
scale and should yield about 50 ml of supernatant containing 1011-1012 cfu of phagemid 
particles per ml which can then be further purified as described in Protocol 04. 
Equipment and Reagents (see p. 278 ff. for details) 
• VCSM13 helper phage stock (Protocol 
03) 
• 2YT/cam/tet agar plates with plated cells 
harboring the phagemid to be analyzed 
(Protocol 06) 
• 2YT/tet/cam media 
• 2YT/tet/cam/Glu media  
• IPTG 
• Culture tubes (14 ml) 
• Culture flasks, non-baffled (300 ml) 
Method 
Day 1 
1. Inoculate 5 ml of 2YT/tet/cam/glu with a single colony of E. coli XL-1 Blue harboring the 
phagemid to be analyzed. Grow overnight at 30°C with shaking. 
Day 2 
2. Inoculate 5 ml of fresh 2YT/tet/cam with the overnight cultures at a ratio of 1:100 (OD600 = 
0.04 - 0.06) and grow at 37°C to an OD600 of 0.5 with shaking (2-3 hours). 
3. Dilute cells 1:10 in prewarmed 50 ml fresh 2YT/tet/cam containing IPTG at 0.22 mM and 
10 minutes later add VCSM13 helper phage to a final concentration of 1010 pfu (plaque 
forming units) per ml and grow overnight at 37°C with shaking. 
Do not grow more than 16 h. 
Day 3 
4. Final cell density obtained should be between OD600 = 3-6. Precipitate and purify the 
phagemid particles displaying DARPins as described in Protocol 04. Resuspend in PBS-
G (~ 1:20 of cell culture volume) or buffer needed for further experiments to a final 
concentration of about 1013 phage/ml. 
5. Determine concentrations of viable phagemid particles by titration on E. coli XL1 Blue 
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(Protocol 06) or estimate concentrations of phage particles by UV absorption (Protocol 
05). 
6. The phagemid solution may be used directly or can be stored at 4°C for several days or at 
-80°C (flash freeze in liquid nitrogen) for several years. 
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Protocol 08 Phage library repropagation 
Comments 
• This protocol is optimized for the DARPin PD library #1 and allows their repropagation to 
produce fresh DARPin displaying phage particles that can be used immediately in selection 
experiments. Alternatively, the repropagated DARPin PD library may be stored at -80°C for 
later use. 
• This protocol is sufficient for libraries with diversities less than 1 x 1011 to ensure that 
diversity of the library is not reduced during amplification. 
• Phagemid particles displaying functional DARPins can be stored in an infectious state at 
-80°C for years. The functionality of the displayed DARPins is not expected to decrease 
under these storage conditions. Therefore, it is recommended to prepare large library 
stocks of displaying phage particles which can be tested for functionality and then be used 
for further selections. 
• Fresh stocks of the library should always be prepared form the primary library by 
repropagation in E. coli. 
• It is important that the number of repropagated unique phagemid particles is higher or at 
least equal to the size of the primary library. 
• It is important to test the amplified library for functionality: 
→ Quantify cfu and pfu of the new phage library stock 
→ Analyze display levels of DARPins by Western-Blotting as described by Steiner et al. 12 
• When doing the first selection with the new phage library stock include control target 
protein for which fast and good enrichment of specific binders after two to three rounds is 
known (e.g. control target human IgG1_Fc). In parallel perform identical selection rounds 
using an old batch of the library as positive controll. 
Equipment and Reagents (see p. 278 ff. for details) 
• Primary DARPin PD library #1stock 
• VCSM13 helper phage stock (Protocol 
03) 
• E. coli XL1-Blue log-phase culture 
(Protocol 01) 
• PBS-G 
• 2YT/tet media 
• 2YT/tet/cam media 
• IPTG 
• 2YT/tet/cam agar plates 
• 2YT/kan agar plates 
Phage display manual   225 
 
Method 
Day 1,2 
1. Determine the infectivity titer of the phage library stock (Protocol 06). 
2. E. coli XL1-Blue plating and pre-culture (Protocol 01). 
Day 3 
3. Prepare 400 ml of E. coli XL1-Blue log-phase culture (Protocol 01). 
Ideally, use a 2 l non-baffled flask with shaking at 200 rpm (shaking radius 50 cm).This 
corresponds to a total of about 1 x 1011 cells (E. coli XL1-Blue at OD600 = 1 contains 
about 5 x 108 cfu/ml). Check for contamination of log-phase XL1-Blue cells by plating 
on a 2YT/tet/cam agar plate and a 2YT/kan agar plate. 
4. Add 1 x 1011 infective phagemid particles (cfu) of the library stock and incubate at 37°C for 
30 min without shaking. 
5. Incubate the culture at 37°C for an additional 30 min with shaking. Remove a small aliquot 
to determine the efficiency of infection by titering 10 µl of 10-4 to 10-6 dilutions on selective 
media (2YT/cam/tet and 2YT/kan agar plates). 
6. Transfer 100 ml culture to each of four 5 l flasks containing 1 l of 2YT/tet/cam media and 
incubate at 37°C to an OD600 = 0.5. 
Ideally, use a 5 l non-baffled flask with shaking at 200 rpm (shaking radius 50 cm). 
7. Add IPTG to 0.2 mM and VCSM13 helper phage to 1010 phage/ml and grow overnight at 
37°C with shaking. 
Do not grow for more than 16 hours. 
Day 4 
8. Final cell density obtained should be between OD600 = 3-6. Precipitate and purify the 
phage particles displaying DARPins as described in Protocol 04. Resuspend the phage in 
PBS-G (1:20 of culture volume) to a final concentration of about 1013 phage/ml. 
The protocol yields 200 ml of repropagated library phage stock. 
9. The library phage stock may be used directly in phage selection experiments. For storage, 
aliquot, flash freeze in liquid nitrogen and store at -80°C. 
10. Determine the phage titer (Protocol 06) of a thawed library phagemid sample (cfu/ml) and 
use this value for the selections. 
11. After thawing, the DARPin-displaying phage particles should be used immediately in 
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phage selection experiments. 
12. Perform test experiments with repropagated library as described in the introduction of this 
chapter. 
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Protocol 09 “In solution-amplification” of selection output 
Comments 
• After each round of selection the eluted pool of phage particles is amplified prior to the next 
round of selection by passage through E. coli. 
• In order to maintain diversity use an excess of log-phase XL1-Blue over eluted phage 
particles to amplify each individual member of the eluted pool. This is most critical for the 
first selection round. 
• “In solution-amplification”: Amplification of the polyclonal phage particles eluted from a 
selection round can be done by directly growing the infected cells in selective liquid media, 
followed by infection with helper phage and subsequent phage production. This procedure 
allows performing a selection round each 24 hours. The potential risk when applying this 
method is, that, due to growth advantage or disadvantage, not every clone will be 
identically amplified and, therefore, the selection biased. Although we never observed any 
negative effects of direct “In solution-amplification” they can not be completely excluded. 
We recommend this method since we successfully selected binders against more than nine 
different target proteins by using direct “In solution-amplification”. 
• Alternatively, plate cells on large 2YT/tet/cam agar plate for “On plate-amplification” as 
described in Protocol 10. 
Equipment and Reagents (see p. 278 ff. for details) 
• Helper phage VCSM13 (stock from 
Protocol 03) 
• E. coli XL1-Blue log-phase culture 
(Protocol 01) 
• 2YT/tet/cam media 
• 2YT/tet/cam agar plates (square) 
• 2YT/kan agar plates (square) 
Method 
1. To each 100 µl neutralized eluate from the respective selection round (Protocol 13 or 
Protocol 14), add 1 ml of the E. coli XL1-Blue log-phase culture. 
Dilute the eluate in at least 10-times larger volume of the log phase culture to guarantee 
proper infection. 
2. Incubate the culture for 30 min at 37°C without shaking and 30 min at 37°C with shaking. 
If 50 ml polypropylene tubes are used, allow sufficient oxygen supply by not closing the 
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lid completely and fixing it with tape. 
3. For monitoring enrichment and for controlling proper infection, the phagemid titers of the 
eluate should be determined by plating 10 µl of 10-1 to 10-4 dilutions (first selection round) 
and 10-2 to 10-5 dilutions (later selection rounds) of the culture on 2YT/tet/cam and 2YT/kan 
agar plates. 
For the first round 104 - 107 and for later rounds 105 – 109 eluted phagemid particles are 
expected. Check for contamination by plating 10 µl of log-phase XL1-Blue cells on a 
2YT/tet/cam and a 2YT/kan agar plate. 
4. Dilute infected cells 1:10 in prewarmed fresh 2YT/tet/cam (results in OD600 of about 0.1) 
and incubate in a non-baffled shaker flask at 37°C with shaking for 4-5 hours. 
The infected cells are grown in solution in the presence of chloramphenicol to select 
against uninfected and helper phage containing cells. During the recovery of 4-5 hours 
the cells infected with a phagemid will divide without producing phage particles. With 
the low amount of phages eluted in the first selection round (possibly also later rounds) 
it would take the culture very long to reach log-growth phase (OD600 = 0.5) where helper 
phage co-infection is done normally, nevertheless monitor OD600 of the culture.  
5. Add IPTG to 0.2 mM and 10 minutes later VCSM13 helper phage to 1010 pfu/ml and grow 
overnight at 37°C with shaking. 
Do not grow for more than 16 hours. 
Day 2 
6. Final cell density obtained should be between OD600 = 3-6. Precipitate phage particles as 
described in Protocol 04 and continue with selection (Protocol 13 or Protocol 14). 
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Protocol 10 “On plate-amplification” of selection output 
Comments 
• After each round of selection the eluted pool of phage particles is amplified prior to the next 
round of selection by passage through E. coli. 
• In order to maintain diversity use an excess of log-phase XL1-Blue over eluted phage 
particles to amplify each individual member of the eluted pool. This is most critical for the 
first selection round. 
•  “On plate-amplification”: For the amplification of the polyclonal phage particles eluted 
from a selection round the infected cells can be plated and grown on selective agar plates. 
Provided that the cells are plated at low density this approach allows each cell to grow 
individually without growth competition. On the second day colonies are eluted from the 
agar plate and used as inoculum for a phage producing culture. The much lower number of 
cell cycles in liquid culture of the “On plate-amplification” protocol compared to “In solution-
amplification” protocol should reduce the influence of growth advantage or disadvantage of 
certain clones. 
• Alternatively, grow cells in solution “In solution-amplification” as described in Protocol 09. 
Equipment and Reagents (see p. 278 ff. for details) 
• Helper phage VCSM13 (stock from 
Protocol 03) 
• E. coli XL1-Blue log-phase culture 
(Protocol 01) 
• 2YT/tet/cam media 
• 2YT/tet/cam agar plates (square) 
• 2YT/kan agar plates (square) 
• 2YT/tet/cam agar plate (large) 
• 2YT/tet/cam/G media  
• Cell scrapers 
Method 
 
Day 1 
1. To each 100 µl neutralized eluate from the respective selection round (Protocol 13 or 
Protocol 14), add 1 ml of the E. coli XL1-Blue log-phase culture. 
Dilute the eluate in at least 10-times larger volume of the log phase culture to guarantee 
proper infection. 
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2. Incubate the culture for 30 min at 37°C without shaking and 30 min at 37°C with shaking. 
If 50 ml polypropylene tubes are used, allow oxygen supply by not closing the lid 
completely and fixing it with tape. 
3. For monitoring enrichment and for controlling proper infection, the phagemid titers of the 
eluate should be determined by plating 10 µl of 10-1 to 10-4 dilutions (first selection round) 
and 10-2 to 10-5 dilutions (later selection round) of the culture on 2YT/tet/cam and 2YT/kan 
agar plates. 
For the first round 104 - 107 and for later rounds 105 – 109 eluted phagemid particles are 
expected. Check for contamination by plating 10 µl of log-phase XL1-Blue cells on a 
2YT/tet/cam and a 2YT/kan agar plate. 
4. Spin down the culture of Step 2 at 3’300 g for 10 min, resuspend the pellet of cells in 1 ml 
of 2YT and spread on a large 2YT/tet/cam agar plate. Incubate at 37°C overnight. 
Growth of the infected cells on agar plates in the presence of chloramphenicol allows 
each colony to grow individually without any growth competition with other clones 
However, colonies can be quite heterogeneous in size, resulting in different numbers of 
cells for individual clones. 
Day 2 
5. Add 10 ml of 2YT/tet/cam/G media to the plate resuspend the colonies with a cell scraper 
and incubate the eluted cells with shaking at 1’000 rpm for 15 min at 4°C to obtain a 
homogenous cell suspension. Measure OD600 of the cell suspension and inoculate 10 ml of 
2YT/tet/cam with a calculated amount of cell suspension to yield an OD600 = 0.05 - 0.1. 
Grow cells at 37°C with shaking to an OD600 = 0.5 (takes ~ 2 hours). Expand 5 ml of the 
culture into 50 ml fresh prewarmed 2YT/tet/cam containing 0.22 mM IPTG and 10 minutes 
later add VCSM13 helper phage to a final concentration of 1010 pfu (plaque forming units) 
per ml and grow overnight at 37°C with shaking. 
Procedure described above is sufficient to amplify phages from about 2 x 107 individual 
colonies (>10-fold oversampling). If more than 2 x 107 individual colonies were plated 
the protocol should be upscaled (e.g. use 5-fold larger volumes for 108 individual 
colonies). Do not grow more than 16 h. 
Day 3 
6. Final cell density obtained should be between OD600 = 3-6. Precipitate phage particles as 
described in Protocol 04 and continue with selection (Protocol 13 or Protocol 14). 
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Target Presentation 
• Throughout the whole selection procedure it is very important to fix parameters like buffer 
composition, temperature, target presentation,…in order to guarantee target presentation in 
its native state. Only then successful selections of binders against epitopes present on 
native target protein can be enriched. Phage particles and DARPins are stable in most 
buffers (also containing detergents) and over a wide range of temperatures. 
• Targets for the phage display selections can be presented in many different ways. Mostly 
the purified target protein is immobilized but binding selections can also be performed on 
whole cells or even in vivo. 
• The quality and purity of the target protein will strongly influence the selection. 
• Many different methods for immobilization and capturing can be applied. The most 
important point is to keep the target protein in its native conformation during the whole 
selections process. 
• The majority of phage display selections are done on target protein immobilized on a solid 
support or on target protein in solution which is subsequently captured. 
• The lower the additional amount of components needed for immobilization the lower the 
chance to enrich binders directed against these components and not your target protein 
(e.g. immobilization via antibodies binding your target protein or an affinity tag) 
• We strongly recommend the immobilization or capturing of biotinylated target protein via 
biotin binding proteins (NeutrAvidin, streptavidin). This method allows presentation of native 
target protein and almost irreversible immobilization or capturing.  
• Biotinylated target protein can be used for selection on immobilized target protein (Protocol 
13) or selection on soluble target protein (Protocol 14) 
• Protocols for chemical biotinylation (Protocol 11) and immobilization of biotinylated proteins 
(Protocol 12) are described. 
• Alternatively, proteins can be enzymatically biotinylated using an Avi-tag as described by 
Cull and Schatz16 and Scholle 17 or other methods for site specific biotinylation18. 
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Protocol 11 Chemical biotinylation of target proteins 
Comments 
• This protocol describes the chemical biotinylation of a target protein. This procedure is 
recommended to immobilize the target protein in a native conformation for most efficient 
binding and selection of DARPins. 
• Biotin is linked to the exposed amino groups of the target protein by acylation with a 
biotinylating reagent. N -Hydroxysulfosuccinimide (Sulfo-NHS) efficiently reacts with 
primary amines and is coupled to the biotin moiety by a variable linker (e.g. NHS-LC-Biotin, 
Pierce).  
• Once the biotins are attached, the modified proteins can be immobilized on solid supports 
(Protocol 12) or be captured from solution (Protocol 14). 
• For storage of the biotinylation reagents and additional information see the manufacturer’s 
instructions (Pierce). 
• The amount of biotinylation is a very critical point for the selection. Optimal would be a 
single biotin attached to each protein. A too high degree of biotinylation leads to the 
blocking of epitopes or even the inactivation of the protein. On the other hand, incomplete 
biotinylation leads to an unconjugated fraction of the protein which is not accessible for 
capturing or immobilization. In "selection on immobilized target protein" (Protocol 11), 
unconjugated protein should not interfere as long as the streptavidin-, NeutrAvidin-coated 
tube or well is charged with an excess of biotinylated protein and carefully washed. In 
"selection on soluble target protein" (Protocol 12), reaction of target phage with 
unconjugated protein (making a complex that cannot be subsequently "captured" on 
streptavidin-coated beads) competes against reaction with conjugated protein (making a 
complex that can be captured); if target phage are limiting, this side-reaction can reduce 
the yield. This reduction in yield is most problematic in the first selection round but in most 
cases, however, not severe enough to interfere noticeably with affinity selection. 
• The use of a 20-fold molar excess of biotinylating agent relative to an antibody molecule 
leads to the incorporation of approximately 6 biotin moieties per protein molecule. Such 
antibodies are effective in biopanning. Some proteins other than antibodies-particularly 
low-molecular-weight proteins may be inactivated by such high-level of biotinylation 
(blocking of epitopes by the biotin moiety). If you are uncertain, it may be advisable to 
biotinylate to a lesser extent. For example, we biotinylated human IgG1 Fc (amino acid 
P100 - K330) and Her2 (amino acid S1 - N509) by using a 4- respectively 6-fold molar 
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excess of biotinylating agent still getting good results for the selections.  
• Test the biotinylated protein by ELISA or Western blotting. A good possibilty to quantify the 
percentage of protein having a biotin moiety attached is a pull down experiment using 
streptavidin-coated beads followed by western blotting. Detect protein in the supernatant, 
wash and elution fraction with streptavidin-AP conjugate and additionally, with an antibody 
directed against target protein or tag of the protein. For quantitation of biotinylation the 
EZ™ Biotin Quantitation Kit (HABA assay; Pierce) can be used, but concentrations of 
biotinylated target protein are mostly below the detection limit of the assay. 
• Biotinylated control target protein (human IgG1 whole molecule) 
Equipment and Reagents (see p. 278 ff. for details) 
• EZ-Link Sulfo-NHS-LC-Biotin or EZ-Link 
Sulfo-NHS-ss-Biotin 
• Dialyis tubing MWCO 3’500 kDa  
• Nap 5 columns  
• PBS (4°C) 
• Streptavidin-AP conjugate 
• antibody directed against target protein 
or tag of the protein 
Method 
All steps should be performed at 4°C using cold buffers. When working with low protein 
concentrations (< 0.5 mg/ml) use siliconized labware to store protein eluates to avoid 
losses due to hydrophobic interactions. 
1. Prepare protein in PBS or other amine-free buffer at pH 7.2 – 8.0.  
The buffer should contain no primary or secondary amines or other groups that might 
react with the reagents, other than those on the protein itself. Proteins in Tris or other 
amine-containing buffers must be exchanged into a suitable buffer (use Nap 5 column 
as described in the supplier’s manual and elute protein with only 0.9 ml of PBS.) 
2. Measure UV spectrum and calculate protein concentration. 
3. Based on the target protein concentration and the sample volume calculate the amount of 
2 mM solution of the biotinylating reagent which is needed to get a x-fold molar excess of 
biotinylating reagent relative to the protein. 
Only a fraction of the biotinylating reagent will react with your protein due to hydrolysis 
and, therefore, inactivation of the NHS group. The excess of biotinylating reagent 
nevertheless determines the degree to which your protein is biotinylated (see 
comments). 
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4. Remove the vial of biotin reagent from freezer and equilibrate it to room temperature 
before opening. Immediately before use, prepare a 2 mM solution of the biotin reagent: 
e.g. for EZ-Link Sulfo-NHS-LC-Biotin add 800 µl of PBS to 1 mg of reagent. 
5. Quickly add the appropriate calculated volume (Step 3) of 2 mM biotin reagent solution to 
the protein solution and incubate reaction on ice for two hours. 
6. Carefully remove excess of non-reacted and hydrolyzed biotin reagent that remains in the 
solution. First use a Nap 5 column as described in the suppliers manual and elute protein 
with 1 ml of PBS. Then dialyze eluate twice against 200-fold volume of PBS (MWCO of 
3’500 kDa of the dialysis tubing is sufficient to remove biotin reagent.) 
Complete removal of free biotin is essential for successful selections 
7. Measure UV spectrum and calculate protein concentration. 
8. For storage at -80 °C add 10% (v/v) glycerol, sterile filter protein solution (0.22 µm), aliquot 
and freeze in liquid N2. 
9. The degree of biotinylation of the target protein should be controlled as described in the 
comments.  
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Protocol 12 Immobilization (Coating of plates and tubes) 
Comments 
• This protocol describes the native immobilization of a target protein in MaxiSorp 96-well 
plates or MaxiSorp Immunotubes by using a biotin moiety attached to the target. It is 
recommended to immobilize the target protein in its native conformation for most efficient 
binding and selection of DARPins. 
• Different biotin-binding proteins can be used for the immobilization of biotinylated proteins: 
NeutrAvidin a deglycosylated form of avidin with low background binding or Streptavidin, a 
on the primary structure level unrelated protein, isolated from Streptomyces avidinii. 
• Alternatively, a target protein may directly be coated to plastic surfaces. This leads to 
partial denaturation of the target. Nevertheless, there may be still enough native epitopes 
present allowing efficient DARPin binding. For this purpose you can use the protocol as 
described below and directly coat your target protein instead of NeutrAvidin. 
• Cover the 96-well plates during all incubations steps with a lid or an appropriate plastic 
seal. 
• For ELISA, appropriate positive and negative control should be included. (control target 
protein IgG1 can be directly immobilized or biotinylated as described in Protocol 11 and 
then immobilized via biotin-binding proteins) 
• Immobilize control target protein (human IgG1 whole molecule) 
Equipment and Reagents (see p. 278 ff. for details) 
• MaxiSorp Immunotubes 
• Stoppers for Immunotubes 
• MaxiSorp 96-well plate  
• Tween20 (25%) 
• PBS 
• NeutrAvidin (300 x) or alternatively Strp 
(300 x) 
• PBS-T 
• PBS-TB 
• Shaker for 96-well plates 
• Equipment for end-over-end rotation 
Method 
Instructions for Immunotubes are given in brackets. 
Day 1 
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1. Coat a MaxiSorp 96-well plate with 0.1 ml per well of 66 nM NeutrAvidin (4 µg/ml, 1:300 
dilution of NeutrAvidin (300x) stock solution) in PBS overnight at 4°C. (for MaxiSorp 
Immunotubes, use 4 ml of 66 nM NeutrAvidin, incubate standing upright) 
The amount of NeutrAvidin in solution is sufficient for maximum high density coating of 
MaxiSorp material. Alternatively, incubate for 1 h at RT. NeutrAvidin may be substituted 
by streptavidin (alternated use is recommended for the selection on plates, Protocol 
13) 
Day 2 
2. Empty the plate and blot it dry on stacked paper towels. Add 300 µl/well of PBS-TB 
blocking buffer and incubate the plate at room temperature (RT) with orbital shaking (900 
rpm) for 1h. (For MaxiSorp Immunotubes, use 4 ml PBS-TB, close tube with stopper and 
incubate with end-over-end mixing) 
3. Wash the plate by emptying the plate as in Step 2, adding of 300 µl/well of PBS-T wash 
buffer and vortexing of the plate 5 seconds. Repeat wash cycle 3 times. (For MaxiSorp 
Immunotubes, rinse 4 times with PBS-T, wash stopper) 
4. Empty the plate as in Step 2. Add 100 µl/well of 0.1 µM biotinylated target protein in 
PBS-TB (or respective buffer needed for target protein) and incubate the plate at RT/4°C 
(dependent on target protein) for 1 h. (For MaxiSorp Immunotubes, use 4 ml of 0.1 µM 
biotinylated target (minimum volume 0.4 ml of 1 µM biotinylated target), close tube with 
stopper, incubate with end-over-end mixing) 
This is an excess of biotinylated target protein, compared to the NeutrAvidin you 
immobilized, and the excess can be reduced. The more of target protein you get 
immobilized, the better for the selection process. For screening by ELISA you can 
easily reduce the amount of target protein immobilized to 100 µl/well of 15 nM 
biotinylated target protein. A pre-experiment with serial dilutions may be needed for the 
determination of minimal amounts of biotinylated target protein needed to detect 
binding signal over background. For ELISA prepare appropriate control wells by 
applying biotinylated control target protein (IgG1) or just PBS-TB to these wells.  
5. Wash the plate or tube as in Step 3. 
6. Proceed with selection on immobilized target protein (Protocol 13) or ELISA (Protocol 17 
and Protocol 20) 
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Affinity selection of DARPins 
• This chapter describes the selection of DARPins from DARPin-displaying phage particles 
that recognize a specific target protein. The library of DARPin-displaying phage particles is 
exposed to immobilized target protein (Protocol 13) or soluble target protein (target protein 
in solution, Protocol 14) which is then subsequently captured. Both methods allow phage 
particles with affinity for the target protein to bind while the others not binding the target 
protein are washed away. The selected DARPin-displaying phage particles are amplified in 
host bacteria to create an enriched pool of phage particles with affinity for the target protein 
which can then be used as input for the next selection round.  
• Throughout the whole selection procedure it is very important to fix parameters like buffer 
composition, temperature, target presentation,…in order to guarantee target presentation in 
its native state. Only then successful selections of binders against epitopes present on 
native target protein can be enriched. Phage particles and DARPins are stable in most 
buffers (also containing detergents) and over a wide range of temperatures. 
• Optimal selection conditions can vary a lot with the target protein used and each of the two 
strategies described above has its advantages and disadvantages. Generally, selection on 
immobilized target protein gives higher recovery of phage particle in the first selection round 
and is cheaper, but the risk of selecting unspecific binders is much higher for this method. 
For selection on soluble target protein, we never observed an enrichment of background 
binders and, additionally, by lowering the concentration of target protein during selection 
high affinity binders can be favored. The best combination in our hands is to perform 
the first selection round on immobilized target protein followed by the further 
selection rounds on soluble target protein. 
• Multiple rounds of selection are needed to enrich specifically binding phage above the 
background yield of non-binding phage. It is expected that after 2 to 4 selection rounds 
significant enrichment of specifically binding phage particles can be observed. 
• Selection on target protein which is biotinylated on accessible amino groups (Protocol 11) 
is very convenient due to the native, rapid and irreversible immobilization and capturing 
using biotin binding proteins such as NeutrAvidin or streptavidin. The protocols described 
below are based on biotinylated target protein but can be adapted to other immobilization or 
capturing methods. 
• Because of monovalent phage display, only a minor part of produced phage particles carry 
a displayed-DARPin and the corresponding phagemid. Thus, about 1000 times more 
chloramphenicol resistant cfu than the transformed library size should be applied to 
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represent all clones of interest in the first round. It is thus recommended to use about 2 ml 
of the Lot #1 (25.01.2006, 1.6 x 1013 cfu/ml) of the DARPin PD-library #1 as input phage for 
the first selection round to cover the full diversity (transformed library size 2.6 x 1010 cfu, 
functional library size 1.1 x 1010 cfu, for details see Appendix data sheet: PD library #1) of 
the library.  
• The stringency of a selection round determines more or less the yield of eluted phage 
particles. Since in the first selection round every clone will only be represented a few times 
low stringency leading to high yield should be applied. Every clone that is lost in the first 
round can never be recovered. In the subsequent rounds every clone will be represented by 
hundreds to thousands of phage particles and, therefore, stringency can be increased. 
• In selection rounds following the first round using about 1011-12 chloramphenicol resistant cfu 
of amplified phage are enough to oversample the selected diversity by far. 
• Due to the differences in “selection volume” and “selection stringency”, independent 
protocols for round one and subsequent rounds will be described. 
• It is very important to avoid carry over of input phage particles to late washing steps or to 
the eluted phage particles (each microliter of the input phage solution will contain 102 – 105 
times more phage particles than the total amount of phage particles eluted after a selection 
round) 
• There are two methods for amplification of the eluted pool of phagemid particles after a 
selection round: “In solution-amplification” (Protocol 09) and “On plate-amplification” 
(Protocol 10). 
• For the quantification of enrichment see p. 252. 
• For background enrichment and epitope focusing see “Troubleshooting” p.276. 
• To perform a model selection spike phagemid particles displaying the DARPin (I_19) at a 
ratio of 1:100 into a sample of the phage library particles. Perform one round of selection on 
control target protein (human IgG1 whole molecule) which should enrich I_19 to almost 100 
%. 
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Figure 5: Work flow of Protocol 13 
Schematic representation of the workflow for a selection round on immobilized target 
protein. Estimation of time needed for the respective steps is given in brackets. For the first 
selection round pre-panning is omitted. 
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Protocol 13 Selection on immobilized target protein 
Comments 
• This protocol describes the selection of DARPins from DARPin-displaying phage particles 
on target protein attached to a solid support: immunotube (MaxiSorp Immunotube) or plate 
(MaxiSorp 96-well plate). 
• The protocol described is based on biotinylated target protein but can be adapted to other 
immobilization methods. The DARPin-displaying phage particles are exposed to the target 
protein which is immobilized via a biotin binding protein for the same amount of time. To 
reduce selection of NeutrAvidin binders it is recommended to alternate in the selection 
rounds between NeutrAvidin and streptavidin (different on sequence and structure level). 
• Due to the large volume of the input phage library in the first round the selection is 
performed in a target protein coated immunotube whereas for the later rounds about 4 
wells of a 96-well plate for each target protein are sufficient. 
• See general phage working rules (p.201) for removal of phage solutions. 
Equipment and Reagents (see p. 278 ff. for details) 
• Helper phage VCSM13 (stock from 
Protocol 03) 
• E. coli XL1-Blue log-phase culture 
(Protocol 01) 
• Target protein coated immunotube for 1st 
round (NeutrAvidin) (Protocol 12) 
• 4 target protein coated wells for >1st 
round (alternate Streptavidin, 
NeutrAvidin) (Protocol 12) and wells for 
background binding to determine 
enrichment factors. 
• Blocked immunotube for >1st round 
(prepanning) 
• glycine (200 mM, pH 2) 
• Tris/base (2 M) 
• PBS-T 
• PBS-TB 
• triethylamine (100 mM) (prepare on the 
day used) 
• Tris/HCl (1 M, pH 7.4) 
• Tween20 (25%) 
• BSA (20%) 
• 2YT/tet/cam agar plates (square) 
• 2YT/kan agar plates (square) 
• PBS-G 
• PEG/NaCl (5x) 
• Culture tubes (14 ml) 
• Polypropylene tubes (50 ml) 
• Equipment for end-over-end rotation 
• For selection output amplification see: 
Protocol 09, Protocol 10 
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Method 
Day 1,2 
1. E. coli XL1-Blue plating and pre-culture (Protocol 01). 
2. Coat immunotube (Protocol 12). 
3. Book shakers, prepare Equipment and Reagents (see p. 278 ff. for details) 
 
Day 3 
4. Prewarm and dry 2YT/cam/tet and 2YT/kan agar plates at 37°C. 
Keep lid ajar to allow plates to dry. 
5. Prepare E. coli XL1-Blue log-phase culture (Protocol 01). 
For each selection you will need 13 ml of the E. coli XL1-Blue log-phase culture. 
Inoculate at the ratio calculate from the time needed for the selection experiment and 
time needed for the cells to grow into the log-phase (see Protocol 01). 
6. Prepare target protein coated immunotube (Protocol 12). 
7. Wash the tube by emptying the tube, blotting it dry on stacked paper towels and rinsing 
with 4 -5 ml of PBS-T wash buffer. Repeat wash cycle 4 times. (wash stopper carefully) 
8. Add 2-3 ml of DARPin-displaying phage solution to the tube, adjust with PBS-TB to 4 ml 
and add BSA and Tween 20 to a final concentration of 0.2% and 0.1%, respectively. 
Input of DARPin PD library should be 1000-fold higher than actual library size to cover 
the full library diversity (see above). More DARPin-displaying phage particles or other 
buffer conditions than the storage buffer of the phage library (PBS-G) can be used by 
simply precipitating the phage particles as described in Protocol 04 prior to the 
selection 
9. Cap the tube, close with parafilm, and incubate with end-over-end mixing on a rotary wheel 
at RT or 4°C for 2 h. 
Temperature of the binding reaction should be chosen depending on the target protein 
stability. If uncertain do at 4°C. 
10. Remove the solution of phage and rinse the tube ten times as described in Step 7. 
Stringency of washing should be kept low in the first selection round to recover all 
binders (See above). If binding was done at 4°C use cold buffer for washing. 
11. Add 500 µl of triethylamine (100 mM) (prepare on the day used) for elution. 
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12. Cap the tube (use a new cap), and incubate with end-over-end rotation for 5-8 min. 
Longer incubation will reduce the infectivity of the phage particles 
13. Transfer the solution to a 50 ml polypropylene tube containing 250 µl of Tris/HCl (1 M, pH 
7.4) for neutralization. Mix to neutralize the triethylamine and keep on ice. 
In round 1 an additional second elution is performed to recover all binding phage. 
14. For second elution add 500 µl of glycine (200 mM, pH 2) to the tube.  
15. Cap the tube, and incubate with end-over-end mixing on a rotary wheel for 10 min. 
16. Transfer the solution to the same 50 ml polypropylene tube as the first elution and add 45 
µl of Tris/base (2 M) for neutralization. Mix to neutralize and keep on ice.  
Check pH (spot 1 µl of neutralized eluate on pH indicator paper), should be about 7. 
After neutralization the phage solution can be kept at 4°C for a few days before 
proceeding to the next step. 
17. Amplify the eluted pool of phagemid particles and determine the phagemid titers of the 
eluates: see “In solution-amplification” (Protocol 09) or “On plate-amplification” (Protocol 
10)  
18. In the mean time titrate input phage solution as described in Protocol 06. 
19. For second selection round prepare: E. coli XL1-Blue pre-culture (Protocol 01) coat wells 
of MaxiSorp plate (Protocol 12) for target protein and for background binding. 
4 wells coated with target protein are sufficient for the second selection round. 
 
Day 4  
phage preparation (parallel to step 23 - 26) 
20. Calculate the elution-titre of the selections by counting the colonies on the plates from the 
different dilutions (check control plate for E. coli XL1-Blue log-phase culture 
contaminations) 
21. Precipitate and purify the amplified phage particles displaying DARPins as described in 
Protocol 04. Resuspend the phage in 1/20 of supernatant volume PBS-G (results in about 
1012-1013 phage/ml). 
Quantify the amount of phage particles obtained by absorbance as described in 
Protocol 05. 
22. The amplified phage pool may be used directly for the next round of selection. For storage, 
aliquot, flash freeze in liquid nitrogen and store at -80°C. 
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For further analysis keep about 50 µl of the phage pool at 4°C (e.g. pool ELISA 
analysis) 
2nd selection cycle 
23. Prewarm and dry 2YT/cam/tet and 2YT/kan agar plates at 37°C. 
Keep lid ajar to allow plates to dry. 
24. Prepare E. coli XL1-Blue log-phase culture (Protocol 01). 
For each selection you will need 5 ml of the E. coli XL1-Blue log-phase culture. 
Inoculate at the ratio calculate from the time needed for the selection experiment and 
time needed for the cells to grow into the log-phase (see Protocol 01). 
25. Prepare target protein coated wells (4 wells) (Protocol 12) and wells for background 
binding and blocked immunotubes for prepanning. 
26. Wash the plate by empting the plate, blotting it dry on stacked paper towels, adding of 300 
µl/well of PBS-T wash buffer and vortexing of the plate for 5 seconds. Repeat wash cycle 3 
times. 
27. Perform prepanning step by adding 500 µl of DARPin-displaying phage solution form Step 
21 to the blocked immunotube which contains 500 µl of PBS-TB and add BSA and Tween 
20 to a final concentration of 0.2% and 0.1%, respectively. Cap the tube, close with 
parafilm, and incubate with end-over-end mixing on a rotary wheel at RT or 4°C for 1 h. 
28. Add 100 µl DARPin-displaying phage solution from Step 27 to each target protein coated 
well and to a well not containing target protein. 
Always add an aliquot of input phages to a blocked well not containing the target 
protein to determine background binding. 
29. Incubate with orbital shaking at 900 rpm for 1 - 2 hours at RT or 4°C. 
Temperature of the binding reaction should be chosen depending on the target protein 
stability. If uncertain do at 4°C. Binding time can be reduced with selection cycles. 
Remove the solution of phage and wash the plate by empting the plate (rapidly invert the plate 
over a plastic tray, see phage handling p.201 for details), blotting it dry on stacked paper 
towels, adding of 300 µl/well of PBS-T wash buffer and orbital shaking (900 rpm) for 1-2 
min. Repeat wash cycle 12 times. 
Stringency of washing can be increased by longer washing times or increased number 
of wash cycles (e.g. 12 cycles 1-2 min on shaker). If binding was done at 4°C use cold 
buffer for washing. 
30. For elution add 100 µl of glycine (200 mM, pH 2) to each well. 
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31. Incubate with orbital shaking at 900 rpm for 10 - 15 min at RT to elute the phages. 
32. Pool the 400 µl elution solution in a 14 ml polypropylene tube containing 36 µl of Tris/base 
(2 M). Mix to neutralize and keep on ice. 
No additional second elution is needed. Check pH (spot 1 µl of neutralized eluate on pH 
indicator paper), should be about 7. After neutralization the phage solution can be kept 
at 4°C for a few days before proceeding to the next step. 
33. Amplify the eluted pool of phagemid particles and determine the phagemid titers of the 
eluates: see “In solution-amplification” (Protocol 09) or “On plate-amplification” (Protocol 
10)  
34. In the mean time titrate input phage solution as described in Protocol 06. 
35. For third selection round prepare E. coli XL1-Blue pre-culture (Protocol 01) coat MaxiSorp 
plate (Protocol 12) and wells not containing target protein to determine enrichment 
factors. 
Day 5 
36. Phage preparation and 3rd selection cycle as described for the second selection cycle on 
day 4. 
 
Day 6 
37. For monitoring the enrichment the amplified pools may be analyzed by phage ELISA as 
described in Protocol 15 to determine the relative amounts of target binding phage 
particles present in the pools. 
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Figure 6: Work flow of Protocol 14 
Schematic representation of the workflow for a selection round on soluble target protein. 
Estimation of time needed for the respective steps is given in brackets. For the first 
selection round pre-panning is omitted. 
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Protocol 14 Selection on soluble target protein 
Comments 
• This protocol describes the selection of DARPins from DARPin-displaying phage particles 
on soluble target protein. The library of phage particles is incubated with biotinylated target 
protein followed by a capturing of the phage-target protein complexes with streptavidin-
coated magnetic beads. 
• The protocol described is based on capturing of biotinylated target protein with streptavidin-
coated magnetic beads but can be adapted to other capturing methods. 
• Buffers used for the selection can be chosen depending on the target protein. Tween 20 
can be replaced by other detergents and BSA by other proteins. 
• To reduce enrichment of streptavidin binders a prepanning step on blocked streptavidin-
coated magnetic beads should be performed from round two on. Alternatively, avidin 
coated beads could be used in an alternating mode. 
• Target protein concentration can be reduced during the selection procedure to favor 
selection of high affinity clones. For successful selections on a new target protein we 
suggest to use a concentration of about 100 nM for the first three selection rounds. To 
increase the affinity of binders selection steps with reduced target protein concentrations 
can be repeated or added after specific enrichment is observed. 
• Concentration of displayed DARPin and target protein concentration: For a concentration of 
1012 cfu/ml of phagemid particles, containing 10% particles with monovalent display would 
give a DARPin concentration of 166 nM. This value will by far overestimate the 
concentration of target binding DARPins during a selection round. Therefore, it can be 
assumed that even at low nM concentration the amount of target protein should not be 
limiting. We never increased the selection pressure by reducing antigen and used a 100 
nM trough out all the selection rounds. 
• Agglutination of streptavidin-coated magnetic beads is one problem when performing 
selections on soluble biotinylated target protein. The reason is the attachment of multiple 
biotin moieties per protein molecule due to chemically biotinylation which leads to a cross-
linking and, therefore, agglutination of the beads. Proper resuspension of the beads during 
the washing is essential to get rid of background phage particles without affinity for the 
target protein. In this respect enzymatic attachment of a single biotin moiety at defined 
position is the clear advantage of Avi-tagged targets. 
• No experiments to determine background binding are performed (too high costs for 
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magnetic beads), therefore no monitoring of enrichment during the selection cycles is 
possible. The enrichment is quantified after three rounds by performing a polyclonal phage 
ELISA (Protocol 15) 
• See general phage working rules (p.201) for removal of phage solutions. 
Equipment and Reagents (see p. 278 ff. for details) 
• Helper phage VCSM13 (stock from 
Protocol 03) 
• E. coli XL1-Blue log-phase culture 
(Protocol 01) 
• Biotinylated target protein (Protocol 11) 
• Streptavidin-coated paramagnetic beads 
• Magnetic tube holder for 2 ml micro 
tubes 
• Micro tubes (2 ml) 
• Culture tubes (14 ml) 
• Polypropylene tubes (50 ml) 
• Equipment for end-over-end rotation 
• PBS-T 
• PBS-TB 
• Tween 20 (25%) 
• BSA (20%) 
• triethylamine (100 mM) ( prepare on the 
day used) 
• 1 M Tris/HCl 
• 200 mM glycine. (pH 2) 
• Tris/base (2 M)  
• 2YT/tet/cam media 
• 2YT/tet/cam agar plates 
• 2YT/kan agar plates  
• PBS-G 
• PEG/NaCl (5x) 
• For selection output amplification see: 
Protocol 09, Protocol 10 
Method 
Day 1,2 
1. E. coli XL1-Blue plating and pre-culture (Protocol 01). 
2. book shakers, prepare Equipment and Reagents (see p. 278 ff. for details) 
 
Day 3 
3. Prewarm and dry 2YT/cam/tet and 2YT/kan agar plates at 37°C. 
Keep lid ajar to allow plates to dry. 
4. Prepare E. coli XL1-Blue log-phase culture (Protocol 01). 
For each selection you will need 5 ml of the E. coli XL1-Blue log-phase culture. 
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Inoculate at the ratio calculate from the time needed for the selection experiment and 
time needed for the cells to grow into the log-phase (see Protocol 01). 
5. Add 1 ml of PBS-TB to five 2 ml micro tubes in order to block non-specific binding to the 
tube. Incubate with end-over-end rotation for 1 hour at RT. 
Label the tubes with the name of the target protein and B (for binding), W1,2,3 (for 
wash 1,2 and 3) and E (for elution) 
6. In a fresh 2 ml micro tube add 100 µl of streptavidin beads to 1 ml of PBS-TB order to 
block non-specific binding to the beads. Incubate with end-over-end rotation for 1 hour at 
RT. 
To save time this step can also be performed overnight. 
7. Discard the PBS-TB from the blocked binding tube (B). 
8. Add 1.8 ml of DARPin-displaying phage solution, BSA and Tween 20 (final concentration 
of 0.2% and 0.1%, respectively) and biotinylated target protein to 100 nM final 
concentration. Adjust with PBS-TB to 2 ml. 
Input phage particles of DARPin PD library should be 1000-fold higher than the actual 
library size to cover the full library diversity (see above). More DARPin-displaying 
phage particles, other volumes or other buffer conditions than the storage buffer of the 
phage library (PBS-G) can be used by simply precipitating the phage particles as 
described in Protocol 04 prior to the selection. Final concentration of the target protein 
in 2 ml binding solution should not be more than 100 nM to allow complete capturing 
with the streptavidin beads) 
9. Incubate with end-over-end rotation for 1 hour at RT or 4°C. 
Temperature of the binding reaction should be chosen depending on the target protein 
stability. If uncertain do at 4°C. 
10. Draw the pre-blocked streptavidin beads to one side of the tube with a magnetic tube 
holder and discard the supernatant. Add the solution from Step 9 containing phage and 
target protein to the pre-blocked beads, resuspend the beads. 
11. Incubate the tube with end-over-end rotation for 20 min at room at RT or 4°C. 
If beads start to form clots incubate with orbital shaking at 900 rpm (see Step 14). 
12. Centrifuge at 100 g for 10 sec and place the tube in the magnetic tube holder for 1 min. 
Buffers with high viscosity may increase the time needed to capture the beads in all 
steps. 
13. Aspirate the supernatant from the tube. 
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14. Wash the beads by adding of 1 ml of PBS-T wash buffer, short resuspension by pipetting, 
centrifugation at 100 g for 10 sec, placing the tube it the magnetic tube holder for 1 min 
and aspirating the supernatant. Repeat wash cycle 9 times. After every second wash step 
resuspend the beads in 0.1 ml of PBS-T wash buffer and transfer to a fresh pre-blocked 
tube (W1,2,3 and E). By washing the old tube a second time with 0.9 ml of PBS-T and 
transferring it to the fresh tube loss of beads can be minimized. 
Chemically biotinylated target protein with multiple biotin moieties per protein molecule 
attached can lead to cross-linking and, therefore, agglutination of the beads. Careful 
resuspension of the beads (e.g. orbital shaking at 900 rpm for 1 min) is needed to 
remove phages without affinity for the target protein.  
Stringency of washing should be kept low in the first selection round to recover all 
binders (see above). If binding was done at 4°C use cold buffer for washing 
15. Add 200 µl of triethylamine (100 mM) (prepare on the day used). 
16. Incubate with end-over-end rotation for 5-8 min. 
Longer incubation will reduce the infectivity of the phage particles 
17. Centrifuge at 100 g for 10 sec and place the tube in the magnetic tube holder for 1 min. 
18. Transfer the supernatant to a 14 ml polypropylene tube containing 100 µl of Tris/HCl (1 M, 
pH 7.4). Mix to neutralize the triethylamine and keep on ice. 
In round 1 an additional second elution is performed to recover all binding phage. 
19. For the second elution add 200 µl of glycine (200 mM, pH 2) to the tube containing the 
beads. 
20. Incubate with end-over-end rotation for 10 min. 
21. Centrifuge at 100 g for 10 sec and place the tube in the magnetic tube holder for 1 min. 
22. Transfer the supernatant to the same 14 ml polypropylene tube as the first elution and add 
18 µl of Tris/base (2 M). Mix to neutralize and keep on ice.  
Check pH (spot 1 µl of neutralized eluate on pH indicator paper), should be about 7. 
After neutralization the phage solution can be kept at 4°C for a few days before 
proceeding to the next step. 
23. Amplify the eluted pool of phagemid particles and determine the phagemid titers of the 
eluates: see “In solution-amplification” (Protocol 09) or “On plate-amplification” (Protocol 
10)  
24. In the mean time titrate input phage solution as described in Protocol 06. 
25. For the second selection round prepare: E. coli XL1-Blue pre-culture (Protocol 01) 
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Day 4 (2nd selection cycle) 
26. Prepare phages as described in Protocol 13, Step 20 to 22 
27. Step 3 to step 5 as described for the first round. 
28. In two 2 ml micro tubes add 50 µl of streptavidin-coated paramagnetic beads (10 µg/ml) to 
1 ml of PBS-TB. Incubate with end-over-end rotation for 1 hour at RT. 
One tube is used for pre-panning to remove streptavidin-binding phage particles and 
the other one for capturing of the target protein. 
29. With a magnetic tube holder draw the pre-blocked streptavidin beads to one side of the of 
the pre-panning tube and discard the supernatant. Resuspend the beads in 0.6 ml PBS-
TB, add 200 µl of the amplified phage particles from round 1 and adjust with BSA and 
Tween 20 to a final concentration of 0.2% and 0.1%, respectively. 
30. Incubate with end-over-end rotation for 1 hour at RT or 4°C. 
31. With a magnetic tube holder draw the beads of the pre-panning tube to one side of the 
tube.  
32. Discard the PBS-TB from the blocked binding tube and add the phage containing 
supernatant from Step 31. Add biotinylated target protein to 100 nM final concentration 
and adjust with PBS-TB to 1 ml. 
Lower volumes can be used to save target protein. 
33. Incubate with end-over-end rotation for 1 hour at RT or 4°C. 
34. With a magnetic tube holder draw the pre-blocked streptavidin beads to one side of the 
capturing tube and discard the supernatant. Add the solution from Step 32 containing 
phage and target protein to the pre-blocked beads, resuspend the beads. 
35. Perform capturing and washing as described in Step 11 to step 14 of the first round. 
Stringency of washing can be increased by longer washing times or increased number 
of wash cycles (e.g. 12 x 1 min). If binding was done at 4°C use cold buffer for washing. 
36. For elution add 400 µl of glycine (200 mM, pH 2) to the tube.  
37. Incubate with end-over-end rotation for 10 - 15 min. 
38. Centrifuge at 100 g for 10 sec and place the tube in the magnetic tube holder for 1 min. 
39. Transfer the supernatant to a 14 ml polypropylene tube containing 36 µl of Tris/base (2 M). 
Mix to neutralize and keep on ice. 
No additional second elution is needed. Check pH (spot 1 µl of neutralized eluate on pH 
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indicator paper), should be about 7. After neutralization the phage solution can be kept 
at 4°C for a few days before proceeding to the next step.. 
40. Amplify the eluted pool of phagemid particles and determine the phagemid titers of the 
eluates: see “In solution-amplification” (Protocol 09) or “On plate-amplification” (Protocol 
10)  
41. For third selection round prepare: E. coli XL1-Blue pre-culture (Protocol 01) 
 
Day 5 (3rd selection cycle) 
42. Phage preparation and 3rd selection cycle as described for the second selection cycle on 
day 4. 
 
Day 6 
43. For monitoring the enrichment the amplified pools may be analyzed by phage ELISA as 
described in Protocol 15 to determine the relative amounts of target binding phage 
particles present in the pools. 
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Quantifying enrichment 
• There are two possibilities for monitoring the selection process:  
• a) Enrichment factors: For each selection round equivalent amounts of the input phage 
particles have to be applied to the target protein coated wells and to wells not containing 
target protein (e.g. only NeutrAvidin for background binding). The enrichment factor is the 
ratio of input cfu to output cfu on target protein coated wells relative to the ratio of input cfu 
to output cfu on wells not containing target protein. Experimental determination of 
enrichment factors is only advisable from the 2nd round on when doing selections on 
immobilized target protein. When doing selections in solution the costs for magnetic beads 
are too high to do this monitoring. Enrichment factors have the advantage that they can be 
done in parallel during the selection cycles. But when doing selections on multiple targets in 
parallel the amount of work will exceed the capacity of one person.  
• b) Pool ELISA (Protocol 15): A simple method for the quantification of enrichment after 
having performed the actual selection rounds. This method can be performed for many 
different selections in parallel and is advisable even if enrichment factors have been 
determined beforehand. The phage ELISA of the pools of amplified phage particles eluted 
from each round gives the information of how many phage particles are binding to the target 
versus the empty matrix (e.g. only NeutrAvidin). Monitoring enrichment by pool ELISA is 
very convenient and additional information about specificity can be obtained by immobilizing 
respective control proteins or doing competition experiments.  
• For percentage of expected binders in a pool giving positive binding signal on target protein 
see Figure 7:. 
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Protocol 15 Polyclonal phage ELISA 
Comments 
• This protocol allows analyzing polyclonal DARPin-displaying phagemid particles for target 
protein binding by a simple ELISA procedure. 
• This polyclonal phage ELISA procedure can be used to monitor phage enrichments and 
should be performed prior to screening of single clones for specific binding.  
• For ELISA, appropriate positive and negative control should be included (coating of wells 
as described in Protocol 12; Use wells with immobilized target protein for specific binding 
and wells coated with NeutrAvidin (or streptavidin if used during the selection) for the 
control of background binding. In the example described below the target protein is 
immobilized via NeutrAvidin, therefore wells only coated with NeutrAvidin and blocked with 
BSA serve a control for background binding) 
• See general phage working rules (p.201) for removal of phage solutions. 
• If possible make triplicates for each measurement 
 
 
 
 
 
 
 
 
 
 
Figure 7: Example showing polyclonal phage ELISA 
The binding to streptavidin (square, open), NeutrAvidin (square, closed) and antigen 
(triangle, closed) of the initial library and of pools of phage particles after selection rounds 
(R1 to R3) was analyzed by phage ELISA. (a) Selection without enrichment of phage 
particles having affinity for the target protein. (b) Selection with enrichment of background 
binding phage particles. (c) Selection with nice enrichment of phage particles having 
affinity for the target protein. Screening of single clones of R2 and R3 resulted in about 
10% and 90% of target specific clones, respectively. 
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Equipment and Reagents (see p. 278 ff. for details) 
• Target protein and NeutrAvidin or 
strepatavidin coated wells of a MaxiSorp 
96-well plate (Protocol 12) 
• PBS-T 
• PBS-TB 
• anti-M13 antibody HRP conjugate 
• BM Blue POD substrate 
• Shaker for 96-well plates 
• Phage pools from different selection 
rounds to be analyzed. (Protocol 13 or 
Protocol 14) 
Method 
Day 1 
1. Coat wells of MaxiSorp 96-well plate (Protocol 12). 
Day 2 
2. Mix 1 µl of phage pools to be analyzed with 99 µl of PBS-TB in the target protein coated 
wells and in the NeutrAvidin coated wells (Protocol 12) and incubate at 4°C or RT for 1 h 
with orbital shaking (900 rpm).  
1 µl of concentrated phage pools should contain by far enough phage particles to 
obtain a binding signal in the phage ELISA. Applying higher amounts of the phage 
pools increases the risk of obtaining signals out of the linear range (can make 
differentiation between high, low binding signal and background binding impossible). 
3. Wash the wells by empting the plate (rapidly invert the plate over a plastic tray, see phage 
handling for details), blotting it dry on stacked paper towels, adding of 300 µl/well of PBS-T 
wash buffer and orbital shaking (900 rpm) for 1-2 min. Repeat wash cycle 3 times. 
4. Empty the plate as described in Step 3. Add 100 µl of 1:40’000 anti-M13 antibody HRP 
conjugate mAb in PBS-TB per well and incubate at 4°C or RT for 1 h. 
The optimal concentration of the anti-M13 antibody HRP conjugate depends strongly on 
the amounts of phage particles bound per well (in our hands 1:40’000 gives good signal 
in the linear range). Shorter incubation times can be compensated by higher antibody 
concentrations. 
5. Wash wells as described in Step 3. (4 cycles) 
6. Empty the plate as described in Step 3. Add 100 µl of soluble Blue POD substrate and 
quench after a few minutes with 50 µl of 1 M H2S04. 
It is possible to measure the reaction before quenching at OD370 - OD492 but sensitivity 
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is lower. Usually, quenching should be performed after no more than 30 min (1 < OD370 
- OD492). 
7. Measure OD450. 
Measure immediately after quenching. Substrate will precipitate over time making 
accurate measurements impossible. 
8. Decide which pools to be screened on single clone level in the phage ELISA format 
(Protocol 17) or as soluble expressed DARPins (Protocol 20). 
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Screening 
• Once target protein specific binding clones have been enriched individual clones can be 
screened for qualitative binding to the target protein by two different methods: 
• Screening by phage ELISA: The fastest way to get single clone data is to screen on the 
phagemid particle level (Protocol 16 and Protocol 17). This method has the clear 
disadvantage that each positive clone has to be individually subcloned into the expression 
vector pMPAG6 or pDST67 for soluble expression and also no secondary screening by 
SDS-PAGE can be performed (see below). However, for some applications it might be 
advisable to use this method due to the binding functionality of the detection antibody used 
(e.g. anti-M13 antibody HRP conjugate is functional in solutions containing 0.2% DDM in 
which many other antibodies fail). 
• Screening DARPins by ELISA: The second possibility is to subclone the whole selected 
pool to be analyzed into the expression vector pMPAG6 or pDST67 (Protocol 18). The 
ELISA can then be performed directly by using crude E. coli lysate containing soluble 
expressed DARPin (Protocol 19 and Protocol 20). The clear advantage of this method is 
the possibility to directly perform a secondary screening by SDS-PAGE before submitting 
clones for sequencing analysis. 
• Secondary screening by SDS-PAGE (Protocol 21): A frequently encountered problem in 
phage display is the reduction of diversity after two to three rounds of selection. In such a 
case many of the positive clones identified by ELISA will be identical on sequence level. To 
identify positive clones with different sequences by sequencing would be time consuming 
and expensive. One approach to circumvent this is the secondary screening by SDS-
PAGE. Due to high expression level of DARPins, crude cell extracts can be directly 
analyzed. DARPins different on the sequence level do show different running behavior on 
SDS-PAGE (mainly due to their stability differences) and expression patterns. These two 
properties allow identifying clones different on sequence level. Differences in running 
behavior are for N2C not as clearly visible as for N3C (probably due to the generally lower 
stability of N2C compared to N3C). 
• Use phage particle displaying DARPin (I_19) or purified DARPin (I_19) and control target 
protein (human IgG1 whole molecule) in the respective experiments. 
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Protocol 16 Production of phages in the 96-well format 
Comments 
• This protocol allows the production of individual phage clones in the 96-well format 
followed by analysis for target-specific binding by phage ELISA (Protocol 17) and 
subsequent sequencing and subcloning into pDST67 or pMPAG6 for soluble expression. 
Equipment and Reagents (see p. 278 ff. for details) 
• 2YT/cam/tet agar plates with colonies to 
be analyzed (Day 1 this protocol and 
Protocol 01) 
• 96-deep well plates for bacterial cell 
cultures 
• IPTG 
• VCSM13 helper phage stock (Protocol 
03) 
• 2YT/tet/cam media  
• Incubator for 96-well bacterial cell 
cultures 
• Gas permeable adhesive seals  
• Autoclaved toothpicks 
• Parafilm 
Method 
Day 1 
1. Infect 0.9 ml of log-phase XL1-Blue cells with 100 µl of 108 and 109 dilutions of the phage 
pool to be screened (dilutions for phage samples containing about 1013 cfu/ml) and 
incubate for 30 min at 37°C without agitation and then for 30 min at 37° C with shaking. 
2. Plate 100 µl of the infected cells on 2YT/cam/tet agar plates and grow overnight at 37°C. 
These final dilutions of 1010 and 1011 should give numbers of colonies per plate that 
allow easy picking of single ones. 
 
Day 2 
3. Aliquot 0.9 ml of 2YT/cam/tet into each well of a 96-deep well plate (phage plate). 
4. Pick individual colonies into each well and seal the plate by applying a gas permeable 
adhesive seal. 
A simple method that avoids cross-contamination and double inoculation is to seal the 
plate with a piece of parafilm. Pick the colonies with sterile toothpicks and stab them 
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through the parafilm into the medium. The toothpicks can be removed after inoculation 
of all the wells. 
5. Incubate the sealed plate in an orbital shaker (540 rpm) and grow at 37°C for 4 h 
6. Aliquot 1.2 ml of 2YT/cam/tet into each well of a new 96-deep well plate (master plate) 
Transfer 0.05 ml from each well of the phage plate to the corresponding well of the master 
plate using a multichannel pipette. Incubate the sealed plate in an orbital shaker (540 rpm) 
and grow at 37°C overnight. 
7. To each well of the phage plate add 0.2 ml of 2YT/cam/tet containing 1 mM IPTG and 
VCSM13 helper phage (5 x 1010 cfu/ml). 
8. Incubate the sealed plate in an orbital shaker (540 rpm) and grow at 37°C overnight. 
 
Day 3 
9. Spin phage plate at 3’000g for 10 min. The supernatant is now used for the phage ELISA 
(Protocol 17) 
10. Spin master plate at 3’000g for 10 min, empty the plate, blot it dry on stacked paper towels 
and store at -20°C for later preparation of plasmid DNA. 
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Protocol 17 Screening phages by ELISA 
Comments 
• This protocol allows the screening of individual phage DARPin clones for target-specific 
binding by phage ELISA  
• Subcloning for large scale expression is needed and can be very cumbersome for large 
number of clones. If possible do screening of unfused DARPins by ELISA to avoid 
subcloning of single clones (Protocol 18). 
• Phages are expressed as described in Protocol 16. 
• For ELISA, appropriate positive and negative controls should be included 
• See general phage working rules (p.201) for removal of phage solutions. 
Equipment and Reagents (see p. 278 ff. for details) 
• Target protein and NeutrAvidin coated 
MaxiSorp 96-well plate (Protocol 12) 
• PBS-T 
• PBS-TB 
• anti-M13 antibody HRP conjugate 
• BM Blue POD substrate  
• Shaker for 96-well plates 
• 96-well plate containing phage 
supernatants (Protocol 16, Step 9) 
Method 
1. Mix 10 µl of supernatant from Protocol 16, Step 9 with 90 µl of PBS-TB in the target 
protein coated plate and in the NeutrAvidin coated plate (Protocol 12) and incubate at RT 
for 1 h with orbital shaking (900 rpm).  
Use one ELISA plate prepared with immobilized target protein and one NeutrAvidin 
coated plate for the control of background binding. 10 µl of phage supernatant should 
contain by far enough phage particles to obtain a binding signal in the phage ELISA. 
Applying higher amounts of supernatant increases the risk of obtaining signals out of 
the linear range (difficult to differentiate between good and bad binders). 
2. Wash the plate by empting the plate (rapidly invert the plate over a plastic tray, see phage 
handling for details), blotting it dry on stacked paper towels, adding of 300 µl/well of PBS-T 
wash buffer and orbital shaking (900 rpm) for 1-2 min. Repeat wash cycle 3 times. 
3. Empty the plate as described in Step 2. Add 100 µl of 1:40’000 anti-M13 antibody HRP 
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conjugate in PBS-TB per well and incubate at RT for 1 h. 
The optimal concentration of the anti-M13 antibody HRP conjugate depends strongly on 
the amounts of phage particles bound per well (in our hands 1:40’000 gives good signal 
in the linear range). Shorter incubation times can be compensated by higher mAb 
concentrations. 
4. Wash plate as described in Step 2. (4 cycles) 
5. Empty the plate as described in Step 2. Add 100 µl of soluble Blue POD substrate and 
quench after a few minutes with 50 µl of 1 M H2S04. 
It is possible to measure the reaction before quenching at OD370 - OD492 but sensitivity 
is lower Usually, quenching should be performed after no more than 30 min (1 < OD370 - 
OD492). 
6. Measure OD450. 
Measure immediately after quenching. Substrate will precipitate over time making 
accurate measurements impossible. 
7. Prepare plasmid DNA from positive clones using a standard kit (e.g. from Qiagen). Directly 
add resuspension buffer to the respective well of the master plate (thaw plate which was 
stored at -20°C) and resuspend the cell pellets for about 10 min at RT with orbital shaking 
plate (900 rpm).  
8. Submit for sequencing using the primer pUCM13r-57 or odst03 (for details see Appendix 
data sheet: pMPAG3). 
9. Selected clones have to be subcloned from phagemid pMPAG3 into expression vectors 
pDST67 or pMPAG6 (for details see Appendix data sheets) by excising the DARPin 
sequence using the BamHI and HindIII restriction sites of pMPAG3 and subcloning of the 
gel-purified fragment into the corresponding BamHI and HindIII restriction sites of pDST67 
or pMPAG6. 
pDST67 and pMPAG6 introduces an 6xHis-tag to the N-terminus of the DARPin 
allowing efficient Ni-NTA (Qiagen) purification of the DARPin after its high level 
cytoplasmic expression in E. coil XL1-Blue. 
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Protocol 18 Subcloning of phagemid pools into expression plasmid 
Comments 
• This protocol allows the subcloning of the DARPins of a polyclonal phagemid pool 
(pMPAG3) into the expression vector pDST67 or pMPAG6 (for details see Appendix data 
sheets) 
• Both expression vectors introduce an 6xHis-tag to the N-terminus of the DARPin allowing 
detection of the protein in ELISA and efficient immobilized-metal affinity chromatography 
(IMAC) purification of the DARPin after its high level cytoplasmic expression in E. coil XL1-
Blue. 
• Analysis of the single DARPin clones in the expression vector by ELISA (Protocol 20) has 
the advantage that no individual subcloning of positive clones is needed and DARPins are 
tested independently of the phage particle and direct secondary screening by SDS-PAGE 
(Protocol 21) is possible. 
• Restriction enzyme unit (U) definition: The amount of enzyme required to completely digest 
1 µg of substrate DNA (mostly phage λ DNA, see supplier information) in a reaction volume 
of 50 µl in one hour using recommended buffer). 
Equipment and Reagents (see p. 278 ff. for details) 
• BamHI (20 U/µl) 
• HindIII (20 U/µl) 
• NEB2 buffer (10x) 
• Chemically competent E. coli XL1 Blue 
• 2YT/amp agar plates (round or square) 
• CiAP (1u/µl) 
• 1.2% agarose gel 
• T4-Ligase 
• T4-buffer (10x) 
• SOC media 
• Plasmid purification kit 
• DNA purification kit 
Method 
Day 1 
1. Infect 0.9 ml of log-phase XL1-Blue cells with 100 µl of 107 and 108 dilutions of the 
phagemid particle pool to be subcloned (dilutions for phage samples containing about 1013 
cfu/ml) and incubate for 30 min at 37°C without agitation and then for 30 min at 37 C with 
shaking. 
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2. Plate 100 µl of the infected cells on 2YT/cam/tet agar plates and grow overnight at 37°C. 
These final dilutions of 109 and 1010 should give more than 1’000 colonies per plate that 
allow the subcloning the pool without loss of diversity. 
Day 2 
3. For subcloning use the plate with more than 1000 individual colonies. 
4. Add 2 ml of 2YT/tet/cam/G media to the plate, resuspend the colonies with a cell scraper 
and incubate the eluted cells with shaking at 1000 rpm at 4°C for 15 min to obtain a 
homogenous solution.  
5. Use 600 µl of the eluted cells to prepare phagemid DNA using a standard plasmid 
purification kit. 
This procedure should yield phagemid DNA at a concentration of 50 - 100 ng/µl 
6. Digest phagemid DNA (~1 µg) with BamHI and HindIII (e.g. for three-fold over digest: 0.33 
µl BamHI (20 U/µl), 0.28 µl HindIII (20 U/ µl), 0.5 µl BSA (100 x stock), 5 µl NEB2 buffer 
(10 x stock), 10 - 20 µl phagemid DNA (1 µg) and UHP to final volume of 50 µl, for 1 hour 
at 37°C) 
7. Gel-purify the polyclonal DARPin fragments by using a standard DNA purification kit. 
Cut out complete gel piece from 300 to 600 base pairs to allow N1C to N4C to be 
recloned. Include bands up to 900 base pairs if visible. 
8. Over-digest target vector pDST67 or pMPAG6 (~1 µg) with BamHI and HindIII and 
dephosphorylate (e.g. for fifteen-fold over digest:1.7 µl BamHI (20 U/µl), 1.4 µl HindIII (20 
U/µl), 0.5 µl BSA (100 x stock), 5 µl NEB2 buffer (10 x stock), 10 – 20 µl pDST67 (1 µg), 1 
µl CiAP and UHP to final volume of 50 µl, for 1 hour at 37°C) 
9. Remove enzymes by using a standard DNA purification kit. 
10. Ligate 5 µl of the DARPin fragments with 1 µl of the digested pDST67 or pMPAG6 from 
Step 8 for 30 min at RT (0.5 µl T4-Ligase, 1 µl T4-buffer, 2.5 µl UHP). 
To quantify background transformation of uncut or relegated target vector make 
negative controls: digested pDST67 or pMPAG6 without and with ligase. 
11. Transform 5 µl of the ligation mix into 50 µl of chemically competent E. coli XL1-Blue cells. 
(mix, keep 30 min on ice and heat shock for 30 sec at 42°C) 
12.  Add 200 µl of SOC and shake at 37°C for 1hour. 
13. Plate 100 µl and 10 µl on 2YT/amp agar plates and incubate at 37°C overnight. 
This subcloning procedure should give numbers of colonies per plate that allow easy 
picking of more than 100 single clones. Check negative controls: background 
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transformation of uncut or relegated target vector should be <10% compared to 
ligations including insert. 
14. Proceed with the screening of DARPin by ELISA (Protocol 19 and Protocol 20). 
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Protocol 19 Expression of DARPins in the 96-well format 
Comments 
• This protocol describes the expression of individual DARPins clones in the 96-well format 
followed by analysis for target-specific binding by ELISA (Protocol 20). 
• No further subcloning for large scale expression needed. 
Equipment and Reagents (see p. 278 ff. for details) 
• 96-deep well plate for bacterial cell 
cultures (round bottom) 
• IPTG 
• amp (1000x) 
• 2YT media 
• Glucose (20%) 
• 2YT/Glu/amp media  
• 2YT/amp media 
• 2YT/amp/IPTG media 
• B-PER II  
• 96-well PCR plate  
• Shaker for 96-well plates 
• Incubator for 96-well bacterial cell 
cultures  
• Gas permeable adhesive seals 
• Autoclaved toothpicks 
Method 
Unless stated otherwise, all handling should be done with an 8 or 12-fold multichannel 
pipette to avoid cross-contamination between wells. 
Day 1  
1. Aliquot 1.2 ml of 2YT/Glu/amp into each well of a 96-deep well plate (master plate). 
Using 2YT instead of LB gives you higher cells densities of the overnight culture and 
subsequently higher plasmid DNA yields. 
2. Pick individual colonies into each well and seal the plate by applying an air permeable 
membrane. 
A simple method that avoids cross-contamination and double inoculation is to seal the 
plate with a piece of parafilm during inoculation. Pick the colonies with sterile toothpicks 
and stab them through the parafilm into the medium. The toothpicks can be removed 
after inoculation of all the wells. As a negative control do at least leave one well without 
inoculation. 
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3. Incubate the sealed plate in an orbital shaker (540 rpm) and grow at 37°C overnight. 
Shaking below 500 rpm may result in reduced cell density of the overnight culture and 
shaking above 550 rpm increases the risk of cross-contamination between wells. 
4. Start preparing target protein coated MaxiSorp 96-well plate and plate to test background 
binding (e.g. only NeutrAvidin coated plate) as described in Protocol 12. 
Day 2 
5. Parallel to the expression continue blocking and coating of MaxiSorp 96-well plates as 
described in Protocol 12. 
6. Aliquot 0.9 ml of 2YT/amp media into each well of a 96-deep well plate (expression plate). 
7. Transfer 0.1 ml from each well of the master plate to the corresponding well of the 
expression plate. 
If the overnight culture did grow properly this will approximately result in an OD600 = 0.4. 
8. Incubate the sealed plate in an orbital shaker (540 rpm) and grow at 37°C for 45 min. 
45 min are sufficient for the cells to get into the log growth phase and obtain high 
expression yields of DARPins. This time can be extended up to 2 hours which leads to 
even slightly higher amounts of expression (not necessary for crude extract ELISA but 
advisable for expression and further 96-well IMAC purification (Protocol 22)). 
9. In the mean time centrifuge master plate at 3’000g for 10 min, empty the plate, blot dry on 
stacked paper towels and store at -20°C for later preparation of plasmid DNA. 
10. To each well of the expression plate add 110 µl of 2YT/amp/IPTG media and incubate the 
sealed plate in an orbital shaker (540 rpm) and grow at 37°C for 3-4 h. 
11. Transfer 0.1 ml from each well of the expression plate to the corresponding well of a 96-
well PCR plate, spin the plate at 3’000g for 6 min, empty the plate, blot it dry on stacked 
paper towels. 
This cell pellets can be used for the secondary screening by SDS-PAGE (Protocol 21). 
12. Spin expression plate at 3’000g for 6 min, empty the plate, blot it dry on stacked paper 
towels. 
Longer centrifugation makes the resuspension of the cell pellet cumbersome. 
13. To each well add 50 µl B-PER II and resuspend the cell pellet completely for 15 min at RT 
(e.g. on an orbital shaker at 500 rpm). 
14. To each well add 950 µl of PBS-TB and spin the plate at 3’000g for 10 min to remove cell 
debris. 
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15. Proceed with the screening of DARPins as described in Protocol 20. 
16. For further experiments store the plate at -20 °C. 
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Protocol 20 Screening DARPins by ELISA 
Comments 
• This protocol allows the screening of individual DARPins for target-specific binding by 
ELISA. 
• No further subcloning for large scale expression or IMAC purification is needed. 
• DARPins are expressed as described in Protocol 19. 
• For ELISA, appropriate positive and negative control should be included 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8: Example showing screening of DARPins by ELISA 
Screening of IgG1_Fc binding DARPins by ELISA using crude cell extracts. 
Equipment and Reagents (see p. 278 ff. for details) 
• Target protein coated plate and control 
plate for background binding (Protocol 
12) 
• anti-RGS(His)4 antibody 
• anti-mouse antibody AP conjugate 
• pNPP substrate 
• PBS-T 
• PBS-TB 
• Shaker for 96-well plates 
• 96-well plate containing crude extracts 
(Protocol 19, Step 14) 
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Method 
Unless stated otherwise, all handling should be done with an 8 or 12-fold multichannel 
pipette to avoid cross-contamination between wells. 
1. Add 90 µl of PBS-TB to each well of the target protein coated plate and control plate for 
background binding (Protocol 12). 
2. Transfer 10 µl of the supernatant from Protocol 19, Step 14 to both plates and incubate 
for 1 h at RT with orbital shaking (900 rpm).  
10 µl of the supernatant contain by far enough DARPins for the ELISA. Supernatants 
can be diluted up to 200-fold for further ELISA experiments (competition). 
3. Wash the plate by empting the plate, blotting it dry on stacked paper towels, adding of 300 
µl/well of PBS-T wash buffer and vortexing of the plate for 5 seconds. Repeat wash cycle 3 
times. 
For washing you can use a squirt bottle filled with PBS-T. 
4. Empty the plate and blot dry on stacked paper towels. Add 100 µl of 1:5’000 anti-
RGS(His)4 antibody in PBS-TB per well and incubate at RT for 1 h. 
5. Wash plate as described in Step 2. (3 wash cycles) 
6. Empty the plate and blot dry on stacked paper towels. Add 100 µl of 1:10’000 anti-mouse 
antibody AP conjugate in PBS-TB per well and incubate at RT for 1 h. 
7. Wash plate as described in Step 2. (4 wash cycles) 
8. Empty the plate as described in Step 2. Add 100 µl of pNPP substrate solution for the 
detection of bound protein. 
Develop the ELISA for up to 12 hours at RT. The reaction can be stopped by the 
addition of 3 M NaOH (100 µl) but background signal will be slightly increased.  
9. Measure OD405 – OD540. 
Perform secondary screening by SDS-PGAE (Protocol 21). 
10. Prepare plasmid DNA from positive clones using a standard plasmid purification kit. 
Directly add resuspension buffer to the respective well of the master plate (thaw plate 
which was stored at -20°C) and resuspend the cell pellets for about 10 min at RT with 
orbital shaking plate (900 rpm).  
11. Submit for sequencing using the primer Qe_30_for or Qe_30_rev for pDST67 (for details 
see Appendix data sheet: pDST67) or Qe_30_for or T7_term for pMPAG6 (for details see 
Appendix data sheet: pMPAG6). 
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Protocol 21 Secondary screening by SDS-PAGE  
Comments 
• This protocol describes the secondary screening of clones giving positive signal in ELISA 
experiments by SDS-PAGE. 
• Due to high expression level of DARPins, crude cell extracts can be directly analyzed. 
DARPins different on the sequence level do show different running behavior on SDS-
PAGE (mainly due to their stability differences) and expression patterns. These two 
properties allow identifying clones different on sequence level. 
 
 
 
Figure 9: Example showing secondary screening of DARPins by SDS-PAGE 
Analysis of whole cell extracts of a subset of IgG1_Fc binders (Binders from ELISA 
depicted in Figure 8:) by SDS-PAGE. On each lane cell extract from ~25 ul of the 
expression culture was loaded. Based on running behavior and expression pattern groups 
of presumably identical members DARPins can be formed (e.g. A1, A7, A8, A9, A10, E4, 
E7 and E8 what aligns quite well with ELISA signals seen in Figure 8:)  
It should be noted that some DARPins having more than two internal repeats run at lower 
apparent molecular mass or show additional bands with faster running behavior. The same 
behavior was also observed for the respective purified proteins, even though they were 
subsequently shown by sequencing and MS to be precise in sequence and not degraded. 
As shown previously11, 12 this is due to an incomplete denaturation of these stable 
molecules by SDS. N2C DARPins do not have this extreme SDS resistance and do run 
where expected 
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Equipment and Reagents (see p. 278 ff. for details) 
• 96-well PCR plate containing cell pellets 
to be analyzed (Protocol 19, Step 11) 
• SDS-PAGE (15%) 
• SDS loading buffer 
Method 
1. Add 20 µl of SDS-PAGE loading buffer to each well of the PCR-plate (expression samples 
prepared in Protocol 19, Step 11) and resuspend the cell pellets by shaking at 1’000 rpm 
for 20 min and heat the samples to 95°C for 5 min using a 96-well PCR-machine. Load 5 
µl of the samples to each lane of an 15% SDS-PAGE. 
2. Run SDS-PAGE. 
3. Stain with Coomassie Brilliant Blue solution and destain with 10% (v/v) acetic acid. 
4. Together with ELISA data try to identify as many different positive clones as possible.  
Differences in running behavior are for N2C not as clearly visible as for N3C (probably 
due to the generally lower stability of N2C compared to N3C, see Figure 9:) 
5. Prepare plasmid DNA from positive clones using a standard plasmid purification kit. 
Directly add resuspension buffer to the respective well of the master plate (thaw plate 
which was stored at -20°C) and resuspend the cell pellets for about 10 min at RT with 
orbital shaking plate (900 rpm).  
6. Submit for sequencing using the primer Qe_30_for or Qe_30_rev for pDST67 (for details 
see Appendix data sheet: pDST67) or Qe_30_for or T7_term for pMPAG6 (for details see 
Appendix data sheet: pMPAG6). 
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96-well DARPin purification 
Protocol 22 96-well IMAC purification of DARPins 
Comments 
• This protocol allows the IMAC purification of 96 individual DARPins in parallel. 
• Using purified DARPins is recommended for the detailed characterization (competition, 
SEC,…) of clones identified as positive in the screening procedure. Clones should be 
sequenced in advance. 
• About 0.25 to 1 mg of purified DARPins is obtained. 
• All steps starting from 96-well transformation to 96-well purification will be described. 
• DARPins are expressed with a modified version of Protocol 19 optimized for maximal 
DARPin expression yields in small scale 96-well cultures. 
• An alternative 96-well purification protocol using Ni-NTA material from QIAgen can be 
found on the supplier’s homepage 
(http://www1.qiagen.com/literature/protocols/pdf/QE04.pdf). 
• It is absolutely essential to regenerate the plate after each use. 
• Be careful not to lose IMAC resin during plate handling, the material is not fixed in 
the plate. 
 
 
Figure 10: Example showing SDS-PAGE of 96-well IMAC purified DARPins  
SDS-PAGE analysis of 96-well IMAC purified DARPins (all N3Cs) (a,b). 4 µl of pooled 
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eluates was loaded per lane and SDS-PAGE performed at room temperature (a), showing 
incomplete denaturation (refolding) of the highly stable DARPins and thereofe appearance 
of multiple bands. If SDS-PAGE of the same samples is run at 60°C (b) most of the 
multiple bands disapear. 
Equipment and Reagents (see p. 278 ff. for details) 
• Chemically competent E. coli XL1 Blue 
cells  
• 96-well PCR plate 
• SOC media 
• 2YT/amp agar plate (square) 
• 96-deep well plate for bacterial cell 
cultures (round bottom) 
• 2YT media 
• NiCl2 (200 mM) 
• 2YT/Glu/amp media 
• 2YT/amp media 
• 2YT/amp/IPTG media 
• IMAC adjusting buffer  
• IMAC wash buffer  
• IMAC elution buffer  
• Vacuum manifold 
• IMAC 96-well plate 
• GdnHCl (6 M), HCl (0.2 M) 
• NaOH (0.5 M) 
Method 
Unless stated otherwise, all handling should be done with an 8 or 12-fold multichannel 
pipette to avoid cross-contamination between wells. Filter tips are not needed if you pipet 
carefully. 
 
Day 1 (transformation) 
 
1. Prewarm a metal 96-well PCR block to 42°C. 
2. Put 96-well PCR plate on ice and aliquot 5 µl of chemically competent E. coli XL1 Blue 
cells into each well. 
3. Add to each well 0.1 µl of respective plasmid DNA and incubate for 30 min on ice. 
Time can be reduced but transformation yield will be lower. 
4. Heat shock for 30 sec at 42°C and add 50 µl of SOC media. 
LB or 2YT-media can be used instead but transformation yield will be lower. 
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5. Incubate at 37°C for 1 hour. 
Time can be reduced but transformation yield will be lower. 
6. Plate drops of 3 µl on a 2YT/amp agar plate by using a multichannel pipette  
Take care to avoid cross contamination. 
Day 2 (preculture) 
7. Aliquot 1.2 ml of 2YT/Glu/amp into each well of a 96-deep well plate (master plate). 
Using 2YT instead of LB gives you higher cells densities of the overnight culture and 
subsequently higher plasmid DNA yields. 
8. Pick multiple colonies from each transformation into wells of a 96-deep well plate and seal 
the plate with an air permeable membrane 
A simple method that avoids cross-contamination and double inoculation is to seal the 
plate with a piece of parafilm during inoculation. Pick the colonies with sterile toothpicks 
and stab them through the parafilm into the medium. The toothpicks can be removed 
after inoculation of all the wells. As a negative control do at least leave one well without 
inoculation. 
9. Incubate the sealed plate in an orbital shaker (540 rpm) and grow at 37°C overnight. 
Shaking below 500 rpm may result in reduced cell density of the overnight culture and 
shaking above 550 rpm increase the risk of cross-contamination between wells. 
 
Day 3 (expression) 
10. Aliquot pre-warmed (37°C) 0.99 ml of 2YT/amp into each well of eight 96-deep well plates 
(expression plates). 
Use round–bottom 96-deep well plates. By using eight expression plates in parallel a 
final culture volume of about 10 ml for each clone will be obtained giving enough 
starting material for the IMAC purification. 
11. Transfer 0.11 ml from each well of the master plate to the corresponding well of the eight 
expression plates. 
If the overnight culture did grow properly this will approximately result in an OD600 = 0.4-
0.6. If you need to prepare plasmid DNA from positive clones, add fresh 2YT/Glu/amp 
media to the master plate (max final volume 1.3 ml), grow for 10 hours at 37°C and 
prepare plasmid DNA using a standard kit. 
12. Incubate the sealed plates in an orbital shaker (540 rpm) at 37°C for 2 hours. 
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Higher cell density at the time point of induction yields higher amounts of DARPin per 
ml of culture. 
13. Add 133 µl of 2YT/amp/IPTG to each well of the expression plate and incubate the sealed 
plate in an orbital shaker (540 rpm) at 37°C for 4-5 h. 
The culture will have a final OD600 = 3-4. 
14. Transfer 0.1 ml from each well of one of the expression plates to the corresponding well of 
a 96-well PCR plate, spin the plate at 3’000g for 6 min, empty the plate, blot it dry on 
stacked paper towels. 
This cell pellets can be used for SDS-PAGE expression analysis of the single clones as 
described (Protocol 21). 
15. Spin expression plate at 3’000g for 6 min, empty the plate, blot it dry on stacked paper 
towels. 
Longer centrifugation makes the resuspension of the cell pellet cumbersome. 
16. Freeze cell pellets at -80°C for at least 1 hour. 
Freezing the cells increases the yield of lysis in Step 17. Do not freese in liquid nitrogen 
which can lead to cracking of the plate. 
Day 4 (purification) 
17. Add 50 µl B-PER II to each well. Resuspend the cell pellet and lyse the cells by shaking on 
an orbital shaker at 800 rpm for 30 min at RT. 
Good lysis is essential to obtain high amounts of purified protein. 
18. Pool the lysates of all expression plates into one expression plate, add 400 µl of the IMAC 
adjusting buffer and mix by orbital shaking. 
19. Centrifuge the plate at 3’000 g for 30 min. 
20. During the mean time prepare IMAC 96-well plate by re-hydrating the nickel-charged 
chelating agarose with 0.5 ml 30% EtOH for 10 min, wash twice with 0.5 ml UHP and 
equilibrate by washing twice with 0.5 ml IMAC wash buffer. Omit EtOH wash if regenerated 
material is used. 
21. Transfer 0.6 ml of the combined and centrifuged lysate into the wells of the IMAC 96-well 
plate and let the liquid pass through the filter plate by gravity flow. Re-centrifuge plate with 
lysate at 3’000 g for 15 min before transferring the rest of the supernatant to the IMAC 96-
well plate. Wait until samples have completely passed through the IMAC resin. 
Take care not to load cell debris into the Ni-NTA plate as this will clog the plate. Some 
wells may flow slower than others, if necessary slight vacuum might be applied to 
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speed up loading of the samples. Be aware that slow passage through the resin is 
essential for efficient binding of the His-tagged DARPins to the Ni-NTA matrix. 
22. Perform wash steps with IMAC wash buffer on a vacuum manifold. Pipette 0.6 ml of IMAC 
wash buffer into each well, draw buffer completely through the filter by applying slight 
vacuum. Wash filter plate thoroughly from lower side by using a squirt bottle filled with 
UHP. 
23. Perform another three wash cycles as described in Step 22. 
24. Place the IMAC-plate on an empty collection plate and centrifuge at 100 x g for 2 min to 
remove residual wash buffer. 
25. Place IMAC-plate on an empty collection plate add 200 µl IMAC elution buffer into each 
well, incubate for 1 min at RT and elute the protein by centrifugation at 50 x g for 2 min. 
26. Perform second and third elution step as described in Step 25. 
27. Pool eluted fractions, measure UV spectra and run SDS-PAGE. 
Extinction coefficients of DARPins can vary strongly, dependent on the amount of 
aromatic residues. If sequence data of the DARPins is not yet available use other 
methods to quantify protein concentration (e.g. BCA, Breadford) 
 
Day 4 (plate regeneration) 
28. Perform all regeneration steps on a vacuum manifold. Pipette 0.6 ml of respective solution 
into each well, draw solution completely through the filter by applying slight vacuum. 
2 x UHP, 2 x GdnHCl (6 M), HCl (0.2 M), 2 x UHP, 2 x NaOH (0.5 M), 2 x UHP, 2 x 
TBS500 (for more stringent purification Ni can be stripped from resin by using 100 mM 
EDTA) 
29. Add 0.2 ml of NiCl2 (200 mM) and let run through by gravity flow. Wash plate with 3 x UHP 
and 1 x 30% v/v EtOH 
30. For storage pipette 0.6 ml of 30% v/v EtOH, seal plate with adhesive seal, put on empty 
collection plate and seal with parafilm 
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Troubleshooting 
• Background binding: During selections on immobilized target protein an increase of 
clones showing unspecific background binding has been observed. The reason for this 
effect can probably be attributed to the “bad state” of the immobilized antigen. There are 
several possibilities to get rid of such background binders.  
→ Increasing the prepanning step (e.g. 2 hours in blocked MaxiSorp Immunotube), did 
lower but not completely avoid background binding in our hands. 
→ Change blocking buffer. BSA seems to have some properties that increase the 
interaction with sticky background binders. In a test-experiment none of these 
background binders did show signal on casein-blocked wells (most other blocking 
proteins tested behaved as BSA). Casein does contain low amounts of biotin that will 
block NeutrAvidin or streptavidin binding sites. Do dialyze casein stock extensively 
against PBS or add an excess of free biotin binding proteins during blocking of the plate 
and target immobilization. This approach has not been tested in selection conditions but 
is very promising. 
→ The simplest and most effective way is to do one or multiple rounds of selection in 
solution. In our hands this completely eliminated all background binders.  
• Low diversity of selection output: Early epitope focusing, meaning that only one very 
dominant binder under all the positive clones is found has been reported for phage display 
and also observed for the DARPin phage library. 
→ We solved this problem by purifying the dominant DARPin and adding it to target protein 
during the selection. The DARPin will bind the target protein and thereby block its 
epitope. Therefore, the selection will be forced to find binders against different epitopes. 
In our hands the addition of different concentrations of purified DARPins to the target 
protein (e.g. for a 100 nM target protein concentration we added 200 nM and 4 µM 
DARPin) resulted in a panel of new DARPins binding the target protein.  
• No enrichment: There are many possibilities why selections on a certain target protein 
might fail. One reason might be the instability of the target protein under the chosen 
selection conditions. 
→ e.g. in our hands reducing the temperature during the selection to 4°C made it possible 
to find binders against Her2 (1-509) which did fail under all selection approaches 
performed at RT. 
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Materials 
Equipment 
• Culture flasks: non-baffled (100 ml, 300 ml, 2 l, 5 l), sterile, phage free flask (re-autoclave 
if you want to be sure) 
• Equipment for end-over-end rotation: for Nunc Immunotubes and 2 ml micro tubes (e.g. 
Stuart scientific roller mixer SRT1, Aldrich no. Z316474 or MACSmix tube rotator, Miltenyi 
Biotech, no. 130-090-753) 
• Incubator for 96-well bacterial cell cultures: e.g. Edmund Bühler, no 6161 000 and 6167 
000 
• Magnetic tube holder for 2 ml micro tubes: e.g. Dynal, MPC-S, no. 120.20 
• Shaker for 96-well plates: e.g. Mikrotiterplattenschüttler TiMix 5, Edmund Bühler, no 
6166 000 
• Vacuum manifold: e.g. Millipore, no. MAVM 096 0R 
• Water bath (heatable): e.g. Heating Circulator with Open Bath Julabo, ED-5, no 9115405 
 
Consumables 
• 96-deep well plate for bacterial cell cultures (round bottom): e.g. AbGene, no. AB-
0932 
• 96-well PCR plate: e.g. Costar, no. 6511 
• Cell scrapers: e.g. BD Falcon, no 353085 
• Culture tubes (14 ml): Sterile 14 ml culture tubes (e.g. Falcon, no. 352059) 
• Dialyis tubing MWCO 3’500 kDa: e.g. Spectra/Por, no 132720 
• DNA purification kit: e.g. Macherey-Nagel, NucleoSpin Extract II, no 740609.50 
• Gas permeable adhesive seals: e.g. ABgene, no AB-0718 
• IMAC 96-well plate: e.g. SwellGel Nickel Chelated Discs, 96-well filter plate, Pierce, no 
75824 
• MaxiSorp 96-well plate: e.g. Nunc MaxiSorp 96-well plate (Nunc, no. 442404) 
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• MaxiSorp Immunotubes: e.g. Nunc MaxiSorp Immunotubes (Nunc, no. 444202) 
• Micro tubes (2 ml): Sterile 2 ml polypropylene micro tubes (e.g. Sarstedt, no. 72.695) 
• Nap 5 columns: e.g. GE healthcare, no. 17-0853-01 
• Parafilm: e.g. Pechiney Plastic Packaging (10cm x 38m), no:PM996 
• Petri plates large: e.g. Nunc Tc Dish 245x245x25, no 166508 
• Petri plates round: e.g. Sarstedt, 92 x 16 mm, no. 83.1473 
• Petri plates square: e.g. Nunc Tc Dish 245x245x25, no 166508 
• Plasmid purification kit: e.g. Macherey-Nagel, NucleoSpin Plasmid, no 740588.50 
• Polypropylene tubes (50 ml): Sterile 50 ml polypropylene tubes (e.g. Sarstedt, no. 
62.547.24) 
• Stoppers for Immunotubes : Nunc stoppers (Nunc, no. 348801) 
• Toothpicks autoclaved 
 
Reagents from third parties 
• anti-M13 antibody HRP conjugate: mouse anti-M13 antibody horseradish peroxidase 
conjugate (Amersham Pharmacia Biotech, UK, No. 27-9421-01) 
• anti-mouse antibody AP conjugate: : goat anti–mouse IgG alkaline phosphatase 
conjugate (Sigma, No. A3562) 
• anti-RGS(His)4 antibody: mouse anti RGS(His)4 IgG1 (Qiagen, no. 34650) 
• BamHI (20 U/µl): e.g. NEB, 20 U/µl, no R0136S 
• BM Blue POD substrate: Roche Diagnostics, no. 11484281001 
• B-PER II: Bacterial Protein Extraction Reagent (Pierce, no.78260) 
• CiAP (1u/µl): Calf Intestine Alkaline Phosphatase (e.g. Fermentas, 1U/µl, no #EF0341) 
• E. coli XL1-Blue: Bacterial strain: E. coli XL1-Blue13 (Stratagene, no 200268): F' [lacIq 
lacZ∆M15 proAB+ Tn10(Tetr)] endA1 supE44 gyrA96 hsdR17 lac recA1 relA1 thi 
• EZ-Link Sulfo-NHS-LC-Biotin: Pierce, no. 21335 
• EZ-Link Sulfo-NHS-ss-Biotin: Pierce, no. 21331 
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• HindIII (20 U/µl): e.g. NEB, 20 U/µl, no R0104S 
• NEB2 buffer (10x): e.g. NEB, no B7002S 
• NeutrAvidin: Pierce, no. 31000 
• Primary DARPin PD library #1stock:  
• Streptavidin (Strp): Sigma, no. S-0677 
• Streptavidin-coated paramagnetic beads: Dynabeads MyOne Streptavidin T1, Dynal, 
no. 656-02 or  Dynabeads M-280 Streptavidin, no.  112-06D (10 µg/ml) 
• Streptavidin-AP conjugate: e.g. Roche Diagnostics, no 1089161 
• T4-buffer (10x): Supplied with enzyme 
• T4-Ligase: e.g. Fermentas, 5u/µl, #EL0014 
• VCSM13 Helper phage: Stratagene, no 200251 (alternatively, M13K07 helper phage 
(New England Biolabs) may be used) 
 
Reagents and Solutions 
• 1.2% TAE/agarose gel: TAE buffer, 1.2% (w/v) agarose, heat to dissolve, cool to 50°C, 
add 1:5’000 ethidium bromide and pour gel 
• 2YT agar: 2YT media, 1.5% agar (15 g/l) and 1% glucose (10 g/l); autoclave, cool 
• 2YT media: 1% bacto-yeast extract (10 g/l), 1.6% bacto-tryptone (16 g/l), 0.5% NaCl (5 
g/l); adjust pH to 7.0 with NaOH; autoclave and cool (To avoid contaminations we 
recommend to heat up media to >80°C in the microwave after each use) 
• 2YT top agar: 2YT media containing 0.75% agar (7.5 g/l); autoclave, cool to 50°C 
• 2YT/amp agar plates (round or square): melt 2YT agar, cool to 55°C, add 50 µg/ml amp, 
pour into petri plates (round: ~ 20 ml/plate), (square: ~ 60 ml/plate) 
• 2YT/amp media: 2YT media, 50 µg/ml amp 
• 2YT/amp/IPTG media: 2YT media, 50 µg/ml amp, 5 mM IPTG 
• 2YT/cam/tet agar plates (round, square or large): melt 2YT agar, cool to 55°C, add 15 
µg/ml tet and 10 µg/ml cam, pour into petri plates (round: ~ 20 ml/plate), (square: ~ 60 
ml/plate), (large :~ 100 ml/plate) 
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• 2YT/Glu/amp media: 2YT media, 1% glucose, 50 µg/ml amp 
• 2YT/Glu/amp media: 2YT media, 1% glucose, 50 µg/ml amp 
• 2YT/kan agar plates (round or square): melt 2YT agar, cool to 55°C, add 10 µg/ml kan, 
pour into petri plates (round: ~ 20 ml/plate), (square: ~ 60 ml/plate) 
• 2YT/kan media: 2YT media, 10 µg/ml kan 
• 2YT/tet agar plates (round): melt 2YT agar, cool to 55°C, add 15 µg/ml tet, pour into 
round petri plates (~ 20 ml/plate) 
• 2YT/tet media: 2YT media, 15 µg/ml tet 
• 2YT/tet/cam media: 2YT media, 15 µg/ml tet, 10 cam 
• 2YT/tet/cam/G media: 2YT media containing 20% v/v glycerol, autoclave and cool, add 
tetracycline to 15 µg/ml and chloramphenicol to 10 µg/ml 
• 2YT/tet/cam/Glu media: 2YT/tet/cam media containing 1% w/v glucose 
• amp (1000x): Ampicilin (amp, 1000 x stock) (50 mg/ml ampicilin dissolve in UHP, filter 
through 0.22 µm filter, store at -20°C) 
• BSA (20%): 20% BSA (20% w/v BSA in UHP, filter through 0.22 µm filter, store at -20°C) 
• Chemically competent E. coli XL1 Blue: Protocol by P.Forrer based on method 
published by Inoue et al 19) 
• cam (1000x): 1000 x chloramphenicol (cam) stock (10 mg/ml chloramphenicol dissolve in 
EtOH, filter through 0.22 µm filter, store at -20°C) 
• E. coli XL1-Blue glycerol stock: E. coli XL1-Blue13 (Stratagene, no 200268): F' [lacIq 
lacZ∆M15 proAB+ Tn10(Tetr)] endA1 supE44 gyrA96 hsdR17 lac recA1 relA1 thi (see 
Protocol 1 for glycerol stock preparation) 
• Glucose (20%): 20% glucose (20% w/v glucose (200 g/l) in UHP, autoclave and cool) 
• glycine (200 mM, pH 2): 200 mM glycine (1.50 g/100 ml) adjust to pH 2, autoclave or filter 
through 0.22 µm filter, store at RT 
• GdnHCl (6 M), HCl (0.2 M): 6 M GdnHCl (57.3 g/100 ml), 0.2 M HCl (0.63 ml/100ml) 
dissolve in UHP, store at RT 
• IMAC adjusting buffer: TBS500 containing 20% v/v glycerol and 40 mM imidazol 
• IMAC elution buffer: TBS500 containing 10% v/v glycerol and 250 mM imidazol 
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• IMAC wash buffer: TBS500 containing 10% v/v glycerol and 20 mM imidazol 
• IPTG: isopropyl-β-D-thiogalactoside (IPTG) stock (1 M IPTG (238 mg/ml) dissolve in UHP, 
filter through 0.22 µm filter, store at -20°C) 
• kan (1000x) : 1000 x kanamycin (kan) stock (10 mg/ml kanamycin dissolve in UHP, filter 
through 0.22 µm filter, store at -20°C) 
• NaOH (0.5 M): 0.5 M NaOH (2g/100 ml) dissolve in UHP, store at RT 
• Neutravidin (300x): 300 x NeutrAvidin (Neu) stock (Pierce, no. 31000) (1.2 mg/ml 
NeutrAvidin dissolve in UHP, filter through 0.22 µm filter, store at -80°C) (final working 
concentration ~ 66 nM of tetrameric Neu) 
• NiCl2 (200 mM): 200 mM NiCl2.6H2O (4.75 g/100 ml) dissolve in UHP, store at RT 
• PBS: 10 x PBS stock (1.37 M NaCl (80.1 g/l), 30 mM KCl (2.24 g/l), 80 mM Na2HPO4.2H2O 
(14.24 g/l), 15 mM KH2PO4 (2.04 g/l), do not adjust pH, autoclave) for 1xPBS dilute 10 x 
PBS stock into UHP, should be about pH 7.4, check first time stock is used 
• PBS-G: PBS containing 10% v/v of glycerol, filter through 0.22 µm filter, store at 4°C 
• PBS-T: PBS containing 0.1% (v/v) Tween20 (4 ml/l of 25% Tween20) 
• PBS-TB: PBS-T containing 0.2% (w/v) BSA 
• PEG/NaCl (5x) : 5 x PEG/NaCl (solve 20% w/v Polyethylene glycol (PEG) 6000 
(20g/100ml) in warm 2.5 M NaCl (146.1 g/l), store at 4°C for max 1 week (hydrolysis of 
PEG) 
• pNPP buffer: 50 mM NaHCO3 (4.2 g/l), 50 mM MgCl2.6H2O (10.2 g/l) dissolve in UHP, 
store at RT 
• pNPP stock (1M): 1 M stock solution of di-sodium 4-nitrophenyl phosphate (pNPP) (371 
mg/ml), dissolve in UHP, store at -20°C 
• pNPP substrate: Add 3 mM pNPP from stock (1M) to the pNPP buffer, final pNPP 
substrate is stable at 4°C for 1-2 weeks (discard when turning yellowish) 
• SOC media: 0.5% bacto-yeast extract (5 g/l), 2% bacto-tryptone (20 g/l), 1mM NaCl (0.58 
g/l) 2.5 mM KCl (0.19 g/l); pH should be about 7.2 otherwise adjust with NaOH; autoclave 
and cool, before use add sterile 10 mM MgCl2,10 mM MgSO4 and 20 mM glucose (To 
avoid contaminations we recommend to heat up media to >80°C in the microwave after 
each use) 
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• Strp (300x): 300 x Streptavidin (Strp) stock (Sigma, no. S-0677) (1.2 mg/ml streptavidin 
dissolve in UHP, filter through 0.22 µm filter, store at -80°C) (final working concentration ~ 
66 nM of tetrameric Strp) 
• TAE: 50x TAE stock (2 M Tris (242g/l), 50 mM EDTA (100 ml/l of 0.5 M EDTA, pH 8) and 
adjust with glacial acetic acid (~ 57 ml) to pH 8, autoclave, cool 
• TBS500: 50 mM Tris.HCl (6.06 g/l), 500 mM NaCl (29.2 g/l), adjust with HCl to pH 8 
• Tet (1000x): 1000 x tetracycline (tet) stock (15 mg/ml tetracycline dissolve in 50% (v/v) 
EtOH containing 3 drops of 6 M HCl/10 ml, filter through 0.22 µm filter, store at -20°C) 
• triethylamine (100 mM): 100 mM triethylamine (140 µl triethylamine in 10 ml UHP), 
prepare on the day used 
• Tris/base (2 M): 2 M Tris (14.22 g/100 ml), autoclave or filter through 0.22 µm filter, store 
at RT 
• Tris/HCl (1 M, pH 7.4): 1 M Tris/HCl (12.11 g/100 ml) adjust to pH 7.4, autoclave or filter 
through 0.22 µm filter, store at RT 
• Tween20 (25%):25% Tween20 (25% (v/v) Tween20 stock solution in UHP, sterile filter 
0.22 µm, store at 4°C) 
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Appendix 
Data sheet: pDST67 
• The plasmid vector pDST67 allows the expression of protein of interests (POI), such as 
designed ankyrin repeat proteins (DARPins), in the cytoplasm of Escherichia coli. The 
vector uses a strong regulated T5 phage promoter for the inducible high level expression of 
the POI. The open reading frame encodes a MRGS-His6-tag for simple purification of the 
POI by immobilized metal affinity chromatography (IMAC). pDST67 relies on a lacI 
repressor gene presented in trans on a separate plasmid (pREP4, Qiagen) or by the strain 
(e.g. XL1-Blue has lacIq on F’ plasmid) for efficient repression of the promoter.  
Handling 
• Storage: -20°C in TE (10 mM TrisHCl, 1 mM EDTA, pH 8.5) 
• Amplification: pDST67 can be amplified in E. coli (e.g. XL1-Blue) using a Luria Broth 
medium supplemented with 50 µg/ml of ampicillin and 1% glucose. 
Vector Map 
pDST67
3465 bp
6xHis
2 x stop
T5P
MCS
ColE1
BamHI
HindIII
PstI
KpnI
SacI
SmaI
bla
lacI
 
Cloning site region 
 M  R  G  S  H  H  H  H  H  H  G  S  A  C  E  L  G  T  P  G  R  P  A  A  K  L  N  *  *  
ATGAGAGGATCGCATCACCATCACCATCACGGATCCGCATGCGAGCTCGGTACCCCGGGTCGACCTGCAGCCAAGCTTAATTAATGA 
                              BamHI       SacI  KpnI SmaI       PstI    HindIII         
                              146         162   168  170        184     188             
Phage display manual   285 
 
Features 
• pDST67 is derived from pQE30 (Qiagen). From the MCS the StuI restriction site was 
removed and in the resulting plasmid the single stop codon (TAA, position 196-196) 
replaced by two stop codon (ochre & opal; TAATGA, position 196-201), leaving the rest of 
the plasmid unchanged. 
• Plasmid vector for high level cytoplasmic protein expression in E. coli. 
• pDST67 contains no lacIq therefore has to be used in a lacIq host background (e.g. XL1-
Blue).  
• Excellent expression yields can be obtained in XL1-Blue cells. 
• Sequences to be expressed are inserted in the MCS. The MCS is compatible to vectors of 
the pMPAG vector series, including the phagemid vector pMPAG3. 
• For example, DARPins selected using pMPAG3 can be shuffled into pDST67 by simple 
transfer of the DARPin encoding BamHI/HindIII vector fragment. 
• The expression of the POI is under the control of a phage T5 promoter/lac operator element 
and the lacIq gene has to be provided in trans. 
→ The phage T5 promoter is recognized by the endogenous E. coli RNA polymerase. 
→ Two lac operator sequences increase lac repressor binding and ensure efficient 
repression of the powerful T5 promoter. 
→ High-level expression is induced by addition of 0.5 mM of Isopropyl-beta-D-
thiogalactopyranoside (IPTG) to the expression culture (typically at OD600 = 0.8). 
→ The addition of 1% glucose to the growth media helps to further repress the promoter in 
its uninduced state by catabolite repression, but has no negative effects on expression 
levels achievable upon induction. 
• Synthetic ribosomal binding site for efficient translation initiation. 
• 6xHis-tag coding sequence 5’ to the multiple cloning site (MCS).  
• The expressed His-tagged POI can be purified by IMAC. 
• Two consecutive stop codons (ochre & opal; TAATGA) after the MCS ensure efficient 
translation termination in one reading frame. 
• Strong transcriptional terminators prevent read-through transcription and ensure stability of 
the expression construct. 
• Vector has a plasmid origin (ColE1) and an ampicillin resistance marker (AmpR) to allow 
propagation as a plasmid in E. coli. The AmpR is provided by β-lactamase (bla), which is 
constitutively expressed from the vector.  
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• The oligonucleotide Qe_30_for (5’-CTTTCGTCTTCACCTCGAG-3’; position 3453 to 6; 
reading forward) or Qe_30_rev (5’- CCAAGCTAGCTTGGATTCTC -3’; position 300 to 319 
of the complement strand; reading reverse) may be used to sequence inserts present in the 
MCS(both oligonucleotides are available at www.microsynth.ch for sequencing). 
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Data sheet: pMPAG3 (pPDV1) 
• The phagemid vector pMPAG3 allows the display of a protein of interest (POI) on 
filamentous phage. The vector uses the cotranslational signal recognition particle (SRP) 
pathway for the translocation of the POI across the cytoplasmic membrane into the 
periplasm of Escherichia coli. This feature (SRP phage display) allows the efficient display 
of stable and fast folding proteins, such as designed ankyrin repeat proteins (DARPins), on 
phage particles.  
Handling 
• Storage:  at -20°C in TE (10 mM TrisHCl, 1 mM EDTA, pH 8.5) 
• Amplification: pMPAG3 can be amplified in E. coli (e.g. XL1-blue) using a Luria Broth 
medium supplemented with 15 µg/ml of chloramphenicol 
Vector Map 
pMPAG3 / pPDV1
4124 bp
DsbAss
lacIq
CAT
lacP
6xHis
EK
FLAG
gIII
ColE1
f1 origin
BamHI
HindIII
KpnI
PstI MSC
G/S
 
Cloning site region 
   M   (DsbAss-Flag) G  S  G  G  T  *  *  *  P  A  A  K  L   (EK-6xHis) T  S  *  (gpIII)           
CATATG---------------GGATCCGGTGGTACCTAATGATAACCTGCAGCCAAGCTT------------ACTAGTTAGGGT---- 
NdeI                 BamHI    KpnI            PstI    HindIII           SpeI 
193                  264      277             293     297               348 
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Features 
• Phagemid vector for monovalent filamentous phage display. 
• The signal sequence of E. coli DsbA (DsbAss) ensures efficient SRP phage display. 
• Sequences for display are inserted in the multiple cloning site (MCS) between the DsbAss 
and a super short variant of filamentous phage gene III (gIII, encoding aa 250-406). 
• The fusion protein (gpIII fusion) is under the control of a lac promoter/operator element and 
the lacIq gene provides high levels of the lac repressor in cis. 
• An amber stop codon (TAG) is interposed between the displayed sequence and the gene III 
→ Allows expression of the POI independent of the gene III product (gpIII) in a non-supE 
host (e.g. JM83). 
→ Requires a supE suppressor host (e.g. XL1-blue) to produce displaying phage particles. 
→ Reduces the level of the gpIII fusion produced as a function of the supE suppressor host 
chosen to reduce potential toxic effect of the gpIII overexpression. 
• The fusion protein contains a Flag-tag, a protease cleavage site (enterokinase site, EK) and 
a 6xHis-tag. 
• Vector carries a f1 origin of replication to permit production of virions using an appropriate 
helper phage, such as VCSM13. 
• Vector has a plasmid origin (ColE1) and an antibiotic resistance marker (the gene for 
chloramphenicol acetyl transferase (CAT) providing resistance to chloramphenicol (cam)) to 
allow propagation as a plasmid in E. coli. 
• Two different oligonucleotides can be used for sequencing inserts present in the MCS: The 
oligonucleotide odst03 (5’-CATAATCAAAATCACCGGAACCAG-3’), corresponds to position 
390 to 367 of the complement strand of pMPAG3 reading upstream the p3 fusion gene. 
Alternatively, the oligonucleotides pUCM13r-57 (5’-TGCTTCCGGCTCGTATGTTG-3’), 
corresponds to position 116 to 135 of the direct strand of pMPAG3 reading downstream the 
p3 fusion gene (oligonucleotides pUCM13r-57 is available at www.microsynth.ch for 
sequencing) 
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Data sheet: pMPAG6 
• The plasmid vector pMPAG6 allows the expression of protein of interests (POI), such as 
designed ankyrin repeat proteins (DARPins), in the cytoplasm of Escherichia coli. The 
vector uses a strong regulated T5 phage promoter for the inducible high level expression of 
the POI. The open reading frame encodes a MRGS-His6-tag for simple purification of the 
POI by immobilized metal affinity chromatography (IMAC). In addition, the vector has a lacIq 
gene providing lac repressor for efficient repression of the promoter.  
Handling 
• Storage: -20°C in TE (10 mM TrisHCl, 1 mM EDTA, pH 8.5) 
• Amplification: pMPAG6 can be amplified in E. coli (e.g. XL1-Blue) using a Luria Broth 
medium supplemented with 50 µg/ml of ampicillin and 1% glucose. 
Vector Map 
pMPAG6
3751 bp
6xHis
2 x stop
T5P
MCS
ColE1
BamHI
HindIII
PstI
KpnI
bla
lacIq
 
Cloning site region 
   M  R  G  S  H  H  H  H  H  H  G  S  G  G  T  *  *  *  P  A  A  K  L  N  *  *  *            
CATATGAGAGGATCGCATCACCATCACCATCACGGATCCGGTGGTACCTAATGATAACCTGCAGCCAAGCTTAATTAATGATAG 
NdeI                             BamHI    KpnI            PstI    HindIII            
113                              145      158             174     178                
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Features 
• Plasmid vector for high level cytoplasmic protein expression in E. coli. 
• No special expression host needed. Excellent expression yields can be obtained in XL1-
Blue cells. 
• Sequences to be expressed are inserted in the MCS. The MCS is compatible to vectors of 
the pMPAG vector series, including the phagemid vector pMPAG3. 
• For example, DARPins selected using pMPAG3 can be shuffled into pMPAG6 by simple 
transfer of the DARPin encoding BamHI/HindIII vector fragment. 
• The expression of the POI is under the control of a phage T5 promoter/lac operator element 
and the lacIq gene provides high levels of the lac repressor in cis. 
→ The phage T5 promoter is recognized by the endogenous E. coli RNA polymerase. 
→ Two lac operator sequences increase lac repressor binding and ensure efficient 
repression of the powerful T5 promoter. 
→ High-level expression is induced by addition of 0.5 mM of Isopropyl-beta-D-
thiogalactopyranoside (IPTG) to the expression culture (typically at OD600 = 0.8). 
→ The addition of 1% glucose to the growth media helps to further repress the promoter in 
its uninduced state by catabolite repression, but has no negative effects on expression 
levels achievable upon induction. 
• Synthetic ribosomal binding site for efficient translation initiation. 
• 6xHis-tag coding sequence 5’ to the multiple cloning site (MCS).  
• The expressed His-tagged POI can be purified by IMAC. 
• Two consecutive stop codons (ochre & opal; TAATGA) after the MCS ensure efficient 
translation termination in one reading frame. 
• Strong transcriptional terminators prevent read-through transcription and ensure stability of 
the expression construct. 
• Vector has a plasmid origin (ColE1) and an ampicillin resistance marker (AmpR) to allow 
propagation as a plasmid in E. coli. The AmpR is provided by β-lactamase (bla), which is 
constitutively expressed from the vector.  
• The oligonucleotides Qe_30_for (5’-CTTTCGTCTTCACCTCGAG-3’; position 3739 to 6; 
reading forward) or T7_term (5’-TGCTAGTTATTGCTCAGCGG-3’; position 277 to 258 of 
the complement strand; reading reverse) may be used to sequence inserts present in the 
MCS (both oligonucleotides are available at www.microsynth.ch for sequencing).  
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Data sheet: PD Library #1 
The phage display library PD library #1 allows the selection of target-specific designed 
ankyrin repeat proteins (DARPins) by monovalent filamentous phage display.  
Lot #1 (25.01.2006) 
• The library is provided as a frozen stock of DARPin-displaying phage particles in PBS (pH 
7.4) supplemented with 10% glycerol. 
• Phage concentration:  1.6 x 1013 chloramphenicol resistant colony forming units (cfu) per 
ml 
• Diversity:  
→ 2.6 x 1010 independent chloramphenicol resistant clones of which 42% are correct 
DARPins, resulting in the functional library size of 1.1 x 1010.  
→ 25% of the clones are N3C DARPin library members. 
→ 17% of the clones are N2C DARPin library members 
→ 58% of the clones (non functional part of the library) had either frame shifts in the 
DARPin sequence or no insert at all. 
• The N2C library members comprise two randomized internal repeat modules between the 
N- and the C-terminal capping repeat, while the N3C library members have three 
randomized repeats 
Handling 
• Background information and protocols for the use of the PD library #1 are provided in the 
Phage Display Manual.  
• Storage: Store at -80°C until use.  
→ Samples may be further aliquoted by thawing, splitting and flash freezing in liquid 
nitrogen. Repeated cycles of freezing and thawing should be avoided. 
→ Long term storage at 4°C may result in loss of displayed DARPins. 
• Because displayed DARPins remain functional upon freezing, defrosted phage samples can 
directly be used for the first selection round without the need of reamplifying them. 
• Repropagation: Repropagation of the library is possible. See Protocol 8 of the Phage 
Display Manual.  
Key features 
• Allows the selection of highly stable target-specific DARPins against native proteins. 
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• The excellent biophysical properties of DARPins ensure that they normally will keep their 
target-specificity and well-behavior independent of being tethered to a phage particle. 
• Based on the phagemid pMPAG3 (for details see Appendix data sheet: pMPAG3) 
→ Monovalent phage display allowing the selection of high (even sub-nanomolar) affinity 
DARPins. 
→ SRP phage display ensures the efficient display of the highly stable and fast folding 
DARPins. 
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A Designed Ankyrin Repeat Protein Evolved to
Picomolar Affinity to Her2
Christian Zahnd1†, Emanuel Wyler1†, Jochen M. Schwenk2
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Frédéric Pecorari1, Colin W. Ward3, Thomas O. Joos2
and Andreas Plückthun1⁎
1Biochemisches Institut
der Universität Zürich,
Winterthurerstr. 190,
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der Universität Tübingen,
Markwiesenstr. 55, D-72770
Reutlingen, Germany
3CSIRO, Molecular and
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Designed ankyrin repeat proteins (DARPins) are a novel class of binding
molecules, which can be selected to recognize specifically a wide variety of
target proteins. DARPins were previously selected against human
epidermal growth factor receptor 2 (Her2) with low nanomolar affinities.
We describe here their affinity maturation by error-prone PCR and
ribosome display yielding clones with zero to seven (average 2.5) amino
acid substitutions in framework positions. The DARPin with highest
affinity (90 pM) carried four mutations at framework positions, leading to
a 3000-fold affinity increase compared to the consensus framework
variant, mainly coming from a 500-fold increase of the on-rate. This
DARPin was found to be highly sensitive in detecting Her2 in human
carcinoma extracts. We have determined the crystal structure of this
DARPin at 1.7 Å, and found that a His to Tyr mutation at the framework
position 52 alters the inter-repeat H-bonding pattern and causes a
significant conformational change in the relative disposition of the repeat
subdomains. These changes are thought to be the reason for the enhanced
on-rate of the mutated DARPin. The DARPin not bearing the residue 52
mutation has an unusually slow on-rate, suggesting that binding occurred
via conformational selection of a relatively rare state, which was stabilized
by this His52Tyr mutation, increasing the on-rate again to typical values.
An analysis of the structural location of the framework mutations suggests
that randomization of some framework residues either by error-prone PCR
or by design in a future library could increase affinities and the target
binding spectrum.
© 2007 Elsevier Ltd. All rights reserved.
*Corresponding author
Keywords: ErbB2/Her2; designed ankyrin repeat protein (DARP)in; in vitro
selection; ribosome display
Introduction
Antibodies with high affinity to disease-relevant
antigens, such as tumor markers or chemokines,
have been widely investigated for their use in
therapy and diagnostics. Antibody engineering
techniques have facilitated the generation of high
affinity protein binders for targeted therapy.1,2 The
introduction of antibody-fragments and novel selec-
tion methods such as phage display or ribosome
display has allowed the fast isolation of specific
binding proteins from vast synthetic libraries in
vitro.3,4 Selections from such libraries have been
shown to routinely yield specific binders, with the
† C.Z. and E.W. contributed equally to this work.
Present addresses: C. Zahnd, Molecular Partners AG,
Grabenstrasse 11a, CH-8952 Schlieren, Switzerland; E.
Wyler, Institute of Biochemistry, ETH Zürich, CH-8093
Zürich, Switzerland; F. Pecorari, Unité de Biochimie
Structurale – CNRS URA 2185, Institut Pasteur, 25 rue du
Dr Roux, 75724 Paris Cedex 15, France.
Abbreviations used: ECD, extracellular domain; IHC,
immunohistochemistry; RIA, radioimmuno assay; RMS,
root mean square; SPR, surface plasmon resonance.
E-mail address of the corresponding author:
plueckthun@bioc.unizh.ch
doi:10.1016/j.jmb.2007.03.028 J. Mol. Biol. (2007) 369, 1015–1028
0022-2836/$ - see front matter © 2007 Elsevier Ltd. All rights reserved.
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highest affinity binders typically being in the low
nanomolar affinity-range.
For therapeutic and diagnostic applications,
particularly against cell-surface targets, the reten-
tion time on the target is usually a crucial factor
limiting the efficacy of the antibody reagent.5
Affinity maturation of binders is therefore consid-
ered to be an important means to improve the
properties of previously selected binders, and the
selection for slower dissociation-rates with compe-
titive off-rate selections has proved to be a powerful
method for improving affinity.6,7 This strategy is
based on the observation that, usually, the on-rates
for forming protein–protein interactions fall into a
narrow window8 and affinity is thus normally
correlated with off-rate. Such evolved high-affinity
antibodies have been used with great success in
many applications.2
An alternative, novel approach to developing
high-affinity binding reagents takes advantage of
another natural class of binding proteins, termed
ankyrin repeat proteins.8 Ankyrin repeat proteins
are built from a single structural motif, which is
assembled into a protein domain. Due to the rel-
atively high sequence homology within these
ankyrin repeats, a consensus sequence module
could be deduced from the natural ankyrin repeat
proteins, identifying putative structure-determining
framework residues (i.e. residues which on the
basis of sequence conservation appear to be im-
portant for maintaining the repeat structure) and
interaction-mediating binding residues.9,10 A syn-
thetic consensus repeat module of the ankyrin
repeat protein family could be assembled into com-
plex libraries of designed ankyrin repeat proteins
(DARPins), from which binding proteins could
be isolated that showed exceptional expression
yields, stabilities9,11 and affinities in the low
nanomolar range.11 Due to the modularity of the
design, DARPins with more binding modules and
consequently larger binding interfaces are feasible
and a stepwise enlargement of the binding interface
could even be considered as a way of affinity
maturation. The exceptional stability and folding
efficiency of DARPins might also allow novel
therapeutic approaches such as potent DARPin-
toxin fusions or bivalent DARPin constructs.
Epidermal growth factor receptor 2 (Her2) is a cell
surface receptor, which has been shown to be over-
expressed in several cancer tissues, including breast
and colon carcinoma, and its over-expression has
been linked to poorer prognosis of the patients. Only
20–30% of all breast cancer patients, however, show
over-expression of Her2, making the determination
of the state of the Her2 expression of a cancer patient
an important diagnostic step in assessing the suit-
ability of anti-Her2 therapy for the patient. Cur-
rently, one antibody against Her2 has been approved
for the treatment of breast cancer and several other
tumor types are in clinical trials.
In a previous study, DARPins binding to the
extracellular domain of Her2 (Her2 ECD) with high
specificity and low nanomolar affinities had been
selected12 from large synthetic libraries in vitro
using ribosome display.3 After six rounds of
selection, several binders with nanomolar affinities
were obtained and characterized. They were shown
to bind the cognate antigen both as a purified
protein and on different Her2-overexpressing cell
lines and in situ in tissue sections of Her2-positive
mammary carcinomas. For both therapeutic and
diagnostic applications, the affinity of the Her-2
binding molecule is expected to be crucial. There-
fore, Her2 is an ideal model system to explore the
potential for affinity maturation of DARPins.
Here, we aimed to explore the affinity limits ob-
tainable for DARPins by subsequent randomization
of the selected pools in combination with in vitro
selection under very stringent conditions, and
particularly to investigate the structural conse-
quences of affinity maturation in this scaffold.
For the present study we used rather small
DARPin molecules containing only two rando-
mized repeat modules (termed N2C). These N2C
DARPins display an interaction surface that is
smaller than the average interaction surface of an
antibody. The small size of the DARPin, which
should allow good tumor penetration, in combina-
tion with its high stability and expression yield,
would provide the basis for the development of an
in vitro and possibly also in vivo diagnostic test for
the expression state of Her2 in cancer tissues. We
have characterized the binding properties of the
affinity-matured DARPins, including their ability
to detect Her2 in solubilized tumor tissue. In addi-
tion, we have determined the crystal structure of
the N2C DARPin with the highest affinity, which
has allowed us to demonstrate that the selected
mutations cause a change in the positioning of the
side-chain of the residue at position 52 and, as a
consequence of this mutation, cause a significant
conformational change in the relative disposition of
the repeat domains in this structure compared with
their counterparts in the previously determined
structures. These structural changes are thought to
be the cause of the enhanced on-rate of the mutated
DARPin.
Results
DARPins had been selected from large synthetic
libraries in vitro using ribosome display3 and
binders specific for Her2 with nanomolar affinities
were obtained.12 We wished to affinity-mature these
binders for their potential application as diagnostics
and therapeutics and characterize the biophysical
and structural consequences of affinity maturation
in this protein architecture.
Selection procedure
Analysis of the previously selected pools revealed
that most binders belonged to only a few sequence
families. To increase the diversity in these pools and
to extend the randomization to framework po-
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sitions, which were fixed in the original library
design,9 error-prone PCR was performed in the
presence of dNTP analogs as described earlier.6,13
Several new pools were generated using all pre-
viously isolated pools as a starting point. The
average mutation rate in the different reactions
(with different mutation rates) was determined by
sequencing to be 1.3–5.9 mutations per gene. For the
following selection, the libraries with different
mutation rates were combined.
The pools obtained were converted into the
ribosome display format and subjected to three
rounds of off-rate selection.6 The selection pressure
is mainly defined by the incubation time of the pools
in the presence of a large molar excess of competitor
antigen. It was increased from round to round, from
10 h initially to 100 h in the second round. In the
third selection round, a first aliquot was isolated
after five days and a second after 25 days. It has been
shown that after very stringent off-rate selections,
the fraction of remaining binders is very low
compared to non-binding background clones.7
This fraction can be increased by applying an ad-
ditional selection round at low stringency, thereby
enriching the diluted binders. Thus an additional
panning roundwith no additional selection pressure
was applied. The percentage increase in the binder
clones after this non-selective selection round could
be monitored by radioimmuno assay of the pools,
resulting in a fivefold increase of the binding signal
(data not shown). In addition, after cloning of the
pools in an expression vector in E. coli, crude extract
ELISA of single clones also indicated that there was
an increase in specific binding clones. After the last
off-rate selection round, five out of 92 analyzed
clones (5%) showed specific binding. After the
additional non-selective panning round, this ratio
increased to 68 out of 92 (74%).
Sequences of binders
Those binders giving a specific binding signal in a
crude extract ELISA were sequenced. Four major
sequence families were found in the selected pool.
According to the amino acid sequence in the first
four randomized positions, the sequence families
were termed the LWRF, the LWRL, the KEYL and
the KWIF family. Representative sequences of
binders are shown in Figure 1, kinetic parameters
from BIAcore measurements are shown in Table 1
and Figure 2. Interestingly, an N1C DARPin show-
ing target binding was also isolated, which might
have been generated by recombination from an N2C
DARPin gene.
Figure 1. Sequences of selected DARPins and framework mutants of H10-2-G3. The sequences of different DARPins
are shown. Randomized positions in the N2C family sequence (first line) are indicated by X. In the lower lines, only
residues that differ from the consensus sequence of an N2C DARPin are printed. Residues that had been randomized in
the original design are boxed. Mutations that showed up at framework positions (outside the boxes) are printed in bold.
Four major sequence families were found after affinity maturation, termed KEYL, KWIF, LWRL and LWRF, according to
the first randomized positions in the first module. The respective sequence family is also indicated. The clone with the
highest affinity found was H10-2-G3. It contained four framework mutations (at residues 52, 55, 96 and 122) in addition to
those residues that had been randomized by design. To investigate the effect of the different frameworkmutations, several
mutants of this clone were constructed, turning the sequence back to the consensus sequence. These clones are listed in the
lower part.
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As described below, the binder with the highest
affinity, H10-2-G3 (KEYL family) has a picomolar
affinity to the target. The KD is about one order of
magnitude better compared to the second best
binder analyzed from the KEYL family. Interest-
ingly, despite its high affinity, clone H10-2-G3 was
only found once out of 68 sequenced clones. Only
six out of the 68 analyzed clones belonged to the
KEYL family. This indicates that high affinity is
either not the only important factor for survival in
the applied selection system or that the enrich-
ment for high affinities has not yet reached its
limit.
Compared to the sequences found in the selected
pools prior to error-prone PCR, many mutations
were found at so-called framework positions9 as a
consequence of the applied randomization. The
average number of amino acid substitutions at
framework positions was about 2.5 per sequence,
ranging from several clones having no framework
mutation, up to seven amino acid substitutions at
framework positions per gene. It is likely that
variable positions had also been randomized
during error-prone PCR. This would not be detect-
able in the final sequence, although the actual
number of mutations in the selected clones was
increased.
The same sequence families that were present
before off-rate selection could also be found after off-
rate selection. However, the relative abundance of
the different sequence families had changed.
Whereas about 50% of the binders found before
off-rate selection belonged to the KWIF-family, only
14% of the binders found after error-prone PCR and
off-rate selections were of the KWIF-type. The
LWRL-family, which finally contributed 28% of all
binders, had not been found before off-rate selection.
Compared to previously described selection
experiments against other targets, such as maltose
binding protein and MAP kinases,11 it was striking
that most of the randomized variable positions in
the selected Her2 ECD binders were hydrophobic.
Up to 11 out of 14 variable residues were either
aromatic or aliphatic amino acids. Ten of these
built up an extended hydrophobic patch on the
binding interface of the ankyrin repeat protein in
the most extreme case. Since the interaction inter-
face of the chosen DARPin library (consisting of
only two ankyrin repeats) was limited in size, this
might have been the only molecular solution to
generate binders with affinities high enough to
survive the selection pressure. However, despite
the relatively large contiguous hydrophobic sur-
face of the selected binders, no non-specific
binding was observed (see below).
Affinities of Her2 binders
Based on the binding signals obtained in crude
extract ELISA and the competition behavior with
free Her2 ECD, several clones were chosen for
expression, purification, affinity determination and
further analysis. For each sequence family, several
DARPins were expressed in the Escherichia coli
strain XL1-blue. Despite the framework mutations,
expression yields were similarly high as found
previously9,11 and also similar among the various
clones, corroborating the robustness of the frame-
work to also carry high mutational loads outside
the randomized positions. The clones were pur-
ified to 95% purity via IMAC, and affinities were
determined using kinetic and equilibrium surface
plasmon resonance (SPR) measurements.
To get an initial affinity ranking, all expressed and
purified clones were injected at a single concentra-
tion and themost promising binders were chosen for
detailed measurements. Affinities were determined
by kinetic SPR measurements with protein samples
having any minor potential non-monomeric frac-
tions removed by preparative gel filtration. The
dissociation constants KD of the measured affinities
were found to be between 91 pMand 94 nM (Table 1).
The binder with the highest affinity, termed H10-2-
G3, was measured several times independently with
different protein preparations and both kinetic and
equilibrium measurements.14–16 The kinetic mea-
surements revealed an association rate constant of
1.1×106 M−1s−1 and a dissociation rate constant of
1.0×10−4 s−1, giving rise to an equilibrium dissocia-
tion constant of 90 pM. Equilibrium measurements
of the dissociation constant resulted in a KD of 91 pM
(Figure 2).
Clone H10-2-G5 (KD of 670 pM) differed mainly
at framework positions from H10-2-G3 (six differ-
ences), but had very similar amino acids at the
variable positions (only two residues differ at po-
sitions 43 and 102; Figure 1). Although they
belong to the same sequence family, their affinities
differ by one order of magnitude. Most other
binders showed affinities in the low nanomolar
range (Table 1).
In the non-affinity-matured pools (starting mate-
rial for this study), the clone with the highest affinity,
termedH6-2-A7, had an affinity of 7.3 nM,12 which is
80-fold lower than the affinity shown by H10-2-G3.
Interestingly, clone H6-2-A7 had the same amino
acid sequence in the first variable module as H10-2-
G3, but a completely different sequence in the second
variable module.
Table 1. Kinetic parameters of the binding of different
DARPins
Clone
name
Sequence
family KD/nM
kon/10
4
M−1s−1 koff/10
−3s−1
H10-2-G3 KEYL 0.091±0.001 112.3±0.19 0.102±0.001
G3-D KEYL 1.48±0.008 76.8±0.36 1.14±0.002
G3-A KEYL 1.21±0.006 61.8±0.26 0.745±0.002
G3-AVD KEYL 10.2±0.055 43.5±0.22 4.42±0.008
G3-HAVD KEYL 269±1.19 0.275±0.001 0.739±0.003
H10-2-G5 KEYL 0.670±0.005 26.6±0.036 0.178±0.001
H10-2-D11 KWIF 35.8±0.149 15.4±0.057 5.52±0.011
H10-2-D12 LWRF 93.9±1.12 30.5±0.31 28.6±0.17
H10-2-A2 LWRF 3.46±0.017 11.9±0.019 0.411±0.002
The statistical errors in the parameters given are those obtained
from the best fit error.
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Influences of framework mutations on affinity
The use of error-prone PCR allowed the introduc-
tion of framework mutations. However, in earlier
selection rounds, several framework mutations
already had become enriched. This intrinsic rando-
mization of pools that are selected by ribosome
display has been described before.16 At position 52,
the frameworkmutation histidine to tyrosine (H52Y)
was found in 86% of all binders. Even before error-
prone PCR, this mutation was found in some
members of the KEYL-sequence family, suggesting
that this mutation evolved independently several
times.12 Since this mutation has not been found in
any of the other selection experiments performed
with DARPins, we concluded that this mutation
would be important for binding to the target Her2.
To test the influence of the observed framework
mutations on the affinity of H10-2-G3, several
mutants were constructed restoring the original
framework residues (Figure 1). The four framework
mutations found in H10-2-G3 were: H52Yand A55T,
both residing in the first variable repeat module,
V96A in the second variable repeat module and
D122G in the C-terminal capping repeat. We
generated four clones, the first termed G3-D, lacking
the D122G mutation, the second termed G3-A,
lacking the A55T mutation, the third G3-AVD
without the mutations A55T, V96A and D122G
and finally clone G3-HAVD, which corresponds to
Figure 2. Affinity determination of clone H10-2-G3 using SPR. (a) The kinetics of binding of clone H10-2-G3 to Her2
ECD was monitored using Biacore. Her2 ECD was immobilized on a flow cell at low concentrations. Binding of the
DARPin to the immobilized target protein was compared to binding to an empty flow cell at increasing concentrations of
the DARPin (1 nM, 5 nM, 10 nM, 20 nM, 30 nM). The data were evaluated using global fitting with the software CLAMP.26
The predicted curves are drawn in red. (b) The affinity was also determined at equilibrium using competition Biacore. The
affinity values obtained by both methods were consistent.
Figure 3. Crystal structure of H10-2-G3. The overall structure is shown in ribbon representation in front view, looking
towards the putative binding surface. The side-chains of residues that had been randomized in the synthetic library are
drawn in red. Side-chains of framework residues that had been mutated in the course of affinity maturation are drawn in
blue. Note that only some of the side-chains that have been drawn are labeled.
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H10-2-G3 with the original DARPin framework. All
clones were expressed and purified and affinities
were determined using kinetic SPR (Supplementary
Data Figure).
All back-mutated clones had lower binding
affinities than clone H10-2-G3 (Table 1). The rever-
sion of the single mutations A55T and D122G had
similar effects on the equilibrium dissociation
constant, decreasing the affinity by about 15-fold
each. The reversion of the triple mutation in G3-AVD
reduced the affinity by over 100-fold, while the
reversion of the additional mutation H52Y lead to a
further 26-fold decreased affinity (compare G3-AVD
with G3-HAVD) and an about 3000-fold decreased
affinity compared to H10-2-G3. Interestingly, rever-
sion of the mutation H52Y influenced mostly the on-
rate, and since the off-rate changes much less, the
affinity is lowered by about two orders of magni-
tude in the mutant.
The major contribution to the improved affinity
obtained by the evolutionary approach was thus
due to an increase in the association rate constant
of the binding. This was not expected, since the
association rate constant is usually governed by
translational diffusion and orientation-dependent
collisions, at least in solutions of moderate or high
ionic strength. Therefore, it tends to be rather
similar in most protein–protein interactions. For
interacting proteins with molecular masses similar
to the present example, association constants of
105–106 s−1 M−1 would be expected, if the process
was diffusion-controlled.8 The association rate
constant of H10-2-G3 was determined to be
1.1×106 s−1 M−1, which is in the expected range.
For most of the non-affinity matured binders, the
association rate constant was two to tenfold lower.
However, in the quadruple “back”-mutant of the
KEYL family, G3-HAVD, kon was dramatically
reduced (400-fold, compared to H10-2-G3 and 160-
fold compared to G3-AVD, which differs only by
carrying His52 instead of Tyr52). This strongly
indicates that there is a rate-limiting step in the
formation of the DARPin Her2-ECD complex other
than simple diffusion. This could either be due to
slowly forming structural rearrangements that have
to occur prior to binding or be due to rapidly
equilibrating conformations, of which an only
sparsely populated one is able to bind. In the other
protein families (KWIF and LWRF), the H52Y
mutation does not correlate with kon, suggesting
that this effect is connected to the epitope recognized
by the members of the KEYL-family (see below).
It should also be noted that most of the framework
mutations are not at the putative binding site of the
DARPin.While D122G could be involved in binding,
andmaybe alsoH52Y,mutations A55TandV96A are
most likely not part of the binding interface, based
on their location (see Figure 3). The differences be-
tween H10-2-G3 and H10-2-G5 (Figure 1) involve
amino acid residues that are part of the hydrophobic
core or reside on the back of the DARPin, except for
K43R. Possible explanations for these observations
are detailed in Discussion.
Crystal structure of H10-2-G3
To further analyze the influence of framework
mutations on the binding kinetics, the crystal
structure of the clone H10-2-G3 was determined to
a final resolution of 1.7 Å, an R-value of 17.8% and
an Rfree of 21.2% (Table 2). The structure solution
with three molecules of H10-2-G3 found in the
crystallographic asymmetric unit was achieved via
molecular replacement. The overall backbone of
H10-2-G3 (Figure 3) was similar to the previously
determined structures of DARPins,11,12,19 with an
overall root mean square (RMS) displacement of the
backbone atoms of 1.13 Å compared to the N2C
model.
However, there are two striking differences
compared to representative N3C structures. The
first is a rotameric17 change at position 52 in con-
formation of the side-chain from m80° if it is
occupied by histidine to t80° if it is occupied by
Tyr in H10-2-G3. This mutation causes a change in
the inter-repeat disposition (see below). H10-2-G3
has four mutations in the designed framework,
H52Y, A55T, V96A and D122G. After testing the
influence of all four mutations on the binding
affinity (see above), mutation H52Y was shown to
have the most substantial influence on the on-rate
and its structural consequences were therefore
analyzed in detail. This mutation, as well as
D122G, is located on the side of the DARPin
potentially facing the target, while the other two
mutations are buried inside the molecule.
Analysis of the crystal structures of unselected
N3C DARPins18 reveals that the histidine at position
52 participates in an extended hydrogen bond
network: His52 Nδ1 to Thr49 Oγ1 and His52 Nε2 to
the carbonyl oxygen of residue 81 (Figure 4(a)).
These inter-repeat unit hydrogen bonds likely con-
tribute to the known extraordinary stability of
DARPins (see below). However, the H52Y mutation
and the concomitant rotameric change at that po-
sition causes a loss of both these hydrogen bonds,
replacing them with a single hydrogen bond
between Tyr52 Oη and Asp77 Oδ2 (Figure 4(b)). No
disruption is caused to the hydrogen-bonding
pattern within the α-helical backbone at that muta-
tion site. Rotameric rearrangement of the side-chain
Table 2. X-ray data collection and processing statistics
Data set 1 Data set 2
Detector 2θ (°) 0 15
Resolution range (Å) ∞–2.00 (2.03–2.00) ∞–1.70 (1.73–1.70)
No. of frames 200 310
Oscillation range (°) 1 1
No. of measurements 144,477 225,321
No. of reflections 35,218 58,105
Redundancy 4.1 (3.7) 3.8 (2.4)
Completeness (%) 97.7 (94.6) 98.6 (93.3)
Rmerge
a 0.11 (>1.0) 0.12 (0.88)
<I>/<σ> 15.5 (1.6) 13.2 (1.3)
Numbers in parentheses refer to the statistics for the outer
resolution shell.
a Rmerge=∑h∑i|<Ih>–Ih,i|/ ∑h|<Ih>|.
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at Leu86 is also evident, presumably to relieve steric
clash with the Tyr52 side-chain. The second, more
dramatic difference is that the positioning of the
phenol ring of Tyr52 in the groove formed by the first
helices of the two randomized repeats necessitates an
opening-up of the N2C structure with respect to its
unmutated counterparts (Figure 4(c)), effected by an
ω=13(±1)° rotation of the second randomized andC-
cap repeat (grouped as a single domain) with respect
to the N-cap and first randomized repeat (grouped
as a single domain). The hinge point of this rotation
lies in the vicinity of residue 76. Whilst the size of ω
and the direction of the rotation axis are closely
similar for all pairwise N2C-to-N3C comparisons
conducted here, the spatial location of the rotation
axis itself is somewhat ill-defined, a mathematical
consequence of ω being small. The relative rotation
of the N and C-terminal halves of the N2C structure
results in the loss of the hydrogen bond between the
backbone carbonyl at position 46 and the backbone
amide at position 78, the respectiveO andN atoms of
these residues nowbeing about 6 Å apart (Figure 4(a)
and (b)).
Since all clones of the KEYL family having this
H52Y mutation had an association rate constant that
was increased by up to two orders of magnitude to
reach values expected for protein–protein interac-
tions (see above), the importance of this residue on
the overall structure of the DARPin may not sur-
prise. It is in principle possible that Tyr52 directly
interacts with Her2 ECD, but we have no evidence
for or against this. It is likely that the “opened-up”
structure is the one that interacts optimally with the
target. The original framework could adopt, as a
sparsely populated state, an overall conformation
that is similar to the conformation found with Tyr52.
Such a break-up of the repeats could even allow
His52 to adopt a similar rotameric conformation as
seen here for Tyr52 (i.e. directed away from the N2C
structure and towards the target), but this does not
imply productive interaction of His52 with the
target. A similar interaction of Tyr and His with the
target would be difficult to conceive because of the
different side-chain characteristics. If binding
occurs by conformational selection, i.e. if only a
minor fraction of the binding molecules is in the
reactive “open” conformation, the bimolecular
binding reaction would appear to be slow. Note
that this effect would not affect the off-rate. The
mutation H52Y most likely stabilizes the outward
rotated conformation and thereby increases the
active concentration of the binder, giving rise to a
“normal” on-rate. In addition, the other mutations
might optimize existing interactions or introduce
new ones. The change in the overall conformation
might assist adaptation to the antigen.
Note that the change in on-rate, interpreted as a
conformational selection that gets stabilized by
mutation, is a phenomenon only found in the
KEYL family. In the other families, completely
normal rates of association are found, despite the
fact that they all contain His52. We interpret this as
indicating a necessity for an open conformation only
for binding to the epitope of the KEYL family, but
clearly not a general phenomenon of DARPins.
Consistent with this view, all association rates mea-
sured with binders to other targets fell in the usual
windows, and all crystal structures determined so
far11,12,19 indicated a consensus spacing of repeats.
Conformational variability or even partial unfold-
ing can be an important parameter controlling
interactions of some natural ankyrin repeat pro-
teins,21–24 whereas other natural ankyrin repeat pro-
teins19 have been shown to be very stable and
display two-state folding. The consensus-designed
DARPins have previously been shown to be parti-
cularly stable.9 We were thus interested in determin-
ing whether the His52Tyr mutation had an effect on
the thermal stability of H10-2-G3 and therefore
measured it and compared it to that of the “restored”
consensus framework variant, G3-HAVD. We found
that G3-HAVD is significantly more stable than H10-
2-G3: the mutations in the framework acquired in
affinity maturation did indeed lead to a decrease of
the midpoint of denaturation from 89.4(±0.6) °C to
69.1(±0.02) °C (Figure 5). For both proteins, H10-2-
G3 and G3-HAVD, the measurement was performed
with material that had been purified by gel filtration
to remove any potential non-monomeric species.
Furthermore, the protein had been analyzed by
multi-angle light scattering (MALS) to verify its
monomeric state. These MALS results exclude that
the observed stability change was due to the
presence of dimers of G3-HAVD. Neither of the
two proteins showed significant dimeric fractions
even at very high concentrations of more than
100 μM (data not shown).
Therefore, the conformational change caused by
the introduction of these evolved framework muta-
tions destabilizes themolecule, but not to the point of
imparting any handling disadvantage on this
evolved protein, as even the affinity-matured H10-
2-G3 still has a stability in the upper range of typical
globular proteins, and no difference in handling was
noticed in purification or any treatment compared to
other DARPins. In particular, the high soluble
expression yield is fully maintained for the evolved
DARPin. The consensus protein G3-HAVD, a typical
member of the original library from which the
directed evolution had presumably started, has
such a high stability that the conformational changes
and some ensuing loss of stability are easily
tolerated. This high stability of the consensus-
designed libraries is one of the key features ensuring
that affinity maturation still leads to molecules with
very favorable properties without further stability
engineering.
A more complete analysis of the influence of the
mutations could be obtained by the analysis of the
binding interface in a co-crystal of Her2 and H10-2-
G3. Presumably not only the randomized positions
(those designed to be variable in the original library)
participate in binding of the DARPin to its target,
but also at least some of the selected framework
positions, as shown, for example, by the consider-
ably lower KD of the G3-Dmutant compared to H10-
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2-G3. The residue where G3-D differs, Gly122, is in
the C-cap, and it could make a direct contact or the
original interaction with Asp122 could have been
unfavorable, even by indirect electrostatic effects. In
a biochemical analysis and in the absence of a
structure of a complex, however, it is difficult to
distinguish between mutations that help the adapta-
tion of the DARPin structure to the antigen epitope
and mutations of amino acids that actually bind to
the target.
Epitope characterization and specificity of
affinity matured binders
DARPins selected before affinity maturation were
shown to bind to different epitopes and some
competed for the same epitope with trastuzumab
(Herceptin™), an antibody used in therapy. We
therefore tested if the binding of the affinity-
matured DARPins could still be inhibited with
antibodies. We assayed the selected clones with
trastuzumab, which has been shown to bind to the
membrane-adjacent cysteine-rich domain IV20 and
pertuzumab, another antibody under development
for its use in therapy, which binds to domain II.21 In
competition ELISA, all binders of the KWIF-
sequence family competed with trastuzumab for
the epitope as shown previously for the non-affinity
matured DARPins.12 None of the selected and
analyzed binders competed with pertuzumab for
Her2 ECD (data not shown).
The highest affinity DARPins were investigated
for their cross-reactivity with unrelated proteins,
including epidermal growth factor receptor 1
(EGFR). As shown in the previous work for non-
matured binders,12 none of the affinity-matured
binders showed non-specific binding (data not
shown).
Sensitivity analysis of the selected DARPins
To evaluate the use of the selected and affinity-
matured DARPins for the quantification of Her2 in
sandwich immunoassays, we tested five binders
(three representative ones are listed in Figure 6(a)) in
amultiplexed format. For this purpose, the DARPins
were expressed with N-terminally fused phage
lambda protein D (pD) containing an avi-tag, to
allow site-specific biotinylation with the E. coli biotin
ligase BirA. Each of the biotinylated DARPins was
immobilized on a different population of spectrally
distinguishable avidin-coated Luminex micro-
spheres. These beads were incubated with various
concentrations of the recombinant ECD of Her2.
After the binding step, detection was performed by
either adding a second DARPin bearing amyc-tag or
commercially available anti-Her2 antibodies to set
up a sandwich assay. This method allowed a fast
screening for the best combination of the five
DARPins and three different commercially available
murine monoclonal antibodies against Her2.
Although several of the DARPin-DARPin combina-
tions could be used in the sandwich format (data not
shown), the best sandwich combination turned out
to be when using a DARPin for capturing and the
antibody sp185 for detection. This is most likely due
to the fact that the investigated high-affinity DAR-
Pins do not make suitable sandwich pairs because
they bind to the same or to nearby epitopes.
Large differences were seen when using the
different DARPins as capture reagents in this assay
Figure 4. A stereo diagram showing detail of the accommodation of the imidazole ring of His52 in a representative
N3C structure (PDB entry 1SVX) is shown in (a). Oxygen atoms are shown in red, nitrogen atoms in blue and carbon
atoms in cyan. The hydrogen bonds between the imidazole ring of His52 and the respective atoms Thr49 Oγ1 and Tyr81 O
are indicated by broken red lines, as is the inter-repeat hydrogen bond between Thr46 O and Val78 N. (b) Stereo diagram
showing detail of the accommodation of the phenol ring of Tyr52 in the N2C structure presented here. Oxygen atoms are
shown in red, nitrogen atoms in blue and carbon atoms in copper. The single hydrogen bond between the side-chain
hydroxyl of Tyr52 and the side-chain carboxylate of Asp77 is indicated by a broken red line. The increased separation (ca
6 Å) of the respective backbone atoms at positions 46 and 78 compared to the N3C structure shown in (a) is apparent. (c)
Stereo diagram showing an overlay of the backbone traces of H10-2-G3 (copper) with an N3C structure (PDB entry 1SVX,
cyan) generated by superimposing the Cα atoms of residues 12 to 74 of the two structures. The rotameric change at
position 52 is indicated. The 13° relative rotation of the two C-terminal ankyrin repeats of H10-2-G3 with respect to their
N3C counterparts is apparent, with the grey line showing the approximate location of the rotation axis and the sphere
at residue 76 indicating the approximate point in the backbone trace at which the overlaid structures begin to diverge.
The Figures were generated using Molmol35 and POVScript+.39
Figure 5. Thermal denaturation of H10-2-G3 (open
circles) and G3-HAVD (filled circles), a variant of H10-2-
G3 that carries no mutations at framework positions.
Both proteins were heated from room temperature to
95 °C and the circular dichroism was measured at
222 nm. The midpoints of denaturation were estimated
from extrapolation of the curves to be at 69 °C and 89 °C,
respectively.
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(Figure 6(a)). The overall performance seemed to
correlate with the affinities of the clones. H10-2-G3
proved to be the most sensitive DARPin and was
capable of detecting Her2 ECD down to a concen-
tration of 20 pg/ml (0.2 pM), which is comparable to
commercial ELISA kits. The dynamic range of the
assay covered more than three orders of magnitude.
The capturing potential of the DARPin H10-2-G3
was further compared to the mAb trastuzumab,
which was immobilized on a microsphere by NHS-
ester chemistry. The sensitivity of this setup was
comparable to the capturing potential of the
DARPin H10-2-G3. However, trastuzumab showed
some deviations from linearity at high Her2 con-
centrations, possibly because of its dimeric nature
and the higher molecular weight. In addition,
trastuzumab showed a more than fivefold higher
background signal with the applied detection sys-
tem than H10-2-G3.
The combination of H10-2-G3 as a capture mol-
ecule and the monoclonal mouse antibody sp185 as
the detector was used in a sandwich assay to
quantify Her2 expression in tumor lysates. Samples
from mammary carcinomas and normal breast
tissue that had been analyzed by immuno-histo-
chemistry (IHC) in a routine clinical laboratory were
used, performing the assay with only 1 μg of total
protein per sample. Data from the bead-based
assays explicitly show a distinction between Her2-
expressing tumors and normal tissue. A clear
correlation of the Her2 expression from the sand-
wich assay with the clinical data from IHC could be
observed (Figure 6(b)).
Discussion
Using ribosome display with a combination of
error-prone PCR and stringent off-rate selection, we
generated the highest affinity DARPin described up
to now, with a monovalent affinity of 90 pM. This
affinity surpasses the high-affinity natural ankyrin
repeat proteins, such as the mouse GA binding
protein (GABP) β1 binding GABPα, which was
described to bind with an affinity of 0.78 nM,22 and
IκBα, whose affinity lies in the low nanomolar
range.23 When comparing the affinity to the size of
the interaction surface, the difference becomes even
more obvious: while the selected DARPins accom-
plish the binding with only two repeat modules,
most natural ankyrin repeat proteins involve several
repeat modules in binding.24 A high percentage of
hydrophobic interactions were found in the putative
selected interaction interface. These contacts can
contribute much to the free energy of the interaction
within a small interaction surface. Nevertheless,
specificity is maintained.
The use of error-prone PCR for the affinity matu-
ration of DARPins proved to be a powerful approach.
The random mutation of framework residues pro-
duced a kink in the rigid backbone of theDARPin and
thereby added some variability to the scaffold by
increasing the diversity of molecular shapes. Many
mutations that contribute to high affinity, when
comparing H10-G3 to the wild-type framework or
to H10-G5 are most likely not part of the binding
interface.We think that these mutations lead to subtle
changes in the overall conformation. These changes
are fundamental for a tight adaptation of the structure
to the target and therefore for highest affinities.
Introducing random mutations in the whole gene,
followed by stringent selection, might be a general
Figure 6. DARPins in immunoassays for Her2 detec-
tion. (a) The capture activities of three representative
DARPins were compared in a sandwich immunoassay.
These DARPins were biotinylated and site-specifically
immobilized on Luminexmicrospheres. In a six-plex assay
format including bead-coupled trastuzumab, capture
activities were analyzed in a titration series of Her2 ECD.
The monoclonal anti-Her2 antibody sp185 was applied for
detection of bound Her2. The sensitivity of the DARPins
appeared to correlate with the affinity. The ratio of signal
over background (S/N: signal to noise ratio) was chosen to
display qualitative differences of capture activities. (b)
Clone H10-2-G3 was used as a capture reagent to detect
Her2 from solubilized breast tissue of patient samples in a
sandwich assay, with monoclonal antibody sp185 as
detection agent. The measurements were performed in
triplicates. Tumor and normal breast tissue from six
patients were used for the assay that had been classified
for Her2 expression using IHC in a routine clinical
laboratory. The Her2 status of patient tumors 2, 3, 4 and
5 were rated 3+ on a scale from 0 to 3+. Tumor samples 1
and 6 were judged as 0. Using bead-based assays, Her2
positive tumor tissues were measured with median fluo-
rescence intensities (MFIs)>1000 AU, whereas Her2
negative tumor tissue resulted in MFIs<100 AU. More-
over, a basal Her2 expression was detected from normal
tissue with MFIs<150 AU.
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means to adapt the binding site to the target surface.
In a very stable framework such as that of a DARPin,
such adaptations by directed evolution are possible,
since the favorable biophysical properties can still be
maintained. In addition, structural and kinetic analy-
sis of the binding revealed some insight into the
dynamics of framework residues.
We propose that a sparsely population of a kinked
conformation was stabilized by a framework muta-
tion at position 52 in the evolved DARPins. This
would also explain the unusually slow association
rate constants of the non-affinity matured clone G3-
HAVD, which did not contain a tyrosine residue at
position 52. Since the association rate of the DARPin
with its antigen is a bimolecular event that is
directly proportional to changes in concentration,
the presence of two conformations of one binding
partner would directly lead to a decrease of the
association rate constant. Mutation of histidine 52 to
tyrosine, however, forces residue 52 to rotate into
the putative binding pocket due to the larger size of
the side-chain ring and the additional hydroxyl
group, thereby inducing the putative active con-
formation, resulting in a dramatic increase of the
association rate constant to the level typical for
protein–protein interactions.8 This particular con-
formation appears to be crucial when binding the
epitope of the KEYL family, but not for the epitopes
recognized by the other families, as the other kon
values are normal, with and without the Tyr52
mutation.
An unexpected finding of our affinity maturation
was that, even though we used off-rate selection,
proteins with improved on-rates were obtained. We
believe, however, that a plausible, albeit purely
speculative rationalization can be proposed. It is
useful to consider the single point mutants of G3
(G3-D, G3-A, G3-AVD, G3-HAVD, Table 1), even
though these clones have not actually been
observed as intermediates in the selection, but
have only been constructed afterwards to investi-
gate the selection procedure. The “wild-type” H3-
HAVD (with unmutated framework) has a KD of
only 288 nM and it would be easily out-competed
at equilibrium by G3-AVD (KD 10 nM), carrying the
His52Tyr mutation, especially since it also equili-
brates much faster. This mutant, the putative
precursor of G3-2-H10, has a relatively fast off-
rate of 4.1×10−3 s−1 and from this point on, the off-
rate decreased (40-fold), whereas the on-rate
increased only slightly (2.5-fold), as expected for a
classical off-rate selection.
The affinity maturation did not influence the
specificity of H10-2-G3. For this mutant as well as
all other tested, still no cross-reactivity was ob-
served, and competition with trastuzumab was seen
for several clones. Also, fusion to phage λ pD and
modification with biotin did not influence the
beneficial behavior of H10-2-G3. In a sandwich-
ELISA approach, similar sensitivities for Her2 were
observed as with a commercial antibody such as
trastuzumab. Compared to the antibody-based
assay, H10-2-G3 showed a lower background.
The accumulated mutations destabilized the
DARPin compared to the clones not carrying frame-
work mutations. The still high stability and the
unchanged expression properties of the evolved
DARPins show that the DARPin scaffold is well
suited to tolerate multiple mutations at framework
positions in addition to the randomized residues.
These favorable biophysical properties in combina-
tion with the exceptional affinity, selectivity and
sensitivity data make DARPins such as clone H10-2-
G3 ideal candidates for miniaturized and even
multiplexed assay systems, useful tools for diagnos-
tic tests on microarray platforms or candidates for
further drug development.
Materials and Methods
Error-prone PCR
Error-prone PCR in the presence of dNTP analogues25
was performed to generate second generation libraries
of pools that were previously selected.12 Therefore, the
pools isolated after round six in this previous study were
used as template for error-prone PCR. Several reactions
were performed with different concentrations of the dNTP
analogues dPTP (6-(deoxy-β-D-erythro-pentofuranosyl)-
3,4-dihydro-8H-pyrimido- [4,5-c][1,2]oxazine-7-one-5′-tri-
phosphate) and 8-oxo-dGTP (8-oxo-2′-deoxyguanosine-
5′-triphosphate) ranging from 2.5 μM to 20 μM each. The
amplification was performed in a 50 μl reaction in the
presence of 0.25 μM primers, one unit of Vent polymerase
exo minus (NEB), 5% DMSO, 1.5 mM MgCl2 and 200 μM
dNTPs. A total of 23 cycles of PCR were performed, and
the mutational load was determined by sequencing to be
1.3–5.9 mutations per DARPin. The distribution of
transitions and transversions was similar to published
values.13
Ribosome display selection rounds
For selection experiments, biotinylated Her2 ECD was
immobilized via neutravidin as described.12 For ELISA
and RIA experiments, 250–500 ng of Her2 ECD were
directly coated to 96-well MaxiSorp polystyrene plates
(Nunc) by overnight incubation at 4 °C in phosphate-
buffered saline (PBS).
Ribosome display off-rate selections were performed
as described.12,15 Biotinylated Her2 ECD was added to
the stopped translation reaction at a concentration of
0.7 nM and equilibrated by shaking overnight at 4 °C.
Non-biotinylated Her2 ECD was added in 500-fold
excess (350 nM). This mixture was kept under slow
shaking at 4 °C for times ranging from 10 h up to 27
days.
Ternary complexes that were still bound to the bio-
tinylated Her2 ECD were isolated using streptavidin-
coated magnetic beads (Roche). For recovery, 60 μl
(0.6 mg) beads were washed three times in WBT
(50 mM Tris acetic acid (pH 7.5), 150 mM NaCl, 50 mM
Mg(CH3COO
−)2, 0.05% Tween 20) and then blocked for
1 h in WBT plus 0.5% (w/v) BSA at room temperature.
After adding the beads, the ribosomal complexes were
allowed to bind by shaking for 30 min at 4 °C. The beads
were then washed three times for 3 min and three times
15 min with WBT before elution.
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Crude extract ELISA, protein expression and surface
plasmon resonance spectroscopy
For affinity analysis of single clones, the selected pools
were cloned into plasmid pQE30 (Qiagen) via BamHI and
HindIII. Because of the very strong expression of the
DARPins, the single stop codon on pQE30 is partially read
over leading to a C-terminal extension bearing a cysteine,
which made an additional purification step for crystal-
lization necessary. This step could be circumvented in the
future by using a vector with two stop codons in tandem
(pQE30SS) (D.S. et al., unpublished). Crude extract ELISAs
were performed as described earlier11 from lysates of 1 ml
expression cultures. For SPR analysis, the DARPins were
expressed in E. coli strain XL1-blue in 500 ml scale and
purified over immobilized metal-ion affinity chromatogra-
phy (IMAC) on a Superflow NTA matrix (Qiagen) as
described.11
All SPR measurements were performed using a Biacore
3000 (Biacore). A CM5 chip was prepared according to the
manufacturer's protocol. For the immobilization of neu-
travidin, a solution of 50 μg/ml neutravidin in 10 mM
sodium acetate, 125 mM NaCl (pH 4.5) was used.
Biotinylated Her2 ECD was then immobilized on the
neutravidin-modified flow cells. For kinetic measure-
ments, a chip was coated with 220 RU of biotinylated
Her2 and for inhibition measurements with 2500 RU.
Kinetic measurements were performed by the serial
injection of a DARPin in concentrations ranging from
1 nM to 250 nM at a buffer-flow of 30 μl/min in HBST
(20 mM Hepes (pH 7.4), 150 mM NaCl, 0.05% Tween 20).
Inhibition measurements were done as described3 at a
constant concentration of DARPin of 5 nM and different
concentrations of soluble Her2 ECD as a competitor in
concentrations ranging from 50 pM to 20 nM. The slope of
the binding to a high-density chip was monitored in the
linear range as a function of the concentration of
competitor at a flow of 25 μl/min. Data evaluation was
performed using BIAEVAL (Biacore), CLAMP26 and
SigmaPlot (Systat Software) as described.16
Construction of point mutants
Tostudythe influenceof the four frameworkmutationsof
H10-2-G3, several clones were constructed where one or
more of these mutations were changed back to the
consensus sequence. The following variants were con-
structed: G3-D (without mutation D122G), G3-A (without
A55T), G3-AVD (without A55T, V96A, D122G) and G3-
HAVD (without A55T, V96A, D122G, V96A, which corre-
sponds to H10-2-G3 having no frameworkmutations).
The mutations were introduced by a PCR-based
approach. Two fragments were amplified overlapping in
the region of the desired mutation. In a second PCR
reaction with outer primers only, the fragments were
joined to yield the mutated sequence. Clone G3-D was
constructedwith a single PCR reaction using a long reverse
primer, as the mutation was near to the C terminus. DNA
of all clones was isolated from agarose gels and cloned via
BamHI and HindIII into pQE-30 (Qiagen). Plasmids were
prepared, sequenced and the mass of the expressed and
purified clones was verified with mass spectrometry
(MALDI-TOF).
Protein crystallization and X-ray data collection
Prior to crystallization, protease inhibitors and oligomeric
protein species were removed from the protein solution by
size-exclusion chromatography on a Superdex 200 10/30
column. Eluted protein was concentrated to 6 mg/ml using
a Millipore Centricon 3 kDa centrifugal concentrator in
20 mM sodium phosphate (pH 7.4), 75 mM NaCl.
An initial screen of 808 commercial and in-house
conditions was performed using a Cartesian Honeybee
robot (Genomic Solutions, Michigan) to set up 96-well
round-bottomed plates (Greiner, Germany) with 100 μl
screening solution per well, 100 nl protein plus 100 nl well
solution in the drops. The screen gave several leads, which
were scaled up using protein at 10 mg/ml and optimized
manually in hanging drops (24 well Linbro plates, 1 ml of
solution per well, 1 μl protein plus 1 μl of well solution in
drops, at room temperature). Crystals grew within three
weeks from a solution containing 0.1 M Tris-HCl (pH 8.5),
2.3 M (NH4)2SO4, 10% (v/v) glycerol. The crystal used for
data collection exhibited a trapezoidal plate-like morphol-
ogy, ca 0.25 mm×0.08 mm×0.15 mm.
A single crystal of the H10-2-G3 DARPin molecule was
transferred to a cryo-protectant solution containing 2.3 M
(NH4)2SO4, 20% glycerol, 0.1 M Tris-HCl (pH 8.5) and
mounted at −160 °C in a rayon loop27 on a RU-3R X-ray
generator (RigakuMSC, Texas) equipped with mono-
capillary focusing optics (AXCO, Australia). The crystal
diffracted to at least 1.7 Å resolution. Two X-ray diffraction
data sets were collected using the oscillation method; the
first data set was collectedwith the camera set at 2θ=0° and
the second at 2θ=15°. Both data sets were processed using
the software HKL.28 The space-group of the crystal was C2
with unit cell dimensions a=152.40 Å, b=51.97 Å,
c=70.07 Å, β=105.21°. X-ray data collection and processing
statistics are presented in Table 2. We note that the Rmerge
statistics is high in the outer resolution shells of both data
sets, however, the <I>/<s>, completeness and data
redundancy statistics in this shell were judged satisfactory
and these data were thus retained.
Structure determination and analysis
A molecular model encompassing 123 residues of the
protein of an N2C DARPin, constructed from the two pre-
viously solved structures of N3CDARPins, E3_5 and E3_19
(with no frameworkmutations) was used for the molecular
replacement search, employing the first diffraction data set
and the programMOLREP29 within the CCP4 suite.30 Three
copies of the search molecule (subsequently labelled A, B
and C) were located within the asymmetric unit. The struc-
ture factor phases obtained by molecular replacement were
then further improved using the program RESOLVE31 and
an atomic model built using the automatedmodel-building
procedure within that program. The atomic model was fur-
ther improved by iterative cycles of crystallographic re-
finement against the second diffraction data set using
REFMAC532 within the CCP4 suite and manual model
building using O.33 The final atomic model encompassed
residues A12 to A135, B12 to B135 and C12 to C136 and
included 488 ordered solvent molecules. Crystallographic
refinement included a bulk solvent model, refinement of
restrained individual atomic temperature factors and the
refinement of individual TLS parameters34 for the three
monomers. Crystallographic refinement statistics are pre-
sented in Table 3. The structure was analyzed using the
programs MolMol35 and Swiss PDB viewer.
Structural comparison with N3C ankyrins
Each of the three copies of H10-2-G3 in the crystal-
lographic asymmetric unit was overlaid using the pro-
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gram LSQMAN36 onto the three N-terminal ankyrin
repeats of three representative N3C structures extracted
from the Protein Data Bank (entries 2BBK, 1MJ0 and
1SVX). Analysis of the resultant geometric transforma-
tions was conducted manually, whilst analysis of relative
changes in the hydrogen bonding patterns was conducted
using HBPLUS.37
Thermal denaturation
Thermal denaturation experiments were performed and
evaluated as described.11 Briefly, 15 μMpurified protein in
PBSwere brought from 20 °C to 92 °Cwith a heating rate of
0.5 deg./min and the CD signal at 222 nm was recorded.
Data were recorded with a Jasco J-715 instrument.
Sensitivity analysis of selected DARPins in Luminex
assays
Biotinylated DARPins H10-2-A2, H10-2-D11, H10-2-
G3, H10-2-G11 and DARPin H6-3-B3, which is an N3C
DARPin that has been described earlier12 were
expressed with the N-terminal fusion protein avi-pD
by cloning into vector pAT224 (GenBank accession
number AY327139) and purified as described above.
By co-expression with BirA, the biotin ligase of E. coli,
the DARPins could be biotinylated site-specifically in
vivo as described earlier.11
Each sample was immobilized on Luminex beads of
distinguishable color-code according to the manufac-
turer's protocol (Luminex-Corp., Austin, Tx, USA). Bioti-
nylated DARPins were immobilized on avidin-coated
beads (LumAvidin Microspheres). Trastuzumab was
coupled to carboxylated beads (COOH Microspheres). A
recombinant Her2 ECD (BenderMed Systems, Vienna,
Austria) served as antigen in sandwich-ELISA set-up.
Breast cancer tumor tissue and corresponding normal
tissue were kindly provided by Helmut Deissler (Uni-
versity of Ulm, Medical School, Germany). All tissue
samples were solubilized as described.38 The total amount
of protein was determined by the Bradford assay.
Immobilized DARPins were studied in multiplexed
sandwich immunoassays to compare capture activities for
quantitative Her2 analysis. All assays were performed in
Blocking Reagent for ELISA (Roche) with 0.005% Tween
at pH 7.4 under permanent shaking in microtiter plates.
Six differently color-coded Luminex beads, each loaded
with a different DARPin or trastuzumab, were mixed.
Titration series of recombinant Her2 protein or tissue
samples were incubated with the bead mixture in a
volume of 50 μl overnight at 4 °C. After filtering the assay
mixture in a 96-well filter plate (Pall, East Hills, NY, USA)
the beads were resuspended in 30 μl of assay buffer
containing 1 μg/ml of anti-Her2 antibody sp185 (Bend-
erMed Systems) and incubated for 60 min. Bound
antibody was detected using R-phycoerythrin (R-PE)
labeled, Fc fragment-specific goat anti-mouse antibody
(Dianova, Hamburg, Germany) at a concentration of
2.5 μg/ml over 45 min incubation. The beads were
analyzed in a Luminex 100 IS System. Results are
presented as median fluorescence intensity (MFI) of 100
events counted per bead population.
Protein Data Bank accession code
Atomic coordinates for the high affinity DARPin have
been deposited in the PDB under accession code 2jab.
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Supplementary Figure 1. The affinities of different DARPins were determined by surface 
Plasmon resonance (SPR) using a Biacore 3000 instrument. Her2 ECD was immobilized on a 
flow cell at low concentrations. Binding of the DARPin to the immobilized target protein was 
compared to binding to an empty flow cell at different concentrations of the DARPin. Data 
were processed by the software Scrubber and evaluated by global fitting using the software 
CLAMP
32
. Each DARPin was injected several times at different concentrations. Note that H3-
HAVD was injected at significantly higher concentrations than the other DARPins. DARPins 
G3-D and G3-A were injected at 20 nM, 50 nM, 100 nM and 150 nM, G3-AVD was injected 
at 50 nM, 100 nM, 200 nM and 300 nM, G3-HAVD was injected at 500 nM, 1000 nM, 
2000 nM, 4000 nM, 6000 nM and 8000 nM, H10-2-G5 was injected at 1 nM, 5 nM, 10 nM, 
20 nM, 30 nM, 50 nM, 75 nM, 100 nM and 150 nM, H10-2-D11 was injected at 10 nM, 
20 nM, 30 nM, 50 nM, 75 nM, 100 nM and 150 nM,  H10-2-D12 was injected at 0 nM, 
100 nM, 200 nM, 300 nM and 400 nM and H10-2-A2 was injected at 0 nM, 1 nM, 5 nM, 
10 nM, 20 nM, 30 nM, 50 nM, 100 nM and 150 nM. 
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1. Abbreviations 
AP alkaline phosphatase 
APH aminoglycoside phosphotransferase IIIa 
BAD biotin acceptor domain 
BCIP substrates 5-bromo-4-chloro-3-indolyl phosphate  
BSA bovine serum albumin 
cat chloramphenicol acetyl transferase 
CDR complementary determining region 
cfu Colony forming units 
CitS Citrate carrier CitS 
cml or cam chloramphenicol 
ColE1 ori plasmid origin of replication ColE1 
CTp3 C-terminal domain (amino acids 250-406) of protein 3 of filamentous phage M13  
DARPin designed ankyrin repeat protein 
DDM n-dodecyl-α-D-maltopyranoside 
DsbAss the signal sequence of the E. coli DsbA 
E. coli Escherichia coli 
ECL electrochemiluminescence 
EK enterokinase site  
ELISA enzyme-linked immunosorbent assay 
ErbB1 human receptor tyrosine-protein kinase ErbB1 
ErbB2 human receptor tyrosine-protein kinase ErbB2 
ErbB4 human receptor tyrosine-protein kinase ErbB4 
f1 ori f1 origin of replication  
Fc fragment crystallizable 
FLAG DNA sequences encoding a FLAG-tag  
gpD phage λ coat protein D  
gpD phage protein D  
HBS Hepes buffered saline 
HuCAL human combinatorial antibody library 
huIgG1_Fc Fc domain of human IgG1 
Ig immunoglobulin 
IMAC immobilized metal ion chromatography  
IPTG isopropyl-β-D-thiogalactoside  
JNK2 c-jun N-terminal kinase 2α2  
kan kanamycin  
KD equilibrium dissociation constant 
koff dissociation rate constants 
kon association rate constants 
lacP lac promoter/operator element  
lacZ p/o promoter/operator element of the lacZ gene of E. coli  
LB Luria-Bertani 
λPP bacteriophage λ protein-phosphatase  
Abbreviations  313 
MALS multi-angle static light scattering  
MBP maltose binding protein 
MCS multiple cloning site  
muIgG mouse IgG 
myc DNA sequences encoding a myc-tag 
NBT nitroblue tetrazolium  
NCCR Swiss National Center of Competence in Research  
p3 minor phage coat protein 3 
PBS phosphate buffered saline 
PD  phage display 
PEG polyethyleneglycol 
PelBss signal sequence of the Erwinia carotovora PelB  
pfu plaque forming units 
PhoAss signal sequence of the E. coli PhoA 
pNPP di-sodium 4-nitrophenyl phosphate 
POD peroxidase  
POI protein of interest  
ps packaging signal 
PVDF polyvinylidene fluoride  
RD Ribosome display 
scFv single-chain Fv antibody  
SDS-PAGE sodium dodecyl sulfate polyacrylamide gel electrophoresis  
SEC size exclusion chromatography 
SHP phage protein SHP 
SPR Surface plasmon resonance 
SRP signal recognition particle 
ss signal sequence 
ssDNA single stranded DNA 
Strp streptavidin 
Taq Taq DNA polymerase  
TBS Tris buffered saline 
tet tetracycline  
TMS transmembrane segment 
TNFα human tumor necrosis factor precursor  
TrxA thioredoxin  
2HCT 2-hydroxy-carboxylate transporters 
4NPP 4-nitrophenyl phosphate 
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2. List of prepared plasmids 
Name Source Ori(s) Res. Use/ORF 
pAT223 PAT ColE1 amp Avi-tag:pD∆N2:His6-tag (GenBank accession number AY327138) 
pDST022 DST (#2) ColE1, f1 cam Phagemid pMorph7 containing: PhoAss_ DARPin 3a 
pDST023 DST (#2) ColE1, f1 cam Phagemid pMorph7 containing: DsbAss_ DARPin 3a 
pDST024 DST (#2) ColE1, f1 cam Phagemid pMorph7 containing: PhoAss_ scFv_gpD 
pDST030 DST (#2) ColE1, f1 cam Phagemid pMorph7 containing: PhoAss_ DARPin E3_5 
pDST031 DST (#2) ColE1, f1 cam Phagemid pMorph7 containing: DsbAss_ scFv_gpD 
pDST032 DST (#2) ColE1, f1 cam Phagemid pMorph7 containing: DsbAss_ DARPin E3_5 
pDST034 DST (#2) ColE1, f1 cam Phagemid pMorph7 containing: PhoAss_ DARPin JNK2_2_3 
pDST037 DST (#2) ColE1, f1 cam Phagemid pMorph7 containing: DsbAss_ DARPin JNK2_2_3 
pDST039 DST (#2) ColE1, f1 cam Phagemid pMorph7 containing: PhoAss_ GCN4 
pDST040 DST (#2) ColE1, f1 cam Phagemid pMorph7 containing: DsbAss_ GCN4 
pDST041 DST (#2) ColE1, f1 cam Phagemid pMorph7 containing: PhoAss_ pD∆N2 
pDST042 DST (#2) ColE1, f1 cam Phagemid pMorph7 containing: DsbAss_ pD∆N2 
pDST045 DST (#2) ColE1, f1 cam Phagemid pMorph7 containing: PhoAss_ JNK2α2 
pDST046 DST (#2) ColE1, f1 cam Phagemid pMorph7 containing: DsbAss_ JNK2α2 
pDST047 DST (#2) ColE1, f1 cam Phagemid pMorph7 containing: PhoAss_ TrxAwt 
pDST048 DST (#2) ColE1, f1 cam Phagemid pMorph7 containing: DsbAss_ TrxAwt 
pDST051 DST (#2) ColE1, f1 cam Phagemid pMorph7 containing: PhoAss_ Taq polymerase 
pDST052 DST (#2) ColE1, f1 cam Phagemid pMorph7 containing: DsbAss_ Taq polymerase 
pDST053 DST (#2) ColE1, f1 cam Phagemid pMorph7 containing: PhoAss_λ-phosphatase 
pDST054 DST (#2) ColE1, f1 cam Phagemid pMorph7 containing: DsbAss_λ-phosphatase 
pDST055 DST (#2) ColE1, f1 cam Phagemid pMorph7 containing: PhoAss_ APH 
pDST056 DST (#2) ColE1, f1 cam Phagemid pMorph7 containing: DsbAss_ APH 
pDST065 DST (#2) ColE1, f1 cam Phagemid pMorph7 containing: PhoAss_ DARPin E3_19 
pDST066 DST (#2) ColE1, f1 cam Phagemid pMorph7 containing: DsbAss_ DARPin E3_19 
pDST067 DST (#3) ColE1 amp Modified pQE30, double stop codon (TAA TGA) after the HindIII 
restriction site: expression of the selected DARPins containing an N-
terminal MRGS(H)6 tag 
pDST067_ 
(T_xx) 
DST (#3, 
Ap. #1) 
ColE1 amp pDST67 containing a DARPin selected against TNF alpha : 
MRGS(H)6 _DARPin (T_01, T_02, T_03, T_04, T_06, T_07, T_08, 
T_09, T_10, T_11, T_12, T_13, T_15, T_16, T_19, T_25, T_27, 
T_30, T_33, T_35, T_37, T_40, T_41, T_44, T_45, T_47, T_49, 
T_51, T_52) 
pDST067_ 
(E_xx) 
DST (#3, 
Ap. #1) 
ColE1 amp pDST67 containing a DARPin selected against ErbB1: MRGS(H)6 
_DARPin (E_01, E_17, E_31, E_36, E_64, E_67, E_68, E_72) 
pDST067_ 
(9_xx) 
DST (#3, 
Ap. #1) 
ColE1 amp pDST67 containing a DARPin selected against ErbB2-509: 
MRGS(H)6 _DARPin (9_01, 9_02, 9_03, 9_04, 9_10, 9_12, 9_16, 
9_18, 9_20, 9_26, 9_29, 9_30, 9_33) 
pDST067_ 
(H_xx) 
DST (#3, 
Ap. #1) 
ColE1 amp pDST67 containing a DARPin selected against ErbB2-631: 
MRGS(H)6 _DARPin (H_01, H_03, H_14) 
pDST067_ 
(B4_xx) 
DST (#3, 
Ap. #1) 
ColE1 amp pDST67 containing a DARPin selected against ErbB4: MRGS(H)6 
_DARPin (B4_01, B4_02, B4_07, B4_11, B4_14, B4_33, B4_45, 
B4_49, B4_50, B4_53, B4_55, B4_56, B4_57, B4_58, B4_60, 
B4_63, B4_64, B4_65, B4_68) 
pDST067_ 
(I_xx) 
DST (#3, 
Ap. #1) 
ColE1 amp pDST67 containing a DARPin selected against Fc domain of human 
IgG1: MRGS(H)6 _DARPin (I_01, I_02, I_03, I_06, I_07, I_10, I_11, 
I_13, I_14, I_19) 
pDST072 DST (#3) ColE1 amp pDST67 containing the selected DARPin G3 (H2R10G3): MRGS(H)6 
_G3 
pDST080 DST (#2) ColE1, f1 cam Phagemid pMorph7 containing: PelBss_DARPin 3a 
pDST081 DST (#2) ColE1, f1 cam Phagemid pMorph7 containing: PelBss_DARPin JNK2_2_3 
pDST084 DST (#2) ColE1, f1 cam Phagemid pMorph7 containing: TolBss_DARPin 3a 
pDST085 DST (#2) ColE1, f1 cam Phagemid pMorph7 containing: TolBss_DARPin JNK2_2_3 
pDST086 DST (#2) ColE1, f1 cam Phagemid pMorph7 containing: SfmCss_DARPin 3a 
pDST087 DST (#2) ColE1, f1 cam Phagemid pMorph7 containing: SfmCss_DARPin JNK2_2_3 
pDST088 DST (#2) ColE1, f1 cam Phagemid pMorph7 containing: TorTss_DARPin 3a 
pDST089 DST (#2) ColE1, f1 cam Phagemid pMorph7 containing: TorTss_DARPin JNK2_2_3 
pDST103 DST (#2) ColE1, f1 cam Phagemid pMorph7 containing: OmpAss_DARPin E3_5 
pDST104 DST (#2) ColE1, f1 cam Phagemid pMorph7 containing: OmpAss_TrxAwt 
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pDST105 DST (#2) ColE1, f1 cam Phagemid pMorph7 containing: PelBss_DARPin E3_5 
pDST106 DST (#2) ColE1, f1 cam Phagemid pMorph7 containing: TolBss_DARPin E3_5 
pDST107 DST (#2) ColE1, f1 cam Phagemid pMorph7 containing: TorTss_DARPin E3_5 
pDST108 DST (#2) ColE1, f1 cam Phagemid pMorph7 containing: SfmCss_DARPin E3_5 
pDST109 DST (#2) ColE1, f1 cam Phagemid pMorph7 containing: MalEss_DARPin E3_5 
pDST110 DST (#2) ColE1, f1 cam Phagemid pMorph7 containing: LamBss_DARPin E3_5 
pDST111 DST (#2) ColE1, f1 cam Phagemid pMorph7 containing: MglBss_DARPin E3_5 
pDST112 DST (#2) ColE1, f1 cam Phagemid pMorph7 containing: PelBss_TrxAwt 
pDST113 DST (#2) ColE1, f1 cam Phagemid pMorph7 containing: TolBss_TrxAwt 
pDST114 DST (#2) ColE1, f1 cam Phagemid pMorph7 containing: TorTss_TrxAwt 
pDST115 DST (#2) ColE1, f1 cam Phagemid pMorph7 containing: SfmCss_TrxAwt 
pDST116 DST (#2) ColE1, f1 cam Phagemid pMorph7 containing: MalEss_TrxAwt 
pDST117 DST (#2) ColE1, f1 cam Phagemid pMorph7 containing: LamBss _TrxAwt 
pDST118 DST (#2) ColE1, f1 cam Phagemid pMorph7 containing: MglBss _TrxAwt 
pDST126 DST (#3) ColE1 amp pAT223 containing DARPin E_01 
pDST127 DST (#3) ColE1 amp pAT223 containing DARPin B4_02 
pPDV1 / 
pMPAG3 
DST (#3) ColE1, f1 cam Phagemid for SRP phage display used for library construction 
Abbreviations used: DST, Daniel Steiner; PAT, Patrik Forrer; #, Chapter in this thesis; Ap. #, Appendix; Res., antibiotics resistance; cam, 
chloramphenicol; amp, ampicilin 
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3. List of oligonucleotides 
Name Source Sequence Comment 
oDST01 DST (#2) 5’- TTCCTCCATGGGTATGAGAGGATCGCATCACC 
ATCACCATCACGGATCCGACCTGGG-3’ 
Fwd. primer: amplification of 
DARPins (NcoI, BamHI) 
oDST02 DST (#2) 5’- TCGAATTCGGCTGCAGATTGCAGGATTTCAGC 
CAGGTCCTCG-3’ 
Rev. primer: amplification of 
DARPins (PstI, EcoRI) 
oDST04 DST (#2) 5’-AGAGCATGCGTAGGAGAAAATAAAATGAAA 
AAGATTTGGCTGGCGCTGGCTGG-3’ 
Inner fwd. primer DsbAss 
oDST05 DST (#2) 5’-TCTTTGTAGTCCGCCGATGCGCTAAACGCTAA 
AACTAAACCAGCCAGCGCCAGCC-3’ 
Inner rev. primer DsbAss 
oDST06 DST (#2) 5’-GCTCTAGAGCATGCGTAGGAG-3’ Outer fwd. primer for all ss 
amplification (XbaI) 
oDST07 DST (#2) 5’-GCCAATTGCACTTCATCTTTGTAGTCCGCCG-3’ Outer rev. primer for DsbAss 
amplification, special for scFv 31 
containing pDST (MfeI) 
oDST08 DST (#2) 5’-GCGGATCCATCTTTGTAGTCCGCCG-3’ Outer rev. primer for DsbAss 
amplification (BamHI) 
oDST09 DST (#2) 5’-CGGGATCCCGTATGAAACAGCTGGAAGACAA 
AGTTGAATTGCTTCCGAAAAATTATCAC-3’ 
Fwd. primer: amplification of 
GCN4 (BamHI) 
oDST10 DST (#2) 5’-CGGAATTCGGCTGCAGAGCGTTCGCCAACTAA 
TTTCTTTAATC-3’ 
Rev. primer: amplification of 
GCN4 (PstI, EcoRI) 
oDST11 DST (#2) 5’-CGAGATCTGGCACCGCAACCGCG-3’ Fwd. primer: amplification of 
pD∆N2 (BglII) 
oDST12 DST (#2) 5’-CGGAATTCGGCTGCAGAGCCAACGATGCTGA 
TTGCCG-3’ 
Rev.: amplification of pD∆N2 
(PstI, EcoRI) 
oDST13 DST (#2) 5’-CGGAATTCGGCTGCAGATCGACAGCCTTCAA 
GG-3’ 
Rev. primer: amplification of JNK2 
(PstI, EcoRI) 
oDST14 DST (#2) 5’-CGGGATCCTCCGACTCTAAATGTGAC-3’ Fwd. primer: amplification of JNK2 
(BamHI) 
oDST15 DST (#2) 5’-CGGGATCCGGCAGCGATAAAATTATTCACC-3’ Fwd. primer: amplification of TrxA 
(BamHI) 
oDST16 DST (#2) 5’-CGGAATTCGGCTGCAGAGGCCAGGTTAGCGT 
CG-3’ 
Rev. primer: amplification of TrxA 
(PstI, EcoRI) 
oDST19 DST (#2) 5’-GAAGATCTGGCAGCCCCAAGGCCCTG-3’ Fwd. primer: amplification of Taq 
(BglII) 
oDST20 DST (#2) 5’-CGGAATTCGGCTGCAGACTCCTTGGCGGAGA 
GC-3’ 
Rev. primer: amplification of Taq 
(PstI, EcoRI) 
oDST21 DST (#2) 5’-GAGGATCCATGCGCTATTACGAAAAAATTGA 
TGG-3’ 
Fwd. primer: amplification of λ-
phosphatase (BamHI) 
oDST22 DST (#2) 5’-CGGAATTCGGCTGCAGAACCTGCGCCTTCTCC 
CTG-3’ 
Rev. primer: amplification of λ-
phosphatase (PstI, EcoRI) 
oDST23 DST (#2) 5’-CGGGATCCGCTAAAATGAGAATATCACC-3’ Fwd. primer: amplification of APH 
(BamHI) 
oDST24 DST (#2) 5’-CGGAATTCGGCTGCAGAAAACAATTCATCCA 
GTAAAA-3’ 
Rev.: amplification of APH (PstI, 
EcoRI) 
oDST29 DST (#3) 5’- GGCCAAGCTTAATTAATGACTGAGCTTGGACT 
CCTG-3’ 
Fwd. primer: Introducing TAA 
TAG into pQE30 (HindIII) 
oDST30 DST (#3) 5’- AAAGCCAAGCTAGCTTGGATTCTC-3’ Rev. primer: Introducing TAA 
TAG into pQE30 (NheI) 
oDST47 DST (#2) 5’-GCGGATCCATCTTTGTAGTC-3’ Outer rev. primer for all ss 
amplification (BamHI) 
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oDST48 DST (#2) 5’-AGAGCATGCGTAGGAGAAAATAAAATGAAAT 
ACCTATTGCCTACGGCAGCCGCTGG-3’ 
Inner fwd. primer PelBss 
oDST52 DST (#2) 5’-AGAGCATGCGTAGGAGAAAATAAAATGAAG 
CAGGCATTACGAGTAGCATTTGGTTTCCTC-3’ 
Inner fwd. primer TolBss 
oDST53 DST (#2) 5’-GGATCCATCTTTGTAGTCAGCATGCAGAACTG 
ATGCCCACAGTATGAGGAAACCAAATGCTACTC
G-3’ 
Inner rev. primer TolBss 
oDST54 DST (#2) 5’-AGAGCATGCGTAGGAGAAAATAAAATGATGA 
CTAAAATAAAGTTACTCATGCTCATTATATTTTA
CCTG-3’ 
Inner fwd. primer SfmCss 
oDST55 DST (#2) 5’-GGATCCATCTTTGTAGTCAGCATGGGCGCTGG 
CCGAAATGATCAGGTAAAATATAATGAGCATGA
G-3’ 
Inner rev. primer SfmCss 
oDST56 DST (#2) 5’-AGAGCATGCGTAGGAGAAAATAAAATGCGCG 
TACTGCTATTTTTACTGCTTTCCCTTTTCATGCTG-
3’ 
Inner fwd. primer TorTss 
oDST57 DST (#2) 5’-GGATCCATCTTTGTAGTCCGAAAATGCCGGCA 
GCATGAAAAGGGAAAGCAG-3’ 
Inner rev. primer TorTss 
oDST60 DST (#2) 5’-AGAGCATGCGTAGGAGAAAATAAAATGAATA 
AGAAGGTGTTAACCCTGTCTGCTGTGATGGCCAG
C-3’ 
Inner fwd. primer MglBss 
oDST61 DST (#2) 5’-GGATCCATCTTTGTAGTCAGCGTGTGCAGCGG 
CACCGAATAACATGCTGGCCATCACAGCAGAC-
3’ 
Inner rev. primer MglBss 
oDST62 DST (#2) 5’-AGAGCATGCGTAGGAGAAAATAAAATGATGA 
TTACTCTGCGCAAACTTCCTCTGGCGGTTGCCGT
CG-3’ 
Inner fwd. primer LamBss 
oDST63 DST (#2) 5’-GGATCCATCTTTGTAGTCAGCCATTGCCTGAG 
CAGACATTACGCCCGCTGCGACGGCAACCGCCA
GAG-3’ 
Inner rev. primer LamBss 
oDST64 DST (#2) 5’-AGAGCATGCGTAGGAGAAAATAAAATGAAAA 
TAAAAACAGGTGCACGCATCCTCGCATTATCCGC
ATTAACGACG-3’ 
Inner fwd. primer MalEss 
oDST65 DST (#2) 5’-GGATCCATCTTTGTAGTCGGCGAGAGCCGAG 
GCGGAAAACATCATCGTCGTTAATGCGGATAAT
GC-3’ 
Inner rev. primer MalEss 
oDST66 DST (#2) 5’-AGAGCATGCGTAGGAGAAAATAAAATGAAA 
AAGACAGCTATCGCGATTGCAGTGGCACTGGC-3’ 
Inner fwd. primer OmpAss 
oDST67 DST (#2) 5’-GGATCCATCTTTGTAGTCGGCCTGCGCTACGG 
TAGCGAAACCAGCCAGTGCCACTGCAATCG-3’ 
Inner rev. primer OmpAss 
EWT3 HKB 5'-TTCCGCGGATCCGACCTGGG-3' Fwd. primer: amplification of 
DARPin library (BamHI) 
WTC4 HKB 5'-TTTGGGAAGCTTTTGCAGGATTTCAGC-3' Rev. primer: amplification of 
DARPin library (HindIII) 
Abbreviations used: DST, Daniel Steiner; HKB, Hans Kaspar Binz; #, Chapter in this thesis; fwd., forward; rev., reverse, Restriction 
enzymes are given in brackets and underlined in the sequence. 
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